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ABSTRACT 
Library Synthesis of Anticancer and Antibacterial Agents via Azide Chemistry 
by 
Jianjun Zhang, Doctor of Philosophy 
Utah State University, 2010 
 
Major Professor: Dr. Cheng-Wei Tom Chang  
Department: Chemistry and Biochemistry 
 
    Various anticancer and antibacterial agents have been synthesized via azide 
chemistry by taking advantage of carbohydrate. Starting from the synthesis of 14 
glycosyl azides,  a library of carbohydrate-oxazolidinone conjugates and a library of 
carbohydrate-cyclopamine conjugates with biological interests were synthesized based 
on a highly efficient “click reaction” assisted by sonication. Some of the conjugates 
have improved solubility and enhanced anticancer activity. 
    A library of neomycin B derivatives with various modifications at the 5′′ position 
has been synthesized. Two leads exhibit prominent activity against both 
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant 
enterococci (VRE). Antibacterial activities were measured when combined with other 
clinically used antibiotics and significant synergistic activities were observed. 
    Three different classes of aryl N-glycosides have been synthesized by employing 
1,4-naphthoquinone and glycosyl azides undergoing a [2+3] cycloaddition. Alkyl 
  
iv
azides can also undergo the same cycloaddition. After the removal of the protecting 
group, a library of 9,10-anthraquinone derivatives with potential anticancer activity and 
a library of 2-aminomethylene-1,3-indanediones with novel antibacterial activity have 
been developed, respectively. 
    A one-pot three-component [2+3] cycloaddition for the synthesis of 1-alkyl 
1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione and 2-alkyl 2H-naphtho[2,3-d][1,2,3] 
triazole-4,9-dione has been developed. By taking the advantage of their difference in 
basicity, both products can be obtained in good purity.  
    Using an allylic azide rearrangement, a convenient method has been developed for 
the synthesis of several 2',3'-dideoxyaminoglycosides. The antibacterial activity of 
these novel aminoglycosides also confirms the indispensable role of the 2'-NH2 group 
for both neomycin and kanamycin classes of aminoglycosides. A novel structural motif 
containing the hexylaminocarbonyl groups at O-5 and/or O-6 of 2',3'-dideoxyneamine 
could lead to the production of new aminoglycosides against resistant bacteria. 
 
 (726 pages) 
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2-oxazolidinone (23t). 
 
Spectrum  65 1H NMR (400 MHz, CDCl3) of N-(1-(2,3,4-Tri-O-acetyl-α-D- 
xylopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-5-acetamidomethyl-2- 
oxazolidinone (23u). 
 
Spectrum  66 13C NMR (100 MHz, CDCl3) of N-(1-(2,3,4-Tri-O-acetyl-α-D- 
xylopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-5-acetamidomethyl-2- 
oxazolidinone (23u). 
 
Spectrum  67 1H NMR (400 MHz, CD3OD) of (R)-(1-(β-D-Glucopyranosyl)- 
1H-1,2,3-triazol-4- yl)methyl-4-benzyl-2-oxazolidinone (OX101). 
 
Spectrum  68 13C NMR (100 MHz, CD3OD) of (R)-(1-(β-D-Glucopyranosyl)- 
1H-1,2,3-triazol-4- yl)methyl-4-benzyl-2-oxazolidinone (OX101). 
 
Spectrum  69 1H NMR (400 MHz, CD3OD) of (R) N-(1-(β-D-Galactopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2-oxazolidinone (OX102). 
 
Spectrum  70 13C NMR (100 MHz, CD3OD) of (R) N-(1-(β-D-Galactopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2-oxazolidinone (OX102). 
 
Spectrum  71 1H NMR (400 MHz, CDCl3) of (R) N-(1-(α-D-Mannopyranosyl)-1H- 
1,2,3-triazol-4-yl)methyl-4-benzyl-2-oxazolidinone (OX103). 
 
Spectrum  72 13C NMR (100 MHz, CD3OD) of (R) N-(1-(α-D-Mannopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2-oxazolidinone (OX103). 
 
Spectrum  73 1H NMR (400 MHz, CD3OD) of (R) N-(1-(β-D-Galactopyranosyl)- 
2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl) 
methyl-4-benzyl-2-oxazolidinone (OX104). 
 
 
 
xviii 
 
Spectrum  74 13C NMR (100 MHz, CD3OD) of (R) N-(1-(β-D-Galactopyranosyl)- 
2,3,6-tri-O-acetyl- β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl) 
methyl-4-benzyl-2-oxazolidinone (OX104). 
 
Spectrum  75 1H NMR (400 MHz, CD3OD) of (R) N-(1-(β-L-Fucopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2-oxazolidinone (OX105). 
 
Spectrum  76 13C NMR (100 MHz, CD3OD) of (R) N-(1-(β-L-Fucopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2-oxazolidinone (OX105). 
 
Spectrum  77 1H NMR (400 MHz, CD3OD) of (R) N-(1-(α-L-Rhamnopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2-oxazolidinone (OX106). 
 
Spectrum  78 13C NMR (100 MHz, CD3OD) of (R) N-(1-(α-L-Rhamnopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2-oxazolidinone (OX106). 
 
Spectrum  79 1H NMR (400 MHz, CD3OD) of (R) N-(1-(α-D-Xylopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2-oxazolidinone(OX107). 
 
Spectrum  80 13C NMR (100 MHz, CD3OD) of (R) N-(1-(α-D-Xylopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2-oxazolidinone(OX107). 
 
Spectrum  81 1H NMR (400 MHz, CD3OD) of N-(1-(β-D-Glucopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone (OX201). 
 
Spectrum  82 13C NMR (100 MHz, CD3OD) of N-(1-(β-D-Glucopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone (OX201). 
 
Spectrum  83 1H NMR (400 MHz, CD3OD) of N-(1-(β-D-Galactopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone (OX202). 
 
Spectrum  84 13C NMR (100 MHz, CD3OD) of N-(1-(β-D-Galactopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone (OX202). 
 
Spectrum  85 1H NMR (400 MHz, CD3OD) of N-(1-(α-D-Mannopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone (OX203). 
 
Spectrum  86 13C NMR (100 MHz, CD3OD) of N-(1-(α-D-Mannopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone (OX203). 
 
Spectrum  87 1H NMR (400 MHz, CD3OD) of N-(1-(β-D-Galactopyranosyl)- 
2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl
-2-oxazolidinone (OX204). 
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Spectrum  88 13C NMR (100 MHz, CD3OD) of N-(1-(β-D-Galactopyranosyl)- 
2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl
-2-oxazolidinone (OX204). 
 
Spectrum  89 1H NMR (400 MHz, CD3OD) of N-(1-(β-L-Fucopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone (OX205). 
 
Spectrum  90 13C NMR (100 MHz, CD3OD) of N-(1-(β-L-Fucopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone (OX205). 
 
Spectrum  91 1H NMR (400 MHz, CD3OD) of N-(1-(α-L-Rhamnopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone (OX206). 
 
Spectrum  92 13C NMR (100 MHz, CD3OD) of N-(1-(α-L-Rhamnopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone (OX206). 
 
Spectrum  93 1H NMR (400 MHz, CD3OD) of N-(1-(α-D-Xylopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone (OX207). 
 
Spectrum  94 13C NMR (100 MHz, CD3OD) of N-(1-(α-D-Xylopyranosyl)- 
1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone (OX207). 
 
Spectrum  95 1H NMR (400 MHz, CD3OD) of N-(1-(β-D-Glucopyranosyl)-1H- 
1,2,3-triazol-4-yl)methyl-5-acetamidomethyl-2-oxazolidione 
(OX301). 
 
Spectrum  96 13C NMR (100 MHz, CD3OD) of N-(1-(β-D-Glucopyranosyl)-1H- 
1,2,3-triazol-4-yl)methyl-5-acetamidomethyl-2-oxazolidione 
(OX301). 
 
Spectrum  97 1H NMR (400 MHz, CD3OD) of N-(1-(β-D-Galactopyranosyl)-1H- 
1,2,3-triazol-4-yl)methyl-5-acetamidomethyl-2-oxazolidinone 
(OX302). 
 
Spectrum  98 13C NMR (100 MHz, CD3OD) of N-(1-(β-D-Galactopyranosyl)-1H- 
1,2,3-triazol-4-yl)methyl-5-acetamidomethyl-2-oxazolidinone 
(OX302). 
 
Spectrum  99 1H NMR (400 MHz, CD3OD) of N-(1-(α-D-Mannopyranosyl)-1H- 
1,2,3- triazol-4-yl)methyl-5-acetamidomethyl-2-oxazolidinone 
(OX303). 
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Spectrum  100 13C NMR (100 MHz, CD3OD) of N-(1-(α-D-Mannopyranosyl)-1H- 
1,2,3- triazol-4-yl)methyl-5-acetamidomethyl-2-oxazolidinone 
(OX303). 
 
Spectrum  101 1H NMR (400 MHz, CD3OD) of N-(1-(β-D-Galactopyranosyl)- 
2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl
-5-acetamidomethyl-2-oxazolidinone (OX304). 
 
Spectrum  102 13C NMR (100 MHz, CD3OD) of N-(1-(β-D-Galactopyranosyl)- 
2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl
-5-acetamidomethyl-2-oxazolidinone (OX304). 
 
Spectrum  103 1H NMR (400 MHz, CD3OD) of N-(1-(β-L-Fucopyranosyl)-1H- 
1,2,3- triazol-4-yl)methyl-5-acetamidomethyl-2-oxazolidinone 
(OX305). 
 
Spectrum  104 13C NMR (100 MHz, CD3OD) of N-(1-(β-L-Fucopyranosyl)-1H- 
1,2,3- triazol-4-yl)methyl-5-acetamidomethyl-2-oxazolidinone 
(OX305). 
 
Spectrum  105 1H NMR (400 MHz, CD3OD) of N-(1-(α-L-Rhamnopyranosyl)-1H- 
1,2,3- triazol-4-yl)methyl-5-acetamidomethyl-2-oxazolidinone 
(OX306). 
 
Spectrum  106 13C NMR (100 MHz, CD3OD) of N-(1-(α-L-Rhamnopyranosyl)-1H- 
1,2,3- triazol-4-yl)methyl-5-acetamidomethyl-2-oxazolidinone 
(OX306). 
 
Spectrum  107 1H NMR (400 MHz, CD3OD) of N-(1-(α-D-Xylopyranosyl)-1H- 
1,2,3- triazol-4-yl)methyl-5-acetamidomethyl-2-oxazolidinone 
(OX307). 
 
Spectrum  108 13C NMR (100 MHz, CD3OD) of N-(1-(α-D-Xylopyranosyl)-1H- 
1,2,3- triazol-4-yl)methyl-5-acetamidomethyl-2-oxazolidinone 
(OX307). 
 
Spectrum  109 1H NMR (400 MHz, CDCl3) of N-Propargylcyclopamine (25). 
Spectrum  110 13C NMR (100 MHz, CDCl3) of N-Propargylcyclopamine (25). 
 
Spectrum  111 1H NMR (400 MHz, CDCl3) of N-(1-(2,3,4,6-Tetra-O-acetyl-β-D- 
glucopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26a).  
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Spectrum  112 13C NMR (100 MHz, CDCl3) of N-(1-(2,3,4,6-Tetra-O-acetyl-β-D- 
glucopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26a).  
 
Spectrum  113 1H NMR (400 MHz, CDCl3) of N-(1-(2,3,4,6-Tetra-O-acetyl-β-D- 
galactopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26b).  
 
Spectrum  114 13C NMR (100 MHz, CDCl3) of N-(1-(2,3,4,6-Tetra-O-acetyl-β-D- 
galactopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26b).  
 
Spectrum  115 1H NMR (400 MHz, CDCl3) of N-(1-(2,3,4,6-Tetra-O-acetyl-β-D- 
mannopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26c). 
 
Spectrum  116 13C NMR (100 MHz, CDCl3) of N-(1-(2,3,4,6-Tetra-O-acetyl-β-D- 
mannopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26c). 
 
Spectrum  117 1H NMR (400 MHz, CDCl3) of N-(1-(4-O-(2,3,4,6-Tetra-O- 
acetyl-β-D-galactopyranosyl)2,3,6-tri-O-acetyl-β-D-glucopyranosyl)
-1H-1,2,3-triazol-4-yl)methylcyclopamine (26d).  
 
Spectrum  118 13C NMR (100 MHz, CDCl3) of N-(1-(4-O-(2,3,4,6-Tetra-O- 
acetyl-β-D-galactopyranosyl)2,3,6-tri-O-acetyl-β-D-glucopyranosyl)
-1H-1,2,3-triazol-4-yl)methylcyclopamine (26d).  
 
Spectrum  119 1H NMR (400 MHz, CDCl3) of N-(1-(2,3,4-Tri-O-acetyl-β-L- 
fucopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26e). 
 
Spectrum  120 13C NMR (100 MHz, CDCl3) of N-(1-(2,3,4-Tri-O-acetyl-β-L- 
fucopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26e). 
 
Spectrum  121 1H NMR (400 MHz, CDCl3) of N-(1-(2,3,4-Tri-O-acetyl-α-L- 
rhamnopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26f). 
 
Spectrum  122 13C NMR (100 MHz, CDCl3) of N-(1-(2,3,4-Tri-O-acetyl-α-L- 
rhamnopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26f). 
 
Spectrum  123 1H NMR (400 MHz, CDCl3) of N-(1-(2,3,4-Tri-O-acetyl-α-D- 
xylopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26g). 
 
Spectrum  124 13C NMR (100 MHz, CDCl3) of N-(1-(2,3,4-Tri-O-acetyl-α-D- 
xylopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26g). 
 
Spectrum  125 1H NMR (400 MHz, CDCl3) of N-(1-(2-Acetamido-3,4,6-tri-O- 
acetyl-2-deoxy-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl) 
methylcyclopamine (26h). 
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Spectrum  126 13C NMR (100 MHz, CDCl3) of N-(1-(2-Acetamido-3,4,6-tri- 
O-acetyl-2-deoxy-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl) 
methylcyclopamine (26h). 
 
Spectrum  127 1H NMR (400 MHz, CDCl3) of N-(1-(2-Acetamido-3,4,6-tri-O- 
acetyl-2-deoxy-β-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl) 
methylcyclopamine (26i). 
 
Spectrum  128 13C NMR (100 MHz, CDCl3) of N-(1-(2-Acetamido-3,4,6-tri-O- 
acetyl-2-deoxy-β-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl) 
methylcyclopamine (26i). 
 
Spectrum  129 1H NMR (400 MHz, CDCl3) of N-(1-(4-O-(2,3,4,6-Tetra-O- 
acetyl-β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-
1H-1,2,3-triazol-4-yl)methylcyclopamine (26j). 
 
Spectrum  130 13C NMR (100 MHz, CDCl3) of N-(1-(4-O-(2,3,4,6-Tetra-O- 
acetyl-β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-
1H-1,2,3-triazol-4-yl)methylcyclopamine (26j). 
 
Spectrum  131 1H NMR (400 MHz, CDCl3) of N-(1-(4-O-(4-O-(2,3,4,6-Tetra-O- 
acetyl-β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-
2,3,6-tri-O-acetyl-β-D-glucopyranosyl))-1H-1,2,3-triazol-4-yl) 
methylcyclopamine (26k). 
 
Spectrum  132 13C NMR (100 MHz, CDCl3) of N-(1-(4-O-(4-O-(2,3,4,6-Tetra-O- 
acetyl-β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-
2,3,6-tri-O-acetyl-β-D-glucopyranosyl))-1H-1,2,3-triazol-4-yl) 
methylcyclopamine (26k). 
 
Spectrum  133 1H NMR (400 MHz, CDCl3) of N-(1-(2,3,4-Tri-O-acetyl-α-D- 
ribofuranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26l). 
 
Spectrum  134 13C NMR (100 MHz, CDCl3) of N-(1-(2,3,4-Tri-O-acetyl-α-D- 
ribofuranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26l). 
 
Spectrum  135 1H NMR (400 MHz, CDCl3) of 2,3,4,5-Tetra-O-acetyl-1H-1,2,3- 
triazol-40yl)methylcyclopmaine-1,6-dideoxy-D-mannitol (26m) 
 
Spectrum  136 13C NMR (100 MHz, CDCl3) of 2,3,4,5-Tetra-O-acetyl-1H-1,2,3- 
triazol-40yl)methylcyclopmaine-1,6-dideoxy-D-mannitol (26m) 
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Spectrum  137 1H NMR (400 MHz, CD3OD) of N-(1-(β-D-Glucopyranosyl)-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27a). 
 
Spectrum  138 13C NMR (100 MHz, CD3OD) of N-(1-(β-D-Glucopyranosyl)-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27a). 
 
Spectrum  139 1H NMR (400 MHz, CD3OD) of N-(1-(β-D-galactopyranosyl)-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27b). 
 
Spectrum  140 13C NMR (100 MHz, CD3OD) of N-(1-(β-D-galactopyranosyl)-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27b). 
 
Spectrum  141 1H NMR (400 MHz, CD3OD) of N-(1-(α-D-Mannopyranosyl)-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27c). 
 
Spectrum  142 13C NMR (100 MHz, CD3OD) of N-(1-(α-D-Mannopyranosyl)-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27c). 
 
Spectrum  143 1H NMR (400 MHz, CD3OD) of N-(1-(4-O-(β-D-Galactopyranosyl) 
-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine 
(27d). 
 
Spectrum  144 13C NMR (100 MHz, CD3OD) of N-(1-(4-O-(β-D-Galactopyranosyl) 
-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine 
(27d). 
 
Spectrum  145 1H NMR (400 MHz, CD3OD) of N-(1-(β-L-Fucopyranosyl)-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27e). 
 
Spectrum  146 13C NMR (100 MHz, CD3OD) of N-(1-(β-L-Fucopyranosyl)-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27e). 
 
Spectrum  147 1H NMR (400 MHz, CD3OD) of N-(1-(α-L-Rhamnopyranosyl)-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27f). 
 
Spectrum  148 13C NMR (100 MHz, CD3OD) of N-(1-(α-L-Rhamnopyranosyl)-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27f). 
 
Spectrum  149 1H NMR (400 MHz, CD3OD) of N-(1-(α-D-Xylopyranosyl)-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27g). 
 
Spectrum  150 13C NMR (100 MHz, CD3OD) of N-(1-(α-D-Xylopyranosyl)-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27g). 
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Spectrum  151 1H NMR (400 MHz, CD3OD) of N-(1-(2-Acetamido-2-deoxy-β-D- 
glucopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (27h). 
 
Spectrum  152 13C NMR (100 MHz, CD3OD) of N-(1-(2-Acetamido-2-deoxy-β-D- 
glucopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (27h). 
 
Spectrum  153 1H NMR (400 MHz, CD3OD) of N-(1-(2-Acetamido-2-deoxy-β-D- 
galactopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (27i). 
 
Spectrum  154 13C NMR (100 MHz, CD3OD) of N-(1-(2-Acetamido-2-deoxy-β-D- 
galactopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (27i). 
 
Spectrum  155 N-(1-(4-O-(β-D-Glucopyranosyl)-β-D-glucopyranosyl)-    
1H-1,2,3-triazol-4-yl)methylcyclopamine (27j). 
 
Spectrum  156 N-(1-(4-O-(β-D-Glucopyranosyl)-β-D-glucopyranosyl)-    
1H-1,2,3-triazol-4-yl)methylcyclopamine (27j). 
 
Spectrum  157 1H NMR (400 MHz, CD3OD) of N-(1-(4-O-(4-O-(β-D- 
glucopyranosyl)-β-D-glucopyranosyl)-β-D-glucopyranosyl))-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27k). 
 
Spectrum  158 13C NMR (100 MHz, CD3OD) of N-(1-(4-O-(4-O-(β-D- 
glucopyranosyl)-β-D-glucopyranosyl)-β-D-glucopyranosyl))-1H- 
1,2,3-triazol-4-yl)methylcyclopamine (27k). 
 
Spectrum  159 1H NMR (400 MHz, CD3OD) of N-(1-(α-D-ribofuranosyl)- 
1H-1,2,3-triazol-4-yl)methylcyclopamine (27l). 
 
Spectrum  160 13C NMR (100 MHz, CD3OD) of N-(1-(α-D-ribofuranosyl)- 
1H-1,2,3-triazol-4-yl)methylcyclopamine (27l). 
 
Spectrum  161 1H NMR (400 MHz, CD3OD) of N-(1,6-(1,2,3-triazol-4-yl) 
methylcyclopmaine)-1,6-dideoxy-D-mannitol (27m). 
 
Spectrum  162 13C NMR (100 MHz, CD3OD) of N-(1,6-(1,2,3-triazol-4-yl) 
methylcyclopmaine)-1,6-dideoxy-D-mannitol (27m). 
 
Spectrum  163 1H NMR (400 MHz, CD3OD) of N-(1-(1,2,3-triazol-4-yl)  
methylcyclopmaine)-1-deoxy-D-mannitol (27n). 
 
Spectrum  164 13C NMR (100 MHz, CD3OD) of N-(1-(1,2,3-triazol-4-yl)  
methylcyclopmaine)-1-deoxy-D-mannitol (27n). 
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Spectrum  165 1H NMR (CD3COCD3, 400 MHz) of Compound (29) 
Spectrum  166 13C NMR (CD3COCD3, 100 MHz) of Compound (29) 
Spectrum  167 1H NMR (CD3OD, 400 MHz) of Compound (30) 
Spectrum  168 13C NMR (CD3OD, 100 MHz) of Compound (30) 
Spectrum  169 1H NMR (D2O, 400 MHz) of NEOF001 (31a)  
Spectrum  170 13C NMR (D2O, 100 MHz) of NEOF001 (31a) 
Spectrum  171 1H NMR (D2O, 400 MHz) of NEOF003 (31b) 
Spectrum  172 13C NMR (D2O, 100 MHz) of NEOF003 (31b) 
Spectrum  173 1H NMR (D2O, 400 MHz) of NEOF007 (31c) 
Spectrum  174 13C NMR (D2O, 100 MHz) of NEOF007 (31c) 
Spectrum  175 1H NMR (D2O, 400 MHz) of NEOF010 (31d) 
Spectrum  176 13C NMR (D2O, 100 MHz) of NEOF010 (31d) 
Spectrum  177 1H NMR (D2O, 400 MHz) of NEOF011 (31e) 
Spectrum  178 13C NMR (D2O, 100 MHz) of NEOF011 (31e) 
Spectrum  179 1H NMR (D2O, 400 MHz) of NEOF013 (31f) 
Spectrum  180 13C NMR (D2O, 100 MHz) of NEOF013 (31f) 
Spectrum  181 1H NMR (D2O, 400 MHz) of NEOF015 (31g) 
Spectrum  182 13C NMR (D2O, 100 MHz) of NEOF015 (31g) 
Spectrum  183 1H NMR (D2O, 400 MHz) of NEOF017 (31h) 
Spectrum  184 13C NMR (D2O, 100 MHz) of NEOF017 (31h) 
Spectrum  185 1H NMR (D2O, 400 MHz) of NEOF020 (31i) 
Spectrum  186 13C NMR (D2O, 100 MHz) of NEOF020 (31i) 
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Spectrum  187 1H NMR (D2O, 400 MHz) of NEOF002 (32a) 
Spectrum  188 13C NMR (D2O, 100 MHz) of NEOF002 (32a) 
Spectrum  189 1H NMR (D2O, 400 MHz) of NEOF004 (32b) 
Spectrum  190 13C NMR (D2O, 100 MHz) of NEOF004 (32b) 
Spectrum  191 1H NMR (D2O, 400 MHz) of NEOF005 (32c) 
Spectrum  192 13C NMR (D2O, 100 MHz) of NEOF005 (32c) 
Spectrum  193 1H NMR (D2O, 400 MHz) of NEOF006 (32d) 
Spectrum  194 13C NMR (D2O, 100 MHz) of NEOF006 (32d) 
Spectrum  195 1H NMR (D2O, 400 MHz) of NEOF008 (32e) 
Spectrum  196 13C NMR (D2O, 100 MHz) of NEOF008 (32e) 
Spectrum  197 1H NMR (D2O, 400 MHz) of NEOF009 (32f) 
Spectrum  198 13C NMR (D2O, 100 MHz) of NEOF009 (32f) 
Spectrum  199 1H NMR (D2O, 400 MHz) of NEOF012 (32g) 
Spectrum  200 13C NMR (D2O, 100 MHz) of NEOF012 (32g) 
Spectrum  201 1H NMR (D2O, 400 MHz) of NEOF016 (32h) 
Spectrum  202 13C NMR (D2O, 100 MHz) of NEOF016 (32h) 
Spectrum  203 1H NMR (D2O, 400 MHz) of NEOF018 (32i) 
Spectrum  204 13C NMR (D2O, 100 MHz) of NEOF018 (32i) 
Spectrum  205 1H NMR (D2O, 400 MHz) of NEOF019 (32j) 
Spectrum  206 13C NMR (D2O, 100 MHz) of NEOF019 (32j) 
Spectrum  207 1H NMR (D2O, 400 MHz) of NEOF022 (32k) 
Spectrum  208 13C NMR (D2O, 100 MHz) of NEOF022 (32k) 
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Spectrum  209 1H NMR (D2O, 400 MHz) of NEOF024 (32l) 
Spectrum  210 13C NMR (D2O, 100 MHz) of NEOF024 (32l) 
Spectrum  211 1H NMR (D2O, 400 MHz) of NEOF025 (32m) 
Spectrum  212 13C NMR (D2O, 100 MHz) of NEOF025 (32m) 
Spectrum  213 1H NMR (D2O, 400 MHz) of NEOF026 (32n) 
Spectrum  214 13C NMR (D2O, 100 MHz) of NEOF026 (32n) 
Spectrum  215 1H NMR (D2O, 400 MHz) of NEOF027 (32o) 
Spectrum  216 13C NMR (D2O, 100 MHz) of NEOF027 (32o) 
Spectrum  217 1H NMR (D2O, 400 MHz) of NEOF028 (32p) 
Spectrum  218 13C NMR (D2O, 100 MHz) of NEOF028 (32p) 
Spectrum  219 1H NMR (D2O, 400 MHz) of NEOF030 (32q) 
Spectrum  220 13C NMR (D2O, 100 MHz) of NEOF030 (32q) 
Spectrum  221 1H NMR (D2O, 300 MHz) of NEOF032 (32r) 
Spectrum  222 13C NMR (D2O, 75 MHz) of NEOF032 (32r) 
Spectrum  223 1H NMR (D2O, 300 MHz) of NEOF033 (32s) 
Spectrum  224 13C NMR (D2O, 75 MHz) of NEOF033 (32s) 
Spectrum  225 1H NMR (D2O, 300 MHz) of NEOF034 (32t) 
Spectrum  226 13C NMR (D2O, 75 MHz) of NEOF034 (32t) 
Spectrum  227 1H NMR (CDCl3, 400 MHz) of N-Propargyl-2-phenyl-4- 
quinolinecarboxamide (35) 
 
Spectrum  228 13C NMR (CDCl3, 100 MHz) of N-Propargyl-2-phenyl-4- 
quinolinecarboxamide (35) 
Spectrum  229 1H NMR (CDCl3, 400 MHz) of N-Propargylisonicotinamide (39) 
Spectrum  230 13C NMR (CDCl3, 100 MHz) of N-Propargylisonicotinamide (39) 
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Spectrum  231 1H NMR (CDCl3, 400 MHz) of N-Propargylcarbobenzyloxy-l- 
prolinamide (40) 
 
Spectrum  232 13C NMR (CDCl3, 100 MHz) of N-Propargylcarbobenzyloxy-l- 
prolinamide (40) 
Spectrum  233 1H NMR (D2O, 400 MHz) of NEOF029 (62)  
Spectrum  234 13C NMR (D2O, 100 MHz) of NEOF029 (62) 
Spectrum  235 1H NMR (CDCl3, 400 MHz) of 2-(N-(2,3,4,6-Tetra-O-acetyl-β- 
D-glucopyranosyl))-2H-2-benzazepine-1,5-dione (68a). 
 
Spectrum  236 13C NMR (CDCl3, 100 MHz) of 2-(N-(2,3,4,6-Tetra-O-acetyl-β- 
D-glucopyranosyl))-2H-2-benzazepine-1,5-dione (68a). 
 
Spectrum  237 DEPT of 2-(N-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl))          
-2H-2-benzazepine-1,5-dione (68a). 
 
Spectrum  238 1H-1H COSY of 2-(N-(2,3,4,6-Tetra-O-acetyl-β-D-    
glucopyranosyl))-2H-2-benzazepine-1,5-dione (68a). 
 
Spectrum  239 HSQC of 2-(N-(2,3,4,6-Tetra-O-acetyl-β-D-         
glucopyranosyl))-2H-2-benzazepine-1,5-dione (68a). 
 
Spectrum  240 1H NMR (CDCl3, 400 MHz) of 1-(N-(2,3,4,6-Tetra-O-acetyl-β-D- 
glucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66a). 
 
Spectrum  241 13C NMR (CDCl3, 100 MHz) of 1-(N-(2,3,4,6-Tetra-O-acetyl-β-D- 
glucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66a). 
 
Spectrum  242 FTIR of 1-(N-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl))-    
1H-naphtho[2,3-d]triazole-4,9-dione (66a). 
 
Spectrum  243 1H NMR (CDCl3, 400 MHz) of 2-(N-(2,3,4,6-Tetra-O-acetyl-β-D- 
glucopyranosyl))aminomethylene-1,3-indanedione (69a). 
 
Spectrum  244 13C NMR (CDCl3, 75 MHz) of 2-(N-(2,3,4,6-Tetra-O-acetyl-β-D- 
glucopyranosyl))aminomethylene-1,3-indanedione (69a). 
 
Spectrum  245 1H-1H COSY of 2-(N-(2,3,4,6-Tetra-O-acetyl-β-D- 
glucopyranosyl))aminomethylene-1,3-indanedione (69a). 
 
Spectrum  246 HSQC of 2-(N-(2,3,4,6-Tetra-O-acetyl-β-D-      
glucopyranosyl))aminomethylene-1,3-indanedione (69a). 
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Spectrum  247 1H NMR (CDCl3, 400 MHz) of 2-(N-(2,3,4,6-Tetra-O-acetyl-β-D- 
galactopyranosyl))-2H-2-benzazepine-1,5-dione (68b). 
 
Spectrum  248 13C NMR (CDCl3, 100 MHz) of 2-(N-(2,3,4,6-Tetra-O-acetyl-β-D- 
galactopyranosyl))-2H-2-benzazepine-1,5-dione (68b). 
 
Spectrum  249 1H NMR (CDCl3, 400 MHz) of 1-(N-(2,3,4,6-Tetra-O-acetyl-β-D- 
galactopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66b). 
 
Spectrum  250 13C NMR (CDCl3, 100 MHz) of 1-(N-(2,3,4,6-Tetra-O-acetyl-β-D- 
galactopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66b). 
 
Spectrum  251 1H NMR (CDCl3, 300 MHz) of 2-(N-(2,3,4,6-Tetra-O-acetyl-β-D- 
galactopyranosyl))aminomethylene-1,3-indanedione (69b). 
 
Spectrum  252 13C NMR (CDCl3, 75 MHz) of 2-(N-(2,3,4,6-Tetra-O-acetyl-β-D- 
galactopyranosyl))aminomethylene-1,3-indanedione (69b). 
 
Spectrum  253 1H NMR (CDCl3, 400 MHz) of 1-(N-(2,3,4,6-Tetra-O-acetyl-α-D- 
mannopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66c). 
 
Spectrum  254 13C NMR (CDCl3, 100 MHz) of 1-(N-(2,3,4,6-Tetra-O-acetyl-α-D- 
mannopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66c). 
 
Spectrum  255 1H NMR (CDCl3, 400 MHz) of 1-(N-(4-O-(2,3,4,6-Tetra-O-acetyl- 
β-D-galactopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl))- 
1H-naphtho[2,3-d]triazole-4,9-dione (66d). 
 
Spectrum  256 13C NMR (CDCl3, 100 MHz) of 1-(N-(4-O-(2,3,4,6-Tetra-O-acetyl- 
β-D-galactopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl))- 
1H-naphtho[2,3-d]triazole-4,9-dione (66d). 
 
Spectrum  257 1H NMR (CDCl3, 400 MHz) of 1-(N-(2,3,4-Tri-O-acetyl-α-D- 
fucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66e). 
 
Spectrum  258 13C NMR (CDCl3, 100 MHz) of 1-(N-(2,3,4-Tri-O-acetyl-α-D- 
fucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66e). 
 
Spectrum  259 1H NMR (CDCl3, 400 MHz) of 2-(N-(2,3,4-Tri-O-acetyl-α-D- 
rhamnopyranosyl))-2H-2-benzazepine-1,5-dione (68f). 
 
Spectrum  260 13C NMR (CDCl3, 100 MHz) of 2-(N-(2,3,4-Tri-O-acetyl-α-D- 
rhamnopyranosyl))-2H-2-benzazepine-1,5-dione (68f). 
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Spectrum  261 1H NMR (CDCl3, 400 MHz) of 1-(N-(2,3,4-Tri-O-acetyl-α-D- 
rhamnopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66f). 
 
Spectrum  262 13C NMR (CDCl3, 100 MHz) of 1-(N-(2,3,4-Tri-O-acetyl-α-D- 
rhamnopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66f). 
 
Spectrum  263 1H NMR (CDCl3, 300 MHz) of 2-(N-(2,3,4-Tri-O-acetyl-α-D- 
rhamnopyranosyl))aminomethylene-1,3-indanedione (69f). 
 
Spectrum  264 13C NMR (CDCl3, 100 MHz) of 2-(N-(2,3,4-Tri-O-acetyl-α-D- 
rhamnopyranosyl))aminomethylene-1,3-indanedione (69f). 
 
Spectrum  265 1H NMR (CDCl3, 400 MHz) of 2-(N-(2,3,4-Tri-O-acetyl-β-D- 
xylopyranosyl))-2H-2-benzazepine-1,5-dione (68g). 
 
Spectrum  266 13C NMR (CDCl3, 100 MHz) of 2-(N-(2,3,4-Tri-O-acetyl-β-D- 
xylopyranosyl))-2H-2-benzazepine-1,5-dione (68g). 
 
Spectrum  267 1H NMR (CDCl3, 400 MHz) of 1-(N-(2,3,4-Tri-O-acetyl-β-D- 
xylopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66g). 
 
Spectrum  268 13C NMR (CDCl3, 100 MHz) of 1-(N-(2,3,4-Tri-O-acetyl-β-D- 
xylopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66g). 
 
Spectrum  269 1H NMR (CDCl3, 400 MHz) of 2-(N-(2,3,4-Tri-O-acetyl-D- 
xylopyranosyl))aminomethylene-1,3-indanedione (69g). 
 
Spectrum  270 13C NMR (CDCl3, 100 MHz) of 2-(N-(2,3,4-Tri-O-acetyl-D- 
xylopyranosyl))aminomethylene-1,3-indanedione (69g). 
 
Spectrum  271 1H NMR (CDCl3, 400 MHz) of 1-(N-(2-Acetamido-3,4,6-tri-O- 
acetyl-2-deoxy-β-D-glucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-
dione (66h). 
 
Spectrum  272 13C NMR (CDCl3, 100 MHz) of 1-(N-(2-Acetamido-3,4,6-tri-O- 
acetyl-2-deoxy-β-D-glucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-
dione (66h). 
 
Spectrum  273 1H NMR (CDCl3, 400 MHz) of 2-(N-(4-O-(2,3,4,6-Tetra-O- 
acetyl-β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl))-
2H-2-benzazepine-1,5-dione (68i). 
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Spectrum  274 13C NMR (CDCl3, 100 MHz) of 2-(N-(4-O-(2,3,4,6-Tetra-O- 
acetyl-β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl))-
2H-2-benzazepine-1,5-dione (68i). 
 
Spectrum  275 1H NMR (CDCl3, 400 MHz) of 1-(N-(4-O-(2,3,4,6-Tetra-O-acetyl- 
β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl))- 
1H-naphtho[2,3-d]triazole-4,9-dione (66i). 
 
Spectrum  276 13C NMR (CDCl3, 100 MHz) of 1-(N-(4-O-(2,3,4,6-Tetra-O-acetyl- 
β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl))- 
1H-naphtho[2,3-d]triazole-4,9-dione (66i). 
 
Spectrum  277 1H NMR (CDCl3, 400 MHz) of 2-(N-(4-O-(2,3,4,6-Tetra-O-acetyl- 
β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl)) 
aminomethylene-1,3-indanedione (69i). 
 
Spectrum  278 13C NMR (CDCl3, 100 MHz) of 2-(N-(4-O-(2,3,4,6-Tetra-O-acetyl- 
β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl)) 
aminomethylene-1,3-indanedione (69i). 
 
Spectrum  279 1H NMR (CDCl3, 300 MHz) of 1-(N-(4-O-(4-O-(2,3,4,6-Tetra-O- 
acetyl-β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-
2,3,6-tri-O-acetyl-β-D-glucopyranosyl))-1H-naphtho[2,3-d] 
triazole-4,9-dione (66j). 
 
Spectrum  280 13C NMR (CDCl3, 75 MHz) of 1-(N-(4-O-(4-O-(2,3,4,6-Tetra-O- 
acetyl-β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-
2,3,6-tri-O-acetyl-β-D-glucopyranosyl))-1H-naphtho[2,3-d] 
triazole-4,9-dione (66j). 
 
Spectrum  281 1H NMR (CDCl3, 400 MHz) of 2-(N-(2,3,5-Tri-O- 
acetyl-β-D-ribofuranosyl))-2H-2-benzazepine-1,5-dione (68k).  
 
Spectrum  282 13C NMR (CDCl3, 100 MHz) of 2-(N-(2,3,5-Tri-O- 
acetyl-β-D-ribofuranosyl))-2H-2-benzazepine-1,5-dione (68k).  
 
Spectrum  283 1H NMR (CDCl3, 400 MHz) of 1-(N-(2,3,5-Tri-O-acetyl- 
β-D-ribofuranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66k). 
 
Spectrum  284 13C NMR (CDCl3, 100 MHz) of 1-(N-(2,3,5-Tri-O- acetyl- 
β-D-ribofuranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66k). 
 
Spectrum  285 1H NMR (CDCl3, 400 MHz) of 2-(N-(2,3,5-Tri-O-acetyl-β- 
D-ribofuranosyl))aminomethylene-1,3-indanedione (69k). 
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Spectrum  286 13C NMR (CDCl3, 100 MHz) of 2-(N-(2,3,5-Tri-O-acetyl-β- 
D-ribofuranosyl))aminomethylene-1,3-indanedione (69k). 
 
Spectrum  287 1H NMR (CDCl3, 400 MHz) of 2,3,4,5-Tetra-O-acetyl-1,6- bis 
(1H-naphtho[2,3-d]triazole-4,9-dione)-1,6-dideoxy-D-mannitol (66l). 
 
Spectrum  288 13C NMR (CDCl3, 100 MHz) of 2,3,4,5-Tetra-O-acetyl-1,6- bis 
(1H-naphtho[2,3-d]triazole-4,9-dione)-1,6-dideoxy-D-mannitol (66l). 
 
Spectrum  289 1H NMR (CDCl3, 400 MHz) of 2,3,4,5,6-Penta-O-acetyl-1- 
(2H-2-benzazepine-1,5-dione)-1-dideoxy-D-mannitol (68m). 
 
Spectrum  290 13C NMR (CDCl3, 100 MHz) of 2,3,4,5,6-Penta-O-acetyl-1- 
(2H-2-benzazepine-1,5-dione)-1-dideoxy-D-mannitol (68m). 
 
Spectrum  291 1H NMR (CDCl3, 400 MHz) of 2,3,4,5,6-Penta-O-acetyl-1- 
(1H-naphtho[2,3-d]triazole-4,9-dione)-1-dideoxy-D-mannitol (66m). 
 
Spectrum  292 13C NMR (CDCl3, 100 MHz) of 2,3,4,5,6-Penta-O-acetyl-1- 
(1H-naphtho[2,3-d]triazole-4,9-dione)-1-dideoxy-D-mannitol (66m). 
 
Spectrum  293 2,3,4,5,6-Penta-O-acetyl-1-(aminomethylene-1,3-indanedione)-1- 
dideoxy-D-mannitol (69m). 
 
Spectrum  294 2,3,4,5,6-Penta-O-acetyl-1-(aminomethylene-1,3-indanedione)-1- 
dideoxy-D-mannitol (69m). 
 
Spectrum  295 1H NMR (CDCl3, 400 MHz) of 1-(4-(N-tert-Butoxycarbonyl 
piperidinyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66n). 
 
Spectrum  296 13C NMR (CDCl3, 100 MHz) of 1-(4-(N-tert-Butoxycarbonyl 
piperidinyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66n). 
 
Spectrum  297 1H NMR (CDCl3, 400 MHz) of 2-(N-(4-(N-tert-Butoxycarbonyl 
piperidinyl)))aminomethylene-1,3-indanedione (69n). 
 
Spectrum  298 13C NMR (CDCl3, 100 MHz) of 2-(N-(4-(N-tert-Butoxycarbonyl 
piperidinyl)))aminomethylene-1,3-indanedione (69n). 
 
Spectrum  299 1-Adamantyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (66o). 
 
Spectrum  300 1-Adamantyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (66o). 
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Spectrum  301 1H NMR (CDCl3, 400 MHz) of 1-Benzyl-1H-naphtho 
[2,3-d]triazole-4,9-dione (66p). 
 
Spectrum  302 13C NMR (CDCl3, 100 MHz) of 1-Benzyl-1H-naphtho 
[2,3-d]triazole-4,9-dione (66p). 
 
Spectrum  303 1H NMR (CDCl3, 400 MHz) of 1-(2-Picolyl)-1H-naphtho 
[2,3-d]triazole-4,9-dione (66q). 
 
Spectrum  304 13C NMR (CDCl3, 100 MHz) of 1-(2-Picolyl)-1H-naphtho 
[2,3-d]triazole-4,9-dione (66q). 
 
Spectrum  305 1H NMR (CDCl3, 400 MHz) of 4-Azido-N-tert- 
butoxycarbonylpiperidine 70 
 
Spectrum  306 13C NMR (CDCl3, 100 MHz) of 4-Azido-N-tert- 
butoxycarbonylpiperidine 70 
 
Spectrum  307 1H NMR (DMSO-d6, 400 MHz) of 1-(N-(β-D-Glucopyranosyl))-1H- 
naphtho[2,3-d]triazole-4,9-dione (74a). 
 
Spectrum  308 13C NMR (DMSO-d6, 100 MHz) of 1-(N-(β-D-Glucopyranosyl))-1H- 
naphtho[2,3-d]triazole-4,9-dione (74a). 
 
Spectrum  309 1H NMR (DMSO-d6, 400 MHz) of 1-(N-(β-D-Galactopyranosyl))- 
1H-naphtho[2,3-d]triazole-4,9-dione (74b) 
 
Spectrum  310 13C NMR (DMSO-d6, 100 MHz) of 1-(N-(β-D-Galactopyranosyl))- 
1H-naphtho[2,3-d]triazole-4,9-dione (74b) 
 
Spectrum  311 1H NMR (DMSO-d6, 400 MHz) of 1-(N-(α-D-Mannopyranosyl))- 
1H-naphtho[2,3-d]triazole-4,9-dione (74c) 
 
Spectrum  312 13C NMR (DMSO-d6, 100 MHz) of 1-(N-(α-D-Mannopyranosyl))- 
1H-naphtho[2,3-d]triazole-4,9-dione (74c) 
 
Spectrum  313 1H NMR (DMSO-d6, 400 MHz) of 1-(N-(4-O-(β-D- 
Galactopyranosyl) β-D-glucopyranosyl))-1H-naphtho 
[2,3-d]triazole-4,9-dione (74d). 
 
Spectrum  314 13C NMR (DMSO-d6, 100 MHz) of 1-(N-(4-O-(β-D- 
Galactopyranosyl)- β-D-glucopyranosyl))-1H-naphtho 
[2,3-d]triazole-4,9-dione (74d). 
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Spectrum  315 1H NMR (DMSO-d6, 400 MHz) of 1-(N-(α-D-Fucopyranosyl))-  
1H-naphtho[2,3-d]triazole-4,9-dione (74e). 
 
Spectrum  316 13C NMR (DMSO-d6, 100 MHz) of 1-(N-(α-D-Fucopyranosyl))- 
1H-naphtho[2,3-d]triazole-4,9-dione (74e). 
 
Spectrum  317 1H NMR (DMSO-d6, 400 MHz) of 1-(N-(α-D-Rhamnopyranosyl))- 
1H-naphtho[2,3-d]triazole-4,9-dione (74f). 
 
Spectrum  318 13C NMR (DMSO-d6, 100 MHz) of 1-(N-(α-D-Rhamnopyranosyl))- 
1H-naphtho[2,3-d]triazole-4,9-dione (74f). 
 
Spectrum  319 1H NMR (DMSO-d6, 400 MHz) of 1-(N-(β-D-Xylopyranosyl))-  
1H-naphtho[2,3-d]triazole-4,9-dione (74g). 
 
Spectrum  320 13C NMR (DMSO-d6, 100 MHz) of 1-(N-(β-D-Xylopyranosyl))- 
1H-naphtho[2,3-d]triazole-4,9-dione (74g). 
 
Spectrum  321 1H NMR (DMSO-d6, 400 MHz) of 1-(N-(2-Acetamido-β-D- 
glucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (74h). 
 
Spectrum  322 13C NMR (DMSO-d6, 100 MHz) of 1-(N-(2-Acetamido-β-D- 
glucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (74h). 
 
Spectrum  323 1H NMR (DMSO-d6, 400 MHz) of 1-(N-(4-O-(β-D-Glucopyranosyl) 
-β-D-glucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (74i). 
 
Spectrum  324 13C NMR (DMSO-d6, 100 MHz) of 1-(N-(4-O-(β-D-Glucopyranosyl) 
-β-D-glucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (74i). 
 
Spectrum  325 1H NMR (DMSO-d6, 400 MHz) of 1-(N-(4-O-(4-O-(β-D- 
Glucopyranosyl)-β-D-glucopyranosyl)-β-D-glucopyranosyl))-1H- 
naphtho[2,3-d]triazole-4,9-dione (74j). 
 
Spectrum  326 13C NMR (DMSO-d6, 100 MHz) of 1-(N-(4-O-(4-O-(β-D- 
Glucopyranosyl)-β-D-glucopyranosyl)-β-D-glucopyranosyl))-1H- 
naphtho[2,3-d]triazole-4,9-dione (74j). 
 
Spectrum  327 1H NMR (DMSO-d6, 400 MHz) of 1-(N-(β-D-Ribofuranosyl))-  
1H-naphtho[2,3-d]triazole-4,9-dione (74k). 
 
Spectrum  328 13C NMR (DMSO-d6, 100 MHz) of 1-(N-(β-D-Ribofuranosyl))-  
1H-naphtho[2,3-d]triazole-4,9-dione (74k). 
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Spectrum  329 1H NMR (DMSO-d6, 400 MHz) of 1,6-Bis(1H-naphtho[2,3-d] 
triazole-4,9-dione)-1,6-dideoxy-d-mannitol (74l). 
 
Spectrum  330 13C NMR (DMSO-d6, 100 MHz) of 1,6-Bis(1H-naphtho[2,3-d] 
triazole-4,9-dione)-1,6-dideoxy-d-mannitol (74l). 
 
Spectrum  331 1H NMR (DMSO-d6, 400 MHz) of 1-(1H-Naphtho[2,3-d]  
triazole-4,9-dione)-1-dideoxy-d-mannitol (74m). 
 
Spectrum  332 13C NMR (DMSO-d6, 100 MHz) of 1-(1H-Naphtho[2,3-d]  
triazole-4,9-dione)-1-dideoxy-d-mannitol (74m). 
 
Spectrum  333 1H NMR (D2O, 300 MHz) of 1-(4-Piperidinyl)-1H-naphtho[2,3-d] 
triazole-4,9-dione (74n). 
 
Spectrum  334 13C NMR (D2O, 100 MHz) of 1-(4-Piperidinyl)-1H-naphtho[2,3-d] 
triazole-4,9-dione (74n). 
 
Spectrum  335 1H NMR (CD3OD, 400 MHz) of 2-(N-(β-D-Glucopyranosyl))     
aminomethylene-1,3-indanedione (75a). 
 
Spectrum  336 13C NMR (CD3OD, 100 MHz) of 2-(N-(β-D-Glucopyranosyl))     
aminomethylene-1,3-indanedione (75a). 
 
Spectrum  337 1H NMR (CD3OD, 400 MHz) of 2-(N-(β-D-Galactopyranosyl))    
aminomethylene-1,3-indanedione (75b). 
 
Spectrum  338 13C NMR (CD3OD, 100 MHz) of 2-(N-(β-D-Galactopyranosyl))   
aminomethylene-1,3-indanedione (75b). 
 
Spectrum  339 1H NMR (DMSO-d6, 400 MHz) of 2-(N-(α-D-Rhamnopyranosyl))  
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Spectrum  340 13C NMR (DMSO-d6, 100 MHz) of 2-(N-(α-D-Rhamnopyranosyl))  
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Spectrum  341 1H NMR (CD3OD, 400 MHz) of 2-(N-(α-D-Xylopyranosyl))      
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Spectrum  342 13C NMR (CD3OD, 100 MHz) of 2-(N-(α-D-Xylopyranosyl))      
aminomethylene-1,3-indanedione (epi-75g). 
 
Spectrum  343 1H NMR (CD3OD, 400 MHz) of 2-(N-(β-D-Xylopyranosyl))      
aminomethylene-1,3-indanedione (75g). 
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Spectrum  344 13C NMR (CD3OD, 100 MHz) of 2-(N-(β-D-Xylopyranosyl))      
aminomethylene-1,3-indanedione (75g). 
 
Spectrum  345 1H NMR (DMSO-d6, 400 MHz) of 2-(N-(β-D-Ribofuranosyl))     
aminomethylene-1,3-indanedione (75k) 
 
Spectrum  346 13C NMR (DMSO-d6, 100 MHz) of 2-(N-(β-D-Ribofuranosyl))    
aminomethylene-1,3-indanedione (75k) 
 
Spectrum  347 1H NMR (DMSO-d6, 400 MHz) of 1-(aminomethylene-1,3-     
indanedione)-1-dideoxy-D-mannitol (75m). 
   
Spectrum  348 13C NMR (DMSO-d6, 100 MHz) of 1-(aminomethylene-1,3-    
indanedione)-1-dideoxy-D-mannitol (75m). 
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Spectrum  350 13C NMR (D2O, 100 MHz) of 2-(N-(4-Piperidinyl)) 
aminomethylene-1,3-indanedione (75n).    
 
Spectrum  351 1H NMR (D2O, 300 MHz) of 2-hydroxyl-aminomethylene- 
1,3-indanedione (76). 
 
Spectrum  352 13C NMR (D2O, 100 MHz) of 2-hydroxyl-aminomethylene- 
1,3-indanedione (76). 
Spectrum  353 Dept of 2-hydroxyl-aminomethylene-1,3-indanedione (76). 
Spectrum  354 1H NMR (CDCl3, 300 MHz) of 1-n-Butyl-1H-naphtho[2,3-d] 
[1,2,3]triazole-4,9-dione (77b). 
 
Spectrum  355 13C NMR (CDCl3, 100 MHz) of 1-n-Butyl-1H-naphtho[2,3-d] 
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Spectrum  357 13C NMR (CDCl3, 100 MHz) of 2-n-Butyl-2H-naphtho[2,3-d] 
[1,2,3]triazole-4,9-dione (79b). 
 
Spectrum  358 1H NMR (CDCl3, 300 MHz) of 1-n-Pentyl-1H-naphtho[2,3-d] 
[1,2,3]triazole-4,9-dione (77c). 
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Spectrum  363 13C NMR (CDCl3, 100 MHz) of 1-n-Octyl-1H-naphtho[2,3-d] 
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Spectrum  364 1H NMR (CDCl3, 400 MHz) of 2-n-Octyl-2H-naphtho[2,3-d] 
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Spectrum  365 13C NMR (CDCl3, 100 MHz) of 2-n-Octyl-2H-naphtho[2,3-d] 
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Spectrum  367 13C NMR (CDCl3, 100 MHz) of 1-n-Dodecyl-1H-naphtho[2,3-d] 
[1,2,3]triazole-4,9-dione (77e). 
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[2,3-d][1,2,3]triazole-4,9-dione (77g). 
 
Spectrum  375 13C NMR (CDCl3, 100 MHz) of 1-(6-Hydroxyhexyl)-1H-naphtho    
[2,3-d][1,2,3]triazole-4,9-dione (77g). 
 
Spectrum  376 1H NMR (CDCl3, 300 MHz) of 2-(6-Hydroxyhexyl)-2H-     
naphtho[2,3-d][1,2,3]triazole-4,9-dione (79g). 
 
Spectrum  377 13C NMR (CDCl3, 100 MHz) of 2-(6-Hydroxyhexyl)-2H-    
naphtho[2,3-d][1,2,3]triazole-4,9-dione (79g). 
 
Spectrum  378 1H NMR (CDCl3, 400 MHz) of 2-(4-(N-tert-butoxycarbonyl 
piperidinyl))-2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (79h). 
 
Spectrum  379 13C NMR (CDCl3, 100 MHz) 2-(4-(N-tert-butoxycarbonyl 
piperidinyl))-2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (79h). 
 
Spectrum  380 1H NMR (CDCl3, 300 MHz) of 1-Ethyl-1H-naphtho[2,3-d] 
[1,2,3]triazole-4,9-dione (77i). 
 
Spectrum  381 13C NMR (CDCl3, 100 MHz) of 1-Ethyl-1H-naphtho[2,3-d] 
[1,2,3]triazole-4,9-dione (77i). 
 
Spectrum  382 1H NMR (CDCl3, 300 MHz) of 2-Ethyl-2H-naphtho[2,3-d] 
[1,2,3]triazole-4,9-dione (79i). 
 
Spectrum  383 13C NMR (CDCl3, 100 MHz) of 2-Ethyl-2H-naphtho[2,3-d] 
[1,2,3]triazole-4,9-dione (79i). 
 
Spectrum  384 1H NMR (CDCl3, 400 MHz) of 1-Methyl-1H-naphtho[2,3-d] 
[1,2,3]triazole-4,9-dione (77j). 
 
Spectrum  385 13C NMR (CDCl3, 75 MHz) of 1-Methyl-1H-naphtho[2,3-d] 
[1,2,3]triazole-4,9-dione (77j). 
Spectrum  386 DEPT of 1-Methyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (77j). 
Spectrum  387 1H NMR (CDCl3, 300 MHz) of 1-(2-Hydroxypropyl)-    
1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (77l). 
 
Spectrum  388 13C NMR (CDCl3, 100 MHz) of 1-(2-Hydroxypropyl)-   
1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (77l). 
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Spectrum  390 13C NMR (CDCl3, 100 MHz) of 2-(2-Hydroxypropyl)-2H-   
naphtho[2,3-d][1,2,3]triazole-4,9-dione (79l). 
 
Spectrum  391 DEPT of 2-(2-Hydroxypropyl)-2H-naphtho[2,3-d][1,2,3] 
triazole-4,9-dione (79l). 
Spectrum  392 1H NMR (CDCl3, 300 MHz) of 2-amino-1,4-naphthoquinone (82). 
Spectrum  393 13C NMR (CDCl3, 100 MHz) of 2-amino-1,4-naphthoquinone (82). 
Spectrum  394 1H NMR (CDCl3, 300 MHz) of 1,4-Bis((2-hydroxy-3-phenoxy) 
propoxy)naphthylene (94). 
 
Spectrum  395 13C NMR (CDCl3, 75 MHz) of 1,4-Bis((2-hydroxy-3-phenoxy) 
propoxy)naphthylene (94). 
 
Spectrum  396 1H NMR (CDCl3, 300 MHz) of 1,4-Bis((2-hydroxy-2-phenyl) 
ethoxy)naphthylene (95). 
 
Spectrum  397 13C NMR (CDCl3, 75 MHz) of 1,4-Bis((2-hydroxy-2-phenyl) 
ethoxy)naphthylene (95). 
 
Spectrum  398 1H NMR (CD3OD, 300 MHz) of 2-(4-piperidinyl)-2H-naphtho[2,3-d] 
[1,2,3]triazole-4,9-dione (96). 
 
Spectrum  399 13C (CD3OD, 100 MHz) of 2-(4-piperidinyl)-2H-naphtho[2,3-d] 
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Spectrum  400 1H NMR (CDCl3, 400 MHz) of 6-O-Hexylaminocarbonyl-1,3,2',6'- 
tetraazido-3',4'-dideoxy-3'-enoneamine (98). 
 
Spectrum  401 13C NMR (CDCl3, 100 MHz) of 6-O-Hexylaminocarbonyl-1,3,2',6'- 
tetraazido-3',4'-dideoxy-3'-enoneamine (98). 
 
Spectrum  402 1H-1H COSY of 6-O-Hexylaminocarbonyl-1,3,2',6'-tetraazido- 
3',4'-dideoxy-3'-enoneamine (98). 
 
Spectrum  403 1H NMR (CDCl3, 400 MHz) of 6-O-Hexylaminocarbonyl-1,3,4',6'- 
tetraazido-2',3',4'-trideoxy-2'-enoneamine (99). 
 
Spectrum  404 13C NMR (CDCl3, 100 MHz) of 6-O-Hexylaminocarbonyl-1,3,4',6'- 
tetraazido-2',3',4'-trideoxy-2'-enoneamine (99). 
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Spectrum  405 1H-1H COSY of 6-O-Hexylaminocarbonyl-1,3,4',6'-tetraazido- 
2',3',4'-trideoxy-2'-enoneamine (99). 
 
Spectrum  406 1H NMR (CDCl3, 400 MHz) of 5,6-Di-O-hexylaminocarbonyl- 
1,3,4',6'-tetraazido-2',3',4'-trideoxy-2'-enoneamine (100). 
 
Spectrum  407 13C NMR (CDCl3, 100 MHz) of 5,6-Di-O-hexylaminocarbonyl- 
1,3,4',6'-tetraazido-2',3',4'-trideoxy-2'-enoneamine (100). 
 
Spectrum  408 1H-1H COSY of 5,6-Di-O-hexylaminocarbonyl-1,3,4',6'- 
tetraazido-2',3',4'-trideoxy-2'-enoneamine (100). 
 
Spectrum  409 1H NMR (CDCl3, 400 MHz) of 1,3,4',6'-Tetraazido-2',3',4'- 
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Spectrum  410 13C NMR (CDCl3, 100 MHz) of 1,3,4',6'-Tetraazido-2',3',4'-trideoxy- 
2'-enoneamine (101). 
 
Spectrum  411 1H-1H COSY of 1,3,4',6'-Tetraazido-2',3',4'-trideoxy-2'-enoneamine 
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carbonyl-1,3,4',6'-tetraamino-2',3',4'-trideoxyneamine (NRR102). 
 
Spectrum  442 13C NMR (D2O, 100 MHz) of 4'-Amino-5,6-di-O- hexylamino 
carbonyl-1,3,4',6'-tetraamino-2',3',4'-trideoxyneamine (NRR102). 
 
Spectrum  443 1H NMR (D2O, 300 MHz) of 6-O-(α-D-galactopyranosyl)        
-2',3',4'-trideoxy-4'-aminoneamine (NRT014). 
 
Spectrum  444 13C NMR (D2O, 100 MHz) of 6-O-( α-D-galactopyranosyl)-       
2',3',4'-trideoxy-4'-aminoneamine (NRT014). 
 
Spectrum  445 1H NMR (D2O, 300 MHz) of 6-O-(α-D-galactopyranosyl)-3',4'- 
dideoxyneamine (RT014). 
 
 
 
xliii 
 
Spectrum  446 13C NMR (D2O, 100 MHz) of 6-O-( α-D-galactopyranosyl)-3',4'- 
dideoxyneamine (RT014). 
 
Spectrum  447 1H NMR (D2O, 300 MHz) of 6-O-(3-amino-3,6-dideoxy-α-D- 
glucopyranosyl)-2',3',4'-trideoxy-4'-aminoneamine (NRT040). 
 
Spectrum  448 13C NMR (D2O, 100 MHz) of 6-O-(3-amino-3,6-dideoxy-α-D- 
glucopyranosyl)-2',3',4'-trideoxy-4'-aminoneamine (NRT040). 
 
Spectrum  449 1H NMR (D2O, 400 MHz) of 6-O-(3-amino-3-deoxy- α-D- 
xylopyranosyl)-3',4'-dideoxyneamine (RT040). 
 
Spectrum  450 13C NMR (D2O, 100 MHz) of 6-O-(3-amino-3-deoxy-α-D- 
xylopyranosyl)-3',4'-dideoxyneamine (RT040). 
 
Spectrum  451 1H NMR (D2O, 300 MHz) of 6-O-(4-amino-4,6-dideoxy-β-D- 
glucopyranosyl)-2',3',4'-trideoxy-4'-aminoneamine (NRR501). 
 
Spectrum  452 13C NMR (D2O, 75 MHz) of 6-O-(4-amino-4,6-dideoxy-β-D- 
glucopyranosyl)-2',3',4'-trideoxy-4'-aminoneamine (NRR501). 
 
Spectrum  453 1H NMR (CDCl3, 300 MHz) of 3',4'-Di-O-benzyl-6-O- 
hexylaminocarbonyl-1,3,4',6'-tetraazidoneamine (116). 
 
Spectrum  454 13C NMR (CDCl3, 100 MHz) of 3',4'-Di-O-benzyl-6-O- 
hexylaminocarbonyl-1,3,4',6'-tetraazidoneamine (116). 
 
Spectrum  455 1H NMR (CDCl3, 300 MHz) of 3',4'-Di-O-benzyl-5,6-Di-O- 
hexylaminocarbonyl-1,3,4',6'-tetraazidoneamine (117). 
 
Spectrum  456 13C NMR (CDCl3, 100 MHz) of 3',4'-Di-O-benzyl-5,6-Di-O- 
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Boc: tert-butyloxycarbonyl 
Boc-ON: 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile  
Bz: benzoyl 
COSY: correlation spectroscopy 
Cbz: carbobenzyloxy 
DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC: N, N’-dicyclohexylcarbodiimide 
DIPEA: N, N’-diisopropylethylamine 
DMAP: 4-(dimethylamino)pyridine 
DMF: dimethylformamide 
DMSO: dimethyl sulfoxide 
EDC: 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride 
ESI: Electrospray ionisation 
FAB: Fast atom bombardment 
HoBt: N-hydroxybenzotriazole 
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MALDI: Matrix-assisted laser desorption/ionization 
MsCl: methanesulfonyl chloride 
NBS: N-bromosuccinimide 
NIS: N-iodosuccinimide 
Py: pyridine 
TBAI: tetrabutylammonium iodide 
TBAHS: tetrabutyl ammonium hydrogen sulfate 
TEA: triethylamine 
Tf2O: trifluoromethanesulfonyl acid anhydride 
TfOH: trifluoromethanesulfonic acid 
TFA: trifluoroacetic acid 
THF: tetrahydrofuran 
TMSOTf: trimethylsilyl trifluoromethanesulfonate 
Trityl: triphenylmethyl 
Ts: tosyl 
TsOH: p-toluenesulfonic acid 
TsCl: toluenesulfonyl chloride 
TIBSCl: triisopropylbenzene sulfonyl chloride 
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CHAPTER I 
GENERAL INTRODUCTION 
 
   The development of both anticancer and antibacterial agents has been two of the 
most important tasks for the pharmaceutical sciences. This is because cancer is the 
second most common cause of death of United States and many serious diseases are 
caused by human pathogenic bacteria. For example, tuberculosis, caused by the 
bacterium, Mycobacterium tuberculosis, kills millions of people every year in the 
world.1 Both the seriousness and high arises of cancer and bacterial infectious diseases 
have promoted more efforts and investments on the developments of anticancer and 
antibacterial agents recently. Extraction of active components from natural products 
and synthesis of therapeutic agents are the two major sources of the drug candidates for 
anticancer and antibacterial. Many therapeutic agents nowadays are isolated from 
natural product resources without undergoing synthetic route such as streptomycin, 
kanamycin, taxol, cyclopamine, and streptonigrin. However, chemical synthesis of new 
antibacterial and anticancer agents is still one the most effective methods to prepared 
drug candidates to treat both cancer and bacterial infectious diseases. On one hand, 
novel therapeutic agents can be synthesized based on the information from active 
components of natural product. On the other hand, the derivatives of active components 
of natural product can be synthesized to improve the activity of the original lead. Drug 
candidates can also be obtained by total synthesis and biosynthetic methods. The 
development of various methods to prepare drug candidates all these years has 
generated many novel antibacterial and anticancer agents to confront the battle against 
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cancer and bacterial infectious diseases. 
   Aminoglycosides and linezolid are two of the most popular applied antibacterial 
agents in clinic area. Cyclopamine and many naphthoquinone derivatives such as 
streptonigrin, daunorubicin, and lapachone have been known as effective anticancer 
agents. Organic azides have been widely applied as reactive agents for the synthesis of 
drug candidates. In this dissertation both the synthesis of novel aminoglycosides and 
oxazolidinone antibiotics and the synthesis of cyclopamine and naphthoquinone 
derivatives via azide chemistry will be described in detail. Series of reactions related to 
azides such as Huisgen reaction, “click chemistry,” cycloaddition of azides, Staudinger 
reaction, and allyl azide rearrangements will be used to library synthesize broad areas 
of anticancer and antibacterial agents. The biology activity and structure activity 
relationship studies will also be discussed.    
 
I.1. Organic azides: Unique classes of compounds 
    The first organic azide, phenyl azide, was reported by Peter Griess in 1864.2 During 
the following 140 years, these energy-rich and flexible azides and nitrenes have 
enjoyed considerable interest, and many functional reactions were found for azides as 
nucleophiles, electrophiles, nitrene precursors, or 1,3 dipole (Figure 1).3 Azides, as N3, 
have a total of four resonance structures. However, UV adsorption (287 nm and 216 nm 
for alkyl azides) 4 and strong IR absorption at 2114 cm-1 proved a structure with a 
shorter N2, N3 distance. The polar resonance structure c is commonly used to explain 
the mechanisms of reactions of azides. 
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Figure 1. Resonance structure and reactions about organic azides 
 
Because azides can react differently under different conditions, organic azides have 
been widely applied in the synthesis of drug candidates. Some novel aminoglycosides, 
oxazolidione antibiotics, cyclopamine derivatives, and naphthoquinone derivatives will 
be synthesized via azides in this dissertation. 
 
I.2. Aminoglycosides: Classification, Mode of action,  
   and Mechanisms of resistance 
I.2.1. History and classification of aminoglycosides 
Aminoglycosides have a broad spectrum of activity that has been clinically used for 
over 50 years. The first aminoglycoside discovered was penicillin in 1928.5 It was 
followed by the discovery of streptomycin as the first antituberculosis agent in 1944 
from the bacterial culture supernatants when M. tuberculosis presents inhibitory 
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activity.6 After that, more and more aminoglycosides were isolated from natural 
product including kanamycin, gentamicin, and tobramycin which were used to treat 
bacterial infectious diseases and have saved many peoples’ lives. However, the major 
problem of aminoglycosides is their renal toxicity, ototoxicity, and bacterial resistance 
caused by repetitive use or misuse. In order to counteract these problems, 
semi-synthetic aminoglycosides such as dibekacin, amikancin, and netimicin, were 
designed to treat bacterial with resistant mechanism to earlier aminoglycosides. Recent 
advances in the structural modification of aminoglycosides and discovering new leads 
with novel molecular conformation can be two ways to revive the clinical efficacy. In 
this dissertation, some novel synthetic aminoglycosides have been synthesized to 
demonstrate good activity against resistant bacteria.   
Aminoglycoside antibiotics are hydrophilic molecules containing aminosugars as 
the main components. The majority of clinically useful aminoglycosides usually 
consists of a 2-deoxystreptamine ring that is coupled with aglycon units. The aglycon 
units can be cyclic or acyclic. Some structures of aminoglycosides are shown in Figure 
2. Despite the availability of many kinds of aminoglycosides, the common properties 
of aminoglycosides are the polycationic functionalities because of the protonation of 
the amino groups. Aminoglycosides are mostly protonated in biological media and are 
primarily responsible for the aminoglycosides’ biological interaction with RNA 
molecules. 
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Figure 2.  Structures of 2-deoxystreptamine containing aminoglycosides 
 
 
I.2.2. Mode of action of aminoglycosides 
Aminoglycosides are famous antibiotics that are active against both Gram-positive 
and Gram-negative bacteria. They enter the cell through active transportation and then 
bind irreversibly to the 30S RNA subunit of the ribosome of bacteria and inhibit the 
protein synthesis. This mode of action of aminoglycosides has been proved by the 
structural information of aminoglycoside-bound rRNA molecules.7 It has been 
proposed that positively charged aminoglycosides firstly bind to the negatively charged 
moieties of phospholipids, lipopolysaccharides, and outer membrane proteins in 
Gram-negative bacteria and to the phospholipids and teichoic acid of Gram-positive 
bacteria. This binding will result in the displacement of the biofilm-associated Mg2+ 
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and Ca2+ ions that link the adjacent lipopolysaccharide molecules so that the outer 
membrane can be damaged and permeability can be increased.8  Then a small quantity 
of aminoglycoside molecules cross the cytoplasmic membrane and bind to the 
ribosome. After aminoglycosides bind to specific sites of RNA in the bacterial 
ribosome, they interfere with the translation accuracy between aminoacyl-tRNA and 
mRNA codons which occur on the small 30S ribosomal submit. This will lead to the 
codon misreading and result in the malformed proteins. Some of the miscoded protein 
can be used to make the cell wall leading to the disruption of the integrity of the 
bacterial membrane even further.9 Because the integrity of the membrane is destroyed, 
more and more aminoglycosides will be allowed to enter the cell through the membrane 
continuously. When the aminoglycosides have accumulated to a concentration high 
enough to prevent the transfer of the peptidyl tRNA from the A-site to the P-site, the 
elongation of the polypeptide chain is inhibited. As a result, a combination of the 
damaged membrane and irreversible blocking of protein biosynthesis will lead to the 
apoptosis of the bacterial cell.10 
 
I.2.3. Mechanism of resistance 
    The major problem that most antibiotics have to confront is that bacteria will form 
resistance after long clinical use or misuse. As for aminoglycosides, there are usually 
three mechanisms of resistance. 
    The first one is reduced uptake into cell because of membrane impermeability. 
Some bacteria, especially Gram-negative bacteria exhibit aminoglycoside resistance 
due to transport defects or membrane impermeabilization.11  
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     The second one involves alterations at the ribosomal binding site, so as to 
eliminate or reduce the binding of aminoglycosides. For example, mutation at the site 
of aminoglycoside attachment may produce resistance to streptomycin, since this agent 
binds only to a single site on the 30S subunit of the ribosome. However, resistance to 
the other aminoglycosides by this mechanism is uncommon, because most of the 
aminoglycosides can bind to multiple sites on ribosomal subunits.  
    The third one is deactivation of aminoglycosides by enzymatic modification. 
Among these three mechanisms, the most common type of resistance mechanism is the 
structural modification of aminoglycosides catalyzed by specific enzymes that are 
developed by bacteria. Enzymatic modification will result in high-level resistance. So 
far, more than 50 different enzymes have been identified.12 These enzymes can be 
classified as N-Acetyltransferases (AAC), O-nucleotidyltransferases (ANT), and 
O-phosphotransferases (APH). The acetyltransferases transfer an acetyl group from 
acetyl coenzyme A to specific amino groups. The ANT and APH can catalyze 
ATP-dependent adenylation and phosphorylation of hydroxyl groups in 
aminoglycosides. Some of the enzymatic modifications of neomycin and kanamycin 
are shown in Figure 3.   
    Aminoglycoside-modifying enzymes are often plasmid encoded and the genes 
encoding for these enzymes have been shown to be associated with transposable 
elements. Both plasmid exchange and dissemination of transposons may facilitate the 
rapid acquisition of the drug-resistance phenotype among various bacterial species. 
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Figure 3.  Modifications from resistant bacteria against neomycin and kanamycin 
    This may explain why widespread aminoglycoside resistance has occurred. 
However, further investigation of the resistance mechanisms, including information 
obtained from X-ray structural studies of aminoglycoside-modifying enzymes has lead 
to the discovery of new leads to counteract the problem caused by aminoglycoside 
resistant bacteria.  
 
I.3. Linezolid: A novel oxazolidinone antibiotic 
I.3.1. History of oxazolidinone antibiotics 
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    Other than aminoglycosides, oxazolidinone derivatives are another new class of 
antibiotics that have been successfully implemented in the clinic over the past 40 years. 
Linezolid is one of the oxazolidinones and is the only oxazolidinone antibiotic 
approved by the FDA in 2000. Linezolid, a completely synthetic antibacterial agent, is 
used for the treatment of serious infections caused by Gram-positive bacteria that are 
resistance to several other antibiotics. Linezolid has been used to treat a number of 
resistant strains of bacteria such as methicillin-resistant Staphylococcus aureus and 
vancomycin-resistant Enterococcus faecium.  
In the 1980s, oxazolidinones were discovered to possess antibacterial properties. 
After decades of investigating on structural variations and activity test, a series of lead 
compounds with improved activities and acceptable safety profiles were developed.13 
In 1996, it was proven by Pharmacia that linezolid is an excellent starting point for drug 
development. Linezolid has high bioavailability and the entire dose can quickly reach 
the bloodstream when given orally.14 FDA approved linezolid in April, 2000. Later, 
linezolid was approved in Brazil, the UK, and other countries. Although linezolid is 
now a popular drug, the emergence of linezolid resistance has been reported. The 
resistant mechanism involves target site modification leading to reduced affinity of 
linezolid to the 50S subunit of RNA.15 Therefore, it is necessary to synthesize more 
oxazolidione deverivatives with improved activity to counteract the resistance of 
bacteria against oxazolidione antibiotics.  
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I.3.2. Mode of action of linezolid 
The mode of action of linezolid is the inhibition of protein synthesis by interacting 
with the ribosome (Figure 4). Unlike most widely known antibiotics, like 
aminoglycosides or macrolides, that inhibit bacterial protein synthesis at the peptide 
chain elongation stage, linezolid can act early by potent interaction with 50S ribosomal 
subunit in the initiation stage of protein synthesis. In the initiation step of translation, 
30S subunit takes mRNA to form 30S initiation complex. Then 50S subunit is 
associated with both fMet-tRNA (initiator tRNA) and 30S initiation complex to form 
the functional 70S ribosomal initiation complex. Linezolid can bind with the specific 
site of peptidyltransferase center of 50S subunit, so that the binding of fMet-tRNA to 
this site is prevented. As a result, the formation of the 70S ribosomal complex is 
inhibited during the initiation stage.16  
Linezolid interacts with the peptidyl-tRNA binding P site at the 50S subunit with 
good affinity. The precise binding site has been elucidated by in vivo cross-linking of a 
photolabile linezolid derivative bound to the 50S subunit.17 The crystal structure of 
linezolid bound to the 50S subunit of a ribosome has been elucidated in 2008.18 
 
I.4. Cyclopamine and its derivatives 
In the beginning, cyclopamine was isolated and recognized as a poisonous 
component from plant Veratrum californicum. For example, cyclopamine can produce 
teratogenic effects.20 Later, cyclopamine was proven to be a popular Hedgehog (Hh) 
signaling antagonist.21 Since more and more evidence has been found on the connection  
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Figure 4. Mode of antibacterial action of linezolid19 
between cyclopamine, the activity of the Hh signaling pathway, and cancer formation, 
scientists have directed more efforts on the study of employing cyclopamine to inhibit 
the Hh pathway and to offer a potential cure for cancers.22 
    In general, the mode of action of cyclopamine in curing cancer is by inhibiting the 
Hh pathway. Hh signaling interaction in the target cells occurs through at least two 
protein receptors: Patched (Ptc) protein23 and Smoothened (Smo) protein.24 Patched 
(Ptc) protein, which is a 12-pass transmembrane domain receptor protein for all 
hedgehog proteins, interacts with Hh and regulates Smo activity.25 Direct binding of Hh 
proteins to Ptc protein is a critical event in transduction of the hedgehog signal.26 
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Malfunction of this interaction has been shown to lead to cancer.27 After Hh binds to Ptc, 
it causes a conformational change in the receptor complex that liberates Smo activity 
from the repressive influence of Ptc. Then the activated Smo will trigger a series of 
intracellular events, culminating in the change of full size zinc-finger transcription 
factor Cubitus interruptus (Ci) and causing the mutation of Ci-dependent genes, which 
will lead to the development of cancer.28 If Hh is inhibited by cyclopamine, Ptc acts to 
prevent high expression and activity of the spanning receptor Smo.29 The regulation 
and suppression of Smo levels can reduce the possibility of cancer that associated with 
constitutive activation of Smo (Figure 5).  
Later study revealed that cyclopamine affects the Hh Pathway by binding directly 
to Smo protein. Cyclopamine is a biological inhibitor of Smo protein. Smo has either 
the phosphorylated and non-phosphorylated form. Phosphorylation of smoothened 
plays a role in Hh dependent regulation of Smo levels.30 By interacting with the Smo 
heptahelical domain, cyclopamine can influence the balance between the active and 
inactive forms of the Smo protein. Cyclopamine can also reverse the retention of 
partially misfolded Smo in endoplasmic reticulum, presumably through 
binding-mediated effects on protein conformation.31 These results have triggered 
efforts to find more molecules that have similar anticancer activity as cyclopamine. The 
discovery of these molecues can optimize the inhibitory effect of cyclopamine. And 
these therapeutic moleculs will be prepared via chemical modifications.  
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Figure 5. Mode of anticancer action of cyclopamine against Hedgehog Pathway  
 
I.5. Naphthoquinone derivatives as anticancer agents 
I.5.1. History of naphthoquinone anticancer agents 
Napththoquinone derivatives have long attracted great interest due to their 
important biological and pharmaceutical applications. Naphthoquinone derivatives are 
widely distributed phenolic compounds in nature and have been found in plants, fungi 
and actinomycetes and play important physiological roles. Although most of the 
naphthoquinone derivatives have cytotoxic properties,32 they are still associated with 
numerous pharmacological properties like antibacterial,33 antifungal,34 antiviral, 
anti-inflammatory, antimalarial,35 and antitumoral.36 Naphthoquinone anticancer 
agents have been known for a long time37 and can be obtained from both natural 
products38 or synthetic sources (Figure 6).39 
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Figure 6. Anticancer agents with naphthoquinone moiety 
 
I.5.2. Biological function of naphthoquinone derivatives 
Naphthoquinone derivatives have a broad-range biological action. In the 
interactions with biological molecules, naphthoquinone derivatives primarily utilize 
two properties.  
First, naphthoquinone derivatives are redox cyclers. Naphthoquinone deverivatives 
have the potential to be reduced, so they are potential acceptor of electrons and protons. 
These properties make naphthoqinone derivatives good redox active organic cofactors. 
In the presence of reductants, naphthoquinones may undergo one or two electron 
reductions, resulting in semiquinones or hydroquinones, respectively. However, most 
of the time reduction of quinones takes place through a one-electron transfer. Firstly 
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formation of a semiquinone radical-anion followed by a protonation step to generate a 
neutral radical. And secondly, the neutral radical is reduced again to yield the 
hydroquinone form. The radicals may in turn in the presence of oxygen initiate a redox 
cycle. As a result, reactive oxygen species (ROS) are generated including semiquinone 
SQ −, superoxide O2 −, and hydrogen peroxide H2O2. These bring about inactivation of 
biological molecules by oxidation. For example, the resultant highly reactive 
semiquinone radicals can damage the thiol groups and other nucleophilic moieties of 
proteins.40 The estimates based on biological systems suggest that reduction potentials 
of napthoquinones are in the approximate range from -270 to -160 mV are conductive 
to redox cycling. Naphthoquinone derivatives are located within mitochondrial 
membrane and act as an electron and proton carrier in the mitochondrial respiratory 
chain.  
Second, naphthoquinones can act as pure arylators. Moiety of α, β unsaturated 
ketone makes naphthoquinone good electrophiles susceptible to nucleophilic attack, 
resulting in the covalent modifications of the nucleophilic sites on biological molecules 
or proteins.  
Naphthoquinone derivatives can bind with enzymes by arylation and oxidation to 
manifest the biological activity.41 The degree to which enzymes are affected by 
naphthoquinones depends on the reductive potential, molecular structure, pH, 
quinone/enzyme ratio, and the presence of oxygen. Sometimes, naphthoquinon 
derivatives can act as bioreductive alkylating agents that can be both arylator and redox 
cycler. 
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I.5.3. Mode of anticancer action of natphoquinone derivatives 
    Naphthoquinone derivatives have several anticancer modes of action: 
1) Decoupling of oxidative phosphorylation. Some naphthquinone derivatives can 
decouple the redox reactions of coenzyme Q, which is essential for oxidative 
phosphorylation and ATP synthesis, leading to apoptosis of cancer cell. Many 
naphthoquinone anticancer agents can induce cancer cell death without causing direct 
damage to DNA, showing low effect on non-tumoral proliferative cells. Furthermore, 
some naphthoquinone derivatives possess the ability to induce oxidative stress so that 
they can just target cancer cells and initiate damage to tumor cells selectively. 
 
 
 
 Figure 7. Decouple oxidative phosphorylation by naphthoquinone derivatives42 
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2) Inhibition of the coenzyme Q mediated enzyme systems, such as NADH oxidase and 
succinoxidase. NAD(P)H:quinine oxidoreductase (NQO1) is a ubiquitous flavoprotein 
found in most eukaryotes that catalyzes a two-electron reduction of quinones using 
either NADH or NADPH as electron doner.42 NQO1 is elevated and over-expressed in 
pancreatic, breast, colon, lung, and prostate tumors. Lapachone and its derivatives have 
been proven potential therapeutic agents for these kinds of tumors.43 
3) Inhibition of protein in related to cancer, extensive and prolonged interaction with 
DNA, RNA, and protein: Hsp 90 is 90KDa family of heat shock proteins that have been 
implicated in the hallmarks of cancer. The Hsp 90 has become a validated target for the 
treatment of cancer. Naphthoquinone derivatives can be used effectively as Hsp 90 
protein inhibitors.44 Inhibition of Hsp 90 by naphthoquinone derivatives can provide a 
multifaceted attack on cancer and malignant cell growth and can be utilized as a 
treatment of cancer. Indoleamine 2,3-dioxygenase (IDO) is emerging as an important 
new therapeutic target for the treatment of cancer, chronic viral infections, and other 
diseases characterized by pathological immune suppression. Napthoquinone can be 
potent inhibitor for IDO and thus exert the anticancer activity.45 
4) Inhibition of pathological angiogenesis. Pathological angiogenesis occurs in tumor 
formation and non-neoplastic diseases. It has been reported that Vitamin K3, 
2-methyl-1,4-naphthoquinone, has a strong inhibitory effect on angiogenesis.46 In 
addition, vitamin K3 inhibits DNA polymerase activity.47 Other than vitamin K3, 
several naphthoquinone derivatives have been found to possess similar anti-angiogenic 
effects.48 
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5) Inhibition of the biosynthesis of DNA. Naphthoquinone derivatives can inhibit DNA 
polymerase activity or DNA topoisomerase.49 For example, actinomycin is a 
topoisomerase II inhibitor. Streptonigrin is an aminoquinone antitumor agent that can 
cause DNA degradation in Escherichia coli. It is also reported that plumbagin induces 
mammalian topoisomerase II mediated DNA cleavage in vitro.50 
 
I.5.4. Significance of synthesis of naphthoquinone derivatives via azide chemistry. 
Because naphthoquinone derivatives have broad biological activites, various 
naphthoquinone derivatives were synthesized long time ago,51 and development of 
naphthoquinone derivatives have been one of the hottest areas in the drug development 
nowadays.52 However, synthesis of naphthoquinone derivatives via azide chemistry has 
seldom been reported. Cycloaddition of azides with naphthoquinones can produce 
several different classes of heterocyclic compounds, including indanedione, 
anthraquinone, benzazepine, and aziridine (Figure 8).53 For example, cleavage of the 
triazole will form a zwitterionic intermediate, which is the precursor for the formation 
of both aziridine and imine. The tautomerization of imine can form indandione or 
amino-naphthoqinone derivatives. All these compounds have long attracted great 
interest due to their important biological and pharmaceutical applications, leading to 
the development and discovery of numerous therapeutics. In this dissertion, 
cycloaddition of naphthoquinone and azide will be investigated to synthesize various 
heterocyclic compounds with enhanced biological activity. At the same time, the 
reaction mechanisms will be discussed in detail too.  
 
  
 
                                                                                  19
O
O
R-N3
O
O
1
N
N
N
R
N
O
O
R
OH
OH
N
N
N
R
O
O
O
N
N
N
R
2
3 4
O
O
N
N
R
N
O
O
N R
5O
O
N
R
O
O
NH
R
6
7
O
O
H  migrate Alkyl  migrate
N R
8
O
O
HN R
9
Hydrolysis
O
O
O
10
 
 
Figure 8. Possible product distribution of cycloaddition of azides and naphthoquinone 
 
I.6. Summary of the synthetic scheme for this dissertation 
    A summary of the contents of this dissertation is shown in Figure 9. The “Click 
reaction” will give novel oxazolidinone-carbohydrate (chapter II) and 
cyclopamine-carbohydrate conjugates (chapter III). Neomycin B can be modified by 
modification of its 5” position with triazole or an amide linkage (chapter IV). 
Cycloaddition of naphthoqine and azides (chapter V) and one pot reaction (chapter VI) 
can offer various heterocyclic compounds. Finally, an allyl azide migration can be used 
to synthesize novel aminoglycosides (chapter VII). 
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CHAPTER II 
SONICATION-ASSISTED LIBRARY SYNTHESIS OF 
OXAZOLIDINONE-CARBOHYDRATE CONJUGATES 
 
II.1. Rationale of the drug design 
Linezolid is a common antibiotic popular in the market nowadays. Linezolid 
represents the first antibacterial with a new mechanism of action to be approved by the 
FDA in over 30 years. Linezolid (or Zyvox) is used to treat infections, including 
pneumonia, urinary tract infections, and infections of the skin and blood. It works by 
inhibiting the protein synthesis of bacteria so that it can stop the growth of bacteria. The 
novel mechanism of action of linezolid has prompted further effort in chemical 
modifications and structure-activity relationship (SAR) studies. The SAR studies have 
revealed the most important features that are responsible for the biological activity of 
linezolid, as summarized in Figure 10. 
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Figure 10. SAR of linezolid 
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It can be seen from Figure 10 that linezolid includes four parts. A: Water Solubility 
Part; B: Aromatic Part; C: Oxazolidinone Part; D: Acylaminomethyl Part. The purpose 
of this project is to mimic these four parts of the linezolid and try to prepare a library of 
new compounds that has antibacterial activity on the base of their similar structure 
composition with linezolid. For the preparation of these compounds, a “click” reaction 
will be utilized between an azide and an alkyne to establish the 1,2,3-triazole that 
mimics the fluoro-substitute aromatic ring (B). Additionally, different kinds of sugars 
will be used to mimic the water soluble morpholine (A) of linezolid because pyranoses 
have the same six-membered ring scaffold as morpholine. The retrosynthetic strategy is 
shown in Figure 11. Three kinds of oxazolidinones will be prepared to build up a library 
of oxazolidinone carbohydrate conjugates (Figure 12).   
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Figure 11. Retrosynthetic analysis of oxzaolidinone-carbohydrates conjugates 
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Figure 12. Structures of three alkyne modified oxazolidinone compounds 
II.2. Results and discussion. 
II.2.1. Synthesis of glycosyl azides. 
The synthesis of various glycosyl azides is the most important part in this 
dissertation. Totally 14 kinds of glycosyl azides were developed (Figure 13). Compared 
with the traditional method of synthesizing glycosyl azides that requires several hours 
of reaction with TMSN3 catalyzed by Lewis acid, two more efficient methods of 
synthesizing different glycosyl azides are applied. One of the methods is that glycosyl 
azides can be prepared from the corresponding glycosyl bromides in DMF with NaN3 
under the assistance of sonication. For example, by this method sonication assisted 
azido substitution can be completed in minutes with modest to good yield to give 
glycosyl azides 4 – 10. Another method is that glycosyl azides can be prepared from the 
corresponding glycosyl bromides in a CH2Cl2/NaHCO3 bi-phase solvent system under 
phase transfer catalyst tertbutyl ammnonium hydrogen sulfate (TBAHS). The reaction 
proceeds rapidly and is easy to handle after the reaction is complete. Furthermore, 
higher stereoselectivity is observed. For example, using the bi-phase method, glycosyl 
azides 4 – 14 can be synthesized with medium to good yield.54  
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Figure 13. Strucutures of 17 glycosyl azides 
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O
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Sonication, 
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N3
(AcO)n
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N3
(AcO)n
4 - 10, 14
4 - 6, 9 - 13  
 
Scheme 1. Synthesis of azidosugars 
 
Azido ribose 15 is prepared from per-acetyl ribose using Lewis acid catalyt 
BF3·OEt2 in CH3CN.55 Azido glucosamine 11 and azido galacosamine 12 were 
prepared from the related glycosyl chloride (Scheme 1).56 Monoazido mannitol 16 and 
diazido mannitol 17 were synthesized using a one pot reaction including tosylation and 
Products Carbohydrate Moiety 
Yield% 
method 1
α/β  
method 1 
Yield% 
method 2 
α/β  
method 2
4 per-O-acetylated -D-glucopyranosyl  38% β only 97% β only 
5 per-O-acetylated-D-galactopyranosyl  73% β only 68% β only 
6 per-O-acetylated R-D-mannopyranosyl  12% 5/1 48% 10/1 
7 per-O-acetylated-lactosyl  79% β only - - 
8 per-O-acetylated-L-fucopyranosyl 66% β only - - 
9 per-O-acetylated R-L-rhamnopyranosyl  44% 5/1 60% 1/1 
10 per-O-acetylated-xylopyranosyl  47% α only 78% β only 
11 
per-O-acetylated 2-acetamido-2-deoxy 
-D-glucopyranosyl  
- - 50% β only 
12 
per-O-acetylated 2-acetamido-2-deoxy 
-D-galactopyranosyl  
- - 35% β only 
13 per-O-acetylated-cellobiosyl  - - 89% β only 
14 per-O-acetylated-cellotriosyl  71% β only - - 
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acetylation of D-mannitol followed by the azido substitution.  
 
II.2.2. Synthesis of allyl oxazolidinone-containing compounds 
The synthesis of a library of oxazolidinone carbohydrate conjugates started from 
three oxazolidinone-containing compounds (Figure 12).  Compounds 1 and 2 can be 
prepared by allylation of commercially available (R)-4-benzyl-2-oxazolidinone and 
2-oxazolidinone, respectively. Compound 3 can be synthesized from commercially 
available 5-chloromethyl-2-oxazolidinone, 18 (Scheme 2). Two individual routes were 
developed by alternation of the order of azido substitution and allylation. However, the 
approach that has azido substitution first provides better overall yields in larger-scale 
synthesis. The other approach that goes through allylation first suffered from a low 
yield in the following azido substitution (from 22 to 20) when scaled up, despite giving 
a good yield in small-scale test reaction (Scheme 2).  
 
II.2.3. Synthesis of library of oxazolidinone-carbohydrate conjugates 
    Synthesis of libraries of oxazolidinone-carbohydrate conjugates started from the 
“click reaction” between alkynes 1 - 3 and glycosyl azides 4 – 10 (Scheme 3). 
Compared with traditional “click reaction” that usually needs 24 hours or even longer, 
the time for the desired click reaction can be shortened to less than 15 minutes with 
excellent regioselectivity. After hydrolysis of the acetyl groups of 23a-u and 
purification with column chromatography, the OX series of compounds (OX1–OX3) 
were obtained (Scheme 4). 
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Scheme 2. Synthesis of 5-acetylamidomethyl oxazolidinone 
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Cu(OAc)2, Na ascorbate
MeOH, THF, H2O
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NO
O
R
N
N
N
O
(AcO)n
23a-u
 
 
Compounds R Azidosugars Yield (%) α/β 
23a (R)4-Bn 4 80 β only 
23b (R)4-Bn 5 99 β only 
23c (R)4-Bn 6 86 5/1 
23d (R)4-Bn 7 70 β only 
23e (R)4-Bn 8 99 β only 
23f (R)4-Bn 9 48 3/1 
23g (R)4-Bn 10 96 10/1 
23h H 4 75 β only 
23i H 5 99 β only 
23j H 6 82 10/1 
23k H 7 95 β only 
23l H 8 43 β only 
23m H 9 67 α only 
23n H 10 80 α only 
23o 5-AcNHCH2- 4 92 β only 
23p 5-AcNHCH2- 5 95 β only 
23q 5-AcNHCH2- 6 86 5/1 
23r 5-AcNHCH2- 7 88 β only 
23s 5-AcNHCH2- 8 99 β only 
23t 5-AcNHCH2- 9 90 2/1 
23u 5-AcNHCH2- 10 99 α only 
 
 
Scheme 3. “Click Reaction” of oxazolidinone and azidosugar 
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O
(OH)n
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OX201-OX207
OX301-OX307
 
 
Compounds R Carbohydrate Moiety Yield (%) α/β 
OX101 (R)4-Bn 4 82 β only 
OX102 (R)4-Bn 5 99 β only 
OX103 (R)4-Bn 6 99 5/1 
OX104 (R)4-Bn 7 95 β only 
OX105 (R)4-Bn 8 90 β only 
OX106 (R)4-Bn 9 98 3/1 
OX107 (R)4-Bn 10 96 α only 
OX201 H 4 99 β only 
OX202 H 5 99 β only 
OX203 H 6 82 7/1 
OX204 H 7 99 β only 
OX205 H 8 99 β only 
OX206 H 9 93 20/1 
OX207 H 10 95 α only 
OX301 5-AcNHCH2- 4 89 β only 
OX302 5-AcNHCH2- 5 99 β only 
OX303 5-AcNHCH2- 6 95 5/1 
OX304 5-AcNHCH2- 7 99 β only 
OX305 5-AcNHCH2- 8 99 β only 
OX306 5-AcNHCH2- 9 55 20/1 
OX307 5-AcNHCH2- 10 86 α only 
 
Scheme 4. Structure of libraries of oxazolidinone carbohydrate conjugates 
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II.3. Antibacterial activity studies 
Using the disk diffusion assay methods described by Grgurina et al.57 and NCCLS, 
we tested the compounds for inhibition of various strains of bacteria, including 
Escherichia coli (ATCC25922), Staphylococcus aureus (ATCC25923), and 
Mycobacterium smegmatis (ATCC 14468), and two strains of fungi, Rhodotorula 
pilimanae58 and Rhototorula rubra (ATCC 9449). No inhibitory activities were 
observed. The lack of activity is consistent with the reported SAR, which states that an 
N-aryl group is essential for activity. And the fluorine on the benzene ring is also 
important for the improvement of the activity. The synthesis for linezolid analogs with 
a triazole ring connected directly to the oxazolidinone (N-aryl-type linkage) has been 
initiated. Although no antimicrobial activity with the newly constructed 
oxazolidinone-carbohydrate conjugates was obtained, the concise synthetic strategy 
and the efficiency of using sonication can pave the way for preparation of other 
oxazolidinone-containing molecules and also other triazole containing biological active 
molecules.  
 
II.4. Summary 
Oxazolidione-carbohydrate conjugates were prepared using “click reaction” 
between three allyl oxazolidinones and seven glycosyl azides under the assistance of 
sonication. Although the synthesized OX series compounds had no inhibitory activities 
against bacteria and fungi, the synthetic strategy is efficient and can facilitate the 
synthesis of 1,2,3-triazoles. 
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CHAPTER III 
SYNTHESIS AND ANTICANCER ACTIVITY STUDIES  
OF CYCLOPAMINE DERIVATIVES 
 
 
III.1. Rationale of the drug design 
Cyclopamine, which is also known as 11-deoxojervine, has been found to exhibit 
remarkable inhibitory effect toward the Hedgehog signaling pathway. Since many 
human cancers were obseerved to have abnormally elevated Hedgehog (Hh) signaling, 
cyclopamine can be used to treat various cancers by inhibiting the Hedgehog signaling 
pathway. For example, cyclopamine has been shown to induce apoptosis and block 
proliferation of pancreatic cancer lines both in vitro and in vivo.59 The Hh pathway in a 
wide range of digestive tract tumors, including esophagus, stomach, biliary tract, and 
pancreas can be inhibited by cyclopamine.60 Cyclopamine has also been noted to kill 
brain tumor,61 lung cancer,62 basal cell carcinoma (BCC),63 and prostate cancer.64 
The low solubilityof cyclopamine in aqueous or polar solvents is a major 
shortcoming, preventing its development as an anticancer agent. In order to develop 
clinically effective drugs, the preparation of cyclopamine derivatives with better 
solubility is essential for studying the structure-activity relationship (SAR), 
pharmacokinetic, and clinical trials. Because carbohydrates contain multiple 
stereocenters and are structure moieties for diversity-oriented synthesis leading to 
higher polarity drug candidates,65 the attachment of carbohydrates to cyclopamine can 
make the cyclopamine derivatives with greater structural diversity, improved solubility, 
and enhanced anticancer activity. The strategy involves the use of 1,3-cycloaddition 
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reaction between glycosyl azides and alkyne-modified cyclopamine by “click 
chemistry” to prepare the cyclopamine-carbohydrate conjugates. The glycosyl azides 
will be similar to those previously prepared (Figure 13). The alkyne will be put on the 
22 amino group position selectively because cyclopamine derivatives with the 
modification at the nitrogen atom have shown improved activity.66 
 
III.2. Results and discussion 
    The diversity-oriented synthesis began with the allylation of cyclopamine using 
allyl bromide and sodium bicarbonate (Scheme 5). The azidosugars were treated with 
N-allylcyclopamine using the sonication-mediated 1,3-dipolar cycloaddition protocol 
that is described in Chapter II. Following the deprotection and purification with a short 
flash column, the desired cyclopamine–carbohydrate conjugates were obtained in 
modest to excellent overall yields. It is worth mentioning that the coupling of 
azidosugars, deprotection of acetyl groups, and purification process can be completed 
in one day with only one fast column, making this synthetic protocol ideal for library 
and diversity construction of cyclopamine derivatives. 
Two of the azidosugars, 6 and 9, employed in the synthesis were mixtures of α and 
β anomers (5/1 for 6 and 1/1 for 9). However, after the “click reaction,” the minor 
products from the β anomeric azidosugars were not isolated or observed, probably due 
to the scarcity of the minor products and the low sensitivity of the NMR instrument. 
Since 26f is the most potential conjugate observed, further investigation into the purity 
of 26f was carried out using LC–MS. From the LC–MS analysis, compound 26f 
contains small quantity of β-l-rhamnose-incorporated cyclopamine (11%). In addition, 
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unreacted 9 was recovered as a mixture of α and β anomers (1/3 ratio). The enrichment 
in the ratio of β anomer and the scarcity of the “click” product from β anomeric 
azidosugars suggest that the steric hindrance of the 2-O-acetyl group may have 
rendered the β-L-rhamopyranosyl azide or, probably, β-D-mannopyranosyl azide less 
reactive than the corresponding α-glycosyl azides. The yields and ratios of the related 
stereoisomers are summarized in Table 1. As expected, all of these 
carbohydrate–cyclopamine conjugates were found to have fair to good solubility in 
aqueous media and excellent solubility in methanol.  
 
Table 1. Yields and ratios of stereisomers 
 
Compound Sugar Part Yield (%) 
α/β 
ratio 
Compound 
Yield 
(%) 
α/β a 
ratio 
26a 
26b 
26c 
26d 
26e 
26f 
26g 
26h 
26i 
26j 
26k 
26l 
26m 
26n 
Glucose 
Galactose 
Mannose 
Lactose 
Fucose 
Rhamnose 
Xylose 
Cellibiose 
Glucosamine 
Galactosamine 
Cellitriose 
Ribose 
Dimeric manitol 
Monomeric manitol
82 
82 
82 
81 
99 
99 
99 
82 
99 
81 
80 
61 
99 
52 
β only
β only
α only
β only
β only
89/11 
β only
β only
β only
β only
β only
β only
- 
- 
27a 
27b 
27c 
27d 
27e 
27f 
27g 
27h 
27i 
27j 
27k 
27l 
27m 
27n 
84 
84 
84 
68 
60 
60 
60 
85 
99 
68 
86 
59 
59 
66 
β only
β only
α only
β only
β only
89/11 
β only
β only
β only
β only
β only
β only
- 
- 
a With the exception of 26f, the α/β ratio are calculated based on the integration of the anomeric protons 
from 1H NMR. The α/β ratio of 26f was calculated from LC–MS analysis.  
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Scheme 5. Synthesis of carbohydrate-cyclopamaine conjugates. 
III.3. Biology activity 
The anticancer activity of the synthesized carbohydrate–cyclopamine conjugates 
were tested against human lung cancer cell-line A549 using commercially available 
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cyclopamine as the control (Table 2) because it has relationship to Hh signaling.67 The 
standard MTS assay was employed.68 We noticed most of the cyclopamine derivatives 
incorporated with β-linked D-sugar including monosaccharide, disaccharide, and 
trisaccharide were less active than cyclopamine or inactive. However, 27f, the 
conjugate with L-rhamnose, exhibits slightly better activity than cyclopamine based on 
the survival amounts of cancer cell (Figure 14). In addition, we also noticed that 
cyclopamine formed a precipite at the effective concentration reported previously 
while 27f was completely soluble at the same concentration. Compound 27f is the only 
conjugate with α-linked L-sugar implying, perhaps, such a unique carbohydrate, 
α-linked L-pyranose, is favored. More related analogs are currently been synthesized. 
Among the cyclopamine–carbohydrate conjugates, 27a, 27d, 27f, 27g, 27h, 27i, 
and 27k were submitted to National Cancer Institute for 60-cell lines testing. 
Interestingly, these compounds along with cyclopamine were found to be less active 
than expected. The drastic difference in anticancer activity reflects the need for further 
investigation on the level of Hh pathway activity in cancer cells from various models at 
various stages. 
 
III.4. Conclusion 
 
Cyclopamine-carbohydrate conjugates with improved water solubility were 
synthesized. One lead has been elucidated to have better activity than cyclopamine. The 
carbohydrate-cylopamine conjugates still possess the inhibitory effects toward HH 
signaling pathway.  
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Table 2. Anticancer activity of carbohydrate-cyclopamine conjugates against lung 
cancer A549 
 
Compound IC50 (μM) 
Cyclopamine 49 
27a 144 
27b Inactivea 
27c Inactive 
27d 183 
27e n.d. 
27f 33 
27g Inactive 
27h Inactive 
27i Inactive 
27j Inactive 
27k 96 
a Inactive is defined as no inhibition on cell growth at 200 μM 
 
 
 
A539 cells were incubated for 48 h in presence of (a) 27f at 10μM; (b) 27f at 30μM; (c) 27f at 100μM; (d) 
cyclopamine a 10μM; (e) cyclopamine at 30μM; and (f) cyclopamine at 100μM. Scale Bar: 100μM 
 
Figure 14. Anticancer activity of 27f and cyclopamine 
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CHAPTER IV 
SYNTHESIS OF 5” MODIFIED NEOMYCIN AND ANTIBACTERIAL 
ACTIVITY AGAINST RESISTANT BACTERIA  
 
Most of the aminoglycoside antibiotics exert their antibacterial activity by binding 
selectively to the A-site decoding region of the16S rRNA and disrupting the functions 
that are vital to bacteria. However, one of the big problems that aminoglycoside 
antibiotics have to confront is the emergence of resistant bacteria, especially those 
equipped with aminoglycoside-modifying enzymes (AMEs).69 Chemical modification 
of aminoglycosides remains an effective approach for reviving their antibacterial 
activities against resistant bacteria, especially against those that are equipped with 
aminoglycoside-modifying enzymes (AMEs). Therefore, modification of the 5” 
position of neomycin B for synthesis of a library neomycin derivative will be discussed. 
Some compounds have shown activity against methicillin-resistant Staphylococcus 
aureus (MRSA) and vancomycin-resistant enterococci (VRE) that are known to exert 
high levels of resistance against clinically used aminoglycosides. Furthermore, 
antibacterial activities were measured when combined with other clinically used 
antibiotics. Significant synergistic activities were observed, which may lead to the 
development of novel therapeutic practices in the battle against infectious bacteria. 
 
IV.1. Rationale for the drug design 
Recently, several examples of neomycin analogs modified at their 5” position have 
been reported. For example, linkage to fluoroquinone,70 conformationally constrained 
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aminoglycosides with an intramolecular linkage between N-2′ and C-5′′, or between 
N-3 and N-6′,71 the dimer of neomycin with a spacing linkage via C-5”,72 neomycin 
with a 2,3-diaminopropanoyl group at 5” position,73 and orthogonal divergent synthesis 
of neomycin derivatives with modifications at various amine functionalities.74 
Neomycin derivatives bearing carbohydrates at the 5′′-OH have also been shown good 
activity against a panel of bacteria.75 It was reported recently that neomycin-lipid 
conjugates exhibit strong Gram-positive activity, but reduced Gram-negative activity.76 
Based on recent advances in the chemistry of neomycin compounds, modification on 5” 
position is still valuable in investigating the SAR against resistant bacteria equipped 
with AME. Since 5” –OH is the only primary hydroxyl group on neomycin that can be 
regioselectively converted to azido group and serve as the site of diversity-oriented 
modification via “click” chemistry or amide linkage. The initial design was to 
randomly introduce moieties containing alkyl, aryl, cationic, and anionic substituents 
for probing SAR and with the goal of finding a lead with enhanced activity. 
 
IV.2. Synthesis of neomycin derivatives  
      by modification of the 5” position 
The synthesis of neomycin derivatives started from a known Cbz protected 
neomycin B derivative, 28,77 followed by regioselective substitution of 5” - OH with 
azide (Scheme 6). The 5”-azido group can undergo 1,3-dipolar cyclization with alkynes 
(class I design). Alternatively, the 5”-azido group of 28 can be reduced to an amino 
group by Staudinger reaction and coupled with various carboxylic acids or amino acids 
(Class II design).  
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Scheme 6. Synthesis of neomycin derivatives 
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Table 3. Yields and structure designs of class I 5”-modified neomycin derivatives 
 
Compound alkynes Yield (%) 
Product 
Code 
Source of 
alkynes 
31a N-propargyl-5-acetamido methyl-2-oxazolidinone (3) 86% NEOF001 Ref. 78 
31b 1-octyne (33) 69% NEOF003 Commercially available 
31c N,N-dimethyl propargylamine (34) 66% NEOF007 
Commercially 
available 
31d N-propargyl-2-phenyl-4- quinolinecarboxamide (35) 69% NEOF010 
Prepared in 
this work 
31e N-methyl propargylamine (36) 61% NEOF011 
Commercially 
available 
31f 2-ethynylpyridine (37) 68% NEOF013 Commercially available 
31g N-carbobenzyloxypropargylamine (38) 77% NEOF015 Ref. 79. 
31h N-propargylisonicotinamide (39) 40% NEOF017 
Prepared in 
this work 
31i N-carbobenzyloxy-L-proline N-propargylamine (40) 49% NEOF020 
Prepared in 
this work 
 
Global deprotection of the Cbz protecting groups of these derivatives from both 
routes provided 5”-modified neomycin derivatives ready for antibacterial assay. The 
yields and structural designs are summarized in Tables 3 and 4.  
With the goal to expand the structural diversity, a dimeric neomycin derivative, 62, 
was prepared by treating the 5′′- NH2 group with succinic anhydride, providing 61, 
which was then coupled to another molecule of 30 (Scheme 7).  
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Table 4. Yields and structure designs of class II 5”-modificed neomycin derivatives 
 
Compounds Carboxylic acids of amino acids 
Yield 
(%) 
Product 
Code Source of acids 
32a Heptanoic Acid (41) 88% NEOF002 Commercially available 
32b Palmitic Acid (42) 63% NEOF004 Commercially available 
32c stearic acid (43) 54% NEOF005 Commercially available 
32d 2-phenyl-4-quinoline carboxylic acid (44) 30% NEOF006 Commercially available 
32e (S)-Z-4-amino-2-benzyloxybutyric acid (45) 90% NEOF008 Ref. 80 
32f Z-Glycine (46) 27% NEOF009 Commercially available 
32g Z-L-Alaline (47) 36% NEOF012 Commercially available 
32h Z- L-Proline (48) 50% NEOF016 Commercially available 
32i Z- L-Trpytophan (49) 67% NEOF 018 Commercially available 
32j Z- L-Serine (50) 52% NEOF019 Commercially available 
32k Z- L-Lysine (51) 61% NEOF022 Commercially available 
32l Succinic anhydride (52) 85% NEOF024 Commercially available 
32m Z-D-Alaline (53) 69% NEOF025 Commercially available 
32n Z- D-Serine (54) 57% NEOF026 Commercially available 
32o Z- D-Proline (55) 53% NEOF027 Commercially available 
32p Z- D-Lysine (56) 25% NEOF028 Commercially available 
32q Z-Glycine-Glycine (57) 42% NEOF030 Commercially available 
32r Lauric acid (58) 80% NEOF032 Commercially available 
32s Decanoic acid (59) 99% NEOF 033 Commercially available 
32t Myristic acid (60) 61% NEOF034 Commercially available 
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Scheme 7. Synthesis of neomycin dimer 
 
IV.3. Antibacterial analysis 
 
IV.3.1. Antibacterial Activity of 5′′-Modified Neomycin B 
 
    The synthesized aminoglycosides were assayed against susceptible and resistant 
bacterial strains using neomycin B as the control. Aminoglycoside susceptible 
Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC 25923) were used 
as standard reference strains. E. coli (pTZ19U-3) and E. coli (pSF815) are laboratory 
resistant strains using E. coli (TG1) as the host. The first one is equipped with the 
pTZ19U-3 plasmid encoded for APH(3′)-I, which catalyzes phosphorylation at the 
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3′-OH of both neomycin and kanamycin classes of aminoglycosides. The second one is 
equipped with the pSF815 plasmid encoded for a bifunctional enzyme, 
AAC(6′)/APH(2′′), which catalyzes acetylation of the 6’ amino group and 
phosphorylation of the 2” hydroxyl group. These enzymes are among the most 
prevalent modes of resistance found in aminoglycoside resistant strains. The minimum 
inhibitory concentrations (MICs) are summarized in Table 5. 
From the MIC results, it appears that the 5′′ position can tolerate the incorporation 
of diverse structural components, which is consistent with previous literature results.75 
Derivatives with a 1,2,3-triazole linkage manifested modest antibacterial activities 
comparable to neomycin B, with 31e and 31g as the most active derivatives. Most of 
the derivatives bearing amide-based linkages were less active than the parent neomycin 
B. Nevertheless, derivatives incorporated with long linear alkyl chains (32b and 32c) 
showed better antibacterial activity than neomycin B, and the one with a shorter linear 
alkyl chain (32a), even against resistant strains.  
Among the derivatives attached with amino acids, glycine (32f), alanine (32g and 
32m), and proline (32h and 32o) manifested similar levels of antibacterial activity with 
no particular difference between D and L amino acids. On average, it appears that these 
5′′-modified neomycin derivatives are more active against Gram positive bacteria (S. 
aureus) than Gram negative bacteria (E. coli). For example, there is only a 4-fold MIC 
difference for neomycin B between Gram positive and Gram negative bacteria while, in 
most of the synthetic derivatives, the differences are in the range of 4 to 16-fold. 
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Table 5. MIC of the 5”-modified neomycin derivatives (Unit: μg/mL) 
 
Compounds E. colia S. 
aureusb 
E. coli 
(TG1)c 
E. coli 
(pSF815)d 
E. coli 
(pTZ19U-3)e 
neomycin B 4 1 4−8 4−8 ≥2000 
31a 32 4−8 16 32 ≥2000 
31b 32 4 8−16 16 500 
31c 8 2 8−16 16 ≥2000 
31d 32 8 8−16 32 500−1000 
31e 8 1−2 16 16 ≥2000 
31f 8−16 2 16 16 ≥2000 
31g 8−16 1−2 16 16 1000 
31h 16−32 4 16 32 ≥2000 
31i 16 2 16 16 ≥2000 
32a 16−32 4 8 16−32 ≥2000 
32b 4 2 2−4 16 8 
32c 4−8 4 2−4 32 8 
32d 8−16 4−8 8−16 16 ≥2000 
32e 8−16 1−2 16 16−32 ≥2000 
32f 16 1 8−16 8−16 500−1000 
32g 8−16 0.5 8−16 16 ≥2000 
32h 16−32 0.5−1 16 16−32 ≥2000 
32i 16 2 8−16 16 ≥2000 
32j 8 1 8−16 16 ≥2000 
32k 16−32 2 16 32 125−250 
32l 64 8 32 64 ≥2000 
32m 16−32 1 16 16−32 ≥2000 
32n 8−16 1 8−16 16 ≥2000 
32o 8−16 0.5−1 8 16 ≥2000 
32p 32 1−2 16 64 ≥2000 
32q 16−32 2−4 16−32 16 125−250 
62 32 2−4 8−16 16−32 500 
a Escherichia coli (ATCC 25922).  
b Staphylococcus aureus (ATCC 25923).  
c E. coli (TG1) (aminoglycoside susceptible strain). 
d E. coli (TG1) (pSF815 plasmid encoded for (AAC(6′)/APH(2′′)).  
e E. coli (TG1) (pTZ19U-3 plasmid encoded for APH(3′)-I). 
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As expected, compound 32l incorporated with a negatively charged carboxylate 
group showed much lower antibacterial activity as compared to other derivatives. With 
the exception of 32b and 32c, all the derivatives are inactive against the resistant strain 
equipped with APH(3′)-I while retaining moderate activities against the susceptible 
control strain. This finding implies that APH(3′)-I has much broader substrate 
promiscuity than the RNA binding site for 5′′-modified neomycin derivatives, which 
again, exemplifies the challenges in developing aminoglycosides against drug-resistant 
bacteria. The activities of 32b and 32c against resistant bacteria are of particular 
interest, which prompts further enzymatic and molecular modeling investigations. 
 
IV.3.2. Enzymatic and Antibacterial Studies 
      of 5′′-Modified Neomycin B  
Although no significant activity against bacteria equipped with APH(3′)-I was 
observed for most of the derivatives, several derivatives did appear to have improved or 
similar activities as compared to the parent neomycin B, especially 32b and 32c. Thus, 
enzyme kinetic studies for 5”-modified neomycin derivatives, kanamycin A, amikacin 
and neomycin B were performed based on APH(3’)-IIIa by reported method.81 The 
results from enzymatic studies and the MIC values are summarized in Table 6. 
From Table 6, most of the 5′′-modified neomycin derivatives manifest much higher 
KM and lower Vmax and kcat implying that these derivatives can better evade the 
enzyme-catalyzed modification. The high KM indicates that these 5′′-modified 
neomycin derivatives are poor substrates for APH(3′)-IIIa. The low kcat suggests that 
the added functionalities at the 5′′ position could disrupt the rate of phosphorylation at 
the 3′-OH, even in the case of 32f where a relatively smaller glycine is incorporated.  
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Table 6. Kinetic parameters and MIC of aminoglycosides against E. Coli (TG1) with 
APH(3’)-IIIa (Unit: μg/mL). 
 
Compound KM (μM) Vmaxa kcat (s−1) 
kcat/KM 
/104 b MIC
c  MIC ratiod 
kanamycin A 8.2± 0.7 6.96± 0.12 3.48± 0.06 42.4 125
(Kan B) 
32 
 (Kan B)
amikacin 57.4± 5.7 2.75± 0.13 1.38± 0.07 2.40 1 1 
neomycin B 6.0± 0.8 3.22± 0.17 1.61± 0.09 26.8 64 8 
31a 160± 15 0.41± 0.03 0.21± 0.02 0.13 125 8 
31b 127± 13 0.75± 0.04 0.38± 0.02 0.30 32−64 4 
31c 120± 14 0.65± 0.05 0.33± 0.03 0.28 64−125 8 
31d 410± 38 0.30± 0.03 0.15± 0.02 0.037 16−32 2 
31e 100± 9 0.72± 0.07 0.36± 0.04 0.36 125 8 
31f 150± 16 0.54± 0.05 0.27± 0.03 0.18 125 8 
31g 111± 12 0.68± 0.04 0.34± 0.02 0.3 64 4 
31h 171± 18 0.41± 0.04 0.21± 0.02 0.12 64−125 8 
31i 175 ± 18 0.40 ± 0.04 0.20 ± 0.02 0.14 64−125 8 
32a 48± 6 0.95± 0.06 0.48± 0.05 1.0 64 8 
32b 58± 4 0.85± 0.08 0.42± 0.05 0.72 1−2 0.5 
32c 60± 7 0.84± 0.05 0.42± 0.03 0.7 2 1−2 
32d 400± 35 0.38± 0.04 0.19± 0.02 0.048 32−64 4 
32e 50± 4 0.93± 0.07 0.47± 0.05 0.94 125 8 
32f 75± 8 0.88± 0.06 0.44± 0.03 0.6 32 2 
32g 60± 5 0.90± 0.09 0.45± 0.05 0.75 64 4 
32h 80± 9 0.63± 0.07 0.32± 0.03 0.4 64 4 
32i 322 ± 31 0.57 ± 0.06 0.29 ± 0.03 0.1 64 4 
32j 42 ± 4 1.01 ± 0.09 0.51 ± 0.05 1.2 32−64 4 
32k 78± 8 0.79± 0.08 0.40± 0.03 0.51 32−64 4 
32l 53 ± 6 0.86 ± 0.09 0.43 ± 0.04 0.81 250 8 
32m 63 ± 7 0.82 ± 0.09 0.41 ± 0.04 0.65 64−125 8 
32n 57± 6 0.93± 0.10 0.47± 0.05 0.82 64 4 
32o 70± 8 0.72± 0.07 0.36± 0.04 0.51 64 8 
32p 75± 8 0.70± 0.07 0.35± 0.04 0.47 64−125 8 
62 >500 <0.1 <0.05 <0.01 64−125 8 
a  Unit: μmol/mg/min.    
b  Unit: s−1M−1.   
c.  MIC against bacterium with APH(3′)-IIIa (μg/ml) 
d.  MIC ratio = (MIC against E. coli (TG1))/(MIC against E. coli (TG1) with APH(3′)-IIIa). 
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In order to better compare the changes of antibacterial efficiency, we calculated the 
MIC ratio by dividing the MIC against susceptible strain with the MIC against resistant 
one (right column, Table 6). Amikacin, which has excellent activity against the resistant 
strain, has an MIC ratio of 1, which means there is no loss of activity against the 
resistant strain. Several interesting findings were noted. While neomycin and most of 
the neomycin derivatives have an MIC ratio ranging from 4 to 8, two compounds, 32b 
and 32c, have ratios of 0.5 and 1, respectively. The kinetic studies also suggested that 
these derivatives should be “poor substrates” for the enzyme. This interesting result 
means these two compounds are especially very active against resistant strains. One of 
the reasons that the observed enhanced activity of 32b and 32c against resistance 
bacteria is that structural modification at the N-5” of 32b and 32c make them “poor 
substrates” for APH(3’)-IIIa, because the kcat/KM of 32b and 32c are only 0.72 and 0.7 
s-1M-1, respectively. However, this might not be the major reason since other derivatives 
with similar or lower kcat/KM values are inactive or less active than 32b and 32c. 
Therefore, 32b and 32c may have different modes of antibacterial action. The details 
will be discussed later.  
Other than 32b and 32c, compounds 32f and 31d exhibit better activity against 
resistant strains than neomycin without suffering significant activity loss against 
susceptible strains (MIC ratio 2). Since protected glycine can be readily prepared in 
large-scale and, in particular, 32f has excellent activity against S. aureus, we decided to 
treat compound 32f as another lead for further chemical modifications to be discussed 
later. 
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Finally, despite having a very low kcat/KM value, the dimer, 62, displayed only 
modest activities against susceptible strains and low activity against resistant strains. 
Once again, this result implies the broader substrate promiscuity of APH(3′)-IIIa than 
the binding pocket of the targeted rRNA site. Overall, the results from enzymatic 
studies suggest that a low kcat/KM value may not be applicable to predict the 
antibacterial activity of aminoglycoside constructs against resistant bacteria equipped 
with AMEs. 
 
IV.3.3. Antibacterial Assay of Selected Derivatives  
      against Other Pathogens 
As mentioned previously, 5′′-modified neomycin derivatives seem to be more 
active against Gram positive bacteria (S. aureus) than Gram negative bacteria (E. coli), 
and 32f appears to be one of the most prominent leads having a similar MIC ratio to 
amikacin. Therefore, 32f was further derivatized to prepare 32q by extending one 
glycidal unit. In addition, we also intend to explore the spectrum of the antibacterial 
activity of 32b and 32c against other clinically significant pathogens including 
Klebsiella pneumoniae (Gram negative), Methicillin-resistant S. aureus (MRSA, Gram 
positive), Pseudomonas aeruginosa (Gram negative), and Enterococcus faecalis (Gram 
positive). 
The results from the antibacterial assay are summarized in Table 7. As expected, the 
derivatives with relatively smaller structural modifications (32f and 32q) display 
similar antibacterial profiles as neomycin suggesting unaltered modes of bactericidal 
and resistant mechanisms. 32f and 32q are more active against P. aeruginosa as 
compared to neomycin but are less active as compared to amikacin and gentamicin. 
  
 
                                                                                  49
Overall, 32f is slightly more active than neomycin and implies that the structural 
modification with the glycidyl group is beneficial. Nonetheless, such a modification is 
insufficient in reviving the antibacterial activity against aminoglycoside resistant 
bacteria. 
Intriguing results were obtained from the screening of 32b and 32c that have drastic 
differences in their antibacterial activity profiles from other aminoglycosides (Table 7).  
In general, 32b and 32c are also more active against Gram positive bacteria than Gram 
negative bacteria as indicated in the MIC values. However, 32b and 32c exhibit 
prominent activities against E. faecalis (ATCC29212), while other aminoglycosides, 
including clinically used amikacin and gentamicin, are much less active. More 
impressively, 32b and 32c show excellent activities against VRE as compared to 
amikacin, gentamicin, and even vancomycin. The MIC of 32b and 32c is 4-8 and 8-16, 
respectively while most of the commenly used aminglycosides are inactive (MIC≥250). 
As mentioned previously, enterococci have intrinsic resistance against 
aminoglycosides because of the dull uptake of aminoglycosides. This result strongly 
supports that 32b and 32c have different modes of antibacterial action. Thus, the 
modifications on 32b and 32c are one of the very few examples of aminoglycoside 
derivatives with clinically useful activity against MRSA, VRE, and other resistant 
strains. These two leads will undergo further investigation on antibacterial activity and 
also their novel mode of anctibacterial action of these two compounds will be 
discussed. 
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Table 7. MIC of the 5”-modified neomycin derivatives against other strains of bacteria 
(Unit: μg/mL). 
 
Entry Compound 
K. 
pneumoniaea
K. 
pneumoniaeb
S. 
aureusc
P. 
aeruginosad 
E. 
faecalise 
E. 
faecalisf
1 32b 8−16 16−32 2−4 4 2−4 4−8 
2 32c 8−16 32 4−8 8−16 4−8 8−16 
3 32f 4 8 16−32 8−16 32−64 ≥250 
4 32q 4 8 32 16−32 64−125 ≥250 
5 neomycin B 4 16−32 125 64 64−125 ≥250 
6 amikacin 1 0.5 8−16 0.5−1 32−64 ≥250 
7 gentamicin 1 8 2−4 0.5−1 8−16 ≥250 
8 vancomycin ND ND ND ND ND 125 
a.  Klebsiella pneumoniae (ATCC 13883). 
b.  K. pneumoniae (ATCC 700603). 
c.  Staphylococcus aureus (ATCC 33591) (MRSA). 
d.  Pseudomonas aeruginosa (ATCC 27853). 
e.  Enterococcus faecalis (ATCC 29212). 
f.  E. faecalis (ATCC51299) (VRE). 
 
 
IV.4. Structural Optimization and Combinational  
    Antibacterial Study of 5"-Modified Neomycin 
IV.4.1. Antibacterial activity of 5” acyl neomycin derivatives 
We have demonstrated that neomycin derivatives bearing linear acyl groups at the 
5” position display unusual antibacterial activities, six additional compounds with 
different length of linear acyl groups were synthesized. These six compounds are 32a 
(C7), 32s (C10), 32r (C12), 32t (C14), 32b (C16) and 32c (C18). These synthesized 
aminoglycosides analogues were assayed against both Gram positive (G+) and Gram 
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negative (G-) susceptible and resistant bacterial strains using neomycin B, amikacin, 
and vancomycin as the controls. The minimum inhibitory concentrations (MIC’s) are 
summarized in Table 8.  
From the MIC values, the 5"-acylated neomycin derivatives are generally more 
active against Gram positive bacteria than Gram negative bacteria. When comparing 
the antibacterial activity of each compound, compound 32a displays a similar MIC 
profile as compared to neomycin: 4-8 fold less active than neomycin against 
aminoglycoside susceptible strains while inactive against aminoglycoside resistant 
strains. This indicates that 32a has similar mode of action as neomycin. Further 
increase of the acyl chain length from heptanoyl (32a) to decanoyl (32s) leads to a 
decrease in antibacterial activity: 8-16 folds less active than neomycin against 
aminoglycoside susceptible strains and inactive against aminoglycoside resistant 
strains. However, the MIC profile of 32s remains similar to that of 32a and neomycin. 
As the acyl chain length extending to C14, C16, and C18 for compounds 32t, 32b and 
32c, respectively, the reviving activity against aminoglycoside resistant strain was 
noted which implicates a different modes of antibacterial action have arose from these 
three derivatives. Among all the neomycin derivatives, 32b is still the best lead which 
will undergo further investigation. 
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According to the relationship between acyl chain length and MIC profile, it appears 
that when a shorter chain length was incorporated, the derivatives maintain the original 
mode of antibacterial action as the parent neomycin: binding to the A-site decoding 
region of 16S rRNA. The added acyl chain, however, reduces the activity of 32a, likely 
due to the steric interference of acyl group on the binding of neomycin derivative 
toward rRNA. As the chain length increases, the steric hindrance will increase resulting 
in further decrease in the antibacterial activity. Nevertheless, when much longer acyl 
chains were incorporated, the constructed neomycin derivatives displayed significant 
antibacterial activity with the SAR in the order of C16 ≈ C18 > C14 against both 
susceptible and resistant strains. Since elevated steric hindrance from these long acyl 
groups are expected, it is unlikely that compounds 32t, 32b, and 32c regain their 
antibacterial activity by exerting the same mode of action as neomycin. The previous 
enzymatic and molecular modeling studies also revealed that AME’s can inactivate 
aminoglycosides with diverse structural motifs. Therefore, it is probable that these 
three neomycin derivatives have different modes of antibacterial action because of the 
increase in lipophilicity. The connection between the lipophilicity and revived 
antibacterial activity indicates that the longer acyl side chain might alter membrane 
permebility so as to increase the uptake of neomycin derivatives into the bacterial cell. 
The activity of 32t, 32b and 32c against Enterococci, which are known to be 
intrinsically resistant against traditional aminoglycosides, also supports this hypothesis. 
 
IV.4.2. Combinational studies of 5” acyl neomycin derivatives 
Using a combination of antibiotics is a common practice in the treatment of 
  
 
                                                                                  54
bacterial infection. Such practice has the advantages of potentially enhancing the 
efficacy of treatment as in the case of synergism, lowering the possibility of inducing 
drug resistance from microbes, and reducing the dose of antibiotics. An example of 
such synergism is the use of vancomycin that targets bacterial cell membrane in 
combination with gentamicin, an aminoglycoside.82 Therefore, it is worthy to explore 
the use of the new neomycin derivatives in combination with clinically used antibiotics. 
Since 32b appears to be the most active neomycin derivative, 32b was selected along 
with amikacin, neomycin B and vancomycin for the combinational antibacterial study. 
A checkerboard assay was employed for the antibiotic combinational study. The 
selected antibiotics were used in combination with the lead, 32b. The results are 
summarized in Table 9. From the fractional inhibitory concentration (FIC) index, 
compound 32b displays a strong synergistic effect with amikacin and/or neomycin 
against Gram neative bacteria including E. coli, K. pneumoniae, and P. aeruginosa. 
Since compound 32b alone is less active against Gram negative bacteria, one possible 
reason could be that 32b causes damage to the bacterial membrane and facilitates the 
entrance of amikacin into bacteria. Such effect appears to be consistent regardless the 
strains of bacteria. The synergistic effect with 32b and aminkacin was consistently 
observed with all Gram negative bacterial strains tested. With Gram positive bacteria, 
the synergistic effects with 32b were inconsistent with the outcomes ranging from 
synergism to indifference with amikacin and vancomycin. The synergism of amikacin 
and 32b against MRSA is of interest. As MRSA is equipped with various AMEs that 
should drastically reduce the activity of aminoglycosides, including amikacin, the 
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observed synergism is unexpected. The synergism of vancomycin and 32b against E. 
faecali is difficult to explain. It is possible that the action of 32b may not interfere with 
the action of vancomycin, and unlike the combinational effect against G- bacteria, it 
may depend on individual bacterial strain. The difference in the combinational effect of 
compound 32b against G+ and G- could possibly reflect the action of compound 32b 
toward inner and outer membranes, respectively. 
 
IV.5. Summary 
A facile and cost-effective method was developed for constructing library 
neomycin derivatives. Enzymatic studies show that low kcat/KM values for the 
structurally modified aminoglycosides may not be applicable to suggest that these 
aminoglycosides could avoid the enzyme-catalyzed inactivation and regain their 
antibacterial activity. Although structural modifications that can be accommodated by 
the binding site of rRNA could also be readily accommodated by AMEs as well which 
make the development of structurally modified aminoglycosides active against 
resistant bacteria not easy, it is possible to revive the antibacterial activity of 
aminoglycoside using structural modifications that can alter the original mode of action. 
For example, two leads 32b and 32c are active against both MRSA and VRE that are 
known to exert a high level resistance to aminoglycosides. This finding is significant 
because the transfer of resistance from enterococci to opportunistic S. aureus has been 
recognized as one of the stringent threats to public health.83 
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    Although compound 32b is more effective when used alone against Gram positive 
bacteria like MRSA and VRE, combination study have shown shown that it is possible 
to use 32b in combination with aminoglycosides against Gram negative bacteria. 
Antibacterial activities were measured when combined with other clinically used 
antibiotics. Significant synergistic activities were observed, which may lead to the 
development of novel therapeutic practices in the battle against infectious bacteria. 
Antibacterial activity of both 32b and 32c support a novel mode of antibacterial activity 
connected with increased lipophilicity. Because they are attached with long acyl side 
chain, they will interfere with the membrane of the bacterial and increase the uptake of 
aminoglysides into the bacterial cell. Good activity against VRE of 32b and 32c and 
synergism of 32b with amikacin against most of the bacterial strains also proved the 
novel mode of antibacterial activity of 32b. More aminoglyside-lipid conjugates will be 
synthesized in future to carry out further research on their activites. 
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CHAPTER V 
  DIVERGENT SYNTHESIS OF THREE CLASSES OF ARYL 
N-GLYCOSIDES BY SOLVENT  
 
Heterocyclic compounds, such as indanedione, benzazepine, and anthraquinone, 
have long attracted great interest due to their important biological and pharmaceutical 
applications leading to the development and discovery of numerous therapeutics 
(Figure 15). For example, compounds bearing 2-methylene-1,3-indanedione or 
2-methylene-4-cyclopentene-1,3-diones scaffold have been studied for their activity as 
fungicide, antitumor agents,84 and potential therapeutic for hypotension. Benzazepine 
analogs have been noted to exert a wide range of pharmacological activities.85 
Anthraquinone, which can be viewed as part of the structural core of anthracycline, has 
also been the focus of synthetic effort in generating novel antibiotics or anticancer 
agents.86 Finally, both naphthoquinone and anthraquinone are known to uncouple 
mitochondria oxidative phosphorylation leading to mechanistic investigations in drug 
toxicity and related applications.87 The syntheses of these three classes of cyclic 
aromatic compounds, in general, require multi-step processes and often begin from 
various starting materials. 
Carbohydrates are ideal building blocks for diversity-oriented synthesis of 
molecules of interest. While various methods for the preparation of O-aryl88 and C-aryl 
glycosides have been documented,89 very little has been devoted to the synthesis of 
N-aryl glycosides.90 The synthesis of N-glycosylated heterocyclic compounds is of 
particular interest since the amino group on any of these three classes of compounds is 
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not considered a good nucleophile to undergo traditional glycosylation via an 
oxycarbenium intermediate. On the other hand, glycosyl amines are not stable enough 
to act as a nucleophile in nucleophilic substitution to make N-glycosyl compounds. 
Azides are known to cyclize with electron-deficient alkene. Azides can react with 
naphthoquinone since the double bond between C2 and C3 of 1,4-naphthoquinone or 
α,β-unsaturated ketones can also be treated as an electron-deficient alkene. Although 
cycloaddition between azides and naphthoquinone have been reported,91 the 
cycloaddition between naphthoquinone and glycosyl azides has never been reported. In 
this chapter, the cycloaddition between naphthoquinone and azides in different reaction 
conditions will be studied and the products formed will be characterized. At the same 
time, some interesting results based on these reactions will also be reported.  
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Figure 15. Examples of cyclic aromatic compounds 
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V.1. Rationale for the drug design 
    In light of their biological applications, it is worthy to develop a method that can 
lead to the formation of not only azepinedione and 4-cyclopentene-1,3-dione adducts 
but also the cycloaddition adduct, or the oxidized form of triazoline, which with 
carbohydrate moieties attached. The synthetic design is shown in scheme 8 based on 
the literature.91b Cycloaddition of napthoquinone 63 and different glycosyl azides will 
give triazoline 64 no matter the solvent is polar or nonpolar. However, if the 
cycloaddition is conducted in polar solvent, it will favor a tautomerization that 
produces the N-glycosylated 9,10-hydroxyanthraquinone analog 65 which can be 
oxidized into the more stable 9,10-anthraquinone analog 66. Compound 66 resembles 
both naphthoquinone and anthraquinone and could possess greater biological 
significance. In contrast, if employing less polar solvent, the initial triazoline may 
fragment into 67, which could produce both N-glycosylated ring-expansion (68) and 
ring-contraction (69) products. Furthermore, Lewis acids can also facilitate the 
degradation of triazoline leading to the formation of only ring-expansion and 
ring-contraction adducts.91b However, the formation of 68 and 69 can also come from 
the intromolecular alkyl migration follwed by release of N2 without undergoing 
decomposition. In either mechanism, by varying solvent or apply Lewis acids, 
heterocyclic compounds, such as indanedione, benzazepine and anthraquinone can be 
prepared for broad biology activity test. 
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Scheme 8. Proposed effect of solvent 
 
V.2. Synthesis of naphthoquinone derivatives  
    by cycloaddition of glycosyl azides and naphthoquinone 
 
V.2.1. Cycloaddtion between naphthoquinone  
       and glycosyl azides by solvent control 
A series of naphthoquinone derivatives were synthesized by the cycloaddtion of 
naphthoquinone and different azides including various glycosyl azides, benzyl azide, 
4-(N-tert-Boc-piperidinyl) azide, adamantyl azide and 2-picolyl azide. The results are 
listed in Table 10. Cycloaddition carried out using toluene as the solvent offered three 
products as a mixture of 66, 68, and 69. The first two components are an anthraquinone 
analogue 66 and azepinedione 68, which often have very close Rf values on TLC can be 
partially separated by column chromatography leaving some fractions a mixture of 66 
and 68. These two compounds will be designated as A1 and A2 because they are close 
in Rf and can be partially separated by column chromatography. Most of time, A1 is 
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eluted out a little earlier than A2 from column. The third and most polar product 
4-cyclopentene-1,3-dione 69 can be separated from the first two as the major 
component. It will be designated as B. Cycloaddition in a more polar solvent than 
toluene will increase the selectivity of 66. For example, cycloaddition using dioxane, 
which has a higher polarity than toluene, yielded only 66a and 69a. By conducting the 
cycloaddition of 1,4-naphthoquinone and azidoglucose in DMF at 120 °C, only the 
oxidized cycloaddition adduct 66a was isolated and all the cycloaddition conducted in 
DMF furnished exclusively the expected products (66a-n) with modest to excellent 
yields. The selectivity is excellent. The cycloaddition protocol is also applicable for the 
preparation of 66l by using a diazido mannitol 17 and for the preparation of 66m by 
using a monoazido mannitol 16. Furthermore, the high selectivity in DMF is not only 
applicable to glycosyl azide, but also alkyl azide. 
 
V.2.2. Epimerization of cycloaddition of azidoxylose with toluene 
The cycloaddition of azidoxylopyranose 10 in toluene produced a mixture of 
anomers (69g and epi-69g) despite that 10 was in pure configuration. A possible 
mechanism involving intramolecular tautomerization is proposed in Scheme 9. Unlike 
other hexoses, xylopyranose lacks the equatorial C-6 which lowers the energy barrier 
for the formation of conformation-constrained imine intermediate leading to the 
epimerization at C-1.  
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Table 10. Cycloaddition of naphthoquinone and azides 
 
Yield (%)a Entry Alkyl azide Solvent 
68 66 69 
toluene 24% 25% 33%
dioxane - 32% 19%1 
Per-O-acetylated β-D-Glucopyranosyl 
4 (a) 
DMF - 67% - 
toluene 17% 17% 34%
2 
Per-O-acetylated 
β-D-Galactopyranosyl 5 (b) DMF - 66% - 
3 
Per-O-acetylated α-D-Mannopyranosyl 
6 (c) 
DMF - 49% - 
4 Per-O-acetylated β-Lactosyl 7 (d) DMF - 97% - 
5 
Per-O-acetylated β-L-Fucopyranosyl 8 
(e) 
DMF - 74% - 
toluene 11% 11% 43%
6 
Per-O-acetylated 
α-L-Rhamnopyranosyl 9 (f) DMF - 87% - 
toluene 12% 11% 23%b 
7 
Per-O-acetylated β-Xylopyranosyl 10 
(g) DMF - 85% - 
8 Per-O-acetylated β-D-GlcNAc 11 (h) DMF - 35% - 
toluene 9% 9% 36%
9 Per-O-acetylated β-Cellobiosyl 13 (i) 
DMF - 73% - 
10 Per-O-acetylated β-Cellotriosyl 14 (j) DMF - 85% - 
toluene 11% 12% 20%
11 
Per-O-acetylated β-D-Ribofuranosyl 
15 (k) DMF - 79% - 
12 
Per-O-acetylated 
1,6-diazido-D-mannitol 17 (l) 
DMF - 99% - 
toluene 28% 34% 25%
13 
Per-O-acetylated 1-azido-D-mannitol 
16 (m) DMF - 91% - 
toluene 5% 64% 18%
14 4-(N-tert-Boc-piperidinyl) 70 (n) 
DMF - 85% - 
15 Adamantyl 71 (o) DMF - 52% - 
16 Benzyl 72 (p) DMF - 82% - 
17 2-Picolyl 73 (q) DMF - 60% - 
All the cycloaddition reactions were conducted with 2/1 ratio of naphthoquinone/azide at 120 °C for 2 
days. a With the exception of 68m and 66m, the yields of 68 and 66 obtained from cycloaddition in 
toluene were calculated from the integral ratio of 1H NMR. b The cycloaddition of azidoxylose in 
toluene produced a mixture of α and β anomers despite that azido xylose was in pure β configuration.  
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Scheme 9. Proposed mechanism for epimerization of 69g 
V.3. Preparation of NQ and NQF series of compounds 
NQ and NQF series of compounds were prepared by the deprotection of acetyl 
groups on cycloaddition products (66) and ring-contraction products (69). These 
reactions were accomplished by using K2CO3 in MeOH or NaOMe/MeOH (Tables 11 
and 12). When NaOMe/MeOH was employed, the crude product and be readily 
purified using solid phase extraction (Amberlite 120(H+)) followed with 
recrystallization. The concise protocol is advantageous in providing library of 
compound in this class.  
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Table 11. Deprotection of 66 
 
Entry Reactant Conditiona Product Code Yield (%) 
1 66a A 74a NQ001 99% 
2 66b B 74b NQ002 46% 
3 66c A 74c NQ003 62% 
4 66d A 74d NQ004 99% 
5 66e A 74e NQ005 41% 
6 66f B 74f NQ006 33% 
7 66g A 74g NQ007 79% 
8 66h A 74h NQ008 56% 
9 66i A 74i NQ010 99% 
10 66j A 74j NQ011 57% 
11 66k A 74k NQ012 57% 
12 66l A 74l NQ013 23% 
13 66m A 74m NQ014 97% 
14 66n C 74n NQ101 94% 
a A: NaOMe, MeOH; B: K2CO3, MeOH, H2O; C: TFA, CH2Cl2 
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Table 12. Deprotection of 69 
 
Entry Reactant Conditiona Product Code Yield (%) 
1 69a A 75a NQF001 64% 
2 69b A 75b NQF002 53% 
3 69f A 75f NQF006 39% 
4 69g A 75g NQF007(A)/(B) α: 35%, β: 53% 
5 69i A 76 NQF000 decomposed 
6 69k A 75k NQF012 46% 
7 69m A 75m NQF014 40% 
8 69n B 75n NQF101 99% 
a A: K2CO3, MeOH, H2O; B: TFA, CH2Cl2. 
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Unfortunately, deprotection of the acetyl groups on ring-expansion products (68) 
under various conditions failed to yield the desired products. Due to the epimerization 
of 69g during the cycloaddition step, deprotection of 69g leads to the isolation of 20g 
and epi-20g (Table 12, entry 4). Deprotection of 69i produces an adduct 76 (NQF000) 
without a carbohydrate component (Table 12, entry 5). In general, the yields for the 
deprotection of acetyl groups of 69 are lower than that of 66. It is likely that the 
4-cyclopentene-1,3-dione scaffold of 69 may function as a Michael acceptor with a loss 
of the carbohydrate component via an addition/elimination process. Deprotection of the 
Boc group on 66n and 69n can be fulfilled using TFA in CH2Cl2. 
 
V.4. Investigation on the Reaction Conditions 
In order to investigate the nature of oxidant and the other factors such as Lewis acid, 
temperature, solvent that might affect the cycloaddition reaction, series reactions in 
different conditions and the related product distribution for 66 (9,10-anthraquinone 
analogue), 68 (ring-expansion), and 69 (ring-contraction) were tested. Four different 
azido compounds including 4, 16, 70, and 72 (benzyl azide) were employed. The azido 
group on glycosyl azide 4 should be the most electron-deficient among all four azido 
compounds examined due to the presence of electron-withdrawing acetyl groups and 
the direct attachment of azide to the anomeric center. The azido group on 16 should be 
more electron-rich than 4 due to the absence of an anomeric center. However, with the 
presence of acetyl groups, the azido group on 16 should be more electron-deficient than 
the one on alkyl azides (70 and 72). Therefore, the sequence of the electron density is 
4<16<70<72. Series reactions have demonstrated some interesting results (Table 13). 
  
 
                                                                                  68
        
T
ab
le
 1
3.
 In
ve
st
ig
at
io
n 
of
 th
e 
ef
fe
ct
 o
f T
M
SO
Tf
 a
nd
 th
e 
po
te
nt
ia
l o
xi
da
nt
 
 
En
try
 
R
ea
ct
an
ts
 (r
at
io
) 
So
lv
en
t, 
te
m
p.
, t
im
e 
A
dd
iti
ve
s (
eq
ui
v.
) 
C
om
po
un
ds
 (y
ie
ld
 %
) 
1 
63
/4
 (1
/1
) 
D
eg
as
se
d 
to
lu
en
e,
 R
T,
 1
 d
ay
 th
en
 6
0°
C
, 1
 
da
y 
TM
SO
Tf
 (2
 e
qu
iv
.) 
N
o 
re
ac
tio
n;
 R
ec
ov
er
ed
 4
 
2 
63
/4
 (1
/1
) 
C
H
2C
l 2,
 R
T,
 1
 d
ay
 th
en
 re
flu
x,
 1
 d
ay
 
TM
SO
Tf
 (2
 e
qu
iv
.) 
N
o 
re
ac
tio
n;
 R
ec
ov
er
ed
 4
 
3 
63
/4
 (1
/1
) 
D
eg
as
se
d 
D
M
F,
 1
20
°C
, 2
 d
ay
s 
- 
66
a 
(3
8%
);R
ec
ov
er
ed
 4
 (4
3%
) a
nd
 6
3 
(3
1%
) 
4 
63
/4
 (2
/1
) 
D
eg
as
se
d 
D
M
F,
 1
20
°C
, 2
 d
ay
s 
- 
66
a 
(6
1%
) 
5 
63
/1
6 
(2
/1
) 
D
eg
as
se
d 
to
lu
en
e,
 1
20
°C
, 2
 d
ay
s 
- 
66
m
 (3
4%
), 
68
m
 (2
8%
), 
69
m
 (2
5%
) 
6 
63
/1
6 
(1
/1
) 
D
eg
as
se
d 
to
lu
en
e,
 1
20
°C
, 2
 d
ay
s 
N
a 
as
co
rb
at
e 
(1
 e
qu
iv
.) 
66
m
 (3
2%
), 
68
m
 (2
5%
), 
69
m
 (1
5%
) 
7 
63
/1
6 
(1
/1
) 
D
eg
as
se
d 
to
lu
en
e,
 1
20
°C
, 2
 d
ay
s 
- 
66
m
 (3
4%
), 
68
m
 (2
3%
), 
69
m
 (1
8%
) 
8 
63
/7
0 
(2
/1
) 
D
eg
as
se
d 
to
lu
en
e,
 1
20
°C
, 2
 d
ay
s 
- 
66
n 
(4
3%
), 
68
n 
(1
3%
), 
69
n 
(1
6%
) 
9 
63
/7
0 
(2
/1
) 
D
eg
as
se
d 
D
M
F,
 1
20
°C
, 2
 d
ay
s 
- 
66
n 
(8
5%
) 
10
 
63
 /7
2 
(2
/1
) 
D
eg
as
se
d 
to
lu
en
e,
 1
20
°C
, 2
 d
ay
s 
- 
66
p 
(6
1%
), 
68
p 
(2
%
)a ,
, 6
9p
 (2
%
)a
 
11
 
63
 /7
2 
(2
/1
) 
D
eg
as
se
d 
D
M
F,
 1
20
°C
, 2
 d
ay
s 
- 
66
p 
(8
2%
) 
12
 
63
 /7
2 
(1
/1
.5
) 
C
H
2C
l 2,
 0
°C
 to
 R
T,
 1
0 
hr
s 
TM
SO
Tf
 (2
 e
qu
iv
.) 
68
p 
(2
0%
), 
69
p(
40
%
) 
13
 
63
 /7
2 
(2
/1
) 
D
eg
as
se
d 
D
M
F,
 0
°C
 to
 R
T,
 1
-2
 d
ay
s 
TM
SO
Tf
 (2
 e
qu
iv
.) 
N
o 
re
ac
tio
n 
14
 
63
 /7
2 
(2
/1
) 
D
eg
as
se
d 
D
M
F,
 1
20
°C
, 2
 d
ay
s 
TM
SO
Tf
 (2
 e
qu
iv
.) 
66
p 
(3
9%
), 
R
ec
ov
er
ed
 6
3 
(1
3%
) 
A
ll 
th
e 
re
ac
tio
ns
 w
er
e 
co
nd
uc
te
d 
un
de
r N
2, 
a  E
st
im
at
ed
 y
ie
ld
s f
ro
m
 1 H
 N
M
R
. 
 
  
 
                                                                                  69
1) Naphthoquinone is the oxidant. With all attempts employing degassed solvents, 
sodium ascorbate, or stoichiometric naphthoquinone to avoid the oxidation of the initial 
triazoline product, the formation of 66 from the oxidation of the initial triazoline adduct 
was observed in all the cases. When stoichiometric naphthoquinone was employed, the 
decreased yield of 66 was noted (entry 3). The results confirm that the reactant, 
naphthoquinone, also functions as the oxidant to oxidize the initial triazoline adducts. 
2) Heating is more efficient in facilitating the cycloaddition than Lewis acid 
(TMSOTf). The presence of Lewis acid (TMSOTf) is less effective in facilitating the 
cycloaddition than heating (temperature effect) when the electron-deficient azide 4 was 
used (Table 13, entries 1 and 2). Apparently, the electron-withdrawing nature of 
anomeric carbon dramatically reduces the reactivity of glycosyl azides. The results 
support that the cycloaddition step is thermodynamically controlled and could be the 
rate-limiting step. 
3) Cycloaddition in DMF offer good selectivity for 66 (9,10-anthraquinone analogue). 
Excellent selectivity for 66 in DMF was obtained regardless of electronic environment 
of azides. For example, under the condition reported by Aube and co-workers 
(TMSOTf, CH2Cl2, rt),91b cycloaddition between naphthoquinone 63 and benzyl azide 
72 provided only 68p and 69p. In contrast, using our protocol, only 66p was produced 
(Table 13, entry 11). This result supports our previous speculation that DMF may favor 
a fast tautomerization of the initial triazoline adduct 64 followed by a fast redox 
reaction with excess naphthoquinone. When less polar solvents (toluene and CH2Cl2) 
were used, the triazoline adduct cannot be tautomerized completely, which leads to the 
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fragmentation of 64 and the formation of 68 and 69 under thermodynamic conditions or 
with the presence of Lewis acid. Interestingly, the use of Lewis acid (TMSOTf) was 
ineffective in facilitating the cycloaddition when DMF (entry 13) was employed. 
4) The more the electron deficient for the azides, the higher the yield of 69 (ring 
contraction) produced. The electronic effect of azides also plays a role in directing the 
product formation: the yield for 66 increases as the electronic environment of azides 
changes from electron-deficient to electron-rich. For example, when the cycloaddition 
was conducted in degassed toluene under nitrogen, the yields for 66 varied from 24% 
(66a), 34% (66m), 43% (66n) to 61% (66p). Electron-rich alkyl azides increase the rate 
of oxidation of 65 and produce more 66 while electron-deficient azides, such as 
glucosyl azide 4, will lower the rate of oxidation, allowing for the formation of more 
fragmentation products (68 and 69). 
 
V.5. Anticancer activity 
From the preliminary screening via the DPT/NCI program, 74f (NQ006) and 74k 
(NQ012) have shown significant anticancer activity (mean growth percent of 17.58 and 
−5.95, respectively) and are subjected for further investigation. It was also found that 
both leads have good anticancer activity against melanoma and leukemia (Figure 16). 
74k (NQ012) has demonstrated good activity against melanoma with an IC 50 smaller 
than 1μM in the five dose test (Figure 17). The good anticancer activity proves that the 
synthesis of NQ series of compounds can pave a way for the discovery of novel 
anticancer agents. 
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V.6. Conclusion 
By varying solvent, three classes of N-glycosylated heterocyclic compounds with 
immense applications can be synthesized. The cycloaddition between naphthoquinone 
and azidosugars conducted in DMF offers excellent selectivity for the formation of 
biologically interesting N-glycosylated 9,10-anthraquinone analogs (66). The 
cycloaddition in toluene gave three products 68, 66 and 69. Although deprotection of 
68 failed to offer the desired product, deprotection of 66 and 69 can prepare 
naphthoquinone and indanedione derivatives. I have also proved that alkyl azide can 
undergo the same cycloaddition with naphthoquinone further expanding the structural 
repertoire available for a broader interest.  
For the synthesized heterocyclic compounds, 74K has been demonstrated good 
anticancer activity against both melanoma and leukemia. In future the oxidative 
potential of the above naphthoquinone derivatives will be measured to further 
investigate the anticancer mode of action of these naphthoquinone derivatives. 
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CHAPTER VI 
 ONE-POT SYNTHESIS OF 1- AND 2-SUBSTITUTED 
NAPHTHO[2,3-d][1,2,3]TRIAZOLE-4,9-DIONES 
 
Azido compounds have been widely used for 1,3-dipolar cycloaddition reactions 
recently and many novel synthetic methodologies have been developed. Numerous 
efforts have been devoted to simplify the synthetic protocol by conducting the 
cycloaddition in a one-pot design, for example, the “click” chemistry has been 
accomplished in one-pot fashion by using sodium azide, alkynes, Cu(I) catalyst, and 
appropriate aryl halides,92 alkyl halides,93 or epoxides.94 Azides can be prepared by the 
reaction between alkyl bromide and sodium azide in DMF. Cycloaddition of azides 
with naphthoquinone can be realized in DMF with high selectivity as well. Therefore, it 
is plausible to think of the one-pot three-component [2+3] cycloaddition in DMF. The 
desired products for the one-pot cycloaddition reaction will be the heterocyclic 
compounds bearing 1,2,3-triazole that will have broad spectrum of applications in 
biological, pharmaceutical and materials areas.95 
Reactions between quinones and azides have been reported.96 One-pot reaction of 
sodium azide with formaldehyde and alkynes has been reported to form both 1- and 
2-substituted 1,2,3-triazoles.97 However, one-pot synthesis with quinones, sodium 
azide, and appropriate alkyl halides has not been noted. 
 
VI.1. Rational for the drug design 
  
 
                                                                                  75
    A one-pot three-component [2+3] cycloaddition in DMF with NaN3, 
naphthoquinone, and alkyl halide will offer 1,2,3-triazole as the product. After 
methylation of 1,2,3-triazole, it can be converted into 1-alkyl-3-methyl-naphtho[2,3-d] 
[1,2,3]triazole-4,9-dione halide whose water solubility will be increased because of the 
presence of the ion. These series of compounds might have broad biology activity 
because the novel naphthoquinone derivatives with high polarity are arylator and redox 
cycler when interacting with biological molecules.  
 
VI.2. One-pot synthesis of 1- and 2- alkyl  
     substituted naphtha[2,3-d] [1,2,3]triazole-4,9-diones 
    The initial attempt by using naphthoquinone, sodium azide, and alkyl bromides in 
DMF successfully provided the anthraquinone analogue, 77, as both the expected 
products and the major products. At the same time, byproduct 2-alkyl 
2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione, 79, was obtained in various yields. 
Because this byproduct is hard to separate from 79 by common column 
chromatography system, it was designated as A3. Although it is difficult to separate 77 
and 79, which display almost identical Rf values on TLC and were mostly inseparable 
with use of silica gel-based column chromatography when eluted with commonly used 
organic solvents, these two compounds can still be separated and purified by using 
column chromatography eluted with a slightly acidic solution of hexane/CH2Cl2/HOAc 
because of different basicities of 77 and 79. The results are shown in Table 14. It can be 
seen that the length of the alkyl chain increases, the ratio of 77/79 also increases.  
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 Table 14. One-pot synthesis of 1-alkyl 1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione 
 
Entry alkyl bromide isolated yield (%) Ratio of 77/79a 
1 BnBr (78a) 66p, 96% 100:0 
2 C4H9Br (78b) 77b, 50%   79b, 25% 3.0:1 
3 C5H11Br (78c) 77c, 41%   79c, 12% 4.7:1 
4 C8H17Br (78d) 77d, 52%   79d, 10% 8.2:1 
5 C12H25Br (78e) 77e, 64%   79e, 4% 10.0:1 
6 C16H33Br (78f) 77f, 68%   79f, 4% 14.9:1 
7 HO(CH2)6Br (78g) 77g, 58%   79g, 5% 8.1:1 
 a The ratio of 77/79 was determined based on the integral ratio of 1H NMR from mixture of 77 and 79. 
 
A metal-mediated three-component method has been shown to selectively offer 1- 
and 2-substituted 1,2,3-triazoles.98 However, it does not have the structural scaffold of 
naphthoquinone fused with 1,2,3-triazole that resembles 77 or 79. Although the 
synthesis of compound similar to 7799 and 79100 have been reported, the syntheses were 
via multiple steps. Thus, this one-pot method offers unique and simple syntheses of not 
only compound 77 but also the unusual compound 79 by just one step. 
 
VI.3. Mechanism of the formation of 77 and 79 
Naphthoquinone can react with azido compounds either via a [2+3] 
cycloaddition.101 Or through a Michael addition and/or oxidation process.102 Judging 
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from the structures of the azide,103 and the isolated products, we favor the cycloaddition 
mechanism for this one-pot synthesis. The formation of compounds 77 and 79 likely 
occurred through an initial cycloaddition of azide (NaN3) with naphthoquinone 
followed by an oxidation by excess naphthoquinone leading to the formation of an ionic 
pair intermediate, sodium naphtho[2,3-d][1,2,3] triazole-4,9-dione, 80 (path a, Scheme 
10). An SN2 nucleophilic substitution via either N-1/N-3 or N-2 of 80 toward the 
corresponding alkyl bromides yields products 77 or 79, respectively. In a different route, 
alkyl azide can be formed first via an SN2 nucleophilic substitution of azide (N3−) and 
then offer only product 77 according to the previously reported mechanism of 
cycloaddition/oxidation process. Finally, a Michael addition of azide with 
naphthoquinone under prolonged reaction and higher temperature can lead to the 
formation of 2-amino-1,4-naphthoquinone, 82 (path c, Scheme 10).104 It is possible that 
with an increase in the alkyl side chain length, the SN2 nucleophilic substitution of alkyl 
bromide 78 with azide (N3-) happened faster (path b) which leads to the increase 
amount of 77 over 79 (Table 14). 
 
VI.4. One-pot synthesis with other electrophiles. 
    The one pot reaction was also carried out with other electrophiles. The 
electrophiles included 4-mesylated N-tert-butoxycarbonylpiperidine (83), diethyl 
bromoethylphosphonate (84), methyl bromoacetate (85), ethyl bromoacetate (86), 
2,3,4,6-tetra-O-acetyl-D-glucopyranosyl bromide (87), ethyl acetate (88), 
1-chloroadamantane (89), and epoxides (90-92). The results were shown in Table 15. 
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Table 15. One-pot reaction with different electrophiles 
 
Entry Starting Material Total 
Yield (%)
77/79 Product 
1 
NMsO Boc
83 
28% 1.3/1 
   
O
O
N
N
N
N
12%
79h
O
O
N
N
N
16%
66n
Boc
Boc
 
2 P
O
O
O
Br
 
84 
46% 1.64:1
O
O
N
N
N
O
O
N
N
N
77i: 53% 79i: 32%
N
O
O
93:15%
 
3 
O
Br
O  
85 
45% 24.2:1
O
O
N
N
N
O
O
N
N
N
77j: 45% 79j: not isolated
a
4 
O
Br
O  
86 
   59% 1:1.44
O
O
N
N
N
O
O
N
N
N
77i: 22% 79i: 37%  
5 
O
Br
OAc
AcO
AcO
OAc
87 
No 
reaction -- -- 
6 Ethyl acetate 88 
No 
reaction -- 
O
O
NH2
82: 20 %  
7 
1-chloroadamantane 
89 
No 
reaction -- 
O
O
NH2
82: 18 %  
8 
O
 
90 
56% 1:1 
O
O
N
N
N
OH
O
O
N
N
N
HO
77l: 28% 79l: 28%
a The presence of 79j can be observed from the 1H NMR of the mixture of 77j and 79j. However, the 
amount of 79j was too scarce to be isolated. 
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Table 15. One-pot reaction with different electrophiles (Continued) 
 
Entry Starting Material Total Yield (%) 77/79 Product 
9 
Ph
O
 
91 
51% -- 
O
O
OH
OH
94:51%  
10 
O
PhO
 
92 
28% -- 
O
O
OH
OH
95:28%
O
O
Ph
Ph
 
a The presence of 79j can be observed from the 1H NMR of the mixture of 77j and 79j. However, the 
amount of 79j was too scarce to be isolated. 
     
    When compound 83105 was employed, both 1- and 2-alkyl 
2H-naphtho[2,3-d][1,2,3]triazole-4,9-diones, 66n and 79h, were obtained (entry 1). 
However, the yield was much lower than the other examples. The reason could be 
attributed to the slower rate of SN2 nucleophilic substitution of the secondary mesylated 
group as compared to that of the primary alkyl bromides, which led to the 
decomposition of the ionic intermediate 80 and, hence, the lower yields. When 
1-chloroadamantane, 89, was employed, no reaction was noticed (entry 7). This result 
implies that cycloadditon of azide (N3-) and naphthoquinone (path a, scheme 10) should 
occur much faster than the SN1 nucleophilic substitution of azide (N3-) or ionic 
intermediate 80 toward 1-chloroadamantane. Ionic intermediate 80 is not stable and it 
decomposes before the SN1 nucleophilic substitution happens which cannot lead to the 
formation of desired product. Interestingly, 2-amino-naphthoquinone was isolated 
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because of the Michael addition. (path c) although no cycloaddition was observed. 
    Surprisingly, when compounds 85 and 86 were used, the expected products from 
alkyl α-azidoacetate generated in situ (entries 3 and 4) were not obtained. Rather, the 
product isolated were determined to be 1-methyl 1H-naphtho[2,3-d][1,2,3] 
triazole-4,9-dione, 77j, and 2-methyl 2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione, 79j, 
generated from 85, and 1-ethyl 1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione, 77i, and 
2-ethyl 2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione, 79i, produced from 86. The ionic 
intermediate 80 can be viewed as a “soft” nucleophile. The ester function group of 85 
and 86 clearly behaves as a leaving group. The ester group, by comparison to the 
α-bromo group, acts as a “softer” leaving group, which could explain the formation of 
the isolated products. Although the results are unexpected, this outcome can be a useful 
alternative method in preparing compounds 77 and 79 with small alkyl groups since 
small molecules of alkyl halides and alkyl azides could be too volatile or unstable to 
handle. When ethyl acetate was used, no product was obtained although 
2-amino-naphthoquinone was isolated from path c (entry 6). Apparently, the inductive 
effect of the bromo group on α-bromoacetyl group is crucial. 
When diethyl 2-bromoethylphosphonate, 84, was used, 77i and 79i were obtained 
(entry 2). At the same time, 2-(N-dimethyl) naphtoquinone 93106 was obtained which 
might come from the Michael addition of dimethyl amine generated in situ from DMF. 
Again, the phosphonate group acts as a “soft” leaving group that gives rise to the 
isolated products, 77i and 79i. Since no expected 1-alkylated or 2-alkylated 
1,2,3-triazoles were produced from azido compounds via a nucleophilic substitution of 
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azide (N3−) toward the alkyl bromides in 84, 85, and 86, the results concurred with our 
previous conclusion that cycloaddition of azide (N3−) should occur much faster than the 
nucleophilic substitution of azide.  
When using 2,3,4,6-tetra-O-acetyl-D-glucopyranosyl bromide, 87, failed to 
provide any products (entry 5). It is likely that a fast cycloaddition of azide (N3−) with 
naphthoquinone prevents the formation of glucopyranosyl azide. In the mean time, the 
intermediate 80 could not react with a relatively “hard” electrophilic anomeric carbon 
of compound 87, and consequently, no expected products were obtained. 
Finally, among the three epoxides tested, only propylene oxide 90 provided the 
expected products (entries 8-10, Table 15).  Styrene oxide 91 and Phenyl glycidyl 
ether 92 could not offer the desired product instead the products are 
1,4-bis((2-hydroxy-3-phenoxy)propoxy) naphthylene, 94, and 1,4-bis 
((2-hydroxy-2-phenyl)ethoxy) naphthylene, 95, respectively. A possible reason for the 
results is that a fast cycloaddition/oxidation converted all the azide to 80 and, in the 
same process, yielded 1,4-dihydroxynaphthalene from the reduction of naphthoquinone. 
This process also prevented the ring-opening of epoxides from azide, which is a step 
analogous to path b in Scheme 10. However, intermediate 80 could not undergo 
nucleophilic ring-opening of epoxides 91 and 92 likely due to their steric hindrance and 
“hardness.” Thus, the isolated products came from the nucleophilic ring-opening of 
epoxides from the hydroxyl groups on 1,4-dihydroxynaphthalene. In the case when less 
hindered propylene oxide, 90, was used, intermediate 80 could still undergo 
nucleophilic ring-opening of epoxide leading to the formation of 77l and 79l (path a). 
  
 
                                                                                  83
VI.5. One Pot reaction in toluene with nBu4NHSO4 
In chapter V, a dramatic solvent effect in dictating the product formation was 
noticed. Therefore, one-pot synthesis was also conducted in toluene with phase-transfer 
catalyst nBu4NHSO4. The products were determined to be 77 and/or 79 in addition to 
2-amino-1,4-naphthoquinone 82 (Table 16). 
For the one-pot reactions carried out in toluene, no products bearing the scaffolds of 
benzazepine-1,5-dione, 68, and 2-aminomethylene-1,3-indanedione, 69, were obtained. 
Two possible reasons can account for the observation. First, since we obtained 
compounds 68 and 69 by using alkyl azides, it is likely that the nucleophilic substitution 
of azide (N3−) to form alkyl azide (path b in Scheme 10) was inhibited when the one-pot 
reactions were conducted in toluene because of poor solubility of azide in toluene. 
Second, the cycloaddition of azide (N3−) and the subsequent nucleophilic substitution 
(path a, Scheme 10) occur much faster than the alkyl azide formation (path b) in toluene 
as well. On the basis of the ratio of 77/79 it appears that toluene favors the production of 
more 79, although compound 77 is still the major product. Since 79 can be formed only 
via path a, the higher yield of 79 is consistent with our speculation that path b is 
suppressed in toluene. In contrast to our previous study in chapter V, no solvent effect 
in favoring the formation of benzazepine-1,5-dione, 68, and 
2-aminomethylene-1,3-indanedione, 69, although decreased ratio of 77/79 was noted. 
The above analysis, however, is inapplicable to results generated from benzyl 
bromide (entry 1, Table 14, and entry 1, Table 16). Benzyl bromide can undergo 
nucleophilic substitution via either SN1 or SN2 mechanism. Thus, it is possible that the 
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formation of benzyl azide via path b occurs much faster than the formation of 80 via 
path a leading to the formation of only 1-alkylated triazole (66p). Nevertheless, such 
hypothesis requires further investigation. The formation of 82 can be explained as 
proposed in the literature (path c, Scheme 10).107 
 
Table 16. One pot reaction in toluene 
O
O
+ + NaN3
toluene, 2 days
 nBu4NHSO4, 120 oC,C4H9Br (78b)
C8H17Br (78d)
BnBr (78a)
O
O
N
N
N
R
O
O
N
N
N
R
O
O
NH2
77a R=Bn
77b R=C4H9
77d R=C8H17
79a R=Bn
79b R=C4H9
79d R=C8H17
+ +
82
 
 
Entry Alkyl Bromides 77 79 82 Ratio of 77/79
21 BnBr (78a) 21% - 51% 100/0 
22 C4H9Br (78b) 44% 21% 34% 1.45/1 
23 C8H17Br (78d) 53% 43% 14% 1.37/1 
 
O
O
N
N
N
N Boc
TFA, CH2Cl2
O
O
N
N
N
NH
79h 96
Scheme 11. Deprotection of 79h 
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One of the disadvantages for the application of 79h as therapeutic agents is the poor 
solubility and lower polarity. After the removal of the Boc protecting group, compound 
96 can be applied as anticancer agents (Scheme 11). Although both 77 and 79 have 
poor solubility and lower polarity, they can be used as potential therapeutic agents 
after methylation of the triazole.108 
 
VI.6. Conclusion 
    In conclusion, our one-pot protocol leads to the facile synthesis of 1-alkyl 
1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione, 77, and 2-alkyl 2H-naphtho[2,3-d][1,2,3] 
triazole-4,9-dione, 79. An efficient purification protocol for separating 77 and 79 has 
also been established for large-scale synthesis of compounds 77 and 79 of interest. 
    From the mechanistic perspective, the results imply that the [2+3] cycloaddition of 
azide (N3−) and naphthoquinone occurs much faster than the nucleophilic substitution 
of azide. Since the ionic intermediate 80 may degrade in prolonged heating, 
electrophiles like alkyl halides that are more reactive toward nucleophilic substitution, 
in general, provide better yields of compounds 77 and 79. However, the match of 
hardness and softness between the nucleophile 80 and the corresponding electrophiles 
is also important in dictating the site of nucleophilic substitution and the product 
formation. The Michael addition of azide to naphthoquinone may occur and 2-amino 
naphthoquinone was the product. Nevertheless, this reaction should be the slowest 
event under our synthetic protocol. With the exception of benzyl bromide, the rate of 
reaction for the proposed routes in our one-pot protocol carried out in DMF has the 
tendency as follow: path a > path b >> path c.109 
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CHAPTER VII 
 SYNTHESIS OF NOVEL AMINOGLYCOSIDES  
VIA ALLYLIC AZIDE REARRANGEMENT 
 
    The neamine core contributes predominately to the antibacterial activity of 
neomycin and kanamycin classes of aminoglycosides (Figure 2).69 Neamine has four 
amino groups located at 1, 3, 2', and 6' positions. The presence of 1-NH2 and 3-NH2 are 
essential for the antibacterial activity of aminoglycosides that contain neamine. The 
6'-NH2 amino group can be replaced with OH without obstructing the activity as in the 
case of paromomycin. Modifications such as deoxygenation at 3' and 4' positions has 
been shown to be effective in reviving the activity of aminoglycoside constructs against 
aminoglycoside resistant bacteria that equipped with aminoglycoside modifying 
enzymes (AMEs). For example, tobramycin that has deoxygenation at 3' position is 
active against bacteria equipped with aminoglycoside phosphotransferases that 
catalyze phosphorylation at 3'-OH position (APH(3')). Therefore, deoxygenation at 3' 
postion is a way to develop aminoglycosides against resistant bacteria equipped with 
APH(3').  
Although a lot of efforts have been spent on the SAR of aminoglycosides with 
neamine core, the roles of 2’-NH2 are multiplex and contradictory, especially, in 
association with the deoxygenation at 3' position. For example, there is no significant 
difference in the antibacterial activity between kanamycin B and kanamycin A that 
have 2'-NH2 and 2'-OH, respectively. However, for the neamine, if the 2'-NH2 is 
replaced with 2'-OH, the neamine with 2'-OH demonstrates much lower antibacterial 
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activity than the parent neamine.110 Furthermore, if 2'-NH2 was removed by 
deamination, the neamine with deamination at 2’ position manifests improved 
antibacterial activity.111 In order to investigate the significance of 2'-NH2 group, it is 
valuable to synthesize aminoglycosides with demaination of the 2'-NH2 group. 
Chemical deamination usually involves multiple steps and has not been noted to be 
accompanied with deoxygenation at 3' position. Since my group member has developed 
a mild method for introducing 3',4'-dideoxygenation on aminoglycosides.112 The 
process involves the synthesis of 3’,4’-dideoxylenoneamine, which is an allyl azide. 
The allylic azide rearrangement should offer a convenient access to deamination and 
deoxygenation at 2' and 3' positions, respectively. In addition, the 4'-OH will be 
replaced with 4'-NH2, which should maintain the interactions involved in the parent 
neamine.111 Adducts from allylic azide rearrangement could offer the information on 
the significance of having 2'-NH2 group and possess the enhanced activity against 
bacterial equipped with APH(3'). Although allyl azide rearrangement has been 
reported,113 such rearrangement has not been noted on azidoaminoglycosides. 
 
VII.1. Initial discovery of the allylic azide rearrangement 
The synthesis of azidoneamine core, 97 with a double bond between 3' and 4' 
positions was conducted according to our protocol.112 The discovery of allylic azide 
rearrangement on 97 was actually an unexpected result (Scheme 12). The initial 
attempts were designed to explore the antibacterial activity of non-carbohydrate 
moieties at O-6 and/or O-5 positions. The added functional groups were attached via 
carbamate linkage. When compound 97 reacted with N-hexylisocyanate generated in 
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situ, the alkylcarbamate was incorporated at O-6 as expected. However, when excess 
N-hexylisocyanate was used, two products, 99 and 100 with mono- and 
di-alkylcarbamates attached were isolated, respectively. Nevertheless, compound 99 
has different 1H NMR from 98. Upon further investigation, we confirmed that the 
double bond of both 99 and 100 were rearranged to 2' and 3' positions via an allylic 
azide rearrangement. 
 
O
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N3
N3
HO
OH
N3O
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NH2
triphosgene (1.5 eq.)
Et3N (8 eq.), CH2Cl2
-78 oC to r.t.
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Scheme 12. Carbamate modification of diol 97 
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Although we did not know the details regarding why such a rearrangement 
occurred in these conditions, we envisioned that this allylic azide rearrangement can be 
triggered with no added reagents and conveniently lead to the production of neamine 
derivative with deamination and deoxygenation at 2' and 3' positions, respectively. 
More importantly, the aminoglycosides resulted from this allylic azide migration will 
provide direct evaluation on the significance of 2'- NH2 group. 
 
VII.2. Allylic azide rearrangement of azidoneamine 
    The allylic azide rearrangement is expected to proceed under thermodynamic 
condition similarly to the [3,3]-sigmatropic rearrangement.113a,114 The allylic azide 
rearrangement using compound 97 can be carried out at 110ºC in toluene (Scheme 13). 
Since such rearrangement can be reversible, we obtained a mixture of 97 and 101, 
which can be separated by column chromatography. Compound 101 was acetylated to 
yield 103 in order to make the proton signals discernable. The structure of the neamine 
derivative, 101 from allylic azide rearrangement was confirmed by 2D NMR (COSY 
and HSQC). Both 97 and 101 were subjected to Staudinger reduction and 
hydrogenation to yield the neamine derivatives, 104 and 105, respectively. Direct 
glycosylation of 101 can provide the syntheses of 2',3'-dideoxykanamycin classes of 
aminoglycosides as reported previously. Regioselective benzoylation of 101 offered 
compound 102, which can be employed for the syntheses of 2',3'-dideoxyneomycin 
classes of aminoglycosides also as reported previously. 
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Scheme 13. Preparation of dideoxyenoneamine 
VII.3. Synthesis of novel aminoglycosides 
    Glycosylation of 101 using phenylthioglycoside, 106 offered the precursors of 
2',3'-dideoxykanamycin derivatives, 107 and epi-107 as the minor product (Scheme 14). 
In order to compare the activity, the corresponding 3',4'-dideoxykanamycin derivatives, 
108 was also prepared. Based on our previous structure-activity relationship (SAR) 
studies of kanamycin B analogs,115 compound 110 was synthesized. In our previous 
work, it has been noticed that the presence of 6"-CH3 is not essential for the 
antibacterial activity.116 Therefore, due to the consideration of availability of glycosyl 
donor, compound 112 was synthesized for comparing the activity of aminoglycosides 
from 110. The glycosyl donor, 111 can be prepared using similar procedures as 
reported.115 
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Scheme 14. Glycosylation on 6 postion of allylic migration neamine core 
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 Scheme 15. Glycosylation on 5 postion of allylic migration neamine core 
    Glycosylation of 102 using 113 yield the desired pyranmycin (a neomycin class 
aminoglycoside) derivative, 114 (Scheme 15). Based on our previous structure-activity 
relationship (SAR) studies of pyranmycin, compound 22 has the carbohydrate moiety 
that generates the most active aminoglycoside.115 The corresponding 3',4'-dideoxy 
pyranmycin derivatives has also been prepared previously. During the syntheses, it was 
found that that the rearrangement adducts with deoxygenation at 2' and double-bond 
between at 2' and 3' positions are very sensitive to acidic conditions. Therefore, all the 
processes were conducted with minimum exposure to acids, with addition of base, or at 
lower temperature. 
All the dexoyl azidoaminoglycosides were subjected to similar global deprotection 
(Staudinger reduction, purification followed by hydrogenation and ion-exchange 
column chromatography) to yield the designed aminoglycosides ready for assay 
(Scheme 16). 
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Scheme 16. Preparation of aminoglycosides by staudinger reaction and hydrogenation 
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Scheme 16. Preparation of aminoglycosides by staudinger reaction and hydrogenation. 
(continued) 
VII.4. Antibacterial activity of aminoglycosides 
    The synthesized compounds were assayed against aminoglycoside susceptible 
bacteria Escherichia coli (ATCC 25922, G-), Staphylococcus aureus (ATCC 25923, G+) 
and using neamine, neomycin and kanamycin as the controls (Table 17). From the 
minimum inhibitory concentration (MIC) results, the 2'-NH2 group appears to have 
contradictory roles. The 2'-NH2 group is important for the antibacterial activity of both 
neomycin and kanamycin classes of aminoglycosides since all the derivatives with 
2',3'-dideoxyaminoglycosides are less active than the corresponding 
3',4'-dideoxyaminoglycosides with the tendency of neamine> 
3',4'-dideoxyneamine>2',3'-dideoxyneamine. However, such tendency is less obvious 
or even reversed with the attachment of hexylaminocarbonyl group. For example, both 
NRR101 and NRR102 are slightly more active than RR101 (entries 4-6). Further 
testing also reveals that NRR102 manifests MIC’s of 32-64 and 125 μg/mL against E. 
coli equipped with APH3'-I and AAC6'/APH2", respectively. In contrast, neamine, 
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neomycin and kanamycin are inactive against these bacteria (MIC > 250 μg/mL). These 
results imply that 2',3'-dideoxyneamine (no 2'-NH2 group) combined with 
hexylaminocarbonyl group at O-5 or O-6 positions could be a novel motif for 
generating new aminoglycosides against resistant bacteria. 
To explore the unexpected effect of hexylaminocarbonyl group, we decided to 
synthesize two addition neamine analogs, RR103 and RR104, with mono- and di- 
hexylaminocarbonyl groups at O-6 and O-5/O-6 positions, respectively, while keeping 
the scaffold of neamine (Scheme 17). The syntheses can be achieved via similar 
processes using compound 115116 as the starting material. 
 
Table 17. MIC of Aminoglycosides (μg/mL) 
 
Entry Compound E. coli (ATCC 25922) S. aureus (ATCC 25923) 
1 Neamine 32 4-8 
2 10 32-64 16-32 
3 11 ≥250 64-125 
4 RR101 ≥250 125 
5 NRR101 ≥250 32-64 
6 NRR102 125 32 
7 Neomycin 4 1 
8 RR501 16 4-8 
9 NRR501 125-250 125-250 
10 Kanamycin 4 2 
11 RT014 64-125 125-250 
12 NRT014 ≥250 ≥250 
13 RT040 4-8 2-4 
14 NRT040 16-32 8-16 
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Scheme 17. Synthesis of RR103 and RR104 
A panel of aminoglycoside susceptible and resistant bacteria, including Klebsiella 
pneumoniae (ATCC 13883, susceptible, G-), K. pneumoniae (ATCC 700603, resistant, 
G-), Pseudomonas aeruginosa (ATCC 27853, resistant, G-), S. aureus (ATCC 33591, 
resistant, G+), were selected for evaluating the antibacterial activity.  
From the result of antibacterial assay, it is obvious that NRR102 is still the most 
active compound while other neamine derivatives with hexylaminocarbonyl group(s) 
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are less active (Table 18). We have recently reported that incorporation of linear alkyl 
chains could alter the tradition antibacterial mode of aminoglycosides leading to the 
generation of novel antibiotics.117 RR103 and RR104 are, however, much less active 
against P. aeruginosa (ATCC 27853) and S. aureus (ATCC 33591) that equipped with 
various APH(3') (entries 5 and 6).118 This result implies that these two analogs are still 
being inactivated by AME’s. Combining the antibacterial activity of these neamine 
analogs, we believe these analogs should exert traditional mode of antibacterial action. 
Therefore, the antibacterial activity of NRR102 against bacteria equipped with AME’s 
should be attributed to the deoxygenation of 3'-OH. Nevertheless, in this new neamine 
motif, the presence of 2'-NH2 group is no longer essential. Although the activity is less 
than what is needed to be clinically significant, it is possible that enhanced activity 
could be obtained by varying the length of the linear alkylamino chain.119 
 
Table 18. MIC of Aminoglycosides (μg/mL) 
 
Entry Compound K. pneumoniae 
(ATCC 13883 
K. pneumoniae 
(ATCC 700603
P. aeruginosa 
(ATCC 27853 
S. aureus 
(ATCC 33591) 
1 Neamine 2-4 16-32 64-125 125-250 
2 RR101 16-32 125 16-32 64-125 
3 NRR101 16-32 ≥250 16-32 64-125 
4 NRR102 4-8 ≥250 16-32 16-32 
5 RR103 16-32 125-250 64-125 ≥250 
6 RR104 32 125-250 125-250 125-250 
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VII.5. Conclusion 
    A convenient method for synthesizing 2',3'-dideoxyneomycin and 
2',3'-dideoxykanamycin derivatives has been developed The reported allylic azide 
rearrangement can also be applicable of making aminosugar derivatives. For example, 
this rearrangement can serve as an alternative method to the reported Pd-catalyzed 
π-allyl method for the preparation of C-4 allylic azides that has been employed in the 
syntheses of several biologically interesting compounds.120 
The antibacterial results confirm that 2'-NH2 group is indispensable for the activity 
of neomycin and kanamycin classes of aminoglycosides, which also suggest that it may 
be difficult to compromise the contradictory roles of 2'-NH2 group for these two classes 
of aminoglycosides. However, the results have indicated that having 
hexylaminocarbonyl groups at O-5 and/or O-6 of neamine along with the 
2',3'-dideoxyneamine core may serve as an alternative structural motif for generating 
novel aminoglycosides against resistant bacteria.  
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CHAPTER VIII 
CONCLUSIONS AND OVERALL SIGNIFICANCE 
    
    Several anticancer and antibacterial agents were developed via azide chemistry. 
Sonication was applied for efficient synthesis of carbohydrate containing therapeutic 
molecules such as oxazolidinone-carbohydrate conjugates as potential antibiotics and 
cyclopamine-carbohydrate conjugates as potential anticancer agents.  
    A library of neomycin derivatives with various modifications at the 5′′ position 
were synthesized via azide chemistry. It was found that neomycin-lipid conjugates with 
5′′ position attached with long acyl chain may possess novel antibacterial modes of 
action, and two leads 32b and 32c were found to be active against MRSA and VRE. 
Cycloaddtion reaction of naphthoquinone and azides in either two or three 
components reactions in different solvent systems was investigated. A library of 
carbohydrate attached anthraquinone and indandione derivatives were synthesized and 
were shown to have broad spectrum of biological activities.  
Using allylic azide rearrangements, a convenient method was developed to 
synthesize several 2',3'-dideoxyaminoglycosides to study SARs of aminoglycoside and 
to facilitate the development of aminoglycoside against resistant bacteria.  
    In this dissertation carbohydrates were incorporated into bioactive molecules with 
different glycosyl azides using either sonication assisted “click chemistry” or the 
cycloaddition reaction with naphthoquinone. An efficient and convenient protocol of 
incorporation of carbohydrates to prepare a serie of N-glycosides in an adaptable 
solvent was established using both routes. These approaches have major advantages as 
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compared to traditional used methods such as glycosylation121, neoglycosylation,122 
and enzyme catalyzed glycosylation.123 Chemical glycosylation requirs anhydrous 
conditions, lower temperatures, and the synthesis of doners is tedious. 
Neoglycosylation needs special alycon acceptor and the stereoselctivity usually is not 
satisfactory. Enzymatic glycosylation needs Nucleoside Diphosphate (NDP) sugars 
that are difficult to prepare and generating diversity is difficult because of the reaction 
specificities of glycosyltransferases. Further advantages of sonication assisted “click 
chemistry” and the cycloaddition reaction with naphthoquinone are that they can be 
applied to disaccharides and trisaccharides that are not typically good doners for other 
glycosylation methods.  Sonication assisted “click chemistry” is superior to the 
commonly and currently applied “click chemistry” nowadays124 in attaching 
carbohydrates onto therapeutic molecules. The new protocol with somication is more 
efficient, and the synthesis can be completed in 14 min. 
    Although an efficient synthetic protocol was established, the present study did not 
succeed in finding highly active glycosyl-based therapeutic moleucules. For example, 
in spite of enhanced water solubility, most of the cyclopamine-carbohydrate conjugates 
had lower anticancer activities although one lead with an α linkage L-rhamnose had 
slightly better activity. Only L-rhamnose and ribose attached to anthraquinone 
analogues showed promising anticancer activity. The attachment of most of the β 
linkage D-sugars did not show any enhanced activity. A possible explanation for this is 
that the β linkage glycosyl-based conjugates lack stablility for hydrolytic enzymes and 
they decompose before reaching their intracellular targets.125 In contrast, α linkage 
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isomers may be more stable to hydrolytic enzymes and capable of reaching target. It 
was found that attachment of α linkage L-rhamnose enhanced the activity. Therefore, 
to address the above problems, future studies are necessary to expand the library of 
glycosyl azides together with SAR investigations of diverse carbohydrate moieties. 
The expanded libraries should include α linkage sugar, L-sugar, amino sugar, sugar 
with branched side chain, or other position substituted azido sugars. The expanded 
sugar library will allow more SAR studies in related to the type or linkage of 
carbohydrates which will pave the way for finding promising glyosyl-based 
therapeutic molecules.  
    In this dissertation, it was found that the incorporation of long linear alkyl chains 
into aminoglycosides alters the traditional antibacterial mode of action of 
aminoglycosides. This stragegy may lead to the generation of novel antibiotics. The 
alkylated analogs also have potential antifungal activities. It was found that the 
incorporation of long alkyl chain on neomycin or 2',3'-dideoxyaminoglycosides have 
both demonstrated novel activities against resistant bacteria. A possible explanation 
for this is that the attachment of linear alkyl chain alters the mechanism of 
antibacterial activity related to interactions with cell membranes. In future studies, 
more aminoglycoside-lipid conjugates with long linear alkyl chain will be synthesized 
to investigate the novel mode of antibacterial activity and also antifungal activity. 
    It was found that not only glycosyl azides, but also benzyl azide, alkyl azides, and 
aryl azides can be attached to target molecules by “click chemistry” or cycloaddition 
reactions with naphthoquinone. Although the prepared “triazole derivatives” have 
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lower polarity than glycosyl azides, they can be protonated or methylated to synthesize 
ionized polar molecules in the future.126 This will extend the library of therapeutic 
molecules with enhanced water solubility and more potential activities.  
    The most promising result from this dissertation is that cycloaddition of 
naphthoquinone and azides under different conditions can yield diversities of 
heterocyclic compounds with potential activities. For example, some anthraquinone 
analogues have demonstrated novel anticancer activity, especially two leads NQ006 
or NQ012. Some indandiones have demonstrated novel antibacterial activity since 
indandiones are Michael acceptor and has interactions with biology molecules. 
Anthraquinones with benzyl or alkyl attached will be methylated to synthesize a novel 
library of biological molecules to test their novel antibacterial activities. The oxidative 
potentials or other properties of all these heterocyclic compounds should be measured 
for the study of mechanisms of action. And the broad spectrums of activities of all 
these compounds are anticipated and would require investigation in future. Results 
generated from these projects may pave the way for new drug development.  
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CHAPTER IX 
 EXPERIMENTAL SECTION 
 
Proton magnetic resonance spectra were recorded using JEOL 300, or Bruker ARX 
400 spectrometers. Chemical shifts were reported as parts per million (ppm) downfield 
from tetramethylsilane in δ unit and coupling constants were given in cycles per second 
(Hz), Signal multiplicities were indicated by s (singlet), d (doublet), t (triplet), and q 
(quartet), m(multiplet). 13C NMR spectra were obtained using JEOL 300 at 75 MHz, or 
Bruker ARX 400 at 100 MHz. Routine 13C NMR spectra were fully decoupled by 
broad-broad WALTZ decoupling. All NMR spectra were recorded at ambient 
temperature. Low-resolution fast-atom bombardment (LRFAB), high-resolution 
fast-atom bombardment (HRFAB), high-resolution MALDI, chemical ionization (CI), 
atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI) were 
provided by the mass spectrometry facilities, University of California, Riverside. 
Sonication was conducted using Bransonic ultrasonic bath (model 5510) at 40 KHz 
with the power of 185 W. 
Chemical reagents and chromatography solvents were purchased from Aldrich 
Chemical Co. or Acros Chemcial Co. and were used without purification unless 
otherwise noted.  Dichloromethane was freshly distilled from calcium hydride under 
nitrogen atmosphere. Pyridine and triethylamine were distilled and stored over 4Å 
molecular sieve. Column chromatographic purifications were carried out on silica gel 
230x450 mesh, Sorbent Tech. Analytical TLC was performed on Sorbent Technologies 
silica gel glass TLC plates. Visualization was accomplished with UV light (254 nm) 
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followed by staining with diluted sulfuric acid (5% in ethanol) solution and heating. 
    General Procedure for MIC Determination. A solution of selected bacteria 
was inoculated in the Trypticase Soy broth at 35 oC for 1-2 h. The bacteria 
concentration was found and diluted with broth, if necessary, to an absorption value 
of 0.08 to 0.1 at 625 nm. The adjusted inoculated medium (100 μL) was diluted with 
10 mL of broth and then applied to a 96-well microtiter plate (50 μL). A series of 
solutions (50 μL each in 2-fold dilution) of the tested compounds was added to the 
testing wells. The 96-well plate was incubated at 35 oC for 12-18 h. The minimum 
inhibitory concentration (MIC) is defined as the minimum concentration of compound 
needed to inhibit the growth of bacteria. The MIC results are repeated at least three 
times. 
    General Procedure for Combinational Study. A block of 8×8 wells on a 
96-well microtiter plate was created with a twofold serial dilution of tested sample 
and the selected antibiotic to locate the optimal range of inhibitory concentrations. 
Thereafter, a block of 8×8 wells on a 96-well microtiter plate with a twofold serial 
dilution of tested sample and the selected antibiotic was created to study the 
combinational studies. For each compound, there was a row or column with only one 
compound so that MIC could be determined. FIC index was calculated using the 
following equation: FIC=[A]/MICA+[B]/MICB. Synergism: FIC≤0.5; Addition: 
FIC=0.5–1.0; Indifference: FIC = 1-4; Antagonism: FIC ≥ 4. 
    General Procedure for the Preparation of Azidosugars Using Method 1. A 
solution of glycosyl bromide and NaN3 (3 equiv.) in DMF was sonicated at ambient 
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temperature for 14 minutes (7 mins×2). After the completion of the reaction, the 
reaction mixture was diluted with ethyl acetate then filtered through Celite. After 
removal of the solvent followed by purification with a gradient column 
chromatography (Hexane: EtOAc = 90:20 to 50:50), the product was obtained as white 
solid. By this method compound 4 – 10, 14 can be prepared. 
     General Procedure for the Preparation of Azidosugars Using Method 2.    
To a solution of glycosyl bromide or glycosyl chloride in CH2Cl2 was added 
tert-butylammonium hydrogen sulfate (1 equiv.) and NaN3 (4 eqiv.). Then the same 
volume of NaHCO3 (sat.) solution was added and the biphase system was stirred 
vigorous for 2 hours. After completion of the reaction, the reaction mixture was diluted 
with enough ethyl acetate and washed with NaHCO3 (sat.), water, and brine. Dried over 
Na2SO4. After removal of the solvent followed by purification with a gradient column 
chromatography (Hexane: EtOAc = 90:20 to 50:50), the product was obtained as white 
solid. By this method compound compound 4 – 13 can be prepared. 
    General Procedure for the “Click Reaction” of Oxazolidinone. A solution of 
glycosyl azide (1.0 mmol), alkynyl oxazolidinone (1.0 mmol), Cu(OAc)2 (2.0 mmol) 
and sodium ascorbate (0.4 mmol) in a mixed solution of MeOH (8 mL), THF (2 mL) 
and water (1.5 mL) was sonicated at ambient temperature for 14 minutes (7 min.x2). 
After completion of the reaction, the reaction mixture was diluted with CH2Cl2 then 
filtered through Celite. After removal of the solvent followed by purification with a 
gradient column chromatography (Hexane: EtOAc = 70:30 to 20:80), the product was 
obtained as white solid. 
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    General Procedure for the Methanolysis of Acetyl Groups by NaOMe in 
MeOH. A solution of acetyl protected carbohydrate conjugates, NaOMe (1 equiv.) in 
MeOH was stirred at room temperature untill the complete consumption of starting 
material (ca. 2 hours). The reaction was quenched by adding Amberlite 120 (H+). The 
reaction mixture was filtered through Celite and washed with EtOAc and MeOH. After 
removal of solvent followed by purification with a gradient column chromatography 
(Hexanes:EtOAc = 70:30 to 30:70), the desired products were afforded as white solid.  
    General Procedure for the Methanolysis of Acetyl Groups by K2CO3. To a 
solution of starting material in MeOH, several drops of water and K2CO3 (catalytic 
amount) were added. The reaction mixture was stirred vigorously at room temperature 
for two hours. After completion of the reaction analyzed by TLC, the reaction was 
quenched by adding Amberlite IR-120 (H+) and stirred for another several minutes. The 
reaction mixture was filtrated through Celite and the residue was washed with MeOH. 
After the removal of the solvent, the product was purified by flash column 
chromatography (eluted from CH2Cl2 to CH2Cl2/MeOH = 4/1). The products were 
obtained as a white solid. 
    General Procedure for Coupling of Amine with Carboxylic Acids. To a 
solution of amine (1 equiv.) and carboxylic acids (1 equiv.) in DMF and Et3N (2 equiv.), 
HOBt (1.5 equiv.) and EDC (1.5 equiv.) were added. The reaction mixture was stirred at 
room temperature overnight. After completion of the reaction, the reaction mixture was 
concentrated and diluted with EtOAc. The organic solution was washed with water, 
saturated NaHCO3(aq), and brine and dried over anhydrous Na2SO4. After removal of 
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the solvent followed by a fast gradient column chromatography, the product was 
usually obtained. This protocol is applicable for the coupling reaction of 30 with 
various carboxylic acids or amino acids. 
    General Procedure for Hydrogenation and Purification. The starting material 
was dissolved in degassed MeOH (9 mL) followed by the addition of 1 mL of 
HOAc/H2O (1/4 ratio) solution. A catalytic amount of Pd(OH)2/C powder was added, 
and the system was well sealed and further degassed. The system was stirred under 
atmospheric H2 at room temperature for 10 h. The reaction mixture was then quenched 
by filtering through Celite and the residue was washed with H2O and the combined 
solutions were concentrated. The crude product was purified with Amberlite CG50 
(NH4+) eluted with a gradient of NH4OH solution (0%−20%). After collection of the 
desired fractions and removal of solvent, the product was redissolved in water and 
loaded onto an ion-exchange column packed with Dowex 1 × 8 200 (Cl− form) and 
eluted with water. After removal of solvent, the product was obtained. 
    General Procedure for Cycloaddition of Azides and Naphthoquinone. The 
glycosyl azide (0.20 g, 1 equiv.) and naphthoquinone (2 equiv.) were dissolved in 
toluene or dioxane and were heated at 120 °C for 2 days. After completion of the 
reaction monitored by TLC (eluted with hexane/EtOAc = 1/1), the reaction was cooled 
and the solvents were removed. The crude products were purified by gradient column 
chromatography (eluted with hexane/EtOAc from 100/0 to 55/45). Component 68 is 
usually the first one being eluted out followed by component 66. In most of the cases, 
the majority part of 68 was mixed with 66. However, the pure fractions of 68 and 66 can 
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provide spectroscopic references for the evaluation of the ratio of 66 and 68 in the 
collected mixture using 1H NMR. The most polar component 69 can be eluted the last 
and easily separated from the previous two components. When DMF was used as the 
solvent, only compound 66 was obtained. 
(R) N-Allyl-4-benzyl-2-oxazolidinone (1). To a solution of (R)-4-benzyl- 
2-oxazolidinone (3.00 g, 16.8 mmol) in acetone (200 mL), K2CO3 (7.50 g, 50.4 mmol), 
TBAI (catalytic amount) and propagyl bromide (2.3 mL, 16.8 mmol) were added. The 
reaction mixture was heated at 70ºC for 2 days. After removal of solvent, the reaction 
mixture was diluted with ethyl acetate and washed with washed with 1 N HCl(aq), 
water, saturated NaHCO3(aq), brine and dried over anhydrous Na2SO4. After removal 
of the solvent followed by purification with a gradient column chromatography 
(Hexane: EtOAc = 80:20 to 30:70), the product was obtained as yellowish oil (2.17 g, 
10.1 mmol, 60%). 1H NMR (CDCl3, 400 MHz) δ 7.2 - 7.3 (m, 5H, Ph-), 4.42 (dd, J = 
17.9, 2.4 Hz, 1H), 4.2 (m, 2H), 4.0 (m, 1H), 3.82 (dd, J = 17.9, 2.5 Hz, 1H), 3.21 (dd, J 
= 14.6, 3.8 Hz, 1H, PhCH-), 2.7 (m, 1H, PhCH-), 2.35 (t, J = 2.6 Hz, 1H); 13C NMR 
(CDCl3, 100 MHz) δ 158.2, 137.1, 129.3 (2 carbons), 129.1 (2 carbons), 128.4, 78.2, 
73.7, 67.4, 55.9, 38.3, 33.4; HRDEI Calcd for C13H14NO2 ([M+H]+) m/e 216.1025; 
measure m/e 216.1027. 
    N-Allyl-2-oxazolidinone (2). Please refer to the preparation of compound 1 for 
the detailed procedure. 1H NMR (CDCl3, 400 MHz) δ 4.27 (dd, J = 8.9, 7.3 Hz, 2H), 
3.99 (d, J = 2.4 Hz, 2H), 3.58 (dd, J = 8.5, 7.7 Hz, 2H), 3.26 (t, J = 2.4 Hz); 13C NMR 
(CDCl3, 100 MHz) δ 157.2, 79.5, 73.5, 62.2, 44.0, 34.2; HRDEI Calcd for C6H7NO2 
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([M]+) m/e 125.0477; measure m/e 125.0471. 
N-Allyl-5-chloromethyl-2-oxazolidinone (3). To a solution of 21 (0.18 g, 1.16 
mmol) in anhydrous CH2Cl2 (5 mL) and pyridine (0.12 mL) at 0oC, Ac2O (0.36 mL, 
3.83 mmol) was added. The reaction mixture was stirred for 2 hours then quenched by 
pouring into a column packed with silica gel. The column was first eluted with CH2Cl2 
to washout pyridine then desired compound was eluted out by a gradient of CH2Cl2 
with increasing amount of MeOH (up to MeOH:CH2Cl2 = 5:95). The crude material 
was combined and purified by flash column chromatography (Hex:EtOAc = 40:60 to 
EtOAc:MeOH = 80:20). The purified product is obtained as white crystal (0.20 g, 1.02 
mmol, 88%). 1H NMR (CDCl3, 400 MHz) δ 6.3 (m, 1H), 4.7 (m, 1H), 4.05(ddd, J = 
36.3, 13.9, 2.5 Hz, 2H), 3.6 – 3.7 (m, 2H), 3.5 (m, 1H), 3.36 (dd, J = 8.9, 6.6 Hz, 1H), 
2.3 (t, J = 2.6 Hz, 1H), 2.00 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 171.2, 157.2, 76.7, 
73.7, 72.9, 46.3, 42.2, 34.1, 23.2; HRESI Calcd for C9H13N2O3 ([M+H]+) m/e 197.0920; 
measure m/e 197.0918. 
per-O-acetylated 2-acetamido-2-deoxy-D-galactopyranosyl azide (12). Please 
refer to the general procedure for the preparation of azidosugars using method 2. 1H 
NMR (CDCl3, 400 MHz) δ 5.77 (d, J = 8.8 Hz, 1H), 5.22 (dd, J = 10.6, 9.5 Hz, 1H), 
5.07 (t, J = 9.7 Hz, 1H), 4.76 (d, J = 9.2 Hz, 1H), 4.24 (dd, J = 12.4, 4.8 Hz, 1H), 4.1 (m, 
1H), 3.88 (dd, J = 10.4, 9.2 Hz, 1H), 3.8 (m, 1H), 2.07 (s, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 
1.96 (s, 3H). 13C NMR (CDCl3, 100 MHz) δ 171.2, 170.9, 170.7, 169.5, 88.6, 74.2, 72.3, 
68.3, 62.1, 54.4, 23.5, 20.9, 20.8, 20.8. ESI/APCI calcd for C14H21N4O8 [(M+H)+] m/e 
373.1354; measure m/e 373.1359.   
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per-O-acetylated-cellobiosyl azide (13). Please refer to the general procedure for 
the preparation of azidosugars using method 2. 1H NMR (CDCl3, 400 MHz) δ 5.16 (t, J 
= 90 Hz, 1H), 5.11 (t, J = 9.4 Hz, 1H), 5.03 (t, J = 9.6 Hz, 1H), 4.88 (t, J = 8.0 Hz, 1H), 
4.83 (t, J = 8.8 Hz, 1H), 4.57 (d, J = 8.6 Hz, 1H), 4.45 (t, J = 11.3 Hz, 2H), 4.33 (dd, J = 
12.4, 3.9 Hz, 1H), 4.09 (dd, J = 11.5, 3.9Hz, 1H), 4.00 (d, J = 12.3 Hz, 1H), 3.76 (t,  J 
= 9.0 Hz, 1H), 3.64 (t, J = 9.6 Hz, 2H), 2.10 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H), 1.99 (s, 
3H), 1.98 (s, 3H), 1.97 (s, 3H), 1.94 (s, 3H).  13C NMR (CDCl3, 100 MHz) δ 170.7, 
170.44, 170.40, 169.9, 169.6, 169.5, 169.2, 101.0, 88.0, 76.2, 75.1, 73.1, 72.4, 72.2, 
71.8, 71.1, 67.9, 61.8, 61.7, 21.0, 20.9, 20.8 (2 carbons), 20.7 (2 carbons), 20.7.  
ESI/APCI calcd for C26H37N3O18 [(M+H2O)+] m/e 679.2072; measure m/e 679.2303.   
per-O-acetylated-cellotriosyl azide (14). Please refer to the general procedure for 
the preparation of azidosugars using method 1. 1H NMR (CDCl3, 400 MHz) δ 5.2 – 5.3 
(m, 3H), 5.1 (m, 2H), 4.91 (t, J = 9.9 Hz, 1H), 4.70 (dd, J = 10.5, 3.9 Hz, 1H), 4.6 – 4.7 
(m, 3H), 4.3 – 4.4 (m, 2H), 4.18 (dd, J = 12.3, 4.2 Hz, 1H), 4.10 (dd, J = 12.5, 3.6 Hz, 
1H), 4.03 (dd, J = 12.3, 3.2 Hz, 1H), 3.8 – 3.9 (m, 5H), 3.7 (m, 1H), 2.03 (s, 3H), 2.01 (s, 
3H), 1.95 (s, 3H), 1.90 (s, 3H), 1.89 (s, 3H), 1.88 (s, 3H), 1.87 (s, 3H), 1.852 (s, 3H), 
1.849 (s, 6H). ). 13C NMR (CDCl3, 100 MHz) δ 170.6 (2 carbons), 170.55, 170.49, 
170.4, 170.1, 170.0, 169.8, 169.6, 169.5, 96.0, 95.8, 87.4, 75.0, 74.2, 73.6, 72.7, 71.7, 
71.6, 70.5, 70.2, 69.4, 69.2, 68.6, 68.0, 62.8, 62.4, 61.5, 21.0, 20.9 (3 carbons), 20.7, 
20.6 (3 carbons), 20.6 (2 carbons). ESI/APCI calcd for C38H51N3O25Na [(M+Na)+] m/e 
972.2704; measure m/e 972.2715. 
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    2,3,4,5-Tetra-O-acetyl-1,6-diazido-1,6-dideoxy-D-mannitol (16) A solution of 
D-mannitol (5.00 g, 0.027 mol), TsCl (7.82 g, 0.041 mol), and catalytic amount of 
DMAP in anhydrous pyridine (40 mL) was stirred at 0 °C overnight, allowing the 
reaction temperature to warm up to room temperature. The reaction mixture was cooled 
to 0°C again, and Ac2O (31 mL, 0.32 mol) was added slowly. After being stirred for 1 
day, the reaction mixture was poured into a mixture of water/EtOAc and then stirred for 
several hours. The aqueous layer was separated from the organic layer and extracted 
with EtOAc. The combined organic layers were washed with 1 N HCl (×3), water (×2), 
saturated NaHCO3(aq) and brine, and dried over anhydrous Na2SO4. After removal of 
solvents, the crude product was re-dissolved in DMF and NaN3 (2.67 g, 0.041 mol) was 
added. After being stirred at 80 °C for 1 day, the reaction was cooled and charcoal was 
added. After filtration through Celite and removal of solvents, crystal was formed. The 
crystal was collected and washed with a mixture of ether/hexane (1/1) and ether. The 
crystal was determined to be hexa-O-acetyl-D-mannitol (2.2 g, 5.07 mmol, 19%). The 
filtrate was concentrated and purified with a gradient column chromatography yielding 
16 (3.01 g, 7.52 mmol, 28%), 17 (2.21 g, 5.30 mmol, 20%), and trace amount of 
hexa-O-acetyl-D-mannitol: 1H NMR (CDCl3, 400 MHz) δ 5.37 (d, J = 8.0 Hz, 2H), 5.0 
(m, 2H), 3.43 (dd, J = 13.6, 3.4 Hz, 2H), 3.23 (dd, J = 13.6, 5.7 Hz, 2H), 2.121 (s, 6H), 
2.120 (s, 6H); 13C NMR (CDCl3, 100 MHz) δ 170.0, 169.9, 68.7, 68.3, 50.8, 20.9, 20.8; 
ESI/APCI calcd for C14H20N6O8Na+ ([M + Na]+) m/e 423.1235; ESI/APCI calcd for 
C14H21N4O8+ ([M − N2 + H]+) m/e 373.1354; measured m/e 373.1360. 
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    2,3,4,5,6-Penta-O-acetyl-1-azido-1-deoxy-D-mannitol (17) Please refer to the 
procedure for the preparation of 16: 1H NMR (CDCl3, 400 MHz) δ 5.36 (d, J = 8.8 Hz, 
2H), 5.0 (m, 2H), 4.13 (dd, J = 12.5, 2.6 Hz, 1H), 4.00 (dd, J = 12.5, 5.2 Hz, 1H), 3.41 
(dd, J = 13.5, 3.3 Hz, 1H), 3.20 (dd, J = 13.5, 5.6 Hz, 1H), 2.04 (s, 3H), 2.03 (s, 3H), 
2.02 (s, 3H), 2.00 (s, 3H), 1.98 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 170.6, 170.0, 
169.9, 169.82, 169.79, 68.7, 68.3, 68.0, 67.5, 61.9, 50.8, 21.0, 20.9, 20.8, 20.7 (2 
carbons); ESI/APCI calcd for C16H23N3O10Na+ ([M + Na]+) m/e 440.1276; Compound 
degraded during the mass spec analysis. 
5-Azidomethyl-2-oxazolidinone (19). A solution of 18 (2.0 g, 14.8 mmol) and 
NaN3 (1.4 g, 22.1 mmol) in DMF (50 mL) was stirred at 80oC overnight. The reaction 
mixture was diluted with ethyl acetate and filtrated through Celite. After removal of 
solvents and purification by column chromatography (Hexane:EtOAc = 70:30 to 
10:90), the product is obtained as yellowish oil (2.05 g, 14.4 mmol, 98%). 1H NMR 
(CDCl3, 400 MHz) δ 6.60 (s, 1H), 4.6 – 4.7 (m, 1H), 3.57 (t, J = 9.1 Hz, 1H), 3.46 (dd, 
J = 13.4, 3.9 Hz, 1H), 3.37 (dd, J = 13.4, 5.5 Hz, 1H), 3.27 (dd, J = 9.1, 6.5 Hz, 1H); 
13C NMR (CDCl3, 100 MHz) δ 160.1, 75.0, 53.3, 43.1. 
    N-Allyl-5-azidomethyl-2-oxazolidinone (20). Synthesis via route (a): To a 
solution of  19 (1.2 g, 8.44 mmol), K2CO3 (3.49 g, 25.3 mmol), TBAI (catalytic 
amount) in acetone (20 mL), propagyl bromide (1.1 mL, 10.1 mmol) was added. The 
reaction mixture was refluxed for 24 hours. After removal of solvent, the crude 
product was diluted with ethyl acetate and washed with 1 N HCl(aq), water, saturated 
NaHCO3(aq), brine and dried over anhydrous Na2SO4. After removal of the solvent, 
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the crude product was used directly for the next step. Synthesis via route (b): A 
solution of 22 (0.25 g, 1.44 mmol) and NaN3 (0.14 g, 2.16 mmol) in DMF (10 mL) 
was stirred at 80oC for 48 hours. After completion of the reaction, the reaction 
mixture was diluted with ethyl acetate and filtrated through Celite. After removal of 
the solvent, the crude product was used directly for the next step. 1H NMR (CDCl3, 
400 MHz) δ 4.7 (m, 1H), 4.10 (t, J = 2.4 Hz, 2H), 3.73 (t, J = 8.8 Hz, 1H), 3.57 (ddd, J 
= 29.5, 13.2, 4.6 Hz, 2H), 3.46 (dd, J = 8.8, 6.2 Hz, 1H), 2.34 (t, J = 2.4 Hz, 1H); 13C 
NMR (CDCl3, 100MHz) δ 156.7, 76.7, 73.8, 71.9, 53.3, 46.3, 34.2. 
N-Allyl-5-aminomethyl-2-oxazolidinone (21). Synthesis via route (a): Same 
procedure as described in route (b) below. The purified product was obtained as white 
oil (96% from 19). Synthesis via route (b): To a solution of 20 (0.25 g, 1.39 mmol) in 
CH3CN (10 mL) and H2O (1mL), PPh3 (0.46 g, 1.73 mmol) was added. After being 
stirred at R.T. overnight, the reaction was quenched by removing solvent and the 
crude product was purified by flash column chromatography (MeOH:CH2Cl2 = 0:100 
to MeOH:CH2Cl2 = 10:90). The purified product was obtained as white oil (0.19 g, 
1.22 mmol, 85% from 22). 1H NMR (CDCl3, 400 MHz) δ 6.0 (m, 1H), 5.3 (m, 1H), 
5.03 (t, J = 8.4 Hz, 1H), 4.7 (m, 2H), 4.2 (s, 1H), 4.1 (m, 2H), 3.3 (m, 2H); 13C 
(CDCl3, 100 MHz) δ 158.2, 76.8, 75.1, 73.4, 45.9, 44.4, 33.3. 
N-Allyl-5-chloromethyl-2-oxazolidinone (22). To a solution of 18 (3.0 g, 
22.1mmol), K2CO3 (9.2 g, 66.4 mmol) and TBAI (catalytic amount) in acetone, 
propagyl bromide (3.0 mL, 26.5 mmol) was added. The reaction mixture was refluxed 
for two days. After the removal of solvent, the crude product was diluted with ethyl 
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acetate and washed with 1N HCl(aq), water, saturated NaHCO3(aq), brine and dried 
over anhydrous Na2SO4. After removal of the solvent followed by purification with a 
gradient column chromatography (Hexane: EtOAc = 70:30 to 20:80), the product was 
obtained as yellowish oil (3.11 g, 17.9 mmol, 81%). 1H NMR (CDCl3, 400 MHz) δ 
4.7 (m, 1H), 4.0 – 4.1 (m, 2H), 3.75 (t, J = 8.8 Hz, 1H), 3.6 – 3.7 (m, 2H), 3.50 (dd, J 
= 8.9, 5.9 Hz, 1H), 2.3 (t, J = 2.6 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 156.6, 76.7, 
73.8, 71.9, 46.9, 44.7, 34.1; HRESI Calcd for C7H8ClNO2 ([M+H]+) m/e 173.0244; 
measure m/e 173.0251. 
(R)-(1-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl) 
methyl-4-benzyl-2-oxazolidinone (23a). Please refer to the general procedure for 
“click reaction”. 1H NMR (CDCl3, 400 MHz) δ 7.86 (s, 1H), 7.1 – 7.3 (m, 5H), 5.84 
(d, J = 9.2 Hz, 1H, H-1), 5.44 (t, J = 9.4 Hz, 1H), 5.32 (t, J = 9.3 Hz, 1H), 5.25 (t, J = 
9.8 Hz, 1H), 4.86 (d, J = 15.6 Hz), 4.38(d, J = 15.6 Hz, 1H), 4.32 (dd, J = 12.6, 7.0 
Hz, 1H), 4.17 (dd, J = 12.6, 2.0 Hz, 1H), 4.12 (t, J = 8.5 Hz, 1H), 4.01 (d, J = 6.6 Hz, 
1H), 3.99 (t, J = 6.4 Hz, 1H), 3.9 (m, 1H), 3.31 (dd, J = 13.5, 4.2 Hz, 1H, PhCH-), 
2.56 (dd, J = 13.4, 9.5 Hz, 1H, PhCH-), 2.08 (s, 3H), 2.07 (s, 3H), 2.01 (s, 3H), 1.83 
(s, 3H); 13C NMR (CDCl3, 100 MHz) δ 170.7, 170.1, 169.5, 168.9, 158.4, 143.8, 
135.7, 129.2 (2 carbons), 129.0 (2 carbons), 127.3, 121.8, 86.1, 75.3, 72.4, 71.1, 67.8, 
67.4, 61.6, 55.8, 38.3, 37.7, 20.8, 20.7, 20.6, 20.2; HRFAB Calcd for C27H33N4O11 
([M+H]+) m/e 589.2146; measure m/e 589.2142. 
(R)N-(1-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl)
methyl-4-benzyl-2-oxazolidinone (23b). 1H NMR (CDCl3, 400 MHz) δ 7.87 (s, 1H), 
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7.1 – 7.3 (m, 5H), 5.77 (d, J = 9.0 Hz, 1H), 5.52 (d, J = 3.3 Hz, 1H), 5.36 (dd, J = 
10.3, 9.1 Hz, 1H), 5.24 (dd, J = 10.3, 3.3 Hz, 1H), 4.86 (d, J = 15.6 Hz), 4.38 (d, J = 
15.6Hz), 4.1 – 4.2 (m, 4H), 3.97 (dd, J = 8.6, 6.5 Hz, 1H), 3.8 (m, 1H), 3.32 (dd, J = 
13.4, 4.1 Hz, 1H, PhCH-), 2.61 (dd, J = 13.4, 9.6 Hz, 1H, PhCH-), 2.21 (s, 3H), 2.02 
(s, 3H), 1.97 (s, 3H), 1.81 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 170.4, 170.2, 169.9, 
169.1, 158.5, 143.8, 135.8, 129.3 (2 carbons), 129.0 (2 carbons), 127.3, 121.9, 86.7, 
74.4, 70.6, 68.7, 67.5, 66.9, 61.4, 55.8, 38.3, 37.8, 20.9, 20.8, 20.6, 20.4; HRFAB 
Calcd for C27H33N4O11 ([M+H]+) m/e 589.2146; measure m/e 589.2154. 
(R)N-(1-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl)-1H-1,2,3-triazol-4-yl)
methyl-4-benzyl-2-oxazolidinone (23c). 1H NMR (CDCl3, 400 MHz) δ 7.86 (s, 1H), 
7.1 – 7.3 (m, 5H), 6.21 (d, J = 1.1 Hz, 1H), 5.63 (dd, J = 2.9 Hz, 1.2 Hz, 1H), 5.2 – 
5.4 (m, 3H), 4.73 (d, J = 15.5 Hz, 1H), 4.33 (d, J = 15.5 Hz, 1H), 4.31 (t, J = 7.0 Hz, 
1H), 4.20 (dd, J = 12.5, 2.2 Hz, 1H), 3.9 – 4.1 (m, 3H), 3.34 (dd, J = 13.5, 3.5 Hz, 1H, 
PhCH-), 2.66 (dd, J = 13.4, 2.9 Hz, 1H), 2.09 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H), 1.97 
(s, 3H); 13C NMR (CDCl3, 100 MHz) δ 170.7, 169.9, 169.6, 169.5, 158.4, 143.1, 
135.4, 129.3 (2 carbons), 129.2 (2 carbons), 127.3, 122.4, 85.0, 75.8, 74.3, 70.8, 68.8, 
67.4, 62.2, 56.1, 38.4, 37.5, 20.8, 20.6, 20.5, 14.3; HRFAB Calcd for C27H33N4O11 
([M+H]+) m/e 589.2146; measure m/e 589.2166. 
(R)N-(1-(4-O-(Tetra-O-acetyl-β-D-galactopyranosyl)-2,3,6-tri-O-acetyl-β-D-
glucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2-oxazolidinone (23d). 1H 
NMR (CDCl3, 400 MHz) δ 7.79 (s, 1H), 7.1 – 7.3(m, 5H), 5.78 (d, J = 9.1 Hz, 1H), 
5.41 (t, J = 8.2 Hz, 1H), 5.35 (d, J = 3.2 Hz, 1H), 5.24 (t, J = 9.3 Hz, 1H), 5.11 (dd, J 
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= 10.3, 7.9 Hz, 1H), 4.97 (dd, J = 10.4, 3.4 Hz, 1H), 4.82 (d, J = 15.6 Hz, 1H), 4.55 (d, 
J = 7.9 Hz, 1H), 4.50 (d, J = 12.4 Hz, 1H), 4.36 (d, J = 15.6 Hz, 1H), 4.1 – 4.2 (m, 
4H), 3.9 – 4.0 (m, 5H), 3.31 (dd, J = 13.4, 4.1 Hz, 1H, PhCH-), 2.64 (dd, J = 13.4, 9.5 
Hz, 1H, PhCH-), 2.14 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 
2.03 (s, 3H), 1.95 (s, 3H), 1.81 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 170.5, 170.4, 
170.3, 170.2, 169.6, 169.2, 169.1, 158.5, 143.8, 135.7, 129.3 (2 carbons), 129.0 (2 
carbons), 127.3, 121.9, 101.2, 86.0, 76.2, 75.7, 72.3, 71.4, 71.1, 69.3, 67.5, 66.9, 61.9, 
61.1, 55.9, 38.3, 37.7, 21.0, 20.9 (2 carbons), 20.8 (2 carbons), 20.7, 20.3; MALDI 
Calcd for C39H48N4O19Na ([M+Na]+) m/e 899.2810; measure m/e 899.2811. 
(R)N-(1-(2,3,4-Tri-O-acetyl-β-L-fucopyranosyl)-1H-1,2,3-triazol-4-yl) 
methyl-4-benzyl-2-oxazolidinone (23e). 1H NMR (CDCl3, 400 MHz) δ 7.90 (s, 1H), 
7.2 – 7.3 (m, 5H), 5.79 (d, J = 9.1 Hz, 1H), 5.43 (t, J = 9.9 Hz, 1H), 5.38 (d, J = 3.2 
Hz, 1H), 5.24 (dd, J = 10.3, 3.4 Hz, 1H), 4.78 (d, J = 15.6 Hz, 1H), 4.44 (d, J = 15.5 
Hz, 1H), 4.0 – 4.1 (m, 4H), 3.31 (dd, J = 13.5 Hz, J = 2.3 Hz, 1H), 2.64 (dd, J = 13.3, 
8.5 Hz, 1H), 2.25 (s, 3H), 1.99 (s, 3H), 1.84 (s, 3H), 1.24 (d, J = 6.3 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 170.6, 170.0, 169.3, 158.4, 143.6, 135.7, 129.4 (2 
carbons), 129.1 (2 carbons), 127.3, 121.7, 86.7, 73.0, 71.2, 70.0, 68.5, 67.4, 56.3, 38.4, 
37.6, 20.9, 20.7, 20.4, 16.3; HRFAB Calcd for C25H31N4O9 ([M+H]+) m/e 531.2091; 
measure m/e 531.2096. 
(R)N-(1-(2,3,4-Tri-O-acetyl-α-L-rhamnopyranosyl)-1H-1,2,3-triazol-4-yl) 
methyl-4-benzyl-2-oxazolidinone (23f). 1H NMR (CDCl3, 400 MHz) δ 7.86 (s, 1H), 
7.1 – 7.3 (m, 5H), 6.07 (d, J = 1.2 Hz, 1H), 5.7 (m, 1H), 5.1 – 5.2 (m, 2H), 4.74 (t, J = 
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15.4 Hz, 1H), 4.38 (dd, J = 15.6, 3.3 Hz, 1H), 4.0 – 4.2 (m, 3H), 3.8 (m , 1H), 3.3 – 
3.4 (m, 1H), 2.6 (m, 1H), 2.08 (s, 3H), 2.07 (s, 3H), 2.02 (s, 3H), 1.2 (m, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 170.0, 169.9, 169.6, 158.4, 143.1, 135.5, 129.3 (2 
carbons), 129.1 (2 carbons), 127.4, 122.3, 85.1, 71.0, 69.8, 69.3, 67.4, 60.6, 56.6, 38.7, 
38.4, 21.2, 20.9, 20.7, 17.7; HRFAB Calcd for C25H31N4O11 ([M+H]+) m/e 531.2091; 
measure m/e 531.2109. 
(R)N-(1-(2,3,4-Tri-O-acetyl-α-D-xylopyranosyl)-1H-1,2,3-triazol-4-yl) 
methyl-4-benzyl-2-oxazolidinone (23g). 1H NMR (CDCl3, 400 MHz) δ 7.85 (s, 1H), 
7.2 – 7. 3 (m, 5H), 6.23 (d, J = 3.8 Hz, 1H), 5.77 (t, J = 6.2 Hz, 1H), 5.20 (dd, J = 6.5, 
3.8 Hz, 1H), 4.95 (dd, J = 10.8, 5.1 Hz, 1H), 4.76 (d, J = 15.6 Hz, 1H), 4.42 (d, J = 
15.6 Hz, 1H), 4.0 – 4.1 (m, 5H), 3.39 (dd, J = 13.4, 3.7 Hz, 1H), 2.67 (dd, J = 13.5, 
8.9 Hz, 1H), 2.13 (s, 3H), 2.12 (s, 3H), 1.98 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 
170.0, 169.6, 169.0, 158.4, 142.9, 135.5, 129.3 (2 carbons), 129.3 (2 carbons), 127.4, 
124.0, 83.1, 68.6, 68.2, 67.5, 67.4, 64.8, 56.6, 38.5, 37.6, 21.0, 20.9, 20.6; HRFAB 
Calcd for C24H29N4O9 ([M+H]+) m/e 517.1935; measure m/e 517.1942. 
N-(1-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl) 
methyl-2-oxazolidinone (23h). 1H NMR (CDCl3, 400 MHz) δ 7.82 (s, 1H), 5.81 (d, J 
= 9.1 Hz, 1H), 5.41 (t, J = 9.6 Hz, 1H), 5.33 (t, J = 9.2 Hz, 1H), 5.22 (dd, J = 10.0, 9.5 
Hz, 1H), 4.53 (d, J = 0.9 Hz, 2H), 4.3 – 4.4 (m, 2H), 4.1 (m, 1H), 3.98 (ddd, J = 10.1, 
4.8, 2.2 Hz, 1H), 3.5 – 3.6 (m, 2H), 3.46 (s, 2H), 2.08 (s, 2H), 2.04 (s, 3H), 2.02 (s, 
3H), 1.85 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 170.7, 170.1, 169.5, 169.0, 158.6, 
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143.8, 121.5, 86.2, 75.5, 72.6, 70.9, 67.8, 62.2, 61.6, 44.6, 39.6, 20.9, 20.7 (2 carbons), 
20.3; HRESI Calcd for C20H27N4O11 ([M+H]+) m/e 499.1670; measure m/e 499.1679. 
N-(1-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl) 
methyl-2-oxazolidinone (23i). 1H NMR (CDCl3, 400 MHz) δ 7.87 (s, 1H), 5.78 (d, J 
= 9.1 Hz, 1H), 5.52 (d, J = 3.3 Hz, 1H), 5.42 (t, J = 9.6 Hz, 1H), 5.20 (dd, J = 10.3 Hz, 
J = 3.3 Hz, 1H), 4.53 (s, 2H), 4.31 (t, J = 8.7 Hz, 2H), 4.1 – 4.2 (m, 3H), 3.56 (dd, J = 
16.0, 7.9 Hz, 2H), 2.21 (s, 3H), 2.02 (s, 3H), 1.98 (s, 3H), 1.86 (s, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 170.5, 170.2, 170.0, 169.2, 158.6, 143.7, 121.6, 86.7, 74.4, 70.7, 
68.4, 66.9, 62.3, 61.4, 44.5, 39.6, 20.9, 20.9, 20.7, 20.5; HRESI Calcd for 
C20H27N4O11 ([M+H]+) m/e 499.1670; measure m/e 499.1667. 
N-(1-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl)-1H-1,2,3-triazol-4-yl) 
methyl-2-oxazolidinone (23j). 1H NMR (CDCl3, 400 MHz) δ 7.82 (s, 1H), 6.15 (d, J 
= 1.2 Hz, 1H), 5.63 (dd, J = 3.1, 1.3 Hz, 1H), 5.2 – 5.4 (m, 2H), 4.4 – 4.5 (m, 2H), 4.2 
– 4.3 (m, 3H), 4.18 (dd, J = 12.6, 2.2 Hz, 1H), 3.94 (ddd, J = 7.4, 5.5, 2.3 Hz, 1H), 3.6 
(m, 2H), 2.07 (s, 6H), 2.05 (s, 3H), 1.96 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 174.6, 
170.7, 170.0, 169.7, 158.6, 143.7, 122.2, 85.1, 76.0, 71.0, 68.9, 65.1, 62.3, 61.7, 44.8, 
39.4, 20.9, 20.8, 20.6; HRESI Calcd for C20H27N4O11 ([M+H]+) m/e 499.1670; 
measure m/e 499.1662. 
N-(1-(4-O-(Tetra-O-acetyl-β-D-galactopyranosyl)-2,3,6-tri-O-acetyl-β-D- 
glucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone (23k). 1H NMR 
(CDCl3, 400 MHz) δ 7.76 (s, 1H), 5.76 (d, J = 9.2Hz, 1H), 5.39 (t, J = 8.9 Hz, 1H), 
5.35 (d, J = 3.3Hz, 1H), 5.27 (t, J = 9.3 Hz, 1H), 5.11 (dd, J =10.4, 7.9 Hz, 1H), 4.96 
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(dd, J = 10.4, 3.3 Hz, 1H), 4.5 (m, 3H), 4.29 (t, J = 8.1 Hz, 2H), 4.19 (t, J = 5.7 Hz, 
1H), 4.1 – 4.2 (m, 3H), 3.9 – 4.0 (m, 2H), 3.58 (dd, J = 16.7, 8.2 Hz, 2H), 2.14 (s, 3H), 
2.11(s, 3H), 2.06 (s, 3H), 2.04 (s, 3H), 2.04 (s, 3H), 1.95 (s, 3H), 1.85 (s, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 170.6, 170.4, 170.3, 170.2, 169.6, 169.3, 169.2, 158.6, 
128.8, 121.5, 101.3, 86.0, 76.2, 75.7, 72.4, 71.1 (2 carbons), 69.3, 66.8, 62.3, 61.8, 
61.0, 44.6, 39.6, 24.9, 21.0, 20.9 (2 carbons), 20.8 (2 carbons), 20.7, 20.4; HRESI 
Calcd for C20H27N4O11Na ([M+Na]+) m/e 809.2335; measure m/e 809.2336. 
N-(1-(2,3,4-Tri-O-acetyl-β-L-fucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-2-
oxazolidinone (23l). 1H NMR (CDCl3, 400 MHz) δ 7.88 (s, 1H), 5.75 (d, J = 9.1 Hz, 
1H), 5.38 (t, J = 10.5 Hz, 2H), 5.22 (dd, J = 10.3, 3.3 Hz, 1H), 4.54 (s, 2H), 4.29 (ddd, 
J = 9.3, 6.6, 3.0 Hz, 2H), 4.1 (m, 1H), 3.55 (dd, J = 14.5, 7.4 Hz, 2H), 2.24 (s, 3H), 
1.97 (s, 3H), 1.87 (s, 3H), 1.24 (t, J = 6.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 
170.7, 170.1, 169.3, 158.6, 129.4, 121.6, 86.8, 73.1, 71.1, 69.9, 68.6, 62.3, 44.5, 39.6, 
20.9, 20.8, 20.5, 16.3; HRESI Calcd for C18H25N4O9 ([M+H]+) m/e 441.1616; 
measure m/e 441.1604. 
N-(1-(2,3,4-Tri-O-acetyl-α-L-rhamnopyranosyl)-1H-1,2,3-triazol-4-yl)methyl
-2-oxazolidinone (23m). 1H NMR (CDCl3, 400 MHz) δ 7.82 (s, 1H), 6.08 (d, J = 1.3 
Hz, 1H), 5.63 (dd, J = 3.0 Hz, J = 1.3 Hz, 1H), 5.1 – 5.2 (m, 2H), 4.48 (dd, J = 28.7, 
15.3 Hz, 2H), 4.26 (t, J = 8.2 Hz, 2H), 3.8 (m, 1H), 3.6 (m, 2H), 2.08 (s, 3H), 2.07 (s, 
3H), 1.97 (s, 3H), 1.33 (d, J = 6.1 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 170.0, 
169.9, 169.5, 158.6, 142.9, 122.1, 85.0, 74.3, 71.0, 69.8, 69.4, 62.3, 44.8, 39.4, 21.2, 
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20.9, 20.7, 17.7; HRESI Calcd for C18H25N4O9 ([M+H]+) m/e 441.1616; measure m/e 
441.1628. 
N-(1-(2,3,4-Tri-O-acetyl-α-D-xylopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-2-
oxazolidinone (23n). 1H NMR (CDCl3, 400 MHz) δ 7.80 (s, 1H), 6.20 (d, J = 3.7 Hz, 
1H), 5.67 (t, J = 6.0 Hz, 1H), 5.12 (dd, J = 6.2, 3.7 Hz, 1H), 4.90 (dd, J = 10.2, 4.9 Hz, 
1H), 4.48 (dd, J = 22.1, 15.5 Hz, 2H), 4.26 (t, J = 7.7 Hz, 2H), 4.02 (d, J = 4.6 Hz, 
2H), 3.63 (dd, J = 8.5, 6.9 Hz, 2H), 2.08 (s, 3H), 2.07 (s, 3H), 1.93 (s, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 170.0, 169.6, 169.0, 158.6, 143.0, 123.7, 83.2, 68.5, 68.1, 67.2, 
64.9, 62.3, 44.9, 39.4, 21.0, 20.9, 20.6; HRESI Calcd for C17H23N4O9 ([M+H]+) m/e 
441.1459; measure m/e 427.1447. 
N-(1-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl) 
methyl-5-acetamidomethyl-2-oxazolidinone (23o). 1H NMR (CDCl3, 400 MHz) δ 
7.92 (s, 1H), 6.5 (m, 1H), 5.83 (d, J = 9.0 Hz, 1H), 5.42 (t, J = 9.3 Hz, 1H), 5.32 (t, J 
= 9.3 Hz, 1H), 5.22 (dd, J = 19.3, 9.7 Hz, 2H), 4.57 (m, 2H), 4.47 (t, J = 14.0 Hz, 1H), 
4.3 (m, 1H), 4.1 (m, 1H), 4.0 (m, 2H), 3.5 – 3.7 (m, 2H), 3.2 – 3.4 (m, 3H), 2.04 (s, 
3H), 2.02 (s, 3H), 1.96 (s, 3H), 1.83 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 171.5, 
170.5, 170.2, 170.0, 169.3, 157.8, 143.2, 121.6, 86.3, 74.1, 72.8, 70.7, 68.5, 67.1, 61.5, 
46.7, 42.3, 39.3, 23.0, 20.7 (2 carbons), 20.6, 20.3; HRESI Calcd for C23H32N5O12 
([M+H]+) m/e 570.2547; measure m/e 570.2064. 
N-(1-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl) 
methyl-5-acetamidomethyl-2-oxazolidinone (23p). 1H NMR (CDCl3, 400 MHz) δ 
7.8 (s, 1H), 6.9 (s, 1H), 5.80 (d, J = 9.0 Hz, 1H), 5.43 (s, 1H), 5.33 (t, J = 9.9 Hz, 1H), 
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5.20 (d, J = 11.8 Hz, 1H), 4.5 (m, 2H), 4.43 (t, J = 12.4 Hz, 2H), 4.24 (t, J = 5.8 Hz, 
1H), 4.0 – 4.1 (m, 3H), 3.5 (m, 3H), 3.3 (m, 1H), 3.2 (m, 1H), 2.08 (s, 3H), 1.90 (s, 
3H), 1.86 (s, 3H), 1.75 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 171.5, 170.5, 170.2, 
170.0, 169.3, 157.8, 143.2, 121.6, 86.3, 74.1, 72.8, 70.7, 68.5, 67.1, 61.5, 46.7, 42.3, 
39.3, 23.0, 20.7 (2 carbons), 20.6, 20.3; HRESI Calcd for C23H32N5O12 ([M+H]+) m/e 
570.2547; measure m/e 570.2045. 
N-(1-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl)-1H-1,2,3-triazol-4-yl) 
methyl-5-acetamidomethyl-2-oxazolidinone (23q).1H NMR (CDCl3, 400 MHz) δ 
7.80 (s, 1H), 6.62 (m, 1H), 6.23 (s, 1H), 5.65 (d, J = 17.2 Hz, 1H), 5.2 – 5.4 (m, 2H), 
4.6 (m, 2H), 4.4 (m, 1H), 4.2 – 4.3 (m, 2H), 4.0 (m, 1H), 3.5 – 3.7 (m, 1H), 3.5 (m, 
1H), 3.3 – 3.4 (m, 2H), 1.9 – 2.1 (m, 15H); 13C NMR (CDCl3, 100 MHz) δ 171.5, 
171.4, 170.7, 169.9, 169.6, 157.7, 142.7, 122.0, 84.9, 75.8, 72.8, 70.9, 69.3, 65.2, 62.3, 
47.2, 42.4, 39.3, 23.0, 20.9, 20.8, 20.7, 20.3; HRESI Calcd for C23H32N5O12 ([M+H]+) 
m/e 570.2547; measure m/e 570.2041. 
N-(1-(4-O-(Tetra-O-acetyl-β-D-galactopyranosyl)-2,3,6-tri-O-acetyl-β-D- 
glucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-5-acetamidomethyl-2- 
oxazolidinone (23r). 1H NMR (CDCl3, 400 MHz) δ 7.73 (s, 1H), 6.8 (m, 1H), 5.79 
(dd, J = 9.2, 1.1 Hz, 1H), 5.3 (m, 1H), 5.2 (m, 2H), 4.98 (dd, J = 10.3, 7.8 Hz, 1H), 
4.89 (dd, J = 10.4, 3.3 Hz, 1H), 4.5 (m, 2H), 4.4 (m, 3H), 4.0 (m, 3H), 3.9 (m, 3H), 
3.5 (m, 2H), 3.3 (m, 1H), 3.2 (m, 1H), 2.02 (s, 3H), 2.00 (s, 3H), 1.93 (s, 6H), 1.90 (s, 
3H), 1.85 (s, 3H), 1.83 (s, 3H), 1.73 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 171.4, 
170.5 (2 carbons), 170.3, 170.2, 169.6, 169.3, 169.2, 157.7, 143.2, 121.6, 101.0, 85.6, 
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76.0, 75.6, 72.7, 72.6, 72.4, 71.1, 70.9, 69.3, 67.0, 62.0, 61.1, 46.8, 42.3, 39.4, 22.9, 
20.8, 20.8, 20.7, 20.7 (2 carbons), 20.6, 20.3; HRESI Calcd for C35H47N5O20Na 
([M+Na]+) m/e 880.2712; measure m/e 880.2708. 
N-(1-(2,3,4-Tri-O-acetyl-β-L-fucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-5-
acetamidomethyl-2-oxazolidinone (23s). 1H NMR (CDCl3, 400 MHz) δ 7.82 (s, 1H), 
6.7 (m, 1H), 5.74 (d, J = 9.0 Hz, 1H), 5.2 – 5.4 (m, 3H), 4.6 (m, 1H), 4.4 – 4.5 (m, 
2H), 4.10 (dd, J = 12.6, 6.2 Hz, 1H), 3.55 (dd, J = 19.9, 9.0 Hz, 2H), 3.2 – 3.3 (m, 2H), 
2.16 (s, 3H), 1.93 (s, 3H), 1.92 (s, 3H), 1.80 (s, 3H), 1.19 (dd, J = 6.3, 2.3 Hz, 3H); 
13C NMR (CDCl3, 100 MHz) δ 171.5, 170.6, 170.0, 169.4, 157.7, 143.2, 121.4, 86.6, 
72.9, 72.8, 71.1, 70.0, 68.7, 46.7, 40.4, 39.4, 23.0, 20.8, 20.7, 20.4, 16.2; HRESI 
Calcd for C21H30N5O10 [M+H]+) m/e 512.1992; measure m/e 512.1994. 
N-(1-(2,3,4-Tri-O-acetyl-α-L-rhamnopyranosyl)-1H-1,2,3-triazol-4-yl)methyl
-5-acetamidomethyl-2-oxazolidinone (23t). 1H NMR (CDCl3, 400 MHz) δ 7.78 (s, 
1H), 6.6 (m, 1H), 6.15 (s, 1H), 5.62 (dd, J = 17.9, 2.6 Hz, 1H), 5.2 – 5.3 (m, 1H), 5.1 
(m, 1H), 4.4 – 4.6 (m, 3H), 3.8 (m, 1H), 3.3 – 3.4 (m, 2H), 3.5 – 3.7 (m, 2H), 1.9 – 2.1 
(m, 12H), 1.3 (m, 3H); 13C NMR (CDCl3, 100 MHz) δ 171.5, 170.0, 170.0, 169.7, 
157.7, 143.3, 121.9, 84.9, 74.2, 72.7, 72.7, 70.9, 69.5, 47.2, 42.4, 39.3, 23.0, 20.9, 
20.8, 20.7, 17.7; HRESI Calcd for C21H30N5O10 ([M+H]+) m/e 512.1992; measure m/e 
512.2004. 
N-(1-(2,3,4-Tri-O-acetyl-α-D-xylopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-5-
acetamidomethyl-2-oxazolidinone (23u). 1H NMR (CDCl3, 400 MHz) δ 7.78 (s, 1H), 
6.9 (m, 1H), 5.72 (d, J = 8.8 Hz, 1H), 5.3 – 5.4 (m, 2H), 5.1 (m, 1H), 4.3 – 4.6 (m, 
  
 
                                                                                  123
3H), 3.9 (m, 1H), 3.4 – 3.6 (m, 3H), 3.3 (m, 2H), 1.9 – 2.0 (m, 12H); 13C NMR 
(CDCl3, 100 MHz) δ 171.5, 170.0, 169.9, 169.2, 157.7, 142.5, 121.6, 86.5, 83.0, 72.6, 
68.5 (2 carbons), 65.7, 47.2, 42.2, 39.3, 23.0, 20.9, 20.7, 20.3; HRESI Calcd for 
C20H27N5O10Na ([M+Na]+) m/e 520.1655; measure m/e 520.1653. 
(R)N-(1-(β-D-Glucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2- 
oxazolidinone (OX101). 1H NMR (CD3OD, 400 MHz) δ 8.13 (s, 1H), 7.2 – 7.3 (m, 
5H), 5.62 (d, J = 9.2 Hz, 1H, H-1), 4.78 (d, J = 17.3 Hz, 1H), 4.47 (d, J = 15.8 Hz, 
1H), 4.2 (m, 2H), 4.1 (m, 2H), 3.92 (d, J = 9.2Hz, 2H), 3.73 (dd, J = 12.2, 5.6 Hz, 1H), 
3.5 – 3.6 (m, 4H), 3.3 – 3.4 (m, 2H), 3.23 (dd, J = 13.4, 3.9 Hz, 1H, PhCH-), 2.80 (dd, 
J = 13.5, 7.5 Hz, 1H, PhCH-); 13C NMR (CD3OD, 100 MHz) δ 160.6, 144.2, 137.3, 
130.6 (2 carbons), 130.0 (2 carbons), 128.2, 124.3, 89.8, 81.3, 78.6, 74.2, 71.1, 68.7, 
62.6, 57.6, 39.0, 38.5; HRFAB Calcd for C19H24N4O7Na ([M+Na]+) m/e 443.1543; 
measure m/e 443.1522. 
(R)N-(1-(β-D-Galactopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2- 
oxazolidinone (OX102). 1H NMR (CD3OD, 400 MHz) δ 8.18 (s, 1H), 7.2–7.3 (m, 
5H), 5.60 (d, J = 9.1 Hz, 1H), 4.46 (d, J = 15.8 Hz, 1H), 4.2 (m, 2H), 4.1 (m, 2H), 
4.01 (d , J = 2.9 Hz, 1H), 3.87 (t, J = 6.4 Hz, 1H), 3.78 (t, J = 6.3 Hz, 2H), 3.72 (dd, J 
= 9.5, 3.3 Hz, 1H), 3.36 (s, 1H), 3.22 (dd, J = 13.5, 3.9 Hz, 1H), 2.78 (dd, J = 13.6, 
7.6 Hz, 1H); 13C NMR (CD3OD, 100 MHz) δ 159.3, 143.0, 136.0, 129.3 (2 carbons), 
128.7 (2 carbons), 126.9, 122.6, 89.0, 78.8, 74.1, 70.2, 69.2, 67.4, 61.3, 56.3, 37.7, 
37.2; HRFAB Calcd for C19H24N4O7Na ([M+Na]+) m/e 443.1543; measure m/e 
443.1525. 
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(R)N-(1-(α-D-Mannopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2- 
oxazolidinone (OX103). 1H NMR (CD3OD, 400 MHz) δ 8.21 (s, 1H), 7.2 – 7.3 (m, 
5H), 6.03 (d, J = 1.3 Hz, 1H), 4.75 (s, 1H), 4.45 (d, J = 15.8 Hz, 1H), 4.1 – 4.2 (m, 
4H), 3.9 – 4.0 (m, 2H), 3.7 – 3.8 (m, 2H), 3.5 – 3.6 (m, 1H), 3.36 (s, 1H), 3.3 (m, 1H); 
13C NMR (CD3OD, 100 MHz) δ 159.3, 142.2, 136.0, 129.2 (2 carbons), 128.7 (2 
carbons), 123.5, 123.0, 87.2, 80.3, 73.8, 71.0, 67.3, 66.6, 61.5, 56.3, 37.7, 37.2; 
HRFAB Calcd for C19H24N4O7Na ([M+Na]+) m/e 443.1543; measure m/e 443.1539. 
(R)N-(1-(β-D-Galactopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-1H-
1,2,3-triazol-4-yl) methyl-4-benzyl-2-oxazolidinone (OX104). 1H NMR (CD3OD, 
400 MHz) δ 8.11 (s, 1H), 7.1 – 7.3 (m, 5H), 5.63 (d, J = 9.2 Hz, 1H), 4.46 (d, J = 12.9 
Hz, 1H), 4.43 (d, J = 4.6 Hz, 1H), 4.1– 4.3 (m, 5H), 4.00 (t, J = 8.9 Hz, 1H), 3.81 (s, 
1H), 3.7–3.8 (m, 8H), 3.5–3.6 (m, 5H), 3.4 (s, 1H), 3.29 (d, J = 1.6 Hz, 2H), 3.21 (dd, 
J = 13.3 Hz, 3.7 Hz, 1H), 2.77 (dd, J = 13.5, 7.5 Hz, 1H); 13C NMR (CD3OD, 100 
MHz) δ 160.6, 144.2, 137.3, 130.6 (2 carbons), 130.0 (2 carbons), 128.2, 124.4, 105.3, 
89.5, 79.9, 79.7, 77.3, 77.0, 72.7, 72.3, 71.2, 70.8, 70.5, 62.7, 62.0, 57.6, 39.0, 38.5; 
HRFAB Calcd for C25H34N4O12Na ([M+Na]+) m/e 605.2071; measure m/e 605.2099. 
(R)N-(1-(β-L-Fucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2-oxazol
idinone (OX105). 1H NMR (CD3OD, 400 MHz) δ 8.17 (s, 1H), 7.2–7.3 (m, 5H), 5.57 
(d, J = 9.2 Hz, 1H), 4.78 (d, J = 15.8 Hz, 1H), 4.46 (d, J = 15.8 Hz, 1H), 4.1 – 4.2 (m, 
3H), 3.97 (d, J = 5.6 Hz, 1H), 3.77 (d, J = 3.2 Hz, 1H), 3.72 (dd, J = 11.1, 3.2 Hz, 1H), 
3.21 (dd, J = 13.5, 3.9 Hz, 1H), 2.80 (dd, J = 13.4, 7.5 Hz, 1H), 1.29 (d, J = 6.5 Hz, 
3H); 13C NMR (CD3OD, 100 MHz) δ 159.2, 143.0, 136.0, 129.3 (2 carbons), 128.7 (2 
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carbons), 126.9, 122.4, 89.0, 74.3, 74.2, 71.8, 70.1, 67.4, 56.2, 37.6, 37.2, 15.7; 
HRFAB Calcd for C19H24N4O6Na ([M+Na]+) m/e 427.1594; measure m/e 427.1578. 
(R)N-(1-(α-L-Rhamnopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2- 
oxazolidinone (OX106). 1H NMR (CD3OD, 400 MHz) δ 8.05 (s, 1H), 7.2 – 7.3 (m, 
5H), 5.97 (d, J = 1.2 Hz, 1H), 4.37 (d, J = 15.8 Hz, 1H), 4.42 (d, J = 15.8 Hz, 1H), 4.0 
– 4.2 (m, 3H), 3.68 (dd, J = 9.1, 3.2 Hz, 1H), 3.5 (m, 2H), 3.33 (s, 1H), 3.21 (dd, J = 
17.5, 8.0 Hz), 2.77 (dd, J = 13.5, 8.0 Hz, 1H), 1.36 (d, J = 5.8 Hz, 3H); 13C NMR 
(CD3OD, 100 MHz) δ 159.2, 142.2, 136.0, 129.3 (2 carbons), 128.7 (2 carbons), 
126.9, 123.4, 87.0, 75.8, 73.6, 72.0, 71.2, 67.4, 56.2, 37.7, 37.2, 17.0; HRFAB Calcd 
for C19H24N4O6Na ([M+Na]+) m/e 427.1594; measure m/e 427.1586. 
(R)N-(1-(α-D-Xylopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-4-benzyl-2- 
oxazolidinone(OX107). 1H NMR (CD3OD, 400 MHz) δ 8.12 (s, 1H), 7.2 – 7.3 (m, 
5H), 6.11 (d, J = 2.8 Hz, 1H), 4.74 (d, J = 16.0 Hz, 1H), 4.43 (d, J = 15.7 Hz, 1H), 4.1 
(m, 2H), 4.0 – 4.1 (m, 3H), 3.9 (m, 2H), 3.7 (m, 1H), 3.19 (dd, J = 13.6, 3.9 Hz, 1H), 
2.76 (dd, J = 13.5, 8.1 Hz, 1H); 13C NMR (CD3OD, 100 MHz) δ 159.3, 142.1, 136.0, 
129.2 (2 carbons), 128.6 (2 carbons), 126.9, 124.3, 85.7, 71.0, 70.3, 69.0, 67.8, 67.3, 
56.2, 37.7, 37.1; HRFAB Calcd for C18H22N4O6Na ([M+Na]+) m/e 413.1437; measure 
m/e 413.1445. 
N-(1-(β-D-Glucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone 
(OX201). 1H NMR (CD3OD, 400 MHz) δ 8.20 (s, 1H), 5.63 (d, J = 9.2 Hz, 1H), 4.57 
(s, 2H), 4.37 (t, J = 8.0 Hz, 2H), 3.9 (m, 1H), 3.89 (s, 1H), 3.74 (dd, J = 12.2, 5.5 Hz, 
1H), 3.5 – 3.8 (m, 2H), 3.38 (s, 1H), 3.34 (t, J = 1.6 Hz, 2H); 13C NMR (CD3OD, 100 
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MHz) δ 159.5, 142.8, 122.7, 88.5, 80.0, 77.3, 72.8, 69.7, 62.6, 61.2, 44.4, 38.9; 
HRFAB Calcd for C12H19N4O7 ([M+H]+) m/e 331.1254; measure m/e 331.1267. 
N-(1-(β-D-Galactopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone 
(OX202). 1H NMR (CD3OD, 400 MHz) δ 8.17 (s, 1H), 5.52 (d, J = 9.2 Hz, 1H), 4.56 
(s, 1H), 4.35 (dd, J = 8.7, 7.9 Hz, 1H), 4.15 (t, J = 9.3 Hz, 1H), 3.99 (d, J = 2.6 Hz, 
1H), 3.85 (t, J = 6.4 Hz, 1H), 3.76 (t, J = 6.5 Hz, 2H), 3.70 (dd, J = 9.6, 3.2 Hz, 1H), 
3.63 (t, J = 8.3 Hz, 1H), 3.63 (d, J = 2.3 Hz, 1H), 3.36 (s, 1H), 3.32 (ddd, J = 3.2, 1.7, 
1.7 Hz, 1H); 13C NMR (CD3OD, 100 MHz) δ 159.6, 142.9, 122.3, 89.1, 78.8, 74.0, 
70.3, 69.2, 62.6, 61.2, 47.2, 39.0; HRFAB Calcd for C12H18N4O7Na ([M+Na]+) m/e 
353.1073; measure m/e 353.1073. 
N-(1-(α-D-Mannopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone 
(OX203). 1H NMR (CD3OD, 400 MHz) δ 8.21 (s, 1H), 6.00 (s, 1H), 4.5 (m, 2H), 4.32 
(t, J = 9.4 Hz, 1H), 4.10 (s, 1H), 3.91 (dd, J = 12.1, 2.2 Hz, 1H), 3.7 – 3.8 (m, 2H), 3.6 
(m, 2H), 3.33 (s, 1H), 3.3 (m, 2H); 13C NMR (CD3OD, 100 MHz) δ 159.5, 142.0, 
123.3, 87.2, 80.3, 73.8, 71.1, 69.7, 62.6, 61.4, 44.4, 39.0; HRFAB Calcd for 
C12H18N4O7Na ([M+Na]+) m/e 353.1073; measure m/e 353.1089. 
N-(1-(β-D-Galactopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-1H-1,2,
3-triazol-4-yl)methyl-2-oxazolidinone (OX204). 1H NMR (CD3OD, 400 MHz) δ 
8.16 (s, 1H), 5.62 (d, J = 9.2 Hz, 1H), 4.53 (s, 2H), 4.39 (d, J = 7.6 Hz, 1H), 4.32 (t, J 
= 7.9 Hz, 2H), 3.94 (t, J = 9.0 Hz, 1H), 3.87 (d, J = 2,3 Hz, 2H), 3.81 (d, J = 3.4 Hz, 
1H), 3.7 – 3.8 (m, 5H), 3.5 – 3.6 (m, 4H), 3.48 (dd, J = 9.7, 3.2 Hz, 1H); 13C (CD3OD, 
100 MHz) δ 159.5, 142.8, 122.7, 103.9, 88.1, 78.5, 78.4, 76.0, 75.6, 73.7, 72.5, 71.4, 
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69.1, 62.6, 61.3, 60.3, 44.4, 38.9; HRFAB Calcd for C18H28N4O12Na ([M+Na]+) m/e 
515.1601; measure m/e 515.1609. 
N-(1-(β-L-Fucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone 
(OX205). 1H NMR (CD3OD, 400 MHz) δ 8.18 (s, 1H), 5.51 (d, J = 9.2 Hz, 1H), 4.53 
(s, 2H), 4.33 (t, J = 7.9 Hz, 1H), 4.06 (t, J = 9.3 Hz, 1H), 3.93 (dd, J = 7.2, 6.5 Hz, 
1H), 3.74 (d, J = 3.2 Hz, 1H), 3.66 (dd, J = 9.5, 3.4 Hz, 1H), 3.60 (dd, J = 7.4, 8.2 Hz, 
2H), 3.29 (ddd, J = 3.2, 1.7, 1.7 Hz, 1H), 1.27 (d, J = 6.5 Hz, 3H); 13C NMR (CD3OD, 
100 MHz) δ 159.6, 142.9, 122.1, 89.0, 74.3, 74.2, 71.8, 70.0, 62.6, 44.4, 39.0, 15.6; 
HRFAB Calcd for C12H19N4O6 ([M+H]+) m/e 315.1305; measure m/e 315.1294. 
N-(1-(α-L-Rhamnopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone 
(OX206). 1H NMR (CD3OD, 400 MHz) δ 8.14 (s, 1H), 5.98 (d, J = 1.2 Hz, 1H), 4.54 
(s, 2H), 4.33 (t, J = 7.9 Hz, 2H), 4.10 (dd, J = 3.1, 1.2 Hz, 1H), 3.68 (d, J = 9.1, 3.1 
Hz, 1H), 3.61 (t, J = 8.1 Hz, 1H), 3.61 (d, J = 2.4 Hz, 1H), 3.50 (d, J = 9.2 Hz, 1H), 
3.3 (m, 1H), 1.37 (d, J = 5.8 Hz, 3H); 13C NMR (CD3OD, 100 MHz) δ 159.2, 142.0, 
123.1, 87.0, 75.8, 73.6, 73.6, 71.9, 62.6, 44.4, 39.0, 16.9; HRFAB Calcd for 
C12H19N4O6 ([M+H]+) m/e 315.1305; measure m/e 315.1305. 
N-(1-(α-D-Xylopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-2-oxazolidinone 
(OX207). 1H NMR (CD3OD, 400 MHz) δ 8.16 (s, 1H), 6.10 (d, J = 2.8 Hz, 1H), 4.52 
(s, 2H), 4.32 (t, J = 7.9 Hz, 1H), 4.32 (d, J = 2.1 Hz, 1H), 4.14 (t, J = 3.2 Hz, 1H), 
4.05 (dd, J = 14.9, 2.8 Hz, 1H), 3.8 – 3.9 (m, 1H), 3.6 (m, 1H), 3.59 (t, J = 8.2 Hz, 
2H), 3.3 (m, 1H); 13C NMR (CD3OD, 100 MHz) δ 159.6, 142.0, 124.1, 85.7, 71.0, 
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70.3, 69.0, 67.8, 62.6, 44.4, 38.9; HRFAB Calcd for C11H17N4O6 ([M+H]+) m/e 
301.1148; measure m/e 301.1149. 
N-(1-(β-D-Glucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-5-acetamidomethyl
-2-oxazolidione (OX301). 1H NMR (CD3OD, 400 MHz) δ 8.17 (s, 1H), 5.60 (d, J = 
8.2 Hz, 1H), 4.6–4.7 (m, 1H), 4.59 (dd, J = 15.6, 3.2 Hz, 1H), 4.48 (dd, J = 15.5, 5.7 
Hz, 1H), 3.9 (m, 2H), 3.7 (m, 2H), 3.4–3.6 (m, 3H), 3.3 (m, 3H), 1.92 (d, J = 6.2 Hz, 
3H); 13C NMR (CD3OD, 100 MHz) δ 172.9, 158.5, 142.6, 122.8, 88.5, 79.9, 77.2, 
72.9 (2 carbons), 69.7, 61.2, 46.8, 41.8, 38.8, 21.3; HRESI Calcd for C15H24N5O8 
([M+H]+) m/e 402.1619; measure m/e 402.1637. 
N-(1-(β-D-Galactopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-5-acetamidometh
yl-2-oxazolidinone (OX302). 1H NMR (CD3OD, 400 MHz) δ 8.21 (s, 1H), 5.57 (dd, 
J = 9.1, 1.4 Hz, 1H), 4.6–4.7 (m, 2H), 4.5–4.6 (m, 1H), 4.2 (m, 1H), 4.0 (m, 1H), 
3.84 (t, J = 6.4 Hz, 1H), 3.8–3.9 (m, 2H), 3.7–3.8 (m, 2H), 3.4 (m, 1H), 3.3 (m, 2H), 
1.93 (d, J = 10.1 Hz, 3H); 13C NMR (CD3OD, 100 MHz) δ 172.9, 158.5, 142.8, 122.4, 
89.1, 78.8, 74.1, 72.9, 70.4, 69.2, 61.3, 46.8, 41.8, 38.8, 21.3; HRESI Calcd for 
C15H24N5O8 ([M+H]+) m/e 402.1619; measure m/e 402.1634. 
N-(1-(α-D-Mannopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-5-acetamidomethy
l-2-oxazolidinone (OX303). 1H NMR (CD3OD, 400 MHz) δ 8.22 (s, 1H), 6.03 (s, 
1H), 4.6–4.7 (m, 1H), 4.4–4.6 (m, 1H), 4.13 (s, 1H), 3.9–4.0 (m, 1H), 3.7–3.8 (m, 
2H), 3.6–3.7 (m, 1H), 3.5–3.6 (m, 2H), 3.44 (d, J = 4.7 Hz, 2H), 3.3 (m, 2H), 1.92 
(d, J = 5.6 Hz, 3H); 13C NMR (CD3OD, 100 MHz) δ 172.8, 158.5, 142.7, 122.5, 87.2, 
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86.6,80.3, 73.7, 72.9, 71.1, 61.5, 46.7, 41.9, 38.8, 21.3; HRESI Calcd for C15H24N5O8 
([M+H]+) m/e 402.1619; measure m/e 402.1622. 
N-(1-(β-D-Galactopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl)-1H-1,2,
3-triazol-4-yl)methyl-5-acetamidomethyl-2-oxazolidinone (OX304). 1H NMR 
(CD3OD, 400 MHz) δ 8.20 (s, 1H), 5.66 (d, J = 9.2 Hz, 1H), 4.7 (m, 1H), 4.57 (d, J = 
3.0 Hz, 1H), 4.51 (d, J = 5.2 Hz, 1H), 4.43 (d, J = 7.6 Hz, 1H), 4.0 (m, 1H), 3.91 (d, J 
= 2.2 Hz, 2H), 3.84 (d, J = 3.2 Hz, 1H), 3.7–3.8 (m, 3H), 3.6–3.7 (m, 2H), 3.51 (dd, 
J = 9.7, 3.2 Hz, 1H), 3.44 (dd, J = 8.2, 3.2 Hz, 2H), 3.4 (m, 2H), 3.3 (m, 2H), 1.92 (d, 
J = 5.5 Hz, 3H); 13C NMR (CD3OD, 100 MHz) δ 172.9, 158.5, 142.7, 122.9, 103.9, 
88.2, 78.7, 78.3, 75.9, 75.6, 73.6, 72.9, 72.5, 71.4, 69.1, 61.4, 60.4, 46.8, 41.9, 38.8, 
21.4; HRESI Calcd for C21H34N5O13 ([M+H]+) m/e 564.2147; measure m/e 564.2170. 
N-(1-(β-L-Fucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-5-acetamidomethyl-
2-oxazolidinone (OX305). 1H NMR (CD3OD, 400 MHz) δ 8.20 (s, 1H), 5.54 (dd, J = 
9.0, 2.6 Hz, 1H), 4.6 (m, 1H), 4.57 (d, J = 9.1 Hz, 1H), 4.51 (d, J = 14.4 Hz, 1H), 4.08 
(dd, J = 17.2, 9.1 Hz, 1H), 4.0 (m, 1H), 3.8 (m, 1H), 3.6–3.7 (m, 2H), 3.4–3.5 (m, 
2H), 3.3 (m, 1H), 1.93 (d, J = 14.3 Hz, 3H), 1.29 (d, J = 6.3 Hz, 3H); 13C NMR 
(CD3OD, 100 MHz) δ 172.9, 158.5, 142.8, 122.3, 89.0, 74.2 (2 carbons), 72.9, 71.8, 
70.0, 46.8, 41.9, 38.8, 21.5, 15.7; HRESI Calcd for C15H24N5O7 ([M+H]+) m/e 
386.1670; measure m/e 386.1685. 
N-(1-(α-L-Rhamnopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-5- 
acetamidomethyl-2-oxazolidinone (OX306). 1H NMR (CD3OD, 400 MHz) δ 8.12 (s, 
1H), 5.99 (d, J = 2.4 Hz, 1H), 4.7 (m, 1H), 4.5 (m, 1H), 4.10 (s, 1H), 3.7 (m, 2H), 3.6 
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(m, 1H), 3.50 (d, J = 9.1 Hz, 1H), 3.5 (m, 2H), 3.31 (d, J = 14.2 Hz, 3H), 1.93 (d, J = 
3.3 Hz, 2H), 1.38 (d, J = 5.7 Hz, 3H); 13C NMR (CD3OD, 100 MHz) δ 172.8, 158.5, 
141.9, 123.3, 87.0, 75.8, 72.9, 71.2, 47.2, 46.8, 46.7, 41.8, 38.8, 21.4, 16.9; HRESI 
Calcd for C15H24N5O7 ([M+H]+) m/e 386.1670; measure m/e 386.1678. 
N-(1-(α-D-Xylopyranosyl)-1H-1,2,3-triazol-4-yl)methyl-5-acetamidomethyl-
2-oxazolidinone (OX307). 1H NMR (CD3OD, 400 MHz) δ 8.17 (s, 1H), 6.12 (d, J = 
2.7 Hz, 1H), 4.6–4.7 (m, 1H), 4.5 (m, 2H), 4.16 (t, J = 5.1 Hz, 1H), 4.1 (m, 1H), 3.9 
(m, 2H), 3.6 (m, 2H), 3.4 (m, 2H), 3.3 (m, 2H), 1.92 (d, J = 3.7 Hz, 3H); 13C NMR 
(CD3OD, 100 MHz) δ 172.9, 158.5, 142.6, 122.7, 89.1, 77.3, 72.8 (2 carbons), 69.5, 
68.6, 46.8, 41.8, 38.8, 21.3; HRESI Calcd for C14H22N5O7 ([M+H]+) m/e 372.1513; 
measure m/e 372.1527. 
N-Propargylcyclopamine (25). To a solution of cyclopamine (0.070 g, 0.17 
mmol) and NaHCO3 (0.021 g, 0.26 mmol) in CH3CN (25 mL), propargyl bromide 
(0.028 mL, 0.26 mmol, 80% in toluene) was added. The reaction mixture was 
refluxed for 2.5 h. After completion of the reaction examined by TLC (eluted with 
MeOH/EtOAc = 3/7), the reaction mixture was allowed to cooled to room 
temperature and then stored in freezer overnight. The solution was carefully removed 
by pipet. The residue was added with hexane (5 mL) and the solution was cooled in 
freezer. After removal of hexane by pipet, the residue was pump-dried and then 
recrystalized from CH2Cl2 and hexane. The purified product was obtained as white 
solid (0.072 g, 0.16 mmol, 94%). 1H NMR (CDCl3, 400 MHz) δ 5.4 (m, 1H), 4.3 (m, 
1H), 3.2 - 3.6 (m, 4H), 2.86 (dd, J = 11.1, 3.5 Hz, 1H), 2.4 (m, 2H), 2.2 (m, 4H), 2.0 
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(m, 2H), 1.6 - 1.8 (m, 10H), 1.4 - 1.6 (m, 2H), 1.2-1.4 (m, 6H), 0.8-1.2 (m, 10H); 13C 
NMR (CDCl3, 100 MHz) δ 143.1, 141.8, 127.0, 122.1, 84.9, 78.5, 74.1, 73.8, 72.0, 
68.7, 61.3, 52.2, 49.5, 43.9, 42.0, 41.7, 39.5, 38.3, 38.2, 36.7, 33.1, 31.6, 31.3, 29.5, 
29.2, 24.8, 19.3, 18.9, 13.7, 10.9; HRESI/APCI Calcd for C30H44NO2 ([M+H]+) m/e 
450.3372; measure m/e 450.3374. 
N-(1-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl) 
methylcyclopamine (26a). 1H NMR (CDCl3, 400 MHz) δ 7.74 (s, 1H), 5.87 (d, J = 
9.1 Hz, 1H), 5.4 (m, 4H), 5.2 – 5.3 (m, 1H), 4.32 (dd, J = 12.7, 5.2 Hz, 1H), 4.1 (m, 
1H), 4.0 (m, 2H), 3.5 – 3.6 (m, 4H), 2.4 (s, 1H), 2.3 (s, 1H), 2.2 (m, 1H), 2.1 (m, 4H), 
2.0 – 2.1 (m, 3H), 2.09 (s, 3H), 2.08 (s, 3H), 2.04 (s, 3H), 1.83 (s, 3H), 0.7 – 1.7 (m, 
25H); 13C NMR (CDCl3, 100 MHz) δ 170.7, 170.1, 169.6, 170.0, 143.2, 141.8, 127.1, 
122.1, 121.2, 117.4, 86.0, 85.0, 75.4, 72.7, 72.0, 70.6, 68.0, 61.9, 52.2, 49.5, 42.0, 
41.7, 39.8, 38.3, 38.2, 36.8, 33.1, 32.1, 32.0, 31.6, 31.3, 30.5, 29.9, 29.5, 29.2, 24.9, 
20.9, 20.8, 20.7, 20.4, 19.2, 18.9, 13.7, 10.9; HRESI/APCI Calcd for C44H63N4O11 
([M+H]+) m/e 823.4493; measure m/e 823.4515. 
N-(1-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl) 
methylcyclopamine (26b). 1H NMR (CDCl3, 400 MHz) δ 7.91 (s, 1H), 5.81 (d, J = 
9.4 Hz, 1H), 5.5 (m, 2H), 5.4 (m, 1H), 5.23 (d, J = 10.0 Hz, 1H), 4.2 (m, 5H), 4.04 (s, 
1H), 3.5 (m, 4H), 2.8 (m, 1H), 2.6 (m, 1H), 2.3 (m, 1H), 2.22 (s, 3H), 2.0 – 2.2 (m, 
8H), 2.02 (s, 3H), 1.98 (s, 3H), 1.85 (s, 3H), 0.8 – 1.8 (m, 23H); 13C NMR (CDCl3, 
100 MHz) δ170.5, 170.2, 170.0, 169.2, 143.2, 141.8, 128.9, 128.6, 127.9, 127.1, 
122.1, 86.6, 85.0, 74.4, 72.3, 70.8, 68.1, 67.1, 61.4, 52.2, 49.5, 42.0, 41.7, 38.4, 36.8, 
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33.1, 32.1, 31.6, 31.3, 29.9 (2 carbons), 29.6, 29.2, 24.8, 22.9, 20.9, 20.9, 20.7, 20.5, 
19.3, 18.9, 14.3, 13.7, 11.0; HRESI/APCI Calcd for C44H63N4O11 ([M+H]+) m/e 
823.4493; measure m/e 823.4503. 
N-(1-(2,3,4,6-Tetra-O-acetyl-β-D-mannopyranosyl)-1H-1,2,3-triazol-4-yl) 
methylcyclopamine (26c). 1H NMR (CDCl3, 400 MHz) δ 7.90 (s, 1H), 6.17 (s, 1H), 
5.70 (s, 1H), 5.3 (m, 4H), 4.32 (dd, J = 12.7, 6.2 Hz, 1H), 4.20 (d, J = 12.1 Hz, 1H), 
4.10 (dd, J = 14.2, 7.0 Hz, 1H), 4.0 (m, 2H), 3.5 (m, 4H), 2.9 (m, 1H), 2.6 (m, 1H), 
2.3 (m, 2H), 2.0 – 2.2 (m, 7H), 2.07 (s, 6H), 1.98 (s, 3H), 1.93 (s, 3H), 0.8 – 1.8 (m, 
23H); 13C (CDCl3, 100 MHz) δ 170.7, 169.9, 169.8, 169.1, 143.4, 141.8 (2 carbons), 
126.8, 122.1 (2 carbons), 85.1, 76.1, 72.0, 70.9, 69.2, 65.2, 62.5, 62.0, 60.6, 52.2, 49.5, 
42.0, 41.7, 39.8, 38.3, 38.2, 36.7, 33.0, 31.6, 31.3, 30.2, 29.3, 24.8, 22.9, 21.3, 21.0, 
20.9, 20.8, 20.7, 19.2, 18.9, 14.4, 13.7, 11.4; HRESI/APCI Calcd for C44H63N4O11 
([M+H]+) m/e 823.4493; measure m/e 823.4497. 
N-(1-(4-O-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-2,3,6-tri-O-acetyl-β
-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26d). 1H NMR 
(CDCl3, 400 MHz) δ 7.64 (s, 1H), 5.79 (d, J = 8.9 Hz, 1H), 5.4 (m, 4H), 5.11 (dd, J = 
10.3, 9.5 Hz, 1H), 4.96 (dd, J = 10.4, 3.4 Hz, 1H), 4.5 (m, 2H), 4.0 – 4.2 (m, 4H), 3.9 
– 4.0 (m, 4H), 3.4 – 3.5 (m, 4H), 2.41 (s, 1H), 2.33 (s, 1H), 2.2 (m, 2H), 2.2 (m, 5H), 
2.22 (s, 3H), 2.20 (s, 3H), 2.1 (m, 3H), 2.06 (s, 6H), 2.01 (s, 1H), 1.95 (s, 3H), 1.83 (s, 
3H), 0.7 – 1.7 (m, 25H); 13C NMR (CDCl3,100 MHz) δ 170.6, 170.4, 170.3 (2 
carbons), 169.6, 169.3 (2 carbons), 143.2, 141.8, 133.5, 127.1, 122.1, 119.2, 101.3, 
85.8, 85.0, 76.2, 75.9, 72.6, 72.0, 71.1, 69.2, 66.8, 62.0, 61.0, 52.2, 49.5, 42.0, 41.7, 
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39.8, 38.3, 38.2, 36.8, 33.1, 32.1, 32.0, 31.6, 31.3, 32.1, 31.6, 29.9 (2 carbons), 29.2, 
24.8, 22.9, 21.0, 20.9 (2 carbons), 20.8 (2 carbons), 20.7, 20.4, 19.2, 18.9, 13.7, 10.9; 
HRESI/APCI Calcd for C56H79N4O19 ([M+H]+) m/e1111.5339; measure m/e 
1111.5320. 
N-(1-(2,3,4-Tri-O-acetyl-β-L-fucopyranosyl)-1H-1,2,3-triazol-4-yl) 
methylcy-clopamine (26e). 1H NMR (CDCl3, 400 MHz) δ 7.85 (s, 1H), 5.80 (d, J = 
9.2 Hz, 1H), 5.5 (m, 1H), 5.4 (m, 3H), 5.3 (m, 2H), 4.1 (m 2H), 4.0 (m, 1H), 3.9 (m, 
1H), 4.4 - 4.6 (m, 5H), 2.80 (s, 1H), 2.6 (m, 2H), 2.2 (m, 2H), 2.25 (s, 3H), 2.01 (s, 
3H), 1.88 (s, 3H), 0.7- 1.9 (m, 29H); 13C NMR (CDCl3, 100 MHz) δ 170.5, 170.0, 
169.4, 143.0, 141.8 (2 carbons), 127.0, 122.1 (2 carbons), 86.7, 85.0, 73.0, 72.0, 71.3, 
70.1, 68.4, 52.3, 49.6, 52.3, 49.6, 42.0, 41.7, 38.4, 36.8, 32.1, 31.6, 31.3, 29.9 (2 
carbons), 29.5, 29.2, 24.8, 22.9, 20.9, 20.7, 20.5, 19.3, 18.9, 16.3, 14.3, 13.7, 11.0; 
HRESI/APCI Calcd for C42H61N4O9 ([M+H]+) m/e 765.4439; measure m/e 765.4433. 
N-(1-(2,3,4-Tri-O-acetyl-α-L-rhamnopyranosyl)-1H-1,2,3-triazol-4-yl) 
methyl-cyclopamine (26f). 1H NMR (CDCl3, 400 MHz) δ 7.61 (s, 1H), 6.09 (s, 1H), 
5.70 (s, 1H), 5.35 (s, 1H), 5.2 (m, 3H), 3.90 (s, 1H), 3.8 (m, 1H), 3.5 (m, 3H), 2.4 (m, 
1H), 2.3 (m, 1H), 2.4 (m, 2H), 2.0 – 2.2 (m, 6H), 2.12 (s, 3H), 2.07 (s, 3H), 1.96 (s, 
3H), 0.7 – 1.9 (m, 29H); 13C NMR (CDCl3, 100 MHz) δ 170.0 (2 carbons), 169.1, 
143.3, 141.8 (2 carbons), 126.9, 122.1 (2 carbons), 85.0, 74.3, 74.1, 72.0, 71.0, 69.9, 
69.5, 52.3, 49.5, 42.0, 41.7, 39.9, 38.4, 38.3, 36.8, 33.0, 32.1,31.6, 31.3, 29.9 (2 
carbons), 29.2, 24.8, 22.9, 20.9, 20.7, 20.7, 19.2, 18.9, 17.7, 14.3, 13.7, 11.1; 
HRESI/APCI Calcd for C42H61N4O9 ([M+H]+) m/e 765.4439; measure m/e 765.4422. 
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N-(1-(2,3,4-Tri-O-acetyl-α-D-xylopyranosyl)-1H-1,2,3-triazol-4-yl) 
methylcyclopamine (26g). 1H NMR (CDCl3, 400 MHz) δ 7.68 (s, 1H), 5.75 (d, J = 
9.0 Hz, 1H), 5.4 (m, 4H), 5.1 (m, 1H), 4.28 (dd, J = 11.5, 5.7 Hz, 1H), 4.1 (dd, J = 
14.4, 7.2 Hz, 1H), 3.8 (m, 1H), 3.4 – 3.6 (m, 4H), 2.8 (m, 1H), 2.6 (m, 1H), 2.2 – 2.3 
(m, 6H), 2.0 – 2.2 (m, 12H), 0.7 – 1.9 (m, 24H); 13C NMR (CDCl3, 100 MHz) δ 170.1, 
170.0, 169.1, 143.1, 141.8, 127.0, 122.1, 121.2, 117.3, 86.6, 85.0, 74.2, 72.2, 72.0, 
70.8, 68.7, 65.9, 52.2, 49.5, 42.0, 41.7, 39.8, 38.3, 38.2, 36.8, 33.1, 31.6, 31.3, 29.9 (2 
carbons), 29.6, 29.2, 24.8, 22.9, 20.8, 20.4, 19.2, 18.9, 14.3, 13.7, 10.9; HRESI/APCI 
Calcd for C41H59N4O9 ([M+H]+) m/e 751.4282; measure m/e 751.4276. 
N-(1-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl)-1H-1,2,3
-triazol-4-yl)methylcyclopamine (26h). 1H NMR (CDCl3, 400 MHz) δ 7.81 (s, 1H), 
5.94 (d, J = 9.8 Hz, 1H), 5.4 (m, 1H), 5.25 (t, J = 9.8 Hz, 1H), 4.6 (m, 1H), 4.30 (dd, J 
= 12.7, 5.1 Hz, 1H), 4.2 (m, 2H), 4.0 (m, 3H), 3.5 (m, 4H), 2.9 (m, 1H), 2.7 (m, 1H), 
2.3 (m, 1H), 2.1- 2.2 (m, 4H), 2.10 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 1.9 (m, 2H), 
1.82 (s, 3H), 0.7 – 1.7 (m, 27H); 13C NMR (CDCl3, 100 MHz) δ 171.1, 170.7, 170.3, 
169.5, 147.1, 141.8, 127.1, 122.1 (2 carbons), 117.4, 86.4, 85.0, 75.4, 74.2, 72.6, 72.0, 
68.1, 62.0, 53.7, 52.3, 49.5, 42.0, 41.7, 39.8, 38.4, 38.2, 36.8, 33.1, 32.0, 31.8, 31.6, 
31.3, 29.9, 29.5, 29.2, 24.8, 23.1, 20.9, 20.8 (2 carbons), 19.2, 18.9, 13.7, 10.9; 
HRESI/APCI Calcd for C44H64N5O10 ([M+H]+) m/e 822.4653; measure m/e 822.4644. 
N-(1-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-galactopyranosyl)-1H-1,2,
3-triazol-4-yl)methylcyclopamine (26i). 1H NMR (CDCl3, 400 MHz) δ 7.90 (s, 1H), 
6.39 (m, 2H), 6.0 (d, J = 9.6 Hz, 1H), 5.4 (m, 7H), 4.6 (m, 2H ), 4.1 (m, 10H), 3.5 (m, 
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4H), 2.9 (m, 1H), 2.6 (m, 1H), 0.8 – 2.2 (m, 34H); 13C NMR (CDCl3, 100 MHz) δ 
171.0, 170.8, 170.4, 169.5, 143.2, 141.8 (2 carbons), 126.9, 122.1 (2 carbons), 95.8, 
85.0, 78.7, 75.5, 75.2, , 70.5, 68.2, 62.8, 62.4, 60.6, 58.0, 52.2, 49.5, 42.0, 41.7, 38.4, 
36.7, 33.0, 31.5, 31.3, 29.9, 29.4, 29.2, 24.8, 23.3, 22.9, 21.3, 21.0, 20.9, 19.3, 18.9, 
14.4, 13.7, 11.0; HRESI/APCI Calcd for C44H64N5O10 ([M+H]+) m/e 822.4653; 
measure m/e 822.4646. 
N-(1-(4-O-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-
D-glucopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (26j). 1H NMR 
(CDCl3, 400 MHz) δ 7.24 (s, 1H), 5.78 (d, J = 8.7 Hz, 1H), 5.3 (m, 4H), 5.13 (t, J = 
9.3 Hz, 1H), 5.04 (t, J = 9.6 Hz, 1H), 4.92 (t, J = 8.1 Hz, 1H), 4.53 (d, J = 7.9 Hz, 1H), 
4.49 (d, J = 12.0 Hz, 1H), 4.36 (dd, J = 12.5, 4.2 Hz, 1H), 4.0 – 4.1 (m, 3H), 3.9 (m, 
3H), 3.8 (m, 1H), 3.6 (m, 1H), 3.5 (m, 3H), 2.40 (s, 1H), 2.32 (s, 1H), 2.2 (m, 2H), 2.2 
(m, 5H), 2.08 (s, 3H), 2.07 (s, 3H), 2.0 (m, 3H), 2.01 (s, 3H), 1.99 (s, 3H), 1.96 (s, 
3H), 1.83 (s, 3H), 0.7 – 1.7 (m, 25H); 13C NMR (CDCl3, 100 MHz) δ 170.7, 170.4, 
170.4, 169.7, 169.5, 169.2 (2 carbons), 143.3, 141.8 (2 carbons), 127.0, 122.1 (2 
carbons), 101.0, 85.9, 85.0, 76.2, 76.1, 73.0, 72.3, 72.0, 71.8, 70.8, 70.3, 67.9, 61.9, 
61.7, 52.2, 49.5, 42.0, 41.7, 39.7, 38.3, 38.2, 36.7, 33.1, 32.1, 31.6, 31.3, 29.9 (2 
carbons), 29.6, 29.2, 24.8, 22.9, 21.0, 20.9, 20.8 (2 carbons), 20.6, 20.4, 19.2, 18.9, 
14.3, 13.7, 11.0; HRESI/APCI Calcd for C56H79N4O19 ([M+H]+) m/e 1111.5339; 
measure m/e 1111.5322. 
N-(1-(4-O-(4-O-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-2,3,6-tri-O-acet
yl-β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl))-1H-1,2,3-triazol-
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4-yl)methylcyclopamine (26k). 1H NMR (CDCl3, 400 MHz) δ 7.70 (s, 1H), 5.87 (d, J 
= 9.2 Hz, 1H), 5.3 – 5.5 (m, 6H), 5.06 (t, J = 9.8 Hz, 1H), 4.86 (dd, J = 10.5, 4.0 Hz, 
1H), 4.76 (dd, J = 10.3, 3.9 Hz, 1H), 4.49 (d, J = 12.0 Hz, 2H), 4.36 (dd, J = 12.4, 4.3 
Hz, 1H), 3.9 – 4.3 (m, 10H), 3.5 (m, 3H), 3.6 (m, 3H), 2.80 (d, J = 9.1 Hz, 1H), 2.6 
(m, 2H), 2.4 (m, 2H), 2.15 (s, 6H), 2.09 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H), 2.03 (s, 
3H), 2.01 (s, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 2.9 (m, 2H), 1.83 (s, 3H), 0.8 – 1.8 (m, 
27H); 13C NMR (CDCl3, 100 MHz) δ 170.9, 170.8, 170.8, 170.6 (2 carbons), 170.1, 
169.9 (2 carbons), 169.7, 169.3, 143.3, 141.8, 131.1, 126.8, 122.1, 121.6, 96.3, 95.9, 
85.6, 85.1, 75.6, 74.9, 73.9, 73.7, 72.6, 72.0, 71.8, 71.3, 70.7, 70.3, 70.1, 69.5, 69.5, 
68.7, 68.1, 62.9, 62.4, 61.6, 61.1, 52.2, 49.9, 49.5, 42.0, 41.7, 39.6, 38.3, 38.1, 36.7, 
33.0, 31.6, 31.3, 29.9, 29.2 (2 carbons), 24.8, 21.1, 21.0 (2 carbons), 21.0, 20.9, 20.8 
(3 carbons), 20.4, 19.2, 18.9, 13.7, 11.0; HRESI/APCI Calcd for C68H95N4O27 
([M+H]+) m/e 1399.6184; measure m/e 1399.6160. 
N-(1-(2,3,4-Tri-O-acetyl-α-D-ribofuranosyl)-1H-1,2,3-triazol-4-yl) 
methylcyclopamine (26l). 1H NMR (CDCl3, 400 MHz) δ 7.71 (s, 1H), 6.16 (d, J = 
3.8 Hz, 1H), 5.77 (t, J = 4.3 Hz, 1H), 5.60 (t, J = 5.3 Hz, 1H), 5.4 (m, 1H), 4.50 (dd, J 
= 7.8, 4.5 Hz, 1H), 4.43 (dd, J = 12.4, 3.0 Hz, 1H), 4.26 (dd, J = 12.4, 4.5 Hz, 1H), 
4.0 (m, 1H), 3.5 -3.6 (m, 3H), 2.93 (d, J = 8.6 Hz, 1H), 2.55 (t, J = 6.9 Hz, 1H), 2.2 – 
2.3 (m, 3H), 2.13 (s, 3H), 2.10 (s, 3H), 2.07 (s, 3H), 0.8 – 2.0 (m, 33H); 13C NMR 
(CDCl3, 100 MHz) δ 170.5, 169.7, 169.5, 143.4, 141.8, 126.8, 122.2, 90.5, 85.0, 81.3, 
74.6, 73.9, 72.0, 71.3, 70.9, 63.2, 62.3, 60.6, 42.0, 41.7, 39.9, 38.4, 38.2, 36.7, 33.0, 
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32.1, 31.6, 31.3, 29.9, 29.4, 29.2, 24.8, 22.9, 21.3, 20.7, 20.6, 19.3, 18.9, 14.4, 13.7, 
11.4; HRESI Calcd for C41H59N4O9 ([M+H]+) m/e 751.4277; measure m/e 751.4297.  
2,3,4,5-Tetra-O-acetyl-1,6-(1,2,3-triazol-4-yl)methylcyclopmaine-1,6-dideoxy
-D-mannitol (26m). 1H NMR (CDCl3, 400 MHz) δ 7.9 (s, 2H), 5.3 (m, 8H), 4.63 (dd, 
J = 14.5, 2.6 Hz, 2H), 4.5 (m, 2H), 4.0 (m, 2H), 3.6 (m, 8H), 2.9 (m, 2H), 2.8 (m, 2H), 
2.4 (m, 2H), 2.17 (s, 6H), 2.01 (s, 6H), 0.8 – 2.3 (m, 64H); 13C NMR (CDCl3, 100 
MHz) δ 170.4 (2 carbons), 169.5 (2 carbons), 143.0 (2 carbons), 141.8 (2 carbons), 
126.8 (2 carbons), 123.0 (2 carbons), 122.1 (2 carbons), 85.1 (2 carbons), 73.0 (2 
carbons), 72.0 (2 carbons), 71.3 (2 carbons), 68.8 (2 carbons), 68.7 (2 carbons), 52.3 
(2 carbons), 50.5 (2 carbons), 49.6 (2 carbons), 42.0 (2 carbons), 41.7 (2 carbons), 
39.9 (2 carbons), 38.4 (2 carbons), 38.3 (2 carbons), 36.7 (2 carbons), 33.0 (2 
carbons), 31.6 (2 carbons), 31.3 (2 carbons), 29.4 (2 carbons), 29.3 (2 carbons), 29.2 
(2 carbons), 24.8 (2 carbons), 21.0 (2 carbons), 20.8 (2 carbons), 19.3 (2 carbons), 
18.9 (2 carbons), 14.5 (2 carbons),14.4 (2 carbons), 13.7 (2 carbons), 11.4 (2 carbons); 
HRESI Calcd for C74H106N8O12 ([M+Na]+) m/e 1321.7822; measure m/e 1321.7815. 
N-(1-(β-D-Glucopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (27a). 
1H NMR (CD3OD, 400 MHz) δ 8.16 (s, 1H), 5.60 (d, J = 9.2 Hz, 1H), 5.40 (s, 1H), 
4.00 (d, J = 14.2 Hz, 1H), 3.89 (t, J = 9.1 Hz, 1H), 3.88 (s, 1H), 3.7 (m, 1H), 3.4 – 3.6 
(m, 8H), 2.9 (m, 1H), 2.7 (m, 1H), 2.2 – 2.4 (m, 6H), 2.0 (m, 2H), 0.9 – 1.8 (m, 24H); 
13C NMR (CD3OD, 100 MHz) δ 143.1 (2 carbons), 141.9, 126.6, 123.6, 121.5, 88.4, 
85.5, 80.0, 77.3, 74.0, 72.8, 71.3, 70.5, 69.7, 61.3, 61.2, 52.2, 49.3, 48.9, 42.2, 41.4, 
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39.5, 38.3, 37.6, 36.5, 32.5, 30.8, 29.6, 29.1, 28.7, 24.5, 18.1, 17.8, 12.6, 10.0; 
HRESI/APCI Calcd for C36H55N4O7 ([M+H]+) m/e 655.4071; measure m/e 655.4075. 
N-(1-(D-galactopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (27b). 
1H NMR (CD3OD, 400 MHz) δ 8.21 (s, 1H), 5.57 (d, J = 9.1 Hz, 1H), 5.40 (s, 1H), 
4.15 (t, J = 9.3 Hz, 1H), 4.0 (m, 2H), 3.6 – 3.9 (m, 5H), 3.4 – 3.5 (m, 3H), 2.93 (d, J = 
8.0 Hz, 1H), 2.70 (t, J = 7.1 Hz, 1H), 2.2 – 2.4 (m, 7H), 2.0 (m, 2H), 0.9 – 1.9 (m, 
24H); 13C NMR (CD3OD, 100 MHz) δ 143.4, 143.1, 141.9, 126.6, 123.0, 121.5, 89.0, 
85.5, 78.8, 74.1, 74.0, 71.3, 70.5, 70.3, 69.2, 61.3, 61.2, 52.2, 49.4, 48.9, 48.2, 42.2, 
41.3, 39.6, 38.2, 37.6, 36.5, 32.5, 30.8, 29.1, 28.7, 24.5, 18.1, 17.7, 12.6, 9.9; 
HRESI/APCI Calcd for C36H55N4O7 ([M+H]+) m/e 655.4071; measure m/e 655.4081. 
N-(1-(α-D-Mannopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (27c). 
1H NMR (CD3OD, 400 MHz) δ 8.22 (s, 1H), 6.02 (d, J = 1.1 Hz, 1H), 5.40 (s, 1H), 
4.14 (s, 1H), 4.0 (d, J = 14.3 Hz, 1H), 3.94 (dd, J = 12.1, 2.0 Hz, 1H), 3.7 – 3.8 (m, 
3H), 3.4 – 3.5 (m, 5H), 2.91 (d, J = 8.5 Hz, 1H), 2.70 (t, J = 7.1 Hz, 1H), 2.2 – 2.4 (m, 
6H), 2.0 (m, 2H), 0.9 – 1.9 (m, 25H); 13C NMR (CD3OD, 100 MHz) δ 143.2, 142.4, 
141.9, 126.6, 124.0, 121.5, 87.1, 85.5, 80.4, 74.0, 73.8, 71.3, 71.1, 70.4, 66.6, 61.4, 
61.3, 52.2, 49.4, 48.9, 48.4, 42.2, 41.4, 39.6, 38.3, 37.6, 36.5, 32.5, 30.8, 29.0, 28.7, 
24.5, 18.1, 17.8, 12.6, 10.0; HRESI/APCI Calcd for C36H55N4O7 ([M+H]+) m/e 
655.4071; measure m/e 655.4083. 
N-(1-(4-O-(β-D-Galactopyranosyl)-β-D-glucopyranosyl)-1H-1,2,3-triazol-4- 
yl)methylcyclopamine (27d). 1H NMR (CD3OD, 400 MHz) δ 8.15 (s, 1H), 5.64 (d, J 
= 9.2 Hz, 1H), 5.39 (s, 1H), 4.43 (d, J = 7.7 Hz, 1H), 3.3 – 4.0 (m, 17H), 2.9 (m, 1H), 
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2.7 (m, 1H), 2.2 – 2.3 (m, 6H), 2.0 (m, 3H), 0.9 – 1.8 (m, 24H); 13C NMR (CD3OD, 
100 MHz) δ 143.2, 143.1, 142.1, 126.3, 123.5, 121.5, 103.9, 88.1, 85.5, 78.6, 78.4, 
76.0, 75.7, 74.0, 73.7, 72.5, 71.4, 71.3, 70.5, 69.1, 61.3 (2 carbons), 60.4, 52.3, 49.4, 
48.9, 42.3, ,41.4, 39.6, 38.1, 37.6, 36.5, 32.5, 30.9 (2 carbons), 29.1, 28.7, 24.5, 18.1, 
17.8, 12.6, 9.9; HRESI/APCI Calcd for C42H65N4O12 ([M+H]+) m/e 817.4599; 
measure m/e 817.4568. 
N-(1-(β-L-Fucopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (27e). 1H 
NMR (CD3OD, 400 MHz) δ 8.19 (s, 1H), 5.54 (d, J = 9.2 Hz, 1H), 5.40 (s, 1H), 4.06 
(t, J = 9.3 Hz, 1H), 4.0 (m, 2H), 3.76 (d, J = 3.1 Hz, 1H), 3.6 – 3.7 (m, 2H), 3.4 – 3.5 
(m, 4H), 2.93 (d, J = 8.7 Hz, 1H), 2.69 (t, J = 7.2 Hz, 1H), 2.2 – 2.3 (m, 7H), 2.0 (m, 
2H), 0.9 – 1.8 (m, 26H); 13C NMR (CD3OD, 100 MHz) δ 143.4, 143.1, 141.9, 126.2, 
122.7, 121.5, 89.0, 85.5, 74.3, 74.1, 74.0, 71.8, 71.3, 70.4, 70.1, 61.3, 52.2, 49.4, 48.9, 
42.2, 41.4, 39.6, 38.3, 37.6, 36.5, 32.5, 30.8, 29.9, 29.1, 28.7, 24.5, 18.1, 17.8, 15.6, 
12.6, 10.0; HRESI/APCI Calcd for C36H55N4O6 ([M+H]+) m/e 639.4122; measure m/e 
639.4113. 
N-(1-(α-L-Rhamnopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (27f). 
1H NMR (CD3OD, 400 MHz) δ 8.10 (s, 1H), 5.98 (d, J = 1.1 Hz, 1H), 5.40 (s, 1H), 
4.10 (dd, J = 3.0, 1.1 Hz, 1H), 4.00 (d, J = 14.2 Hz, 1H), 3.70 (dd, J = 9.1, 3.2 Hz, 
1H), 3.65 (s, 1H), 3.4 – 3.6 (m, 6H), 2.90 (d, J = 8.7 Hz, 1H), 2.67 (t, J = 7.2 Hz, 1H), 
2.2 – 2.3 (m, 7H), 2.0 (m, 2H), 0.9 – 1.8 (m, 26H); 13C NMR (CD3OD, 100 MHz) δ 
143.1, 142.5, 141.9, 126.6, 123.8, 121.5, 87.0, 85.5, 75.8, 74.0, 73.6, 71.9, 71.3, 71.2, 
70.5, 61.2, 52.2, 49.4, 48.9, 42.2, 41.4, 39.6, 38.3, 37.6, 36.5, 32.5, 30.8, 30.2, 29.0, 
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28.7, 24.5, 18.1, 17.8, 16.9, 12.6, 10.0; HRESI/APCI Calcd for C36H55N4O6 ([M+H]+) 
m/e 639.4122; measure m/e 639.4118. 
N-(1-(α-D-Xylopyranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (27g).  
1H NMR (CD3OD, 400 MHz) δ 8.11 (s, 1H), 5.50 (d, J = 9.2 Hz, 1H), 5.40 (s, 1H),  
4.03 (t, J = 5.6 Hz, 1H), 4.0 (d, J = 4.2 Hz, 1H), 3.92 (t, J = 9.1 Hz, 1H), 3.7 (m, 3H), 
3.5 (m, 5H), 2.91 (d, J = 9.2 Hz, 1H), 2.67 (t, J = 7.1 Hz, 1H), 2.2 – 2.3 (m, 6H), 2.0 
(m, 2H), 0.9 – 1.9 (m, 24H); 13C NMR (CD3OD, 100 MHz) δ 143.2 (2 carbons), 142.0, 
126.6, 123.5, 121.5, 89.0, 85.5, 77.5, 74.0, 72.7, 71.3, 70.4, 69.5, 68.7, 61.3, 52.3, 
48.8, 48.9, 42.3, 41.4, 39.6, 38.2, 37.6, 36.5, 32.5, 30.9, 30.8, 29.1, 28.7, 24.5, 18.1, 
17.7, 12.6, 9.9; HRESI/APCI Calcd for C35H53N4O6 ([M+H]+) m/e 625.3965; measure 
m/e 625.3956. 
N-(1-(2-Acetamido-2-deoxy-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl) 
methylcyclopamine (27h). 1H NMR (CD3OD, 400 MHz) δ 8.12 (s, 1H), 5.78 (d, J = 
9.9 Hz, 1H), 5.39 (s, 1H), 4.26 (t, J = 8.0 Hz, 1H), 3.92 (t, J = 10.0 Hz, 2H), 3.7 (m, 
1H), 3.4 – 3.7 (m, 9H), 2.82 (d, J = 7.7 Hz, 1H), 2.7 (m, 1H), 2.1 – 2.3 (m, 6H), 1.9 – 
2.0 (m, 2H), 0.9 – 1.8 (m, 26H); 13C NMR (CD3OD, 100 MHz) δ 171.9, 143.1, 142.7, 
141.9, 126.6, 123.0, 121.5, 87.0, 85.5, 80.1, 74.6, 74.0, 71.3, 70.2, 69.8, 61.1, 60.8, 
55.4, 52.2, 48.9, 48.4, 42.2, 41.4, 39.5, 38.3, 37.5, 36.5, 32.5, 30.8, 29.6, 29.1, 28.7, 
24.5, 21.6, 18.1, 17.8, 12.7, 10.0; HRESI/APCI Calcd for C38H58N5O7 ([M+H]+) m/e 
696.4336; measure m/e 696.4338. 
N-(1-(2-Acetamido-2-deoxy-β-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl) 
methylcyclopamine (27i). 1H NMR (CD3OD, 400 MHz) δ 8.12 (s, 1H), 5.77 (d, J = 
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9.9 Hz, 1H), 5.39 (s, 1H), 4.26 (t, J = 10.0 Hz, 1H), 3.9 (m, 2H), 3.6 –3.8 (m, 7H), 3.4  
– 3.5 (m, 2H), 2.9 (m, 1H), 2.8 (m, 1H), 2.1 – 2.3 (m, 5H), 2.0 (m, 5H), 0.9 -1.9 (m, 
25H); 13C NMR (CD3OD, 100 MHz) δ 171.9, 143.1, 142.6, 141.9, 126.6, 123.0, 121.5, 
87.0, 85.5, 80.1, 74.6, 74.0, 71.3, 70.2, 69.3, 68.4, 61.2, 60.7, 55.4, 52.2, 48.9, 48.7, 
42.2, 41.4, 39.5, 38.3, 37.5, 36.5, 32.5, 30.8, 29.0, 28.7, 24.5, 21.6, 18.1, 17.8, 12.7, 
10.0; HRESI/APCI Calcd for C38H58N5O7 ([M+H]+) m/e 696.4336; measure m/e 
696.4333. 
N-(1-(4-O-(β-D-Glucopyranosyl)-β-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl)
methylcyclopamine (27j). 1H NMR (CD3OD, 400 MHz) δ 8.15 (s, 1H), 5.64 (d, J = 
9.2 Hz, 1H), 5.40 (s, 1H), 4.48 (d, J = 7.8 Hz, 1H), 3.3 – 4.0 (m, 17H), 2.9 (m, 1H),  
2.7 (m, 1H), 2.2 – 2.3 (m, 7H), 2.0 (m, 3H), 0.7 – 1.8 (m, 23H); 13C NMR (CD3OD, 
100 MHz) δ 143.3, 143.1, 142.0, 126.6, 123.5, 121.5, 103.4, 88.1, 85.5, 78.5, 78.4, 
77.0, 76.7, 75.7, 74.0, 73.7, 72.6, 71.3, 70.5, 70.2, 61.3 (2 carbons), 60.3, 52.3, 49.4, 
48.9, 42.3, 41.4, 39.6, 38.3, 37.6, 36.5, 32.5, 30.8 30.7, 29.1, 28.7, 24.5, 18.1, 17.8, 
12.6, 9.9; HRESI/APCI Calcd for C42H65N4O12 ([M+H]+) m/e 817.4599; measure m/e 
817.4586. 
N-(1-(4-O-(4-O-(β-D-Glucopyranosyl)-β-D-glucopyranosyl)-β-D- 
glucopyranosyl))-1H-1,2,3-triazol-4-yl)methylcyclopamine (27k). 1H NMR 
(CD3OD, 400 MHz) δ 8.17 (s, 1H), 5.64 (d, J = 9.0 Hz, 1H), 5.40 (s, 1H), 5.26 (d, J = 
3.7 Hz, 1H), 5.17 (d, J = 3.8 Hz, 1H), 3.5 – 4.0 (m, 24H), 2.89 (d, J = 8.0 Hz, 1H), 2.7 
(m, 1H), 2.0 – 2.3 (m, 8H), 0.7 – 1.8 (m, 24H); 13C NMR (CD3OD, 100 MHz) δ 143.3, 
143.1, 141.9, 126.6, 123.6, 121.5, 101.8, 101.6, 88.2, 85.5, 80.2, 79.2, 78.5, 77.1, 74.0, 
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73.9, 73.8, 73.6, 73.1, 72.6, 72.5, 72.3, 71.3, 70.5, 70.3, 61.5, 61.3, 60.9, 60.7, 52.2, 
49.4, 48.9, 42.3, 41.4, 39.6, 38.3, 37.6, 36.5, 32.5, 30.8, 29.6, 29.1, 28.7, 24.5, 18.1, 
17.8, 12.6, 10.0; HRESI/APCI Calcd for C48H75N4O17 ([M+H]+) m/e 979.5127; 
measure m/e 979.5109. 
N-(1-(α-D-ribofuranosyl)-1H-1,2,3-triazol-4-yl)methylcyclopamine (27l). 1H 
NMR (CD3OD, 400 MHz) δ 8.24 (s, 1H), 6.04 (d, J = 3.9 Hz, 1H), 5.4 (m, 1H), 5.51 (t, 
J = 4.3 Hz, 1H), 4.32 (t, J = 5.0 Hz, 1H), 4.2 (m, 1H), 4.0 (d, J = 14.2 Hz, 1H), 3.82 
(dd, J = 15.3, 3.2 Hz, 1H), 3.71 (dd, J = 15.0, 4.2 Hz, 1H), 3.4 – 3.5 (m, 4H), 2.7 (m, 
1H), 2.6 (m, 1H), 0.9 -2.3 (m, 33H); 13C NMR (CD3OD, 100 MHz) δ 143.1, 141.9, 
126.6, 123.0, 121.5, 93.2, 86.0, 85.5, 75.9, 74.0, 71.3, 70.7, 70.4, 61.6, 61.3, 52.2, 
52.2, 49.3, 48.9, 42.2, 41.4, 39.5, 38.3, 37.6, 36.5, 32.5, 30.8, 29.6, 28.7, 24.5, 18.1, 
17.8, 13.3, 12.6, 10.0; HRESI Calcd for C35H53N4O6 ([M+H]+) m/e 625.3960; 
measure m/e 625.3967. 
N-(1,6-(1,2,3-triazol-4-yl)methylcyclopmaine)-1,6-dideoxy-D-mannitol (27m). 
1H NMR (CD3OD, 300 MHz) δ 7.92 (s, 2H), 5.37 (d, 2H), 4.77 (dd, J = 13.7, 2.4 Hz, 
2H), 4.45 (dd, J = 14.1, 7.6 Hz, 2H), 4.9 (m, 4H), 3.6 (m, 4H), 3.3 – 3.4 (m, 6H), 2.9 
(m, 2H), 2.6 (m, 2H), 0.8 – 2.3 (m, 66H); 13C NMR (CD3OD, 100 MHz) δ 143.2 (2 
carbons), 141.9 (2 carbons), 126.6 (2 carbons), 125.4 (2 carbons), 121.5 (2 carbons), 
85.5 (2 carbons), 74.0 (2 carbons), 71.3 (2 carbons), 70.5 (2 carbons), 70.3 (2 
carbons), 70.1 (2 carbons), 61.3 (2 carbons), 53.8 (2 carbons), 52.2 (2 carbons), 49.4 
(2 carbons), 48.2 (2 carbons), 42.2 (2 carbons), 41.4 (2 carbons), 39.6 (2 carbons), 
38.3 (2 carbons), 37.6 (2 carbons), 36.5 (2 carbons), 32.5 (2 carbons), 30.8 (4 
  
 
                                                                                  143
carbons), 29.6 (2 carbons), 29.1 (2 carbons), 28.7 (2 carbons), 24.5 (2 carbons), 18.2 
(2 carbons), 17.8 (2 carbons), 12.6 (2 carbons), 10.0 (2 carbons); HRESI Calcd for 
C66H98N8O8Na ([M+Na]+) m/e 1153.7400; measure m/e 1153.7402. 
N-(1-(1,2,3-triazol-4-yl)methylcyclopmaine)-1-deoxy-D-mannitol (27n). 1H 
NMR (CD3OD, 400 MHz) δ 7.95 (s, 1H), 5.4 (m, 1H), 4.8 (m, 1H), 4.5 (m, 1H), 4.0 
(m, 2H), 3.9 (m, 3H), 3.6 (m, 6H), 3.3 (m, 3H), 2.9 (m, 1H), 2.8 (m, 1H), 0.8 – 2.3 (m, 
30H); 13C NMR (CD3OD, 100 MHz) δ 143.2, 142.7, 141.9, 126.6, 125.4, 121.5, 85.5 , 
74.0, 71.7, 71.3, 70.9, 70.5, 70.2, 69.8, 63.9, 61.3, 53.9, 52.2, 49.4, 48.9, 42.2, 41.4, 
39.6, 38.2, 37.6, 36.5, 32.5, 29.6, 29.1, 28.7, 24.5, 18.1, 17.8, 13.2, 12.6, 10.9; HRESI 
Calcd for C36H57N4O7 ([M+H]+) m/e 657.4222; measure m/e 657.4227. 
Compound (29). A solution of compound 28 (1.50 g, 0.89 mmol) and NaN3 
(0.12 g, 1.78 mmol) in DMF was stirred at 80 °C overnight. TLC showed the 
completion of the reaction (Rf = 0.50 eluted with EtOAc/MeOH = 97/3). The reaction 
mixture was filtered through Celite, and the residue was washed with EtOAc. After 
the removal of the solvent followed by purification with gradient column 
chromatography (CH2Cl2/MeOH = 100/0 to 90/10), the product was obtained as a 
white solid (0.81 g, 63%). 1H NMR (CD3COCD3, 400 MHz) δ 7.2−7.4 (m, 30H), 6.6 
(m, 2H), 6.36 (d, J = 9.6 Hz, 1H), 4.8−5.3 (m, 18H), 4.5 (m, 4H), 3.8−4.1 (m, 6H), 
3.3−3.9 (m, 20H). 13C NMR (CD3COCD3, 100 MHz) δ 157.6 (2 carbons), 157.4, 
156.8, 156.5 (2 carbons), 137.4−137.7 (6 carbons), 127.7−128.7 (30 carbons), 110.0, 
100.3, 99.1, 86.6, 80.5, 79.4, 74.8, 74.4, 73.1, 72.6, 72.3, 71.7, 70.3, 67.9, 66.0−67.9 
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(8 carbons), 56.6, 53.2, 51.9, 51.3, 42.6, 41.3, 34.8. ESI/APCI calcd for 
C71H81N9O24Na ([M+Na]+) m/e 1466.5292; found m/e 1466.5263. 
Compound (30). To a solution of compound 29 (1.98 g, 1.37 mmol) in THF (20 
mL) and several drops of water, PMe3 in THF (8.2 mL, 8.2 mmol) was added. The 
reaction mixture was stirred at 50 °C for an hour, and TLC showed the completion of 
the reaction (Rf = 0.02 eluted with EtOAc/MeOH = 97/3). After the removal of the 
solvent followed by purification with gradient column chromatography 
(CH2Cl2/MeOH = 100/0 to 70/30), the product was obtained as a white solid (1.80 g, 
93%). 1H NMR (CD3OD, 400 MHz) δ 7.3 − 7.4 (m, 30H), 5.1 (m, 10H), 3.3 − 3.9 (m, 
37H). 13C NMR (CD3OD, 100 MHz) δ 157.6−158.0 (6 carbons), 136.9−137.1 (6 
carbons), 127.7−128.4 (30 carbons), 110.9, 98.8, 98.1, 86.6, 79.4, 78.7, 74.8, 74.0, 
73.3, 71.9, 71.8, 71.1, 70.3, 67.8, 56.2, 52.9, 51.7, 50.8, 43.4, 42.0, 41.1, 39.0, 33.6, 
30.4, 29.6, 28.9, 24.4, 23.7, 22.8. ESI/APCI calcd for C71H84N7O24 ([M + H]+) m/e 
1418.5568; found m/e 1418.5536. 
NEOF001 (31a). 1H NMR (D2O, 400 MHz) δ 8.08 (s, 1H), 5.95 (d, J = 3.4 Hz, 
1H), 5.34 (s, 1H), 5.24 (s, 1H), 4. 3 (t, J = 5.0 Hz, 2H), 4.14 (s, 2H), 4.06 (t, J = 9.7 
Hz, 1H), 3.8−4.0 (m, 6H), 3.8 (m, 2H), 3.6−3.8 (m, 3H), 3.4−3.5 (m, 4H), 3.2−3.4 (m, 
11H), 2.3 (m, 1H), 2.0 (m, 1H), 1.82 (s, 3H). 13C NMR (D2O, 100 MHz) δ 174.8, 
159.4, 142.8, 125.5, 110.1, 95.5, 95.0, 84.9, 79.9, 76.8, 75.3, 73.5, 73.1, 72.4, 70.6, 
70.4, 69.9, 68.2, 67.8, 67.5, 53.5, 52.2, 51.0, 49.9, 48.7, 47.0, 41.9, 40.7, 40.2, 38.6, 
28.3, 22.0. ESI/APCI calcd for C32H58N11O15 ([M + H]+) m/e 836.4108; found m/e 
836.4107. 
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NEOF003 (31b). 1H NMR (D2O, 400 MHz) δ 7.80 (s, 1H), 5.78 (d, J = 3.7 Hz, 
1H), 5.30 (d, J = 3.8 Hz, 1H), 5.2 (m, 1H), 4.5 (m, 2H), 4.2 (m, 1H), 3.9 (m, 1H), 
3.7−3.9 (m, 6H), 3.5 (m, 2H), 3.3 (m, 5H), 3.2 (m, 3H), 2.62 (t, J = 7.4 Hz, 2H), 2.22 
(m, 1H), 1.97 (m, 1H), 1.6 (m, 2H), 1.1−1.2 (m, 8H), 0.75 (m, 3H). 13C NMR (D2O, 
100 MHz) δ 149.4, 123.9, 109.9, 95.9, 95.4, 85.4, 79.9, 78.0, 77.2, 73.2, 73.0, 70.9, 
69.3, 68.9, 67.8, 67.5, 53.8, 51.7, 51.0, 50.3, 48.8, 46.8, 40.7, 40.3, 30.8, 30.4, 28.8, 
27.9, 24.5, 22.1, 13.5. ESI/APCI calcd for C31H60N9O12 ([M + H]+) m/e 750.4356; 
found m/e 750.4333. 
NEOF007 (31c). 1H NMR (D2O, 400 MHz) δ 8.39 (s, 1H), 5.97 (d, J = 3.6 Hz, 
1H), 5.40 (d, J = 2.9 Hz, 1H), 5.33 (s, 1H), 4.9 (dd, J = 14.0 , 1.0 Hz, 1H), 4.81 (dd, J 
= 15.0, 7.4 Hz, 1H), 4.61 (t, J = 5.7 Hz, 1H), 4.5 (m, 4H), 4.5 (s, 2H), 4.35 (t, J = 5.3 
Hz, 1H), 4.22 (t, J = 3.0 Hz, 1H), 4.12 (dd, J = 7.6, 2.9 Hz, 1H), 4.0 (m, 1H), 3.98 (t, J 
= 9.2 Hz, 2H), 3.8−3.9 (m, 3H), 3.7 (m, 2H), 3.6 (m, 1H), 3.4−3.5 (m, 6H), 3.2−3.3 
(m, 3H), 2.3 (m, 1H), 1.7 (m, 1H). 13C NMR (D2O, 100 MHz) δ 137.2, 128.4, 110.4, 
95.7, 95.4, 85.3, 79.8, 77.0, 76.9, 73.1, 73.0, 71.0, 70.6, 69.5, 69.0, 67.9, 67.6, 53.9, 
52.9, 51.3, 51.1, 50.4, 49.0, 42.5 (2 carbons), 40.8, 40.5, 30.1. ESI/APCI calcd for 
C28H55N10O12 ([M+H]+) m/e 723.3995; found m/e 723.4022. 
NEOF010 (31d). 1H NMR (D2O, 400 MHz) δ 8.14 (s, 1H), 7.88 (t, J = 8.6 Hz, 
2H), 7.73 (m, 3H), 7.68 (t, J = 8.2 Hz, 1H), 7.49 (t, J = 8.1 Hz, 1H), 7.4 (m, 3H), 5.94 
(d, J = 3.9 Hz, 1H), 5.32 (d, J = 3.5 Hz, 1H), 5.21 (d, J = 1.5 Hz, 1H), 4.5 (m, 2H), 4.2 
(m, 2H), 4.1 (m, 1H), 3.8−3.9 (m, 6H), 3.7 (m, 1H), 3.6 (m, 1H), 3.5 (m, 2H), 3.2−3.4 
(m, 9H), 2.31 (dt, J = 8.4, 4.1 Hz, 1H), 1.73 (m, 1H). 13C NMR (D2O, 100 MHz) δ 
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169.7, 157.7, 147.5, 144.8, 142.2, 137.9, 131.3, 130.4, 129.2 (2 carbons), 128.3, 128.1, 
127.9 (2 carbons), 125.0, 124.8, 123.0, 118.2, 110.0, 95.7, 95.2, 85.0, 79.9, 76.9, 76.2, 
73.1, 72.6, 70.7, 70.3, 69.7, 68.4, 67.8, 67.5, 53.6, 52.2, 50.9, 50.0, 48.7, 40.7, 40.2, 
35.1, 28.9. ESI/APCI calcd for C42H59N11O13 ([M+H]+) m/e 948.4186; found m/e 
948.4208. 
NEOF011 (31e) 1H NMR (D2O, 400 MHz) δ 8.22 (s, 1H), 5.85 (d, J = 3.5 Hz, 
1H), 5.30 (d, J = 2.9 Hz, 1H), 5.24 (d, J = 1.5 Hz, 1H), 4.82 (dd, J = 15.0, 2.8 Hz, 2H), 
4.52 (t, J = 5.9 Hz, 1H), 4.5 (m, 1H), 4.32 (s, 2H), 4.27 (t, J = 5.1 Hz, 1H), 4.14 (t, J = 
3.0 Hz, 1H), 4.05 (dd, J = 4.6, 2.9 Hz, 1H), 3.96 (m, 1H), 3.85 (t, J = 9.3 Hz, 2H), 3.8 
(m, 1H), 3.6 (m, 1H), 3.51 (s, 1H), 3.3−3.4 (m, 5H), 3.2 (m, 4H), 2.7 (m, 3H), 2.2 (m, 
1H), 1.6 (m, 1H). 13C NMR (D2O, 100 MHz) δ 138.5, 127.1, 110.3, 95.6, 95.4, 85.4, 
79.7, 78.0, 76.8, 73.0, 72.9, 71.0, 70.5, 69.3, 69.2, 67.9, 67.6, 53.9, 52.7, 51.0, 50.4, 
48.9, 42.7, 40.7, 40.4, 32.3, 31.2. ESI/APCI calcd for C27H52N10O12Na ([M + Na]+) 
m/e 731.3658; found m/e 731.3693. 
NEOF013 (31f). 1H NMR (D2O, 400 MHz) δ 8.18 (s, 1H), 5.90 (d, J = 3.2 Hz, 
1H), 5.31 (s, 1H), 5.21 (s, 1H), 4.5 (m, 1H), 4.46 (d, J = 8.9 Hz, 2H), 4.3 (m, 1H), 4.1 
(m, 2H), 3.8−3.9 (m, 5H), 3.1−3.6 (m, 14H), 2.2 (m, 2H), 1.9 (m, 3H), 1.6 (m, 3H). 
13C NMR (D2O, 100 MHz) δ 144.4, 124.9, 110.4, 95.6, 95.3, 85.4, 82.0, 79.7, 77.0, 
76.9, 75.2, 72.9, 71.0, 70.5, 69.3, 69.0, 67.9, 67.6, 53.8, 52.0, 51.0, 50.4, 48.9, 45.1, 
40.7, 40.4, 30.5, 28.3, 21.7, 21.6. ESI/APCI calcd for C30H57N10O12 ([M + H]+) m/e 
749.4152; found m/e 749.4165. 
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NEOF015 (31g). 1H NMR (D2O, 400 MHz) δ 8.19 (s, 1H), 6.04 (d, J = 3.9 Hz, 
1H), 5.36 (d, J = 3.1 Hz, 1H), 5.26 (d, J = 1.6 Hz, 1H), 4.53 (t, J = 5.2 Hz, 1H), 4.4 
(m, 1H), 4.3 (m, 3H), 4.0−4.1 (m, 2H), 3.9−4.0 (m, 4H), 3.7−3.8 (m, 2H), 3.2−3.5 (m, 
10H), 2.4 (m, 1H), 2.0 (m, 1H). 13C NMR (D2O, 100 MHz) δ 140.3, 126.1, 110.2, 
95.5, 95.1, 85.0, 80.0, 76.8, 75.0, 73.0, 72.5, 70.6, 70.4, 70.0, 68.2, 67.8, 67.5, 53.4, 
52.7, 51.0, 49.9, 48.6, 40.7, 40.3, 34.2, 28.1. ESI/APCI calcd for C26H50N10O12 ([M + 
Na]+) m/e 717.3502; found m/e 717.3525. 
NEOF017 (31h). 1H NMR (D2O, 400 MHz) δ 7.96 (s, 1H), 5.90 (d, J = 3.8 Hz, 
1H), 5.31 (d, J = 3.3 Hz, 1H), 5.24 (d, J = 1.6 Hz, 1H), 4.5 (m, 2H), 4.39 (s, 2H), 4.26 
(t, J = 4.6 Hz, 1H), 4.14 (t, J = 3.1 Hz, 1H), 3.8−3.9 (m, 5H), 3.7 (m, 1H), 3.6 (dd, J = 
9.0, 7.0 Hz, 1H), 3.5 (m, 1H), 3.2−3.4 (m, 12H), 2.96 (td, J = 12.9, 3.0 Hz, 2H), 2.6 
(m, 1H), 23 (dt, J = 8.6, 4.2 Hz, 1H), 2.0 (m, 2H), 1.7−1.8 (m, 3H). 13C NMR (D2O, 
100 MHz) δ 176.5, 145.2, 124.6, 110.2, 95.6, 95.2, 85.2, 79.9, 76.9, 76.8, 73.0, 72.8, 
70.8, 70.4, 69.5, 68.6, 67.8, 67.5, 53.7, 52.3, 51.0, 50.1, 48.7, 43.3 (2 carbons), 40.7, 
40.3, 39.8, 34.6, 29.0, 25.2 (2 carbons). ESI/APCI calcd for C32H59N11O13Na ([M + 
Na]+) m/e 828.4186; found m/e 828.4170. 
NEOF020 (31i) 1H NMR (D2O, 400 MHz) δ 8.01 (s, 1H), 5.98 (d, J = 4.0 Hz, 
1H), 5.34 (d, J = 3.5 Hz, 1H), 5.24 (s, 1H), 4.4−4.5 (m, 4H), 4.31 (t, J = 2.9 Hz, 1H), 
4.26 (t, J = 5.4 Hz, 1H), 4.14 (t, J = 3.0 Hz, 1H), 3.97 (t, J = 9.0 Hz, 1H), 3.95 (dd, J 
= 10.5, 9.0 Hz, 1H), 3.9 (m, 3H), 3.8 (s, 1H), 3.64 (t, J = 10 Hz, 1H), 3.2−3.5 (m, 
13H), 2.4 (m, 2H), 2.0 (m, 3H), 1.84 (dd, J = 14.0, 12.0 Hz, 1H). 13C NMR (D2O, 100 
MHz) δ 169.8, 144.6, 124.7, 110.1, 95.7, 95.1, 84.9, 80.0, 77.0, 75.1, 73.1, 72.5, 70.6, 
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70.4, 69.8, 68.2, 67.8, 67.5, 59.9, 53.4, 52.3, 50.9, 49.8, 48.6, 46.7, 40.7, 40.2, 34.8, 
29.8, 28.1, 24.0. ESI/APCI calcd for C31H58N11O13 ([M + H]+) m/e 792.4210; found 
m/e 792.4236. 
NEOF002 (32a). 1H NMR (D2O, 400 MHz) δ 5.80 (d, J = 3.8 Hz, 1H), 5.30 (d, 
J = 10.7 Hz, 1H), 5.19 (d, J = 1.3 Hz, 1H), 4.33 (t, J = 4.9 Hz, 1H), 4.22 (t, J = 5.0 
Hz, 1H), 4.16 (t, J = 2.9 Hz, 1H), 3.8 − 3.9 (m, 4H), 3.7 (m, 1H), 3.65 (t, J = 9.6 Hz, 
1H), 3.55 (dd, J = 12.8, 3.8 Hz, 1H), 3.5 (m, 1H), 3.2 − 3.4 (m, 10H), 2.6 (m, 1H), 
2.17 (t, J = 7.2 Hz, 2H), 1.5 (m, 1H), 1.2 (m, 2H), 1.2 (m, 8 H), 0.74 (t, J = 6.5 Hz, 
3H); 13C NMR (D2O, 100 MHz) δ 178.0, 109.3, 95.9, 95.2, 85.2, 80.8, 77.5, 76.5, 
73.6, 72.7, 70.7, 70.3, 69.3, 68.5, 67.8, 67.5, 53.6, 51.0, 49.9, 48.8, 41.5, 40.7, 40.3, 
36.1, 30.9, 27.8, 28.2, 25.6, 22.1, 13.5. ESI/APCI calcd for C30H60N7O13 ([M + H]+) 
m/e 726.4244; found m/e 726.4226. 
NEOF004 (32b). 1H NMR (D2O, 400 MHz) δ 5.72 (d, J = 3.6 Hz, 1H), 5.28 (d, 
J = 4.1 Hz, 1H), 5.18 (d, J = 1.4 Hz, 1H), 4.31 (t, J = 3.6 Hz, 1H), 4.22 (t, J = 4.0 Hz, 
1H), 4.17 (t, J = 4.9 Hz, 2H), 4.12 (t, J = 3.0 Hz, 1H), 3.95 (m, 1H), 3.7−3.8 (m, 3H), 
3.4−3.6 (m, 3H), 3.3−3.4 (m, 6H), 3.2 (m, 3H), 2.2 (m, 3H), 1.6 (m, 1H), 1.5 (m, 2H), 
1.2 (m, 26H), 0.7 (m, 3H). 13C NMR (D2O, 100 MHz) δ 178.1, 109.4, 96.0, 95.5, 85.4, 
80.6, 77.5, 73.6, 73.0, 70.9, 70.3, 69.4, 69.1, 67.8, 67.6, 53.9, 51.0, 50.2, 49.0, 41.2, 
40.7, 40.3, 36.1, 31.4, 28.5−29.0 (12 carbons), 25.6, 22.2, 13.6. ESI/APCI calcd for 
C39H78N7O13 ([M + H]+) m/e 852.5652; found m/e 852.5633. 
NEOF005 (32c). 1H NMR (D2O, 400 MHz) δ 5.75 (d, J = 3.3 Hz, 1H), 5.31 (s, 
1H), 5.17 (s, 1H), 4.35 (t, J = 4.6 Hz, 1H), 4.1−4.2 (m, 4H), 4.0 (m, 1H), 3.8−3.9 (m, 
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3H), 3.62 (t, J = 8.8 Hz, 1H), 3.5 (m, 3H), 3.1−3.4 (m, 8H), 2.2 (m, 3H), 1.6 (m, 1H), 
1.5 (m, 2H), 1.2 (m, 30H), 0.8 (m, 3H). 13C NMR (D2O, 100 MHz) δ 177.6, 109.4, 
96.0, 95.6, 85.1, 80.3, 77.6, 73.4, 72.9, 71.1, 70.3, 69.4, 67.9, 67.7, 54.0, 51.1, 50.3, 
49.0, 41.5, 40.7, 40.4, 39.0, 36.2, 31.7, 28.9−29.9 (14 carbons), 25.8, 22.5, 13.9. 
ESI/APCI calcd for C41H82N7O13 ([M + H]+) m/e 880.5965; found m/e 880.5959. 
NEOF006 (32d). 1H NMR (D2O, 400 MHz) δ 8.13 (t, J = 8.8 Hz, 2H), 7.98 (dd, 
J = 8.0 Hz, J = 2.0 Hz, 1H), 7.95 (s, 1H), 7.87 (t, J = 8.4 Hz, 1H), 7.70 (t, J = 7.2 Hz, 
1H), 7.6 (m, 3H), 7.4 (m, 1H), 5.7 (m, 1H), 5.36 (d, J = 3.7 Hz, 1H), 5.2 (m, 1H), 
4.55 (t, J = 5.3 Hz, 1H), 4.3 (m, 3H), 4.2 (m, 1H), 4.1 (m, 1H), 4.0 (m, 2H), 3.7−3.9 
(m, 3H), 3.6 (m, 3H), 3.5 (m, 2H), 3.3−3.4 (m, 2H), 3.1−3.3 (m, 2H), 3.0−3.1 (m, 2H), 
2.8 (m, 1H), 2.2 (m, 1H), 1.6 (m, 1H). 13C NMR (D2O, 100 MHz) δ 170.6, 158.1, 
147.0, 142.8, 137.0, 131.6, 130.6, 129.5 (2 carbons), 128.6, 128.4, 128.0 (2 carbons), 
124.9, 123.0, 118.7, 109.8, 95.8, 95.5 (2 carbons), 85.3, 80.3, 77.8, 73.6, 73.2, 70.8, 
70.4, 69.2, 67.6, 67.2, 66.0, 53.9, 51.1, 50.3, 49.0, 41.5, 40.4, 40.2, 32.0. ESI/APCI 
calcd for C41H82N7O13 ([M + H]+) m/e 845.4040; found m/e 845.4021. 
NEOF008 (32e). 1H NMR (D2O, 400 MHz) δ 5.80 (s, 1H), 5.31 (d, J = 3.3 Hz, 
1H), 5.22 (s, 1H), 4.40 (t, J = 5.2 Hz, 1H), 4.2−4.3 (m, 6H), 4.13 (t, J = 3.1 Hz, 1H), 
3.8−3.9 (m, 5H), 3.74 (s, 1H), 3.65 (t, J = 9.7 Hz, 1H), 3.5 (m, 4H), 3.2−3.4 (m, 4H), 
3.07 (t, J = 7.2 Hz, 2H), 2.3 (m, 1H), 2.1 (m, 1H), 1.9 (m, 1H), 1.7 (m, 1H). 13C NMR 
(D2O, 100 MHz) δ 176.1, 109.5, 95.8, 95.3, 85.0, 80.4, 77.4, 73.5, 72.7, 70.8, 70.3, 
69.7, 69.5, 69.0, 67.9, 67.6, 53.8, 51.0, 50.2, 48.9, 41.3, 40.7, 40.3, 36.9, 31.2, 30.1, 
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30.0. ESI/APCI calcd for C27H54N8O14Na ([M + Na]+) m/e 737.3652; found m/e 
737.3682. 
NEOF009 (32f). 1H NMR (D2O, 400 MHz) δ 5.88 (d, J = 3.9 Hz, 1H), 5.32 (d, J 
= 3.5 Hz, 1H), 5.21 (d, J = 1.5 Hz, 1H), 4.35 (t, J = 5.4 Hz, 1H), 4.26 (t, J = 5.3 Hz, 
1H), 4.22 (d, J = 3.7 Hz, 1H), 4.1 (m, 2H), 4.03 (t, J = 9.0 Hz, 1H), 3.9 (m, 2H), 3.78 
(s, 1H), 3.7 (m, 2H), 3.71 (t, J = 9.4 Hz, 1H), 3.6 (m, 1H), 3.2−3.5 (m, 11H), 2.4 (m, 
1H), 1.80 (dd, J = 24.0, 14.6 Hz, 1H). 13C NMR (D2O, 100 MHz) δ 170.0, 109.2, 95.9, 
95.6, 84.8, 80.6, 78.3, 77.0, 73.3, 72.8, 70.8, 70.3, 69.5, 69.1, 67.9, 67.6, 53.8, 51.0, 
50.3, 49.0, 41.8, 40.7 (2 carbons), 40.3, 30.0. ESI/APCI calcd for C25H51N8O13 ([M + 
H]+) m/e 671.3570; found m/e 671.3591. 
NEOF012 (32g). 1H NMR (D2O, 400 MHz) δ 5.88 (d, J = 3.9 Hz, 1H), 5.34 (d, J 
= 3.8 Hz, 1H), 5.22 (s, 1H), 4.31 (t, J = 5.3 Hz, 1H), 4.26 (t, J = 2.0 Hz, 1H), 4.18 (t, J 
= 4.9 Hz, 2H), 4.13 (t, J = 3.0 Hz, 1H), 4.0−4.1 (m, 2H), 3.9−4.0 (m, 3H), 3.74 (dd, J 
= 3.1, 1.5 Hz, 1H), 7.72 (d, J = 9.7 Hz, 1H), 3.2−3.6 (m, 11H), 2.36 (dt, J = 8.5, 4.2 
Hz, 1H), 1.8 (m, 1H), 1.45 (d, J = 7.1 Hz, 3H). 13C NMR (D2O, 100 MHz) δ 171.6, 
108.8, 95.9, 95.2, 84.6, 80.9, 77.0, 73.4, 72.4, 70.6, 70.3, 69.8, 68.6, 67.8, 67.7, 53.5, 
51.0, 50.0, 49.3, 48.8, 41.7, 40.8, 40.2, 27.0, 16.9. ESI/APCI calcd for C25H53N8O13 
([M + H]+) m/e 685.3727; found m/e 685.3735. 
NEOF016 (32h). 1H NMR (D2O, 400 MHz) δ 5.91 (d, J = 4.0 Hz, 1H), 5.35 (d, 
J = 3.9 Hz, 1H), 5.21 (d, J = 1.7 Hz, 1H), 4.30 (t, J = 9.2 Hz, 1H), 4.31 (d, J = 10.8 
Hz, 1H), 4.3 (m, 1H), 4.1−4.2 (m, 2H), 3.9−4.0 (m, 3H), 3.7 (m, 2H), 3.3−3.6 (m, 
15H), 2.4 (m, 2H), 2.0 (m, 3H), 1.9 (m, 1H). 13C NMR (D2O, 100 MHz) δ 170.3, 
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108.8, 95.9, 95.2, 84.5, 81.0, 77.1, 75.2, 73.4, 72.3, 70.5, 70.2, 70.0, 68.4, 67.8, 67.7, 
60.1, 53.3, 50.9, 49.8, 48.7, 46.6, 41.8, 40.7, 40.2, 29.9, 28.0, 24.1. ESI/APCI calcd 
for C28H54N8O13Na ([M + Na]+) m/e 733.3703; found m/e 733.3725. 
NEOF018 (32i). 1H NMR (D2O, 400 MHz) δ 7.55 (d, J = 7.9 Hz, 1H), 7.44 (d, J 
= 8.3 Hz, 1H), 7.26 (s, 1H), 7.17 (t, J = 7.1 Hz, 1H), 7.10 (t, J = 7.8 Hz, 1H), 5.66 (d, 
J = 3.7 Hz, 1H), 5.19 (d, J = 3.4 Hz, 1H), 4.94 (s, 1H), 4.26 (t, J = 6.9 Hz, 2H), 4.1 (m, 
2H), 3.6−4.0 (m, 8H), 3.1−3.5 (m, 12H), 2.22 (dt, J = 8.8, 4.6 Hz, 1H), 1.6 (m, 1H), 
1.2 (m, 1H). 13C NMR (D2O, 100 MHz) δ 170.7, 136.3, 126.8, 125.3, 122.5, 119.8, 
118.4, 112.4, 108.5, 106.7, 96.0, 95.9, 84.7, 80.6, 78.0, 76.7, 70.9, 71.3, 70.0, 69.4, 
69.3, 67.8, 67.5, 53.9, 53.8, 51.2, 50.8, 50.3, 49.1, 41.2, 40.7, 40.3, 30.2, 27.1. 
ESI/APCI calcd for C34H58N9O13 ([M + H]+) m/e 800.4149; found m/e 800.4139. 
NEOF019 (32j). 1H NMR (D2O, 400 MHz) δ 5.95 (d, J = 3.9 Hz, 1H), 5.35 (d, J 
= 3.1 Hz, 1H), 4.38 (t, J = 5.4 Hz, 1H), 4.26 (t, J = 3.2 Hz, 2H), 4.1−4.2 (m, 4H), 
3.9−4.0 (m, 5H), 3.6−3.8 (m, 3H), 3.2−3.5 (m, 11H), 2.42 (dt, J = 8.5, 4.3 Hz, 1H), 
1.86 (q, J = 12.6 Hz, 1H). 13C NMR (D2O, 100 MHz) δ 168.8, 109.3, 95.6, 95.2, 84.6, 
80.3, 76.7, 75.1, 73.3, 72.4, 70.6, 70.3, 69.9, 68.3, 67.8, 67.6, 60.5, 54.5, 53.3, 51.0, 
49.9, 48.7, 41.8, 40.7, 40.2, 28.1. ESI/APCI calcd for C26H53N8O14 ([M + H]+) m/e 
701.3676; found m/e 701.3695. 
NEOF022 (32k). 1H NMR (D2O, 400 MHz) δ 5.75 (d, J = 3.5 Hz, 1H), 5.32 (d, 
J = 4.1 Hz, 1H), 5.21 (d, J = 1.5 Hz, 1H), 4.30 (t, J = 5.3 Hz, 1H), 4.26 (t, J = 3.7 Hz, 
1H), 4.1−4.2 (m, 3H), 3.9−4.0 (m, 2H), 3.8−3.9 (m, 3H), 3.7 (m, 1H), 3.6−3.7 (m, 
2H), 3.2−3.5 (m, 11H), 2.9 (t, J = 7.7 Hz, 1H), 2.2 (m, 1H), 1.8 (m, 2H), 1.6 (m, 3H), 
  
 
                                                                                  152
1.38 (m, 2H). 13C NMR (D2O, 100 MHz) δ 170.9, 109.0, 96.0, 95.9, 84.8, 80.9, 77.1, 
73.2, 72.8, 70.8, 70.2, 69.5, 69.1, 67.8, 67.7, 53.9, 53.3, 51.0, 50.2, 49.0, 42.0, 40.8, 
40.3, 39.2 (2 carbons), 30.8, 30.0, 26.6, 21.7. MALDI calcd for C29H59N9O13Na ([M + 
Na]+) m/e 764.4125; found m/e 764.4163. 
NEOF024 (32l). This compound was prepared by subjecting compound to 61 
hydrogenation and sequential purification. 1H NMR (D2O, 300 MHz) δ 5.85 (d, J = 
4.2 Hz, 1H), 5.31 (d, J = 4.1 Hz, 1H), 5.20 (d, J = 1.4 Hz, 1H), 4.35 (t, J = 4.8 Hz, 
1H), 4.1 − 4.2 (m, 4H), 3.8 − 4.0 (m, 4H), 3.7 (m, 2H), 3.2−3.6 (m, 11H), 2.4 − 2.6 (m, 
5H), 1.9 (m, 1H). 13C NMR (D2O, 100 MHz) δ 177.4, 175.6, 84.8, 80.8, 77.2, 75.3, 
75.1, 73.5, 72.2 (2 carbons), 70.4, 70.2, 69.8 (2 carbons), 68.1, 67.7, 67.4, 53.3, 50.8, 
49.7, 48.6, 41.0, 40.6, 40.1, 30.4, 29.5, 28.0. MALDI calcd for C21H57N7O15Na ([M + 
Na]+) m/e 736.3335; found m/e 736.3331. 
NEOF025 (32m). 1H NMR (D2O, 300 MHz) δ 5.87 (d, J = 7.9 Hz, 1H), 5.34 (d, 
J = 3.8 Hz, 1H), 5.20 (s, 1H), 4.40 (t, J = 5.5 Hz, 1H), 3.8−4.3 (m, 10H), 3.7 (m, 2H), 
3.2 − 3.7 (m, 10H), 2.41 (dt, J = 8.6, 4.1 Hz, 1H), 1.9 (m, 1H), 1.46 (d, J = 6.9 Hz, 
3H). 13C NMR (D2O, 100 MHz) δ 171.5, 108.8, 95.7, 95.2, 84.5, 80.9, 76.8, 75.2, 
73.4, 72.2, 70.5, 70.2, 69.8, 68.2, 67.7, 67.5, 53.3, 50.9, 49.7, 49.2, 48.6, 40.6, 40.2, 
28.0, 16.9. MALDI calcd for C26H52N8O13Na ([M + Na]+) m/e 707.3546; found m/e 
707.3518. 
NEOF026 (32n). 1H NMR (D2O, 300 MHz) δ 5.69 (d, J = 3.8 Hz, 1H), 5.28 (d, 
J = 5.0 Hz, 1H), 5.20 (s, 1H), 4.33 (t, J = 5.1 Hz, 1H), 4.1−4.2 (m, 5H), 3.6−3.8 (m, 
9H), 3.1−3.5 (m, 10H), 2.19 (dt, J = 11.0, 4.5 Hz, 1H), 1.6 (m, 1H). 13C NMR (D2O, 
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100 MHz) δ 170.2, 109.0, 95.9, 84.8, 80.4, 79.1, 77.0, 73.2, 72.9, 70.9, 70.2, 69.4, 
69.2, 67.8, 67.6, 61.1, 54.9, 53.9, 52.0, 50.9, 50.3, 49.0, 41.5, 40.6, 40.3, 30.7. 
MALDI calcd for C26H52N8O14Na ([M + Na]+) m/e 723.3495; found m/e 723.3494. 
NEOF027 (32o). 1H NMR (D2O, 400 MHz) δ 5.86 (d, J = 3.9 Hz, 1H), 5.33 (d, J 
= 3.6 Hz, 1H), 5.22 (s, 1H), 4.3−4.4 (m, 2H), 4.3 (m, 1H), 4.1− 4.2 (m, 4H), 3.9 −4.0 
(m, 3H), 3.2−4.0 (m, 14H), 2.4 (m, 2H), 2.0 (m, 4H), 1.9 (m, 1H). 13C NMR (D2O, 
100 MHz) δ 170.4, 109.1, 95.8, 95.3, 84.7, 80.9, 77.0, 75.3, 73.5, 72.4, 70.7, 70.3, 
70.0, 68.3, 67.8, 67.6, 60.0, 53.4, 51.0, 49.8, 48.7, 46.8, 41.8, 40.7, 40.4, 30.2, 28.1, 
24.1. ESI/APCI calcd for C28H55N8O13 ([M+H]+) m/e 711.3883; found m/e 711.3873. 
NEOF028 (32p). 1H NMR (D2O, 400 MHz) δ 5.90 (d, J = 4.0 Hz, 1H), 5.34 (d, 
J = 3.4 Hz, 1H), 5.21 (d, J = 1.5 Hz, 1H), 4.39 (t, J = 6.5 Hz, 1H), 4.3 (m, 1H), 4.1 − 
4.3 (m, 4H), 3.9 − 4.0 (m, 4H), 3.7 (m, 2H), 3.2 − 3.6 (m, 11H), 2.91 (t, J = 7.6 Hz, 
2H), 2.41 (dt, J = 8.4, 4.0 Hz, 1H), 1.8 − 2.0 (m, 3H), 1.6 − 1.7 (m, 2H), 1.4 (m, 2H). 
13C NMR (D2O, 100 MHz) δ 170.6, 109.1, 95.6, 95.3, 84.6, 80.8, 76.6, 75.2, 73.3, 
72.4, 70.7, 70.4, 69.9, 68.4, 67.8, 67.6, 53.4, 53.3, 51.0, 49.9, 48.7, 41.7, 40.8, 40.3, 
39.2, 30.7, 28.1, 26.6, 21.7. ESI/APCI Calcd for C29H59N9O13Na ([M + Na]+) m/e 
764.4125; found m/e 764.4116. 
NEOF030 (32q). 1H NMR (D2O, 400 MHz) δ 5.95 (d, J = 3.9 Hz, 1H), 5.33 (d, 
J = 3.2 Hz, 1H), 5.20 (s, 1H), 4.42 (t, J = 5.2 Hz, 1H), 4.3 (m, 2H), 4.1 (m, 3H), 
3.8−4.0 (m, 7H), 3.7 (m, 2H), 3.3−3.5 (m, 11H), 2.42 (dt, J = 12.4, 4.0 Hz, 1H), 1.91 
(dd, J = 12.2, 3.6 Hz, 1H). 13C NMR (D2O, 100 MHz) δ 172.0, 168.2, 109.7, 95.6, 
94.8, 84.8, 80.2, 77.5, 75.1, 73.4, 72.4, 70.6, 70.4, 69.8, 68.3, 67.8, 67.4, 53.5, 51.0, 
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49.9, 48.8, 42.9, 41.9, 40.8, 40.7, 40.2, 28.2. ESI/APCI calcd for C27H54N9O14 ([M + 
H]+) m/e 728.3785; found m/e 728.3780. 
NEOF032 (32r). 1H NMR (D2O, 300 MHz) δ 5.87 (d, J = 5.0 Hz, 1H), 5.32 (d, J 
= 4.1 Hz, 1H), 5.18 (d, J = 1.7 Hz, 1H), 4.35 (t, J = 5.2 Hz, 1H), 4.1 – 4.2 (m, 4H), 
3.9 – 4.0 (m, 3H), 3.6 – 3.7 (m, 2H), 3.2 – 3.6 (m, 12H), 2.40 (dt, J = 12.4, 4.1 Hz, 
1H), 2.18 (t, J = 7.2 Hz, 2H), 1.8 (m, 1H), 1.5 (m, 2H), 1.1 (m, 12H), 0.72 (t, J = 6.5 
Hz, 3H); 13C NMR (D2O, 75 MHz) δ 178.0, 109.1, 95.7, 94.9, 84.8, 80.7, 77.3, 75.0, 
73.5, 72.3, 70.5, 70.2, 69.8, 68.1, 67.6, 67.4, 53.3, 50.9, 49.6, 48.6, 41.1, 40.6, 40.1, 
36.0, 31.2, 28.7, 28.5 (2 carbons), 28.4, 28.0, 25.5, 22.1, 13.5; ESI/APCI Calcd for 
C33H66N7O13+ ([M+H]+) m/e 768.4713; measure m/e 768.4698. 
NEOF033 (32s). 1H NMR (D2O, 300 MHz) δ 5.86 (d, J = 4.1 Hz, 1H), 5.31 (d, J 
= 4.1 Hz, 1H), 5.18 (d, J = 1.4 Hz, 1H), 4.34 (t, J = 4.8 Hz, 1H), 4.1 – 4.2 (m, 4H), 
3.9 – 4.0 (m, 3H), 3.6 – 3.7 (m, 2H), 3.2 – 3.6 (m, 12H), 2.40 (dt, J = 8.2, 4.1 Hz, 1H), 
2.16 (t, J = 7.2 Hz, 2H), 1.9 (m, 1H), 1.5 (m, 2H), 1.1 (m, 16H), 0.72 (t, J = 6.5 Hz, 
3H); 13C NMR (D2O, 75 MHz) δ 177.9, 109.2, 95.7, 94.9, 84.8, 80.7, 77.3, 75.0, 73.5, 
72.3, 70.5, 70.2, 69.8, 68.1, 67.6, 67.4, 53.3, 50.8, 49.6, 48.6, 41.1, 40.5, 40.1, 36.0, 
31.2, 28.8 (2 carbons), 28.7, 28.6, 28.5, 28.4, 28.0, 25.5, 22.1, 13.5; ESI/APCI Calcd 
for C35H70N7O13+ ([M+H]+) m/e 796.5026; measure m/e 796.5016. 
NEOF034 (32t). 1H NMR (D2O, 300 MHz) δ 5.86 (d, J = 3.8 Hz, 1H), 5.31 (d, J 
= 4.1 Hz, 1H), 5.18 (d, J = 1.7 Hz, 1H), 4.34 (t, J = 5.2 Hz, 1H), 4.1–4.2 (m, 4H), 
3.9–4.0 (m, 3H), 3.6–3.7 (m, 2H), 3.2–3.6 (m, 12H), 2.40 (dt, J = 12.4, 4.1 Hz, 1H), 
2.17 (t, J = 7.2 Hz, 2H), 1.8 (m, 1H), 1.5 (m, 2H), 1.1 (m, 20H), 0.72 (t, J = 6.5 Hz, 
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3H); 13C NMR (D2O, 75 MHz) δ 178.0, 109.1, 95.7, 94.9, 84.8, 80.7, 77.3, 75.0, 73.5, 
72.3, 70.5, 70.2, 69.8, 68.1, 67.6, 67.4, 53.3, 50.8, 49.6, 48.6, 41.1, 40.6, 40.1, 36.0, 
31.2, 28.9 (2 carbons), 28.8 (2 carbons), 28.7, 28.6, 28.5, 28.4, 28.0, 25.5, 22.1, 13.5; 
ESI/APCI Calcd for C37H74N7O13+ ([M+H]+) m/e 824.5339; measure m/e 824.5333. 
N-Propargyl-2-phenyl-4-quinolinecarboxamide (35). To a solution of 
2-phenyl-4-quinolinecarboxylic acid (2.09 g, 8.02 mmol) and propargylamine (0.49 g, 
8.83 mmol) in DMF (30 mL), Et3N (2.3 mL), EDC (2.31 g, 12.0 mmol), and HOBt 
(1.63 g, 12.0 mmol) were added. The reaction mixture was stirred at room 
temperature for 2 days. After completion of the reaction, the reaction mixture was 
concentrated and then diluted with EtOAc. The organic solution was washed with 1 N 
HCl, H2O, NaHCO3, and brine and then dried over Na2SO4. After removal of solvent 
and recrystallization from ether, the desired product was obtained as a crystal (1.69 g, 
5.90 mmol, 74%). 1H NMR (CDCl3, 400 MHz) δ 8.17 (d, J = 9.5 Hz, 1H), 8.1 (m, 
2H), 7.81 (s, 1H), 7.72 (td, J = 9.2, 1.1 Hz, 1H), 7.4−7.5 (m, 5H), 6.54 (s, 1H), 4.36 
(dd, J = 5.9, 2.9 Hz, 2H), 2.35 (t, J = 2.9 Hz, 1H). 13C NMR (CDCl3, 100 MHz) δ 
166.6, 156.1, 148.0, 141.1, 138.1, 129.8, 129.5, 129.3, 128.4 (2 carbons), 127.0, 126.9 
(2 carbons), 124.3, 122.7, 116.0, 78.3, 72.0, 29.3. ESI/APCI calcd for C19H15N2O 
([M+H]+) m/e 287.1179; found m/e 287.1176. 
N-Propargylisonicotinamide (39). The product was synthesized similarly as 
compound 35 except the purification was accomplished using gradient column 
chromatography (eluted from hexane/EtOAc = 60/40 to hexane/EtOAc = 0/100, 92%). 
1H NMR (CDCl3, 400 MHz) δ 8.71 (dd, J = 4.5, 1.7 Hz, 2H), 7.61 (dd, J = 4.5, 1.6 Hz, 
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2H), 6.81 (s, 1H), 4.23 (dd, J = 5.3, 2.6 Hz, 2H), 2.27 (dd, J = 2.4, 1.1 Hz, 1H); 13C 
NMR (CDCl3, 100 MHz) δ 165.5, 150.8 (2 carbons), 136.0, 121.2 (2 carbons), 79.0, 
72.5, 30.1. ESI/APCI calcd for C9H9N2O ([M+H]+) m/e 161.0709; found m/e 
161.0713. 
N-Propargylcarbobenzyloxy-l-prolinamide (40). The product was synthesized 
similarly as compound 35 except the purification was accomplished using gradient 
column chromatography (eluted from hexane/EtOAc = 90/10 to hexane/EtOAc = 
30/70, 74%). 1H NMR (CDCl3, 400 MHz) δ 7.3 (m, 5H), 5.1 (m, 2H), 4.26 (s, 1H), 
3.90 (d, J = 9.7 Hz, 2H), 3.4 (m, 2H), 1.8−2.2 (m, 6H). 13C NMR (CDCl3, 100 MHz) 
δ 172.4, 156.1, 136.6, 128.7 (2 carbons), 128.2, 128.0 (2 carbons), 79.9, 71.6, 60.8, 
47.7, 31.3, 29.2, 28.9, 24.7. ESI/APCI calcd for C16H19N2O3+ ([M+H]+) m/e 287.1390; 
found m/e 287.1401. 
NEOF029 (62). To a solution of compound 30 (0.20 g, 0.14 mmol) in anhydrous 
DMF (5 mL), succinic anhydride (0.02 g, 0.20 mmol) was added. After being stirred 
at room temperature overnight, the reaction mixture was concentrated. After removal 
of the solvent followed by fast gradient column chromatography (eluted from 
CH2Cl2/MeOH = 100/0 to 80/20), the product, 61 was obtained as a solid and 
subjected to the next step without further purification. The acid crude product was 
redissolve in DMF (8 mL) and added with compound 30 (0.20 g, 0.14 mmol), Et3N 
(0.04 mL, 0.28 mmol), HOBt (0.030 g, 0.21 mmol), and EDC (0.040 g, 0.21 mmol). 
After being stirred overnight at room temperature, the reaction mixture was 
concentrated and diluted with EtOAc. The organic solution was washed with saturated 
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NaHCO3(aq), water, and brine and dried over anhydrous Na2SO4. After removal of 
the solvent followed by a fast gradient column chromatography (eluted from 
CH2Cl2/MeOH = 100/0 to 80/20), the product was obtained as a solid subjected to 
hydrogenation without further purification. 1H NMR (D2O, 400 MHz) δ 5.94 (d, J = 
3.8 Hz, 2H), 5.37 (d, J = 3.5 Hz, 2H), 5.22 (s, 2H), 4.40 (t, J = 5.2 Hz, 2H), 4.2−4.3 
(m, 8H), 3.9 (m, 6H), 3.8 (m, 6H), 3.2−3.6 (m, 22H), 2.52 (s, 4H), 2.43 (dt, J = 8.8, 
4.5 Hz, 2H), 1.9 (m, 2H). 13C NMR (D2O, 100 MHz) δ 175.5 (2 carbons), 109.4 (2 
carbons), 95.7 (2 carbons), 95.0 (2 carbons), 84.7 (2 carbons), 80.5 (2 carbons), 77.3 
(2 carbons), 75.2 (2 carbons), 73.4 (2 carbons), 72.4 (2 carbons), 70.6 (2 carbons), 
70.4 (2 carbons), 69.9 (2 carbons), 68.3 (2 carbons), 67.8 (2 carbons), 67.5 (2 
carbons), 53.5 (2 carbons), 51.0 (2 carbons), 49.9 (2 carbons), 48.8 (2 carbons), 41.8 
(2 carbons), 40.8 (2 carbons), 40.3 (2 carbons), 31.1 (2 carbons), 28.1 (2 carbons). 
ESI/APCI calcd for C50H97N14O26 ([M+H]+) m/e 1309.6693; found m/e 1309.6684. 
2-(N-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl))-2H-2-benzazepine-1,5- 
dione (68a). 1H NMR (CDCl3, 400 MHz) δ 8.36 (dd, J = 7.4, 1.9 Hz, 1H), 8.16 (dd, J 
= 7.0, 2.0 Hz, 1H), 7.8 (m, 2H), 6.94 (d, J = 11.2 Hz, 1H), 6.34 (d, J = 9.2 Hz, 1H), 
6.06 (d, J = 11.1 Hz, 1H), 5.44 (t, J = 9.5 Hz, 1H), 5.26 (t, J = 9.5 Hz, 1H), 5.18 (t, J 
= 9.7 Hz, 1H), 4.30 (dd, J = 12.6, 4.9 Hz, 1H), 4.2 (m, 1H), 4.0 (m, 1H), 2.11 (s, 3H), 
2.08 (s, 3H), 2.04 (s, 3H), 1.89 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 187.5, 170.7, 
170.1, 169.6, 169.5, 168.1, 137.4, 134.0, 133.6, 133.2, 131.6, 130.9, 129.9, 113.9, 
82.5, 75.2, 73.2, 70.1, 68.1, 61.9, 21.0, 20.8 (2 carbons), 20.5; ESI/APCI calcd for 
C24H25NO11Na+ ([M+Na]+) m/e 526.1320; measured m/e 526.1322. 
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1-(N-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl))-1H-naphtho[2,3-d] 
triazole-4,9-dione (66a). 1H NMR (CDCl3, 400 MHz) δ 8.33 (dd, J = 6.7, 1.9
 Hz, 1H), 8.27 (dd, J = 7.1, 1.9 Hz, 1H), 7.8 (m, 2H), 6.35 (d, J = 9.5 Hz,
 1H), 6.15 (t, J = 9.2 Hz, 1H), 5.50 (t, J = 9.4 Hz, 1H), 5.47 (t, J = 9.6 H
z, 1H), 4.3 (m, 2H), 4.1 (m, 1H), 2.10 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 1.
84 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 176.8, 174.3, 170.7, 170.3, 169.5, 
169.1, 147.0, 135.6, 134.8, 134.7, 133.1, 133.0, 128.1, 127.9, 86.1, 75.4, 73.0, 
69.3, 67.7, 61.6, 20.9, 20.8 (2 carbons), 20.4; ESI/APCI calcd for C24H23N3O11
Na+ ([M+Na]+) m/e 552.1225; measured m/e 552.1228. 
2-(N-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl))aminomethylene-1,3- 
indanedione (69a). 1H NMR (CDCl3, 400 MHz) δ 9.22 (dd, J = 13.2, 8.8 Hz, 1H), 
7.8 (m, 2H), 7.70 (d, J = 13.2 Hz, 1H), 7.6 (m, 2H), 5.29 (t, J = 9.6 Hz, 1H), 5.14 (t, J 
= 9.2 Hz, 1H), 5.10 (t, J = 9.6 Hz, 1H), 4.6 (m, 1H), 4.23 (dd, J = 4.6, 1.2 Hz, 1H), 
4.1 (m, 1H), 3.8 (m, 1H), 2.1 (m, 3H), 2.03 (s, 3H), 2.02 (s, 6H); 13C NMR (CDCl3, 
75 MHz) δ 193.2, 189.9, 170.8, 170.2, 170.0, 169.5, 149.3, 140.4, 140.2, 134.2, 134.1, 
122.6, 122.3, 107.4, 87.4, 74.4, 72.5, 70.8, 68.0, 61.8, 20.9, 20.8 (2 carbons), 20.7; 
ESI/APCI calcd for C24H26NO11+ ([M+H]+) m/e 504.1500; measured m/e 504.1506. 
2-(N-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl))-2H-2-benzazepine-1,5- 
dione (68b). 1H NMR (CDCl3, 400 MHz) δ 8.36 (dd, J = 7.6, 1.4 Hz, 1H), 8.17 (dd, J 
= 7.2, 1.9 Hz, 1H), 7.8 (m, 2H), 7.01 (d, J = 11.1 Hz, 1H), 6.31 (d, J = 9.2 Hz, 1H), 
6.08 (d, J = 11.1 Hz, 1H), 5.53 (d, J = 3.1 Hz, 1H), 5.39 (t, J = 9.7 Hz, 1H), 5.25 (dd, 
J = 10.1, 3.2 Hz, 1H), 4.2 (m, 3H), 2.23 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.89 (s, 
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3H); 13C NMR (CDCl3, 100 MHz) δ 187.5, 170.5, 170.1, 169.9, 169.7, 168.1, 137.4, 
133.9, 133.6, 133.1, 131.9, 130.9, 129.9, 113.8, 82.9, 73.9, 71.3, 67.8, 67.2, 61.4, 20.8 
(2 carbons), 20.7, 20.5; ESI/APCI calcd for C24H25NO11Na+ ([M+Na]+) m/e 526.1320; 
measured m/e 526.1342. 
1-(N-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl))-1H-naphtho[2,3-d] 
triazole-4,9-dione (66b). 1H NMR (CDCl3, 400 MHz) δ 8.35 (dd, J = 6.9, 1.9 Hz, 
1H), 8.28 (dd, J = 7.2, 2.0 Hz, 1H), 7.87 (td, J = 6.4, 1.5 Hz, 1H), 7.84 (td, J = 6.7, 
1.6 Hz, 1H), 6.4 (m, 2H), 5.59 (d, J = 3.2 Hz, 1H), 5.3 (m, 1H), 4.34 (t, J = 7.0 Hz, 
1H), 4.23 (dd, J = 10.0, 6.9 Hz, 1H), 4.15 (dd, J = 10.2, 6.9 Hz, 1H), 2.32 (s, 3H), 
2.04 (s, 6H), 1.84 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 176.9, 174.4, 170.6 (2 
carbons), 170.2, 169.0, 146.0, 135.5, 134.7, 134.6, 133.1, 133.0, 128.0, 127.8, 86.5, 
74.4, 71.5, 67.0, 66.9, 61.5, 20.9, 20.8 (2 carbons), 20.5; ESI/APCI calcd for 
C24H23N3O11Na+ ([M+Na]+) m/e 552.1225; measured m/e 552.1230. 
2-(N-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl))aminomethylene-1,3- 
indanedione (69b). 1H NMR (CDCl3, 300 MHz) δ 9.34 (dd, J = 13.1, 8.6 Hz, 1H), 
7.8 (m, 2H), 7.71 (d, J = 13.4 Hz, 1H), 7.6 (m, 2H), 5.45 (d, J = 3.4 Hz, 1H), 5.33 (t, 
J = 10.3 Hz, 1H), 5.13 (dd, J = 10.3, 3.4 Hz, 1H), 4.59 (t, J = 8.6 Hz, 1H), 4.1 (m, 
3H), 2.20 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.00 (s, 3H); 13C NMR (CDCl3, 75 MHz) 
δ 193.1, 189.9, 170.5, 170.2, 170.1, 170.0, 149.3, 140.3, 140.1, 134.0, 133.9, 122.4, 
122.2, 107.1, 87.5, 73.0, 70.6, 68.2, 67.0, 61.5, 20.7 (2 carbons), 20.6 (2 carbons); 
ESI/APCI calcd for C24H26NO11+ ([M+H]+) m/e 504.1500; measured m/e 504.1501.        
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1-(N-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl))-1H-naphtho[2,3-d] 
triazole-4,9-dione (66c). 1H NMR (CDCl3, 400 MHz) δ 8.31 (dd, J = 7.4, 1.4 Hz, 
1H), 8.20 (dd, J = 7.4, 1.2 Hz, 1H), 7.9 (m, 2H), 6.63 (s, 1H), 5.96 (d, J = 3.0 Hz, 1H), 
5.49 (t, J = 10.0 Hz, 1H), 5.39 (dd, J = 10.0, 3.1 Hz, 1H), 4.3 (m, 2H), 4.2 (m, 1H), 
2.18 (s, 3H), 2.12 (s, 3H), 2.07 (s, 3H), 2.04 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 
176.6, 175.3, 170.8, 170.3, 170.1, 169.8, 145.1, 135.8, 134.7, 133.8, 133.3, 132.8, 
128.2, 127.6, 83.9, 76.3, 71.2, 67.6, 65.7, 62.3, 21.0, 20.9 (2 carbons), 20.8; 
ESI/APCI calcd for C24H23N3O11Na+ ([M+Na]+) m/e 552.1225; measured m/e 
552.1227. 
1-(N-(4-O-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-2,3,6-tri-O-acetyl-β
-D-glucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66d). 1H NMR (CDCl3, 
400 MHz) δ 8.35 (dd, J = 7.0, 1.5 Hz, 1H), 8.24 (dd, J = 8.0, 1.6 Hz, 1H), 7.89 (td, J 
= 7.2, 1.4 Hz, 1H), 7.86 (td, J = 7.4, 1.6 Hz, 1H), 6.31 (d, J = 9.4 Hz, 1H), 6.06 (t, J 
= 9.6 Hz, 1H), 5.48 (t, J = 9.3 Hz, 1H), 5.40 (d, J = 3.3 Hz, 1H), 5.17 (dd, J = 10.4, 
7.9 Hz, 1H), 5.01 (dd, J = 10.4, 3.4 Hz, 1H), 4.62 (t, J = 7.8 Hz, 2H), 4.1 (m, 4H), 4.0 
(m, 2H), 2.18 (s, 3H), 2.12 (s, 3H), 2.10 (s, 3H), 2.09 (s, 3H), 2.08 (s, 3H), 1.99 (s, 
3H), 1.84 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 176.7, 174.4, 170.6, 170.3 (2 
carbons), 170.2, 169.9, 169.3 (2 carbons), 146.1, 135.6, 134.7, 134.6, 133.0, 132.9, 
128.0, 127.7, 101.2, 85.8, 77.7, 77.4, 77.0, 76.2, 75.4, 72.8, 71.1, 71.0, 69.5, 69.3, 
66.9, 61.5, 61.1, 20.9, 20.8, 20.7, 20.4; ESI/APCI calcd for C36H39N3O19Na+ 
([M+Na]+) m/e 840.2070; measured m/e 840.2088. 
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1-(N-(2,3,4-Tri-O-acetyl-α-D-fucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-
dione (66e). 1H NMR (CDCl3, 400 MHz) δ 8.32 (dd, J = 6.8, 1.8 Hz, 1H), 8.26 (dd, J 
= 7.2, 1.4 Hz, 1H), 7.86 (td, J = 7.4, 1.6 Hz, 1H), 7.83 (td, J = 7.2, 2.0 Hz, 1H), 6.37 
(d, J = 9.4 Hz, 1H), 6.31 (t, J = 9.6 Hz, 1H), 5.42 (d, J = 3.2 Hz, 1H), 5.31 (dd, J = 
9.7, 3.4 Hz, 1H), 4.24 (dd, J = 12.6, 6.2 Hz, 1H), 2.33 (s, 3H), 2.03 (s, 3H), 1.82 (s, 
3H), 1.27 (d, J = 6.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 176.9, 174.5, 171.0, 
170.3, 169.1, 145.9, 135.5, 134.6 (2 carbons), 133.1, 133.0, 128.0, 127.9, 86.4, 73.2, 
72.0, 70.0, 67.1, 21.0, 20.8, 20.5, 16.2; ESI/APCI calcd for C22H21N3O9Na+ ([M+Na]+) 
m/e 494.1170; measured m/e 494.1180. 
2-(N-(2,3,4-Tri-O-acetyl-α-D-rhamnopyranosyl))-2H-2-benzazepine-1,5- 
dione (68f). 1H NMR (CDCl3, 400 MHz) δ 8.4 (m, 1H), 8.19 (dd, J = 6.7, 2.2 Hz, 1H), 
7.7 (m, 2H), 7.2 (m, 1H), 6.09 (s, 1H), 5.93 (dd, J = 11.5, 0.7 Hz, 1H), 5.71 (d, J = 3.4 
Hz, 1H), 5.29 (dd, J = 12.9, 3.4 Hz, 1H), 5.14 (t, J = 9.7 Hz, 1H), 3.8 (m, 1H), 2.11 (s, 
3H), 2.08 (s, 3H), 1.99 (s, 3H), 1.36 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 187.4, 
170.1, 169.9 (2 carbons), 167.3, 137.2, 133.9, 133.7, 133.2, 132.8, 130.8, 129.8, 111.4, 
82.7, 74.3, 70.6, 70.4, 69.0, 21.0 (2 carbons), 20.8, 17.8; ESI/APCI calcd for 
C22H24NO9+ ([M+H]+) m/e 446.1451; measured m/e 446.1446. 
1-(N-(2,3,4-Tri-O-acetyl-α-D-rhamnopyranosyl))-1H-naphtho[2,3-d]triazole-
4,9-dione (66f). 1H NMR (CDCl3, 400 MHz) δ 8.35 (dd, J = 7.5, 1.5 Hz, 1H), 8.25 
(dd, J = 7.4, 1.4 Hz, 1H), 7.88 (td, J = 7.3, 1.5 Hz, 1H), 7.85 (td, J = 7.3, 1.4 Hz, 1H), 
6.68 (d, J = 0.8 Hz, 1H), 5.89 (t, J = 0.9 Hz, 1H), 5.4 (m, 2H), 4.0 (m, 1H), 2.21 (s, 
3H), 2.13 (s, 3H), 2.05 (s, 3H), 1.42 (d, J = 6.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) 
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δ 176.7, 175.0, 170.5, 170.2, 169.9, 145.0, 135.8, 134.7, 133.1, 133.3, 132.8, 128.2, 
127.8, 84.0, 74.9, 71.1, 70.2, 68.1, 21.0 (2 carbons), 20.8, 17.7; ESI/APCI calcd for 
C22H21N3O9Na+ ([M+Na]+) m/e 494.1170; measured m/e 494.1177. 
2-(N-(2,3,4-Tri-O-acetyl-α-D-rhamnopyranosyl))aminomethylene-1,3- 
indanedione (69f). 1H NMR (CDCl3, 300 MHz) δ 9.41 (dd, J = 13.2, 8.8 Hz, 1H), 
7.82 (d, J = 13.0 Hz, 1H), 7.7−7.8 (m, 2H), 7.5−7.6 (m, 2H), 5.50 (t, J = 1.4 Hz, 1H), 
5.1 (m, 2H), 5.00 (d, J = 8.9 Hz, 1H), 3.7 (m, 1H), 2.30 (s, 3H), 2.08 (s, 3H), 1.98 (s, 
3H), 1.24 (d, J = 6.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 193.5, 189.9, 170.5, 
170.4, 170.0, 149.5, 140.3, 140.1, 134.0, 133.9, 122.5, 121.9, 106.7, 84.2, 72.8, 71.1, 
69.8, 69.5, 21.0, 20.9, 20.8, 17.7; ESI/APCI calcd for C22H24NO9+ ([M+H]+) m/e 
446.1451; measured m/e 446.1439. 
2-(N-(2,3,4-Tri-O-acetyl-β-D-xylopyranosyl))-2H-2-benzazepine-1,5-dione 
(68g). 1H NMR (CDCl3, 400 MHz) δ 8.34 (dd, J = 2.4, 1.6 Hz, 1H), 8.15 (dd, J = 6.9, 
1.9 Hz, 1H), 7.8 (m, 2H), 6.93 (d, J = 11.2 Hz, 1H), 6.24 (d, J = 9.4 Hz, 1H), 6.03 (d, 
J = 11.1 Hz, 1H), 5.44 (t, J = 9.5 Hz, 1H), 5.19 (t, J = 9.4 Hz, 1H), 5.10 (dt, J = 4.7, 
0.7 Hz, 1H), 4.27 (dd, J = 11.4, 5.7 Hz, 1H), 3.58 (t, J = 10.9 Hz, 1H), 2.08 (s, 3H), 
2.05 (s, 3H), 1.87 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 187.6, 170.1 (2 carbons), 
170.0, 168.1, 137.4, 133.9, 133.6, 133.1, 131.7, 130.9, 129.8, 113.7, 83.2, 72.7, 70.3, 
68.9, 65.7, 20.8 (2 carbons), 20.5; ESI/APCI calcd for C21H22NO9+ ([M+H]+) m/e 
432.1289; measured m/e 432.1294. 
1-(N-(2,3,4-Tri-O-acetyl-β-D-xylopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-
dione (66g). 1H NMR (CDCl3, 400 MHz) δ 8.32 (dd, J = 7.7, 1.9 Hz, 1H), 8.25 (dd, J 
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= 7.1, 1.8 Hz, 1H), 7.8 (m, 2H), 6.29 (d, J = 9.2 Hz, 1H), 6.09 (t, J = 9.3 Hz, 1H), 
5.47 (t, J = 9.4 Hz, 1H), 5.3 (m, 1H), 4.35 (dd, J = 11.6, 5.6 Hz, 1H), 3.67 (t, J = 10.2 
Hz, 1H), 2.08 (s, 3H), 2.06 (s, 3H), 1.82 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 176.8, 
174.5, 170.3, 169.9, 169.2, 146.1, 135.6, 134.7, 134.6, 133.1, 133.0, 128.0, 127.9, 
86.7, 72.6, 69.5, 68.6, 65.9, 20.9 (2 carbons), 20.4; ESI/APCI calcd for 
C21H19N3O9Na+ ([M+Na]+) m/e 480.1014; measured m/e 480.1007. 
2-(N-(2,3,4-Tri-O-acetyl-D-xylopyranosyl))aminomethylene-1,3-indanedione 
(69g). (α/β = 1/1) 1H NMR (CDCl3, 400 MHz) δ 9.5 (m, 1H), 9.4 (m, 1H), 7.67 (d, J = 
13.2 Hz, 2H), 7.6−7.8 (m, 8H), 5.3 (m, 2H), 5.14 (dd, J = 5.7, 2.0 Hz, 1H), 5.0 (m, 
3H), 4.8 (m, 1H), 4.61 (t, J = 5.6 Hz, 1H), 4.2 (m, 1H), 3.9 (m, 1H), 3.8 (m, 1H), 3.5 
(m, 1H), 2.20 (s, 3H), 2.09 (s, 6H), 2.05 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 193.7, 193.2, 189.9, 189.8, 170.0, 170.0, 169.9 (2 carbons), 
169.8, 169.0, 149.6, 149.5, 140.4 (2 carbons), 140.2, 140.1, 134.2, 134.1 (2 carbons), 
134.0, 122.6, 122.5, 122.2, 122.0, 107.3, 107.2, 87.2, 82.4, 71.1, 70.3, 68.3, 68.2, 67.7, 
66.9, 64.1, 63.2, 21.0, 20.9 (3 carbons), 20.7 (2 carbons); ESI/APCI calcd for 
C21H22NO9+ ([M+H]+) m/e 432.1289; measured m/e 432.1303. 
1-(N-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl))-1H- 
naphtho[2,3-d]triazole-4,9-dione (66h). 1H NMR (CDCl3, 400 MHz) δ 8.36 (d, J = 
5.8 Hz, 1H), 8.35 (d, J = 5.7 Hz, 1H), 7.9 (m, 2H), 6.59 (d, J = 9.7 Hz, 1H), 5.83 (t, J 
= 9.4 Hz, 1H), 5.76 (d, J = 7.6 Hz, 1H), 5.27 (t, J = 9.6 Hz, 1H), 4.60 (d, J = 9.8, 7.8 
Hz, 1H), 4.32 (dd, J = 12.6, 4.9 Hz, 1H), 4.1 (m, 2H), 2.09 (s, 3H), 2.08 (s, 3H), 2.07 
(s, 3H), 1.79 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 177.2 (2 carbons), 170.8 (2 
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carbons), 170.7, 169.6, 146.0, 135.1 (3 carbons), 134.2, 128.2 (3 carbons), 89.6, 75.2, 
71.4, 68.2, 61.9, 54.9, 23.3, 20.9, 20.8 (2 carbons); ESI/APCI calcd for 
C24H24N4O10Na+ ([M+Na]+) m/e 551.1385; measured m/e 551.1395. 
2-(N-(4-O-(2,3,4,6-Tetra-O-acetyl-β-d-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D
-glucopyranosyl))-2H-2-benzazepine-1,5-dione (68i). 1H NMR (CDCl3, 400 MHz) 
δ 8.34 (dd, J = 7.4, 1.8 Hz, 1H), 8.15 (dd, J = 7.9, 2.0 Hz, 1H), 7.8 (m, 2H), 6.87 (d, J 
= 11.1 Hz, 1H), 6.28 (d, J = 9.3 Hz, 1H), 6.01 (d, J = 11.1 Hz, 1H), 5.41 (t, J = 8.9 
Hz, 1H), 5.1 (m, 3H), 4.96 (t, J = 8.0 Hz, 1H), 4.56 (d, J = 7.9 Hz, 1H), 4.53 (dd, J = 
12.2, 7.9 Hz, 1H), 4.39 (dd, J = 12.5, 4.3 Hz, 1H), 4.16 (dd, J = 12.1, 4.3 Hz, 1H), 
4.08 (dd, J = 12.4, 7.9 Hz, 1H), 3.9 (m, 2H), 3.7 (m, 1H), 2.15 (s, 3H), 2.11 (s, 3H), 
2.06 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.00 (s, 3H),1.88 (s, 3H); 13C NMR (CDCl3, 
100 MHz) δ 187.6, 170.7 (2 carbons), 170.4, 169.7, 169.6, 169.5, 169.2, 168.0, 137.3, 
134.0, 133.7, 133.2, 131.5, 130.9, 129.8, 113.7, 100.9, 82.5, 76.2, 76.0, 73.1, 72.7, 
72.3, 71.8, 70.2, 67.9, 61.9, 61.8, 21.1, 20.9, 20.8 (3 carbons), 20.7, 20.5; ESI/APCI 
calcd for C36H41NO19Na+ ([M+Na]+) m/e 814.2165; measured m/e 814.2165. 
1-(N-(4-O-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-
D-glucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (66i). 1H NMR (CDCl3, 
400 MHz) δ 8.30 (dd, J = 7.8, 1.5 Hz, 1H), 8.19 (dd, J = 7.3, 1.3 Hz, 1H), 7.84 (td, J 
=7.4, 1.4 Hz, 1H), 7.81 (td, J = 7.4, 1.6 Hz, 1H), 6.27 (d, J = 9.5 Hz, 1H), 6.02 (t, J = 
9.6 Hz, 1H), 5.42 (t, J = 9.4 Hz, 1H), 5.16 (t, J = 9.3 Hz, 1H), 5.07 (t, J = 9.7 Hz, 1H), 
4.95 (t, J = 8.0 Hz, 1H), 4.6 (m, 2H), 4.40 (dd, J = 12.5, 4.5 Hz, 1H), 4.0 (m, 4H), 3.7 
(m, 1H), 2.09 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.00 (s, 3H), 1.96 (s, 
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3H), 1.80 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 176.8, 174.5, 170.7, 170.4, 170.3, 
169.9, 169.5, 169.3 (2 carbons), 146.2, 135.6, 134.7, 134.6, 133.1, 133.0, 128.1, 127.7, 
101.1, 86.0, 76.3, 75.7, 73.1, 72.6, 72.3, 71.8, 69.4, 68.0, 61.8, 61.3, 20.9, 20.8, 20.7 
(3 carbons), 20.6, 20.4; ESI/APCI calcd for C36H39N3O19Na+ ([M+Na]+) m/e 
840.2070; measured m/e 840.2083. 
2-(N-(4-O-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-
D-glucopyranosyl))aminomethylene-1,3-indanedione (69i). 1H NMR (CDCl3, 400 
MHz) δ 9.25 (dd, J = 13.0, 8.2 Hz, 1H), 7.8 (m, 2H), 7.68 (d, J = 13.1 Hz, 1H), 7.7 (m, 
2H), 5.31 (t, J = 8.9 Hz, 1H), 5.17 (t, J = 9.1 Hz, 1H), 5.13 (t, J = 9.6 Hz, 1H), 5.09 (t, 
J = 9.9 Hz, 1H), 4.94 (t, J = 8.0 Hz, 1H), 4.60 (t, J = 8.7 Hz, 1H), 4.5 (m, 2H), 4.39 
(dd, J = 12.6, 4.5 Hz, 1H), 4.1 (m, 2H), 3.81 (t, J = 9.0 Hz, 1H), 3.7 (m, 2H), 2.15 (s, 
3H), 2.11 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H), 2.01 (s, 3H), 1.99 (s, 3H); 
13C NMR (CDCl3, 100 MHz) δ 193.3, 189.9, 170.7, 170.4 (2 carbons), 170.1, 169.8, 
169.5, 169.3, 149.3, 140.4, 140.2, 134.2, 134.1, 122.6, 122.3, 107.3, 101.1, 87.1, 76.1, 
75.2, 73.1, 72.3, 72.0, 71.8, 71.0, 67.9, 61.8, 61.7, 21.1, 20.9, 20.8 (3 carbons), 20.7 
(2 carbons); ESI/APCI calcd for C36H41NO19Na+ ([M+Na]+) m/e 814.2165; measured 
m/e 814.2158. 
1-(N-(4-O-(4-O-(2,3,4,6-Tetra-O-acetyl-β-d-glucopyranosyl)-2,3,6-tri-O- 
acetyl-β-D-glucopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl))-1H-naphtho 
[2,3-d]triazole-4,9-dione (66j). 1H NMR (CDCl3, 300 MHz) δ 8.33 (dd, J = 7.2, 1.7 
Hz, 1H), 8.24 (dd, J = 7.9, 1.7 Hz, 1H), 7.8 (m, 2H), 6.37 (d, J = 9.3 Hz, 1H), 5.99 (t, 
J = 9.3 Hz, 1H), 5.55 (t, J = 9.3 Hz, 1H), 5.4 (m, 4H), 5.07 (t, J = 10.0 Hz, 1H), 4.86 
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(dd, J = 10.6, 4.1 Hz, 1H), 4.79 (dd, J = 10.3, 4.1 Hz, 1H), 4.65 (dd, J = 12.4, 2.4 Hz, 
1H), 4.5 (m, 1H), 4.3 (m, 4H), 4.0 (m, 5H), 2.17 (s, 3H), 2.13 (s, 3H), 2.10 (s, 3H), 
2.07 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H), 2.02 (s, 6H), 2.00 (s, 3H), 1.81 (s, 3H); 13C 
NMR (CDCl3, 75 MHz) δ 176.7, 174.3, 170.7 (2 carbons), 170.6, 170.5, 170.3, 170.2, 
170.0, 169.8, 169.5, 169.2, 146.0, 135.5, 134.6, 134.4, 133.0, 132.9, 128.0, 127.7, 
96.2, 95.6, 85.5, 75.6, 75.2, 72.9, 72.4, 71.8, 70.6, 70.2, 69.8, 69.4, 69.3, 68.6, 68.0, 
62.3, 62.1, 61.4, 21.0, 20.9 (2 carbons), 20.8, 20.7, 20.6 (4 carbons), 20.3; ESI/APCI 
calcd for C48H55N3O27Na+ ([M+Na]+) m/e 1128.2915; measured m/e 1128.2903. 
2-(N-(2,3,5-Tri-O-acetyl-β-D-ribofuranosyl))-2H-2-benzazepine-1,5-dione 
(68k). Compound 68k was eluted out after compound 66k. 1H NMR (CDCl3, 400 
MHz) δ 8.34 (dd, J = 9.3, 2.1 Hz, 1H), 8.17 (dd, J = 9.2, 2.1 Hz, 1H), 7.7−7.8 (m, 2H), 
7.07 (d, J = 11.1 Hz, 1H), 6.30 (d, J = 4.4 Hz, 1H), 5.97 (d, J = 11.2 Hz, 1H), 5.38 (t, 
J = 5.8 Hz, 1H), 5.34 (d, J = 5.2 Hz, 1H), 4.4 (m, 3H), 2.14 (s, 3H), 2.09 (s, 6H); 13C 
NMR (CDCl3, 100 MHz) δ 187.4, 170.4, 169.8, 169.7, 168.0, 137.2, 133.9, 133.6, 
133.2, 131.8, 131.3, 129.8, 113.1, 90.6, 79.8, 73.7, 70.1, 63.0, 21.0, 20.7 (2 carbons); 
ESI/APCI calcd for C21H22NO9+ ([M+H]+) m/e 432.1295; measured m/e 432.1287. 
1-(N-(2,3,5-Tri-O-acetyl-β-D-ribofuranosyl))-1H-naphtho[2,3-d]triazole-4,9-
dione (66k). Compound 68k was eluted out after compound 66k. 1H NMR (CDCl3, 
400 MHz) δ 8.36 (d, J = 7.4 Hz, 1H), 8.25 (d, J = 7.5 Hz, 1H), 7.9 (m, 2H), 6.97 (d, J 
= 2.8 Hz, 1H), 6.2 (m, 1H), 5.84 (t, J = 5.6 Hz, 1H), 4.6 (m, 1H), 4.48 (dd, J = 12.4, 
3.1 Hz, 1H), 4.23 (dd, J = 12.4, 4.5 Hz, 1H), 2.17 (s, 3H), 2.16 (s, 3H), 2.07 (s, 3H); 
13C NMR (CDCl3, 100 MHz) δ 176.7, 175.3, 170.7, 169.7, 169.6, 145.6, 135.7, 134.7, 
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134.0, 133.2, 132.9, 128.1, 127.8, 89.9, 81.6, 74.2, 70.9, 62.6, 20.8, 20.7 (2 carbons); 
ESI/APCI calcd for C21H19N3O9Na+ ([M+Na]+) m/e 480.1014; measured m/e 
480.1013. 
2-(N-(2,3,5-Tri-O-acetyl-β-D-ribofuranosyl))aminomethylene-1,3- 
indanedione (69k). 1H NMR (CDCl3, 400 MHz) δ 9.38 (dd, J = 13.0, 8.6 Hz, 1H), 
7.75 (d, J = 13.2 Hz, 1H), 7.7−7.8 (m, 2H), 7.6 (m, 2H), 5.33 (dd, J = 5.3, 3.4 Hz, 1H), 
5.24 (t, J = 5.5 Hz, 1H), 5.17 (dd, J = 8.6, 5.6 Hz, 1H), 4.31 (dd, J = 6.0, 2.9 Hz, 1H), 
4.2 − 4.3 (m, 2H), 2.25 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H); 13C NMR (CDCl3, 100 
MHz) δ 193.6, 189.9, 170.8, 169.8, 169.7, 148.9, 140.2, 140.1, 134.1, 133.9, 122.5, 
122.0, 106.6, 91.4, 80.7, 74.9, 71.4, 63.4, 21.1, 20.8, 20.6; ESI/APCI calcd for 
C21H22NO9+ ([M+H]+) m/e 432.1289; measured m/e 432.1289. 
2,3,4,5-Tetra-O-acetyl-1,6-bis(1H-naphtho[2,3-d]triazole-4,9-dione)-1,6- 
dideoxy-d-mannitol (66l). 1H NMR (CDCl3, 400 MHz) δ 8.31 (d, J = 7.6 Hz, 2H), 
8.16 (d, J = 7.5 Hz, 2H), 7.85 (td, J = 7.4, 1.1 Hz, 2H), 7.78 (td, J = 7.5, 1.2 Hz, 2H), 
5.56 (d, J = 7.8 Hz, 2H), 5.49 (t, J = 9.2 Hz, 2H), 5.09 (dd, J = 14.2, 2.1 Hz, 2H), 
4.94 (dd, J = 14.2, 9.3 Hz, 2H), 2.23 (s, 6H), 1.94 (s, 6H); 13C NMR (CDCl3, 100 
MHz) δ 176.7 (2 carbons), 175.9 (2 carbons), 170.5 (2 carbons), 169.9 (2 carbons), 
145.7 (2 carbons), 135.6 (2 carbons), 134.6 (2 carbons), 133.9 (2 carbons), 133.7 (2 
carbons), 132.8 (2 carbons), 128.1 (2 carbons), 127.5 (2 carbons), 68.7 (2 carbons), 
68.4 (2 carbons), 51.2 (2 carbons), 20.9 (2 carbons), 20.6 (2 carbons); ESI/APCI calcd 
for C34H29N6O12+ ([M+H]+) m/e 713.1838; measured m/e 713.1851. 
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2,3,4,5,6-Penta-O-acetyl-1-(2H-2-benzazepine-1,5-dione)-1-dideoxy-D- 
mannitol (68m). Compound 68m eluted out after 66m: 1H NMR (CDCl3, 400 MHz) 
δ 8.4 (m, 1H), 8.2 (m, 1H), 7.7−7.8 (m, 2H), 6.73 (d, J = 10.9 Hz, 1H), 5.85 (d, J = 
11.0 Hz, 1H), 5.52 (dd, J = 8.9, 2.3 Hz, 1H), 5.4−5.5 (m, 2H), 5.2 (m, 1H), 4.62 (dd, J 
= 12.5, 2.7 Hz, 1H), 4.23 (dd, J = 12.5, 2.7 Hz, 1H), 4.10 (dd, J = 12.5, 5.2 Hz, 1H), 
3.53 (dd, J = 13.9, 9.1 Hz, 1H), 2.19 (s, 3H), 2.11 (s, 3H), 2.10 (s, 3H), 2.05 (s, 3H), 
1.99 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 187.6, 170.8, 170.6, 170.1 (2 carbons), 
170.0, 167.4, 137.9, 137.2, 133.9, 133.7, 133.2, 130.9, 129.8, 112.2, 69.6, 68.3, 68.1, 
67.7, 62.0, 54.6, 21.1, 21.0 (2 carbons), 20.9 (2 carbons); ESI/APCI calcd for 
C26H30NO12+ ([M+H]+) m/e 548.1768; measured m/e 548.1765. 
2,3,4,5,6-Penta-O-acetyl-1-(1H-naphtho[2,3-d]triazole-4,9-dione)-1-dideoxy-
D-mannitol (66m). 1H NMR (CDCl3, 400 MHz) δ 8.27 (d, J = 7.2 Hz, 1H), 8.18 (d, J 
= 7.3 Hz, 1H), 7.8 (m, 2H), 5.5 (m, 2H), 5.3 (m, 1H), 5.1 (m, 1H), 5.00 (dd, J = 14.1, 
2.1 Hz, 1H), 4.89 (dd, J = 12.5, 9.4 Hz, 1H), 4.19 (dd, J = 12.5, 2.7 Hz, 1H), 4.03 (dd, 
J = 12.5, 5.1 Hz, 1H), 2.26 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.98 (s, 3H), 1.87 (s, 
3H); 13C NMR (CDCl3, 100 MHz) δ 176.7, 175.8, 170.7, 170.6, 170.0, 169.9, 169.8, 
145.6, 135.6, 134.5, 133.9, 133.6, 132.8, 128.0, 127.5, 68.9, 68.1, 68.0, 67.3, 61.9, 
51.4, 21.0, 20.9, 20.8, 20.7, 20.6; ESI/APCI calcd for C26H27N3O12Na+ ([M+Na]+) m/e 
596.1487; measured m/e 596.1502. 
2,3,4,5,6-Penta-O-acetyl-1-(aminomethylene-1,3-indanedione)-1-dideoxy-D-
mannitol (69m). 1H NMR (CDCl3, 400 MHz) δ 9.3 (m, 1H), 7.7 (m, 2H), 7.6 (m, 2H), 
7.24 (d, J = 13.8 Hz, 1H), 5.40 (dd, J = 9.3, 2.2 Hz, 1H), 5.30 (dd, J = 9.4, 2.3 Hz, 
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1H), 5.1 (m, 1H), 5.0 (m, 1H), 4.16 (dd, J = 12.6, 2.7 Hz, 1H), 4.02 (dd, J = 12.6, 5.0 
Hz, 1H), 3.5 (m, 1H), 3.4 (m, 1H), 2.15 (s, 3H), 2.08 (s, 3H), 2.06 (s, 6H), 2.01 (s, 
3H); 13C NMR (CDCl3, 100 MHz) δ 193.5, 190.2, 171.1, 170.8, 170.2, 170.0, 169.8, 
152.4, 140.1, 140.0, 133.6, 133.6, 122.2, 121.7, 105.5, 68.2, 67.9, 67.8, 67.3, 62.0, 
49.7, 21.0, 21.0, 20.9, 20.8, 20.8; ESI/APCI calcd for C26H30NO12+ ([M+H]+) m/e 
548.1768; measured m/e 548.1757. 
1-(4-(N-tert-Butoxycarbonylpiperidinyl))-1H-naphtho[2,3-d]triazole-4,9- 
dione (66n). 1H NMR (CDCl3, 300 MHz) δ 8.33 (dd, J = 7.5, 1.7 Hz, 1H), 8.22 (dd, J 
= 6.9, 2.1 Hz, 1H), 7.86 (td, J = 7.6, 1.7 Hz, 1H), 7.81 (td, J = 7.6, 1.7 Hz, 1H), 5.36 
(tt, J = 7.2, 4.5 Hz, 1H), 4.3 (m, 2H), 2.97 (t, J = 11.7 Hz, 2H), 2.1−2.4 (m, 4H), 1.48 
(s, 9H); 13C NMR (CDCl3, 75 MHz) δ 177.0, 175.7, 154.6, 145.6, 135.4, 134.5, 133.3, 
133.0, 133.0, 127.9, 127.5, 80.3 (2 carbons), 59.2, 42.9, 31.7 (2 carbons), 28.5 (3 
carbons); ESI/APCI calcd for C20H23N4O4+ ([M+H]+) m/e 383.1714; measured m/e 
383.1726. 
2-(N-(4-(N-tert-Butoxycarbonylpiperidinyl)))aminomethylene-1,3- 
indanedione (69n). 1H NMR (CDCl3, 400 MHz) δ 9.2 (m, 1H), 7.74 (d, J = 14.4 Hz, 
1H), 7.7 (m, 2H), 7.6 (m, 2H), 4.1 (m, 2H), 3.4 (m, 1H), 2.86 (t, J = 11.4 Hz, 2H), 2.0 
(m, 2H), 1.6 (m, 2H), 1.43 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ 194.0, 190.2, 
154.7, 150.0, 140.0, 133.6, 133.5, 122.1, 121.5, 104.8, 80.4, 57.0 (2 carbons), 43.0 (2 
carbons), 32.8 (2 carbons), 28.6 (3 carbons); ESI/APCI calcd for C20H25N2O4+ 
([M+H]+) m/e 357.1809; measured m/e 357.1807. 
  
 
                                                                                  170
1-Adamantyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (66o). 1H NMR 
(CDCl3, 300 MHz) δ 8.31 (dd, J = 4.8,1.4 Hz, 1H), 8.26 (dd, J = 4.8, 1.4 Hz, 1H), 7.8 
(m, 2H), 2.52 (s, 6H), 2.32 (s, 3H), 1.84 (d, J = 12.0 Hz, 3H), 1.82 (d, J = 12.4 Hz, 
3H); 13C NMR (CDCl3, 75 MHz) δ 174.5, 174.5, 147.0, 134.8, 134.5, 134.3, 133.7, 
132.5, 128.1, 127.4, 65.3, 40.6 (3 carbons), 35.8 (3 carbons), 29.8 (3 carbons); 
ESI/APCI Calcd for C20H20N3O2+ ([M+H]+) m/e 333.1477; measure m/e 334.1556. 
1-Benzyl-1H-naphtho[2,3-d]triazole-4,9-dione (66p). 1H NMR (CDCl3, 400 
MHz) δ 8.30 (dd, J = 7.5, 1.8 Hz, 1H), 8.20 (dd, J = 7.4, 1.6 Hz, 1H), 7.81 (td, J = 7.3, 
1.6 Hz, 1H), 7.78 (td, J = 7.1, 1.5 Hz, 1H), 7.5 (m, 2H), 7.3 (m, 3H), 5.99 (s, 2H); 13C 
NMR (CDCl3, 100 MHz) δ 177.0, 175.6, 145.9, 135.4 (2 carbons), 134.5 (2 carbons), 
134.1, 133.6, 133.3, 133.0, 129.3 (2 carbons), 128.9, 128.1, 127.6, 54.0; ESI/APCI 
calcd for C17H12N3O2+ ([M+H]+) m/e 290.0930; measured m/e 290.0931. 
1-(2-Picolyl) -1H-naphtho[2,3-d]triazole-4,9-dione (66q). 1H NMR (CDCl3, 
300 MHz) δ 8.51 (d, J = 4.8 Hz, 1H), 8.34 (dd, J = 7.6, 1.4 Hz, 1H), 8.20 (dd, J = 7.5, 
1.7 Hz, 1H), 7.85 (td, J = 7.2, 1.4 Hz, 1H), 7.79 (td, J = 7.6, 1.7 Hz, 1H), 7.70 (td, J = 
7.6, 1.7 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 7.2 (m, 1H), 6.18 (s, 2H); 13C (CDCl3, 100 
MHz) δ 177.0, 175.6, 153.4, 150.2, 145.7, 137.4, 135.4, 134.5, 134.1, 133.7, 133.1, 
128.1, 127.6, 123.7, 122.3, 55.0; ESI/APCI Calcd for C16H11N4O2+ ([M+H]+) m/e 
291.0877; measure m/e 291.0879. 
4-Azido-N-tert-butoxycarbonylpiperidine 70. To a solution of 
4-hydroxypiperidine (1.0 g, 4.94 mmol) in CH2Cl2 (10 mL) and Et3N (1.5 mL, 6.92 
mmol) was added Boc2O (2.4 g, 5.93 mmol). After being stirred for 2 h, the reaction 
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was diluted with EtOAc and washed with saturated NaHCO3, water, and brine, and 
then dried over Na2SO4. After removal of solvents, the crude product was dissolved in 
anhydrous CH2Cl2 (50 mL) and Et3N (1.0 mL, 7.50 mmol). The reaction mixture was 
cooled to 0 °C, and MsCl (0.69 mL, 8.94 mmol) was added slowly. After being stirred 
for 2 h, the reaction mixture was concentrated and diluted with EtOAc. The solution 
was filtered through Celite, and the residue was washed with more EtOAc. The 
filtrate was concentrated and re-dissolved in DMF (50 mL). After the addition of 
NaN3 (1.17 g, 18.0 mmol), the reaction mixture was stirred at 100 °C for 24 h. The 
reaction mixture was concentrated and diluted with EtOAc. The solution was filtered 
through Celite, and the residue was washed with EtOAc. After the removal of solvent 
and purification with gradient column chromatography (hexane/EtOAc from 100/0 to 
1/1), the desired product was obtained as an oil (0.90 g, 3.99 mmol, 41% for three 
steps): 1H NMR (CDCl3, 300 MHz) δ 3.7 (m, 2H), 3.48 (tt, J = 13.1, 4.8 Hz, 1H), 3.01 
(dt, J = 13.1, 3.4 Hz, 2H), 1.8 (m, 2H), 1.5 (m, 2H), 1.37 (s, 9H); 13C NMR (CDCl3, 
100 MHz) δ 154.7, 79.9 (2 carbons), 57.7, 41.6, 30.7 (2 carbons), 28.5 (3 carbons); 
ESI/APCI calcd for C10H19N4O2+ ([M+H]+) m/e 227.1503; measured m/e 227.1503. 
    General Procedure for the Deprotection of Acetyl Groups Using 
NaOMe/MeOH for NQ compounds. To a solution of starting material (0.10 g, 66) in 
anhydrous MeOH (10 mL), a catalytic amount of NaOMe (ca. 1 M in MeOH) was 
added. The solution was stirred at room temperature for 1 h. After complete 
consumption of the starting material, the reaction mixture was loaded to a column 
packed with Amberlite 120 (H+) resin, which was balanced with MeOH. The column 
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was eluted with more MeOH, and the eluent was collected. After the removal of the 
solvent, the product was purified by recrystallization from a mixture of 
MeOH/EtOAc/hexane. 
    General Procedure for the Deprotection of Acetyl Groups Using 
K2CO3/MeOH/H2O for NQF compounds. To a solution of starting material (0.10 g, 
69) in MeOH (10 mL) and few drops of water, a catalytic amount of K2CO3 was 
added and the solution was stirred at room temperature for 1 h. After complete 
consumption of the starting material, the reaction was quenched with Amberlite 120 
(H+) resin and filtered through Celite. After removal of the solvent, the crude product 
was purified by gradient column chromatography (eluted with CH2Cl2/MeOH from 
100/0 to 4/1). The product was further purified by recrystallization by a mixture of 
MeOH/EtOAc/hexane. 
1-(N-(β-d-Glucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (74a). 1H 
NMR (DMSO-d6, 400 MHz) δ 8.2 (m, 2H), 8.0 (m, 2H), 6.15 (d, J = 9.2 Hz, 1H), 5.5 
(m, 1H), 5.34 (d, J = 5.2 Hz, 1H), 5.22 (d, J = 5.6 Hz, 1H), 4.6 (m, 1H), 4.1 (m, 1H), 
3.7 (m, 1H), 3.5 (m, 4H); 13C NMR (DMSO-d6, 100 MHz) δ 177.5, 175.4, 145.6, 
136.0, 135.4, 135.1, 133.6, 133.4, 127.7, 127.6, 88.2, 81.4, 77.6, 72.2, 70.2, 61.4; 
ESI/APCI calcd for C16H15N3O7Na+ ([M+Na]+) m/e 384.0802; measured m/e 
384.0801. 
1-(N-(β-d-Galactopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (74b). 1H 
NMR (DMSO-d6, 400 MHz) δ 8.2 (m, 2H), 8.0 (m, 2H), 6.13 (d, J = 9.1 Hz, 1H), 
5.37 (d, J = 5.4 Hz, 1H), 5.1 (m, 1H), 4.8 (m, 1H), 4.69 (t, J = 5.4 Hz, 1H), 4.4 (m, 
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1H), 3.8 (m, 1H), 3.79 (t, J = 5.7 Hz, 1H), 3.5 (m, 3H); 13C NMR (DMSO-d6, 100 
MHz) δ 177.5, 175.5, 145.5, 135.9, 135.3, 135.1, 133.6, 133.5, 127.7 (2 carbons), 
88.4, 79.7, 74.3, 69.5, 68.9, 61.0; ESI/APCI calcd for C16H15N3O7Na+ ([M+Na]+) m/e 
384.0802; measured m/e 384.0801. 
1-(N-(α-d-Mannopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (74c). 1H 
NMR (DMSO-d6, 400 MHz) δ 8.2 (m, 2H), 7.9 (m, 2H), 6.38 (s, 1H), 5.05 (s, 2H), 
4.89 (s, 1H), 4.65 (s, 1H), 4.09 (s, 1H), 3.82 (d, J = 11.7 Hz, 1H), 3.5 (m, 4H); 13C 
NMR (DMSO-d6, 100 MHz) δ 177.7, 175.5, 145.0, 135.9, 135.3, 134.1, 133.6, 133.4, 
127.7 (2 carbons), 87.8, 82.1, 74.0, 70.6, 67.0, 61.8; ESI/APCI calcd for 
C16H15N3O7Na+ ([M+Na]+) m/e 384.0802; measured m/e 384.0806. 
1-(N-(4-O-(β-d-Galactopyranosyl)-β-d-glucopyranosyl))-1H-naphtho[2,3-d] 
triazole-4,9-dione (74d). 1H NMR (DMSO-d6, 400 MHz) δ 8.2 (m, 2H), 7.9 (m, 2H), 
6.22 (d, J = 9.3 Hz, 1H), 5.72 (s, 1H), 5.14 (d, J = 4.0 Hz, 1H), 4.99 (s, 1H), 4.83 (s, 
1H), 4.68 (s, 1H), 4.65 (s, 1H), 4.56 (s, 1H), 4.31 (d, J = 7.2 Hz, 1H), 4.2 (m, 1H), 3.8 
(m, 1H), 3.6 (m, 7H), 3.3 (m, 3H); 13C NMR (DMSO-d6, 100 MHz) δ 177.5, 175.3, 
145.7, 136.0, 135.4, 135.2, 133.6, 133.4, 127.7, 127.6, 104.5, 87.8, 80.4, 79.1, 76.3, 
75.7, 73.9, 71.9, 71.2, 68.9, 61.1, 60.7; ESI/APCI calcd for C22H25N3O12Na+ 
([M+Na]+) m/e 546.1330; measured m/e 546.1331. 
1-(N-(α-d-Fucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (74e). 1H 
NMR (DMSO-d6, 400 MHz) δ 8.18 (dd, J = 7.5, 1.8 Hz, 1H), 8.15 (dd, J = 6.8, 1.5 
Hz, 1H), 7.9 (m, 2H), 6.11 (d, J = 9.1 Hz, 1H), 5.34 (d, J = 5.4 Hz, 1H), 5.08 (s, 1H), 
4.83 (s, 1H), 4.4 (m, 1H), 3.98 (dd, J = 12.6, 6.2 Hz, 1H), 3.63 (s, 2H), 1.19 (d, J = 
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6.3 Hz, 3H); 13C NMR (DMSO-d6, 100 MHz) δ 177.6, 175.5, 145.5, 135.9, 135.3, 
135.0, 133.6, 133.5, 127.6 (2 carbons), 88.3, 74.7, 74.5, 71.7, 69.1, 17.2; ESI/APCI 
calcd for C16H15N3O6Na+ ([M+Na]+) m/e 368.0853; measured m/e 368.0853. 
1-(N-(α-d-Rhamnopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (74f). 1H 
NMR (DMSO-d6, 400 MHz) δ 8.1 − 8.2 (m, 2H), 8.0 (m, 2H), 6.36 (s, 1H), 5.08 (d, J 
= 5.6 Hz, 1H), 5.02 (d, J = 5.9 Hz, 1H), 4.89 (d, J = 5.8 Hz, 1H), 4.1 (m, 1H), 3.6 (m, 
2H), 3.4 (m, 1H), 3.33 (d, J = 6.0 Hz, 3H); 13C NMR (DMSO-d6, 100 MHz) δ 177.7, 
175.5, 145.0, 135.9, 135.3, 134.0, 133.5, 133.4, 127.6 (2 carbons), 87.9, 76.6, 73.3, 
71.8, 70.7, 18.5; ESI/APCI calcd for C16H15N3O6Na+ ([M+Na]+) m/e 368.0853; 
measured m/e 368.0855. 
1-(N-(β-d-Xylopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (74g). 1H 
NMR (DMSO-d6, 400 MHz) δ 8.2 (m, 2H), 8.0 (m, 2H), 6.08 (d, J = 9.2 Hz, 1H), 
5.54 (d, J = 5.4 Hz, 1H), 5.38 (d, J = 5.2 Hz, 1H), 5.26 (d, J = 5.1 Hz, 1H), 4.11 (dt, J 
= 12.2, 9.0 Hz, 1H), 3.96 (dd, J = 11.1, 5.2 Hz, 1H), 3.57 (m, 1H), 3.41(m, 2H); 13C 
NMR (DMSO-d6, 100 MHz) δ 177.6, 175.3, 145.7, 135.9, 135.3, 135.1, 133.6, 133.4, 
127.7, 127.6, 88.9, 77.6, 72.1, 69.7, 69.4; ESI/APCI calcd for C15H13N3O6Na+ 
([M+Na]+) m/e 354.0697; measured m/e 354.0699. 
1-(N-(2-Acetamido-β-d-glucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9- 
dione (74h). 1H NMR (DMSO-d6, 400 MHz) δ 8.21 (d, J = 5.7 Hz, 1H), 8.20 (d, J = 
5.6 Hz, 1H), 7.9 (m, 3H), 6.02 (d, J = 9.6 Hz, 1H), 5.31 (d, J = 5.4 Hz, 2H), 4.7 (m, 
1H), 4.1 (m, 1H), 3.7 (m, 1H), 3.5 (m, 4H), 1.58 (s, 3H); 13C NMR (DMSO-d6, 100 
MHz) δ 177.7, 170.0 (2 carbons), 145.8, 135.5 (3 carbons), 134.6, 127.8 (3 carbons), 
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91.5, 81.1, 74.2, 70.6, 61.4, 56.1, 23.3; ESI/APCI calcd for C18H18N4O7Na+ ([M+Na]+) 
m/e 425.1068; measured m/e 425.1068. 
1-(N-(4-O-(β-d-Glucopyranosyl)-β-d-glucopyranosyl))-1H-naphtho[2,3-d] 
triazole-4,9-dione (74i). 1H NMR (DMSO-d6, 400 MHz) δ 8.2 (m, 2H), 8.0 (m, 2H), 
6.22 (d, J = 9.2 Hz, 1H), 5.71 (s, 1H), 5.30 (s, 1H), 5.03 (s, 2H), 4.98 (s, 1H), 4.68 (s, 
2H), 4.37 (d, J = 7.8 Hz, 1H), 4.21 (s, 1H), 3.6 (m, 7H), 3.3 (m, 2H), 3.20 (t, J =8.6 
Hz, 1H), 3.08 (t, J = 9.2 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 177.5, 175.3, 
145.7, 135.9, 135.4, 135.2, 133.6, 133.4, 127.7, 127.6, 103.8, 87.8, 80.1, 79.1, 77.5, 
77.1, 75.8, 74.0, 71.9, 70.8, 61.8, 60.7; ESI/APCI calcd for C22H25N3O12Na+ 
([M+Na]+) m/e 546.1330; measured m/e 546.1326. 
1-(N-(4-O-(4-O-(β-d-Glucopyranosyl)-β-d-glucopyranosyl)-β-d- 
glucopyranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (74j). 1H NMR(DMSO-d6, 
400 MHz) δ 8.2 (m, 2H), 8.0 (m, 2H), 6.20 (d, J = 8.9 Hz, 1H), 5.15 (d, J = 3.6 Hz, 
1H), 5.01 (d, J = 3.6 Hz, 1H), 4.2 (m, 1H), 3.5 (m, 27H); 13C NMR (DMSO-d6, 100 
MHz) δ 177.5, 175.3, 145.7, 136.0, 135.3, 135.2, 133.6, 133.4, 127.8, 127.6, 101.5 (2 
carbons), 101.3, 80.2, 79.7, 79.3, 77.1, 74.2, 74.0, 73.8, 73.2, 72.7, 72.5, 71.7, 70.6, 
61.5, 61.0, 49.3; ESI/APCI calcd for C28H35N3O17Na+ ([M+Na]+) m/e 708.1859; 
measured m/e 708.1851. 
1-(N-(β-d-Ribofuranosyl))-1H-naphtho[2,3-d]triazole-4,9-dione (74k). 1H 
NMR (DMSO-d6, 400 MHz) δ 8.2 (m, 2H), 8.0 (m, 2H), 6.60 (d, J = 3.0 Hz, 1H), 
5.73 (s, 1H), 5.34 (s, 1H), 4.7 (m, 1H), 4.35 (t, J = 5.2 Hz, 1H), 4.05 (dd, J = 13.8, 
5.6 Hz, 1H), 3.62 (dd, J = 11.9, 3.9 Hz, 1H), 3.48 (dd, J = 11.9, 5.7 Hz, 1H), 3.33 (s, 
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1H); 13C NMR (DMSO-d6, 100 MHz) δ 177.6, 175.6, 145.5, 135.8, 135.3, 135.2, 
133.7, 133.5, 127.6 (2 carbons), 92.3, 86.7, 74.9, 71.2, 62.2; ESI/APCI calcd for 
C15H13N3O6Na+ ([M+Na]+) m/e 354.0697; measured m/e 354.0703. 
1,6-Bis(1H-naphtho[2,3-d]triazole-4,9-dione)-1,6-dideoxy-d-mannitol (74l). 
1H NMR (DMSO-d6, 400 MHz) δ 8.21 (dd, J = 7.5, 2.3 Hz, 2H), 8.17 (dd, J = 7.3, 
2.4 Hz, 2H), 7.9 (m, 4H), 5.07 (dd, J = 7.7, 3.3 Hz, 2H), 5.07 (d, J = 6.3 Hz, 2H), 
4.87 (dd, J = 13.4, 9.4 Hz, 2H), 4.79 (d, J = 8.2 Hz, 2H), 4.1 (m, 2H), 3.72 (t, J = 8.4 
Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 177.7 (2 carbons), 175.7 (2 carbons), 
145.5 (2 carbons), 135.8 (2 carbons), 135.5 (2 carbons), 135.3 (2 carbons), 133.7 (4 
carbons), 127.7 (4 carbons), 71.9 (2 carbons), 69.9 (2 carbons), 55.0 (2 carbons); 
ESI/APCI calcd for C26H20N6O8Na+ ([M+Na]+) m/e 567.1235; measured m/e 
567.1236. 
1-(1H-Naphtho[2,3-d]triazole-4,9-dione)-1-dideoxy-d-mannitol (74m). 1H 
NMR (DMSO-d6, 400 MHz) δ 8.1 (m, 2H), 7.9 (m, 2H), 5.05 (dd, J = 13.4, 3.1 Hz, 
1H), 4.97 (d, J = 6.4 Hz, 1H), 4.83 (dd, J = 13.4, 9.5 Hz, 1H), 4.63 (d, J = 7.3 Hz, 
1H), 4.50 (d, J = 4.9 Hz, 1H), 4.40 (s, 1H), 4.27 (d, J = 7.7 Hz, 1H), 4.1 (m, 1H), 3.71 
(t, J = 7.6 Hz, 1H), 3.6 (m, 1H), 3.57 (t, J = 8.1 Hz, 1H), 3.5 (m, 1H), 3.4 (m, 1H); 
13C NMR (DMSO-d6, 100 MHz) δ 177.6, 175.6, 145.4, 135.8, 135.4, 135.3, 133.6 (2 
carbons), 127.6, 127.5, 72.0, 71.8, 70.1, 70.0, 64.4, 55.0; ESI/APCI calcd for 
C16H18N3O7+ ([M+H]+) m/e 364.1139; measured m/e 364.1141. 
1-(4-Piperidinyl)-1H-naphtho[2,3-d]triazole-4,9-dione (74n). A solution of 
66n (0.13 g, 0.34 mmol) in CH2Cl2 (4 mL) and TFA (1 mL) was stirred at 0 °C for 30 
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min. After completion of the reaction, the reaction mixture was concentrated and 
purified with column chromatography (eluted with CH2Cl2/MeOH from 100/0 to 4/1). 
The desired product was obtained as a solid (0.090 g, 0.32 mmol, 94%): 1H NMR 
(D2O, 300 MHz) δ 7.82 (dd, J = 5.5, 1.1 Hz, 1H), 7.75 (dd, J = 5.5, 1.0 Hz, 1H), 7.64 
(td, J = 4.5, 0.7 Hz, 1H), 7.60 (td, J = 4.0, 0.7 Hz, 1H), 5.39 (tt, J = 14.8, 8.3 Hz, 1H), 
3.62 (dt, J = 13.7, 3.4 Hz, 2H), 3.3 (m, 2H), 2.4 (m, 4H); 13C NMR (D2O, 100 MHz) δ 
178.2, 175.5, 144.8, 135.9, 135.5, 133.7, 132.5, 132.1, 127.7, 127.4, 55.8, 42.8 (2 
carbons), 27.9 (2 carbons); ESI/APCI calcd for C15H15N4O2+ ([M+H]+) m/e 283.1190; 
measured m/e 283.1189. 
2-(N-(β-d-Glucopyranosyl))aminomethylene-1,3-indanedione (75a). 1H NMR 
(CD3OD, 400 MHz) δ 8.00 (s, 1H), 7.74 (m, 4H), 4.61 (d, J = 8.4 Hz, 1H), 3.90 (dd, J 
= 12.0, 1.9 Hz, 1H), 3.72 (dd, J = 12.0, 5.3 Hz, 1H), 3.4 (m, 4H); 13C NMR (CD3OD, 
100 MHz) δ 193.1, 191.0, 151.2, 139.8, 139.7, 133.8, 133.7, 121.7, 121.3, 101.8, 88.8, 
79.3, 77.1, 73.3, 69.8, 61.3; ESI/APCI calcd for C16H18NO7+ ([M+H]+) m/e 336.1078; 
measured m/e 336.1088. 
2-(N-(β-d-Galactopyranosyl))aminomethylene-1,3-indanedione (75b). 1H 
NMR (CD3OD, 400 MHz) δ 8.01 (s, 1H), 7.68 (m, 4H), 4.56 (d, J = 8.6 Hz, 1H), 3.93 
(d, J = 2.8 Hz, 1H), 3.7−3.8 (m, 4H), 3.59 (dd, J = 9.5, 3.1 Hz, 1H); 13C NMR 
(CD3OD, 100 MHz) δ 193.2, 191.0, 151.2, 139.8, 139.7, 133.8, 133.7, 121.6, 121.3, 
104.8, 89.4, 78.0, 74.0, 70.8, 69.3, 61.4; ESI/APCI calcd for C16H18NO7+ ([M+H]+) 
m/e 336.1078; measured m/e 336.1085. 
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2-(N-(α-d-Rhamnopyranosyl))aminomethylene-1,3-indanedione (75f). 1H 
NMR (DMSO-d6, 400 MHz) δ 9.6 (m, 1H), 8.03 (d, J = 6.0 Hz, 1H), 7.7 (m, 4H), 
5.36 (d, J = 5.3 Hz, 1H), 4.94 (s, 1H), 4.93 (d, J = 5.3 Hz, 1H), 4.86 (d, J = 4.3 Hz, 
1H), 3.8 (m, 1H), 3.2 (m, 3H), 1.18 (d, J = 6.0 Hz, 3H); 13C NMR (DMSO-d6, 100 
MHz) δ 193.3, 189.5, 151.8, 139.9, 134.5 (2 carbons), 122.2, 121.8 (2 carbons), 104.7, 
85.6, 74.6, 73.9, 71.8, 70.6, 18.5; ESI/APCI calcd for C16H18NO6+ ([M+H]+) m/e 
320.1129; measured m/e 320.1136. 
2-(N-(α-d-Xylopyranosyl))aminomethylene-1,3-indanedione (epi-75g). 1H 
NMR (CD3OD, 300 MHz) δ 8.10 (s, 1H), 7.7 (m, 4H), 5.09 (d, J = 2.4 Hz, 1H), 3.95 
(dd, J = 12.0, 2.8 Hz, 1H), 3.81 (t, J = 5.5 Hz, 1H), 3.6−3.7 (m, 2H), 3.5 (m, 1H); 13C 
NMR (CD3OD, 75 MHz) δ 193.4, 190.7, 151.1 (2 carbons), 139.7, 139.6, 133.7, 
133.7, 121.6, 121.2, 83.9, 70.3, 70.0, 68.5, 65.6; ESI/APCI calcd for C15H16NO6+ 
([M+H]+) m/e 306.0972; measured m/e 306.0977. 
2-(N-(β-d-Xylopyranosyl))aminomethylene-1,3-indanedione (75g). 1H NMR 
(CD3OD, 300 MHz) δ 7.90 (s, 1H), 7.6−7.7 (m, 4H), 4.52 (d, J = 8.2 Hz, 1H), 3.95 
(dd, J = 11.3, 5.2 Hz, 1H), 3.5 (m, 1H), 3.2−3.4 (m, 3H); 13C NMR (CD3OD, 75 MHz) 
δ 192.9, 190.9, 150.9, 139.6 (2 carbons), 133.7, 133.6, 121.5, 121.2, 104.8, 89.3, 76.6, 
72.9, 69.4, 67.6; ESI/APCI calcd for C15H16NO6+ ([M+H]+) m/e 306.0972; measured 
m/e 306.0976. 
2-(N-(β-D-Ribofuranosyl))aminomethylene-1,3-indanedione (75k). 1H NMR 
(DMSO-d6, 400 MHz) δ 9.62 (dd, J = 13.5, 6.7 Hz, 1H), 8.00 (d, J = 14.2 Hz, 1H), 
7.6−7.7 (m, 4H), 5.31 (d, J = 6.2 Hz, 1H), 5.1 (m, 3H), 4.06 (dd, J = 10.5, 5.1 Hz, 1H), 
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4.0 (m, 1H), 3.85 (d, J = 2.9 Hz, 1H), 3.5−3.6 (m, 2H); 13C NMR (DMSO-d6, 100 
MHz) δ 192.2, 189.7, 150.9, 140.0, 139.9, 134.4 (2 carbons), 122.1, 121.7, 104.4, 
94.2, 86.2, 75.9, 71.4, 61.9; ESI/APCI calcd for C15H16NO6+ ([M+H]+) m/e 306.0972; 
measured m/e 306.0976. 
1-(Aminomethylene-1,3-indanedione)-1-dideoxy-d-mannitol (75m). 1H 
NMR(DMSO-d6, 300 MHz) δ 9.55 (s, 1H), 7.80 (s, 1H), 7.6 (m, 4H), 4.0−5.0 (m, 5H), 
3.4−3.7 (m, 8H); 13C (DMSO-d6, 100 MHz) δ 190.2, 189.0, 154.4, 139.8 (2 carbons), 
133.9 (2 carbons), 122.0 (2 carbons), 103.5, 71.8, 70.8, 70.0, 69.6, 64.6, 54.2; 
ESI/APCI calcd for C16H20NO7+ ([M+H]+) m/e 338.1234; measured m/e 338.1246. 
2-(N-(4-Piperidinyl))aminomethylene-1,3-indanedione (75n). 1H NMR (D2O, 
300 MHz) δ 7.4 (m, 2H), 7.31 (s, 1H), 7.16 (td, J = 4.5, 1.7 Hz, 1H), 7.06 (td, J = 4.1, 
1.4 Hz, 1H), 3.65 (tt, J = 11.3, 3.8 Hz, 1H), 3.5 (m, 1H), 3.4 (m, 1H), 3.01 (td, J = 
13.0, 2.7 Hz, 2H), 2.1 (m, 2H), 1.88 (dd, J = 14.0, 4.1 Hz, 1H), 1.77 (dd, J = 13.0, 4.1 
Hz, 1H); 13C NMR (D2O, 100 MHz) δ 193.5, 192.4, 151.0, 138.2 (2 carbons), 134.2, 
134.0, 121.6, 121.2, 103.3, 54.6, 42.8 (2 carbons), 28.7 (2 carbons); ESI/APCI calcd 
for C15H17N2O2+ ([M+H]+) m/e 257.1285; measured m/e 257.1293. 
2-hydroxyl-aminomethylene-1,3-indanedione 76. Compound 76 is the 
decomposed product when doing the methanolysis of 69i. 1H NMR (D2O, 300 MHz) 
8.95 (s, 1H), 7.4 (m, 2H), 7.3 (m, 2H); 13C NMR (D2O, 100 MHz) δ 182.4 (2 carbons), 
137.9 (2 carbons), 133.3 (2 carbons), 120.8 (2 carbons), 110.3 (2 carbons); ESI/APCI 
calcd for C10H7O3+ ([M+H]+) m/e 175.0390; measured m/e 175.0395. 
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General Procedure for One-Pot Cycloaddition of Naphthoquinone. A 
solution of alkyl bromides (ca. 0.1 g), NaN3 (2 equiv), and naphthoquinone (2 equiv) 
in DMF or in toluene (5 mL) with nBu4NHSO4 (1 equiv) was stirred at 120 °C for 2 
days. The solvent was evaporated and the crude product was purified by column 
chromatography (eluted from hexane:EtOAc = 100:0 to 50:50) to afford a mixture 
containing both 1-alkyl and 2-alkyl 2H-naphtho[2,3-d][1,2,3]triazole-4,9-diones. The 
mixture was purified again with a smaller column (eluted from hexane:CH2Cl2:AcOH 
= 100:0:0 to hexane:CH2Cl2:AcOH = 45:50:5) to achieve the separation of 1-alkyl 
and 2-alkyl 2H-naphtho[2,3-d][1,2,3]triazole-4,9-diones. The collected fractions of 
each product were concentrated and redissolved in ether, and then passed through a 
short column packed with layers of Celite, silica gel, and NaHCO3(s) to neutralize the 
residual acid. More ether was used to elute the column and the products can be 
recrystallized from a solution of ether and hexane. 
1-n-Butyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (77b). 1H NMR (CDCl3, 
300 MHz) δ 8.35 (ddd, J = 6.5, 1.7, 1.0 Hz, 1H), 8.23 (ddd, J = 7.2, 2.0, 1.0 Hz, 1H), 
7.86 (td, J = 7.2, 1.7 Hz, 1H), 7.81 (td, J = 7.2, 1.4 Hz, 1H), 4.86 (t, J = 7.2 Hz, 2H), 
2.0 (m, 2H), 1.4 (m, 2H), 0.99 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 
177.1, 175.7, 145.8, 135.4, 134.5, 133.6, 133.5, 133.1, 128.1, 127.6, 50.7, 32.2, 19.8, 
13.7; ESI/APCI Calcd for C14H14N3O2+ ([M+H]+) m/e 256.1081; measure m/e 
256.1088. 
2-n-Butyl-2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (79b). 1H NMR (CDCl3, 
300 MHz) δ 8.34 (dd, J = 5.9, 3.5 Hz, 2H), 7.83 (dd, J = 5.9, 3.5 Hz, 2H), 4.68 (t, J = 
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7.2 Hz, 2H), 2.1 (m, 2H), 1.3 (m, 2H), 0.97 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 
MHz) δ 177.5 (2 carbons), 145.6 (2 carbons), 134.8 (2 carbons), 134.1 (2 carbons), 
128.0 (2 carbons), 57.0, 31.7, 19.8, 13.6; ESI/APCI Calcd for C14H14N3O2+ ([M+H]+) 
m/e 256.1081; measure m/e 256.1088. 
1-n-Pentyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (77c). 1H NMR (CDCl3, 
300 MHz) δ 8.35 (ddd, J = 7.2, 2.1, 0.8 Hz, 1H), 8.24 (ddd, J = 6.9, 2.1, 0.8 Hz 1H), 
7.87 (td, J = 7.1, 3.8 Hz, 1H), 7.82 (td, J = 5.5, 1.4 Hz, 1H), 4.85 (t, J = 7.5 Hz, 2H), 
2.0 (m, 2H), 1.4 (m, 4H), 0.91 (t, J = 6.9 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 
177.0, 175.6, 145.5, 135.3, 134.4, 133.5, 133.4, 133.0, 128.0, 127.5, 50.8, 29.8, 28.5, 
22.2, 13.9; ESI/APCI Calcd for C15H16N3O2+ ([M+H]+) m/e 270.1237; measure m/e 
270.1244. 
2-n-Pentyl-2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (79c). 1H NMR (CDCl3, 
300 MHz) δ 8.33 (dd, J = 5.9, 3.5 Hz, 2H), 7.83 (dd, J = 5.9, 3.5 Hz, 2H), 4.66 (t, J = 
7.2 Hz, 2H), 2.1 (m, 2H), 1.3 (m, 4H), 0.89 (t, J = 6.5 Hz, 3H); 13C NMR (CDCl3, 100 
MHz) δ 177.5 (2 carbons), 145.6 (2 carbons), 134.8 (2 carbons), 134.1 (2 carbons), 
128.0 (2 carbons), 57.3, 29.5, 28.7, 22.2, 14.0; ESI/APCI Calcd for C15H16N3O2+ 
([M+H]+) m/e 270.1237; measure m/e 270.1243. 
1-n-Octyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (77d). 1H NMR (CDCl3, 
300 MHz) δ 8.34 (ddd, J = 7.6, 2.1, 1.0 Hz, 1H), 8.24 (ddd, J = 6.9, 2.0, 1.0 Hz, 1H), 
7.86 (td, J = 7.5, 1.7 Hz, 1H), 7.82 (td, J = 5.1, 1.4 Hz, 1H), 4.85 (t, J = 7.5 Hz, 2H), 
2.0 (m, 2H), 1.4 (m, 10H), 0.86 (t, J = 6.5 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 
177.1, 175.7, 145.8, 135.4, 134.5, 133.7, 133.5, 133.1, 128.1, 127.6, 50.9, 31.9, 30.2, 
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29.2, 29.1, 26.6, 22.8, 14.3; ESI/APCI Calcd for C18H22N3O2+ ([M+H]+) m/e 
312.1707; measure m/e 312.1716. 
2-n-Octyl-2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (79d). 1H NMR (CDCl3, 
400 MHz) δ 8.36 (dd, J = 6.9, 2.4 Hz, 2H), 7.85 (dd, J = 5.8, 3.1 Hz, 2H), 4.68 (t, J = 
7.1 Hz, 2H), 2.1 (m, 2H), 1.3 (m, 10H), 0.87 (t, J = 6.7 Hz, 3H); 13C NMR (CDCl3, 
100 MHz) δ 177.6 (2 carbons), 145.6 (2 carbons), 134.8 (2 carbons), 134.1 (2 
carbons), 128.0 (2 carbons), 57.3, 31.9, 29.7, 29.2, 29.2, 26.2, 22.8, 14.3; ESI/APCI 
Calcd for C18H22N3O2+ ([M+H]+) m/e 312.1707; measure m/e 312.1713. 
1-n-Dodecyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (77e). 1H NMR 
(CDCl3, 400 MHz) δ 8.38 (ddd, J = 7.2, 2.1, 1.0 Hz, 1H), 8.25 (ddd, J = 7.2, 2.1, 1.0 
Hz, 1H), 7.87 (td, J = 7.4, 1.6 Hz, 1H), 7.83 (td, J = 7.3, 1.7 Hz, 1H), 4.86 (t, J = 7.2 
Hz, 2H), 2.0 (m, 2H), 1.4 (m, 2H), 1.3 (m, 16H), 0.91 (t, J = 6.6 Hz, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 177.1, 175.7, 145.8, 135.4, 134.5, 133.7, 133.5, 133.1, 128.1, 
127.6, 50.9, 32.1, 30.2, 29.8 (2 carbons), 29.7, 29.68, 29.65, 29.2, 26.6, 22.9, 14.3; 
ESI/APCI Calcd for C22H30N3O2+ ([M+H]+) m/e 368.2333; measure m/e 368.2335. 
2-n-Dodecyl-2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (79e). 1H NMR 
(CDCl3, 300 MHz) δ 8.33 (dd, J = 5.9, 3.5 Hz, 2H), 7.83 (dd, J = 5.9, 3.5 Hz, 2H), 
4.67 (t, J = 7.5 Hz, 2H), 2.1 (m, 2H), 1.3 (m, 2H), 1.2 (m, 16H), 0.87 (t, J = 6.2 Hz, 
3H); 13C NMR (CDCl3, 100 MHz) δ 177.6 (2 carbons), 146.2 (2 carbons), 134.8 (2 
carbons), 134.1 (2 carbons), 128.0 (2 carbons), 32.1, 29.9 (2 carbons), 29.8 (2 
carbons), 29.7, 29.6, 29.5, 29.1, 26.6, 22.9, 14.3; ESI/APCI Calcd for C22H30N3O2+ 
([M+H]+) m/e 368.2333; measure m/e 368.2341. 
  
 
                                                                                  183
1-n-Hexadecyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (77f). 1H NMR 
(CDCl3, 300 MHz) δ 8.35 (ddd, J = 7.2, 1.7, 1.0 Hz, 1H), 8.24 (ddd, J = 6.9, 2.4, 1.0 
Hz, 1H), 7.85 (td, J = 5.5, 1.7 Hz, 1H), 7.82 (td, J = 5.2, 1.7 Hz, 1H), 4.85 (t, J = 7.2 
Hz, 2H), 2.0 (m, 2H), 1.4 (m, 2H), 1.3 (m, 24H), 0.87 (t, J = 6.5 Hz, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 177.1, 175.7, 145.5, 135.4, 134.5, 133.7, 133.5, 133.1, 128.1, 
127.6, 50.9, 32.1, 30.2, 29.88 (3 carbons), 29.86 (2 carbons), 29.8, 29.7, 29.6 (2 
carbons), 29.2, 26.6, 22.9, 14.3; ESI/APCI Calcd for C26H38N3O2+ ([M+H]+) m/e 
424.2959; measure m/e 424.2969. 
2-n-Hexadecyl-2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (79f). 1H NMR 
(CDCl3, 300 MHz) δ 8.34 (dd, J = 5.9, 3.5 Hz, 2H), 7.83 (dd, J = 5.9, 3.5 Hz, 2H), 
4.68 (t, J = 7.2 Hz, 2H), 2.1 (m, 2H), 1.3 (m, 26H), 0.87 (t, J = 6.7 Hz, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 177.6 (2 carbons), 145.6 (2 carbons), 134.8 (2 carbons), 134.1 (2 
carbons), 128.0 (2 carbons), 57.3, 32.1, 29.9 (4 carbons), 29.79 (2 carbons), 29.78, 
29.7, 29.6, 29.5, 29.1, 26.6, 22.9, 14.3; ESI/APCI Calcd for C26H38N3O2+ ([M+H]+) 
m/e 424.2959; measure m/e 424.2961. 
1-(6-Hydroxyhexyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (77g). 1H 
NMR (CDCl3, 300 MHz) δ 8.33 (ddd, J = 6.5, 2.0, 1.0 Hz, 1H), 8.22 (ddd, J = 7.2, 2.1, 
1.0 Hz, 1H), 7.84 (td, J = 5.5, 1.7 Hz, 1H), 7.81 (td, J = 5.2, 1.4 Hz, 1H), 4.85 (t, J = 
7.2 Hz, 2H), 3.63 (t, J =6.2 Hz, 2H), 2.1 (m, 2H), 1.4 – 1.8 (m, 6H), 1.2 (s, 1H); 13C 
NMR (CDCl3, 100 MHz) δ 177.1, 175.7, 145.8, 135.4, 134.5, 133.6, 133.5, 133.1, 
128.1, 127.6, 62.8, 50.8, 32.6, 30.1, 26.3, 25.3; ESI/APCI Calcd for C16H18N3O3+ 
([M+H]+) m/e 300.1343; measure m/e 300.1351. 
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2-(6-Hydroxyhexyl)-2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (79g). 1H 
NMR (CDCl3, 300 MHz) δ 8.34 (dd, J = 5.9, 3.5 Hz, 2H), 7.84 (dd, J = 5.9, 3.5 Hz, 
2H), 4.69 (t, J = 6.9 Hz, 2H), 3.63 (t, J = 6.2 Hz, 2H), 2.2 (m, 2H), 1.6 (m, 2H), 1.4 
(m, 4H), 1.25 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 177.5 (2 carbons), 145.6 (2 
carbons), 134.8 (2 carbons), 134.1 (2 carbons), 128.0 (2 carbons), 62.8, 57.2, 32.6, 
29.7, 26.3, 25.3; ESI/APCI Calcd for C16H18N3O3+ ([M+H]+) m/e 300.1343; measure 
m/e 300.1348. 
2-(4-(N-tert-butoxycarbonylpiperidinyl))-2H-naphtho[2,3-d][1,2,3]triazole-4,
9-dione (79h). This compound was prepared similarly according to the General 
Procedure for One-Pot Cycloaddition of Naphthoquinone except 4-myslate 
N-tert-butoxycarbonylpiperidine was used in place of alkyl bromide. 1H NMR (CDCl3, 
400 MHz) δ 8.35 (dd, J = 5.5, 3.5 Hz, 2H), 7.84 (dd, J = 5.8, 3.1 Hz, 2H), 4.9 (m, 1H), 
4.3 (m, 2H), 3.0 (m, 2H), 2.3 (m, 4H), 1.48 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ 
177.5 (2 carbons), 154.6, 145.4 (2 carbons), 134.8 (2 carbons), 134.1 (2 carbons), 
128.0 (2 carbons), 80.4, 64.7 (2 carbons), 43.0, 31.7 (2 carbons), 28.6 (3 carbons); 
ESI/APCI Calcd for C20H22N4O4Na+ ([M+Na]+) m/e 405.1533; measure m/e 
405.1529. 
1-Ethyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (77i). This compound was 
prepared similarly according to the General Procedure for One-Pot Cycloaddition of 
Naphthoquinone except ethyl bromoacetate or diethyl 2-bromoethylphosphonate was 
used in place of alkyl bromide. 1H NMR (CDCl3, 300 MHz) δ 8.35 (ddd, J = 6.2, 1.7, 
1.0 Hz, 1H), 8.23 (ddd, J = 6.8, 2.4, 1.0 Hz, 1H), 7.86 (td, J = 7.6, 1.7 Hz, 1H), 7.81 
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(td, J = 7.2, 1.7 Hz, 1H), 4.90 (q, J = 7.6 Hz, 2H), 1.65 (t, J = 7.2 Hz, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 177.1, 175.7, 145.9, 135.4, 134.5, 133.6, 133.4, 133.1, 128.1, 
127.6, 46.3, 15.5; ESI/APCI Calcd for C12H10N3O2+ ([M+H]+) m/e 228.0768; measure 
m/e 228.0769. 
2-Ethyl-2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (79i). This compound was 
prepared similarly according to the General Procedure for One-Pot Cycloaddition of 
Naphthoquinone except ethyl bromoacetate or diethyl 2-bromoethylphosphonate was 
used in place of alkyl bromide. 1H NMR (CDCl3, 300 MHz) δ 8.34 (dd, J = 5.5, 3.4 
Hz, 2H), 7.83 (dd, J = 5.5, 3.3 Hz, 2H), 4.74 (q, J = 7.6 Hz, 2H), 1.73 (t, J = 7.6 Hz, 
3H); 13C NMR (CDCl3, 100 MHz) δ 177.5 (2 carbons), 145.6 (2 carbons), 134.8 (2 
carbons), 134.1 (2 carbons), 128.0 (2 carbons), 52.5, 14.9; ESI/APCI Calcd for 
C12H10N3O2+ ([M+H]+) m/e 228.0768; measure m/e 228.0770. 
1-Methyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (77j). This compound 
was prepared similarly according to the General Procedure for One-Pot Cycloaddition 
of Naphthoquinone except methyl bromoacetate was used in place of alkyl bromide. 
1H NMR (CDCl3, 400 MHz) δ 8.35 (ddd, J = 7.2, 1.7, 1.0 Hz, 1H), 8.24 (ddd, J = 7.2, 
1.7, 1.0 Hz, 1H), 7.86 (td, J = 7.1, 1.4 Hz, 1H), 7.81 (td, J = 7.4, 1.6 Hz, 1H), 4.52 (s, 
3H); 13C NMR (CDCl3, 75 MHz) δ 176.8, 175.7, 145.6, 135.3, 134.4, 133.9, 133.6, 
132.9, 128.0, 127.4, 37.3; ESI/APCI Calcd for C11H8N3O2+ ([M+H]+) m/e 214.0611; 
measure m/e 214.0614. 
 1-(2-Hydroxypropyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (77l). 1H 
NMR (CDCl3, 300 MHz) δ 8.27 (ddd, J = 5.9, 1.7, 0.8 Hz, 1H), 8.22 (ddd, J = 6.5, 1.7, 
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0.8 Hz, 1H), 7.87 (td, J = 7.2, 1.7 Hz, 1H), 7.80 (td, J = 7.6, 2.1 Hz, 1H), 4.92 (dd, J = 
13.7, 2.5 Hz, 1H), 4.85 (dd, J = 13.7, 7.2 Hz, 1H), 4.4 (m, 1H), 2.43 (d, J = 5.5 Hz, 
1H), 1.39 (d, J = 8.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 176.9, 176.1, 145.5, 
135.3, 134.6, 134.3, 133.5, 133.1, 128.0, 127.7, 67.3, 57.1, 21.0; ESI/APCI Calcd for 
C13H12N3O2+ ([M+H]+) m/e 258.0873; measure m/e 258.0880. 
2-(2-Hydroxypropyl)-2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (79l). 1H 
NMR (CDCl3, 300 MHz) δ 8.31 (dd, J = 5.5, 3.1 Hz, 2H), 7.83 (dd, J = 6.9, 3.8 Hz, 
2H), 4.72 (dd, J = 13.7, 2.5 Hz, 1H), 4.68 (dd, J = 13.7, 7.2 Hz, 1H), 4.5 (m, 1H), 2.58 
(d, J = 4.8 Hz, 1H), 1.35 (d, J = 6.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 177.3 (2 
carbons), 145.7 (2 carbons), 134.9 (2 carbons), 134.0 (2 carbons), 128.0 (2 carbons), 
66.7, 63.6, 20.7; ESI/APCI Calcd for C13H12N3O2+ ([M+H]+) m/e 258.0873; measure 
m/e 258.0874. 
    2-Amino-1,4-naphthoquinone (82).96c 1H NMR (CDCl3, 300 MHz) δ 8.07 (dd, J = 
7.6, 1.0 Hz, 1H), 8.04 (dd, J = 7.6, 1.1 Hz, 1H), 7.73 (td, J = 7.6, 1.4 Hz, 1H), 7.64 (td, 
J = 7.6, 1.4 Hz, 1H), 6.00 (s, 1H), 5.17 (s, broad, 2H); 13C NMR (CDCl3, 100 MHz) δ 
183.9, 181.9, 148.5, 134.7, 133.4, 132.3, 130.6, 126.3, 126.2, 105.7. 
1,4-Bis((2-hydroxy-3-phenoxy)propoxy)naphthylene (94). This compound 
was isolated from the one-pot cycloaddition using naphthoquinone, sodium azide and 
phenyl glycidyl ether. 1H NMR (CDCl3, 300 MHz) δ 8.20 (dd, J = 9.9, 6.5 Hz, 2H), 
7.51 (dd, J = 9.6, 3.4 Hz, 2H), 7.3 (m, 4H), 7.0 (m, 6H), 6.72 (s, 2H), 4.5 (m, 2H), 4.2 
– 4.3 (m. 8H), 2.85 (s, broad, 2H); 13C NMR (CDCl3, 75 MHz) δ 158.5 (2 carbons), 
148.7 (2 carbons), 129.7 (4 carbons), 126.4 (2 carbons), 126.2 (2 carbons), 121.7 (2 
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carbons), 121.4 (2 carbons), 114.7 (4 carbons), 104.8 (2 carbons), 69.5 (2 carbons), 
69.1 (2 carbons), 69.05 (2 carbons); ESI/APCI Calcd for C28H29O6+ ([M+H]+) m/e 
461.1959; measure m/e 461.1994. 
1,4-Bis((2-hydroxy-2-phenyl)ethoxy)naphthylene (95). This compound was 
isolated from the one-pot cycloaddition using naphthoquinone, sodium azide and 
styrene oxide. 1H NMR (CDCl3, 300 MHz) δ 8.21 (dd, J = 6.5, 3.1 Hz, 2H), 7.5 (m, 
6H), 7.4 (m, 6H) , 6.63 (s, 2H), 5.25 (dd, J = 8.3, 3.8 Hz, 2H), 4.2 (M, 4H), 3.0 (s, 
broad, 2H); 13C NMR (CDCl3, 100 MHz) δ 148.8 (2 carbons), 140.1 (2 carbons), 
128.8 (4 carbons), 128.4 (3 carbons), 126.5 (4 carbons), 126.4 (3 carbons), 121.9 (2 
carbons), 105.0 (2 carbons), 74.2 (2 carbons), 73.0 (2 carbons). 
2-(4-piperidinyl)-2H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (96). 1H NMR 
(CD3OD, 300 MHz) δ 8.29 (dd, J = 5.9, 3.4 Hz, 2H), 7.89 (dd, J = 5.9, 3.4 Hz, 2H), 
5.1 (m, 1H), 3.4 (td, J = 13.1, 4.1 Hz, 2H), 3.28 (td, J = 11.4, 3.1 Hz, 2H), 2.4 (m, 4H); 
13C NMR (CD3OD, 100 MHz) δ 177.4 (2 carbons),145.5 (2 carbons), 134.5 (2 
carbons), 134.2 (2 carbons), 127.2 (2 carbons), 61.6, 42.7 (2 carbons), 29.5 (2 
carbons); ESI/APCI Calcd for C15H15N4O2+ ([M+H]+) m/e 283.1190; measure m/e 
283.1197.      
6-O-Hexylaminocarbonyl-1,3,2',6'-tetraazido-3',4'-dideoxy-3'-enoneamine 
(98). To a solution of 1-heptamine (0.10 g, 1.0 mmol) and Et3N (0.42 g, 4.2 mmol) in 
anhydrous CH2Cl2 (5 mL) at -78ºC, triphosgene (0.22g, 0.75 mmol) was added, and 
the reaction was stirred for several hours allowing the temperature to warm up to 
room temperature. The reaction mixture was cooled to 0ºC and added with compound 
  
 
                                                                                  188
97 (0.20 g, 0.51 mmol). After being stirred overnight, the reaction was quenched with 
water and diluted with EtOAc. The combined organic solution was washed with 1M 
HCl, water, saturated NaHCO3, and brine, and then dried over anhydrous Na2SO4. 
After the removal of the solvents and purification with column chromatography 
(eluted with hexane/EtOAc from 100/0 to 60/40), the product was obtained as an oil 
(0.08 g, 0.15 mmol, 34%) along with the recovered compound 97 (0.09 g). 1H NMR 
(CDCl3, 400 MHz) δ 5.93 (d, J = 10.5 Hz, 1H), 5.89 (d, J = 10.4 Hz, 1H), 5.74 (d, J 
= 3.9 Hz, 1H), 4.85 (t, J = 6.2 Hz, 1H), 4.7 (m, 1H), 4.67 (t, J = 9.9 Hz, 1H), 3.9 (m, 
1H), 3.8 (m, 1H), 3.68 (t, J =9.1 Hz, 1H), 3.58 (t, J = 9.4 Hz, 1H), 3.4 – 3.5 (m, 2H), 
3.3 – 3.4 (m, 2H), 3.2 (m, 2H), 2.27 (td, J = 13.3, 4.5 Hz, 1H), 1.6 (m, 1H), 1.5 (m, 
2H), 1.2 (m, 6H), 0.85 (t, J = 6.7 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 156.5, 
129.6, 123.1, 97.4, 81.4, 75.9, 69.0, 59.2, 58.4, 55.4, 54.0, 41.7, 32.5, 32.0, 31.6, 29.9, 
26.5, 22.7, 14.2; ESI/APCI Calcd for C19H30N13O5+ ([M+H]+) m/e 520.2487; 
measured m/e 520.2476. 
6-O-Hexylaminocarbonyl-1,3,4',6'-tetraazido-2',3',4'-trideoxy-2'- 
enoneamine (99). Compound 99 was prepared similarly to the synthesis of compound 
98 except the following amount of reagents were used: 1-heptamine (0.21 g, 2.0 
mmol), Et3N (1.2 mL, 8.6 mmol) and triphosgene (0.45 g, 1.53 mmol) for reacting 
with compound 97 (0.20 g, 0.51 mmol). Two products were isolated after column 
chromatography (eluted with hexane/EtOAc from 100/0 to 60/40): compound 99 
(0.14 g, 0.27 mmol, 53%) and compound 100 (0.13 g, 0.20 mmol, 39%). 1H NMR 
(CDCl3, 400 MHz) δ 5.9 (m, 2H), 5.38 (d, J = 4.0 Hz, 1H), 4.93 (t, J = 5.4 Hz, 1H), 
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4.8 (m, 2H), 3.8 (m, 1H), 3.6 – 3.7 (m, 2H), 3.4 – 3.5 (m, 3H), 3.2 – 3.3 (m, 3H), 2.25 
(td, J = 8.1, 3.9 Hz, 1H), 1.4 – 1.6 (m, 4H), 1.2 – 1.3 (m, 6H), 0.86 (t, J = 6.6 Hz, 3H); 
13C NMR (CDCl3, 100 MHz) δ 157.1, 129.6, 123.3, 98.1, 78.7, 78.2, 76.5, 69.2, 60.8, 
59.6, 54.9, 54.2, 41.8, 32.2, 32.0, 29.8, 26.6, 22.8, 14.2; ESI/APCI Calcd for 
C19H30N13O5+ ([M+H]+) m/e 520.2487; measured m/e 520.2481. 
1,3,4',6'-Tetraazido-2',3',4'-trideoxy-2'-enoneamine (101). A solution of 
compound 97 (0.30 g, 0.77 mmol) in toluene was refluxed overnight. After the 
removal of the solvents and purification with column chromatography (eluted with 
hexane/EtOAc from 90/10 to 50/50), the product was obtained as an oil (0.14 g, 0.36 
mmol, 47%) along with the recovered compound 97 (0.12 g, 0.31 mmol, 40%). 1H 
NMR (CDCl3, 400 MHz) δ 6.01 (d, J = 10.2 Hz, 1H), 5.99 (dd, J = 12.0, 1.8 Hz, 1H), 
5.57 (s, 1H), 4.0 (m, 1H), 3.91 (d, J = 9.8 Hz, 1H), 3.4 – 3.6 (m, 4H), 3.3 – 3.4 (m, 
3H), 2.71 (s, 1H), 2.28 (td, J = 13.4, 4.3 Hz, 1H), 1.4 – 1.6 (m, 2H); 13C NMR (CDCl3, 
100 MHz) δ 128.5, 128.2, 94.7, 79.8, 76.3, 76.2, 69.7, 60.5, 59.6, 54.8, 51.8, 32.4; 
ESI/APCI Calcd for C12H17N12O4+ ([M+H]+) m/e 393.1490; measured m/e 393.1502. 
6-O-Benzoyl-1,3,4',6'-tetraazido-2',3',4'-trideoxy-2'-enoneamine (102). To 
a solution of compound 99 (0.10 g, 0.26 mmol) and DIPEA (0.05 mL, 0.31 mmol) in 
anhydrous CH2Cl2 (10 mL) at -50°C, BzCl (0.03 mL, 0.26 mmol) was added. After 
being stirred for 2 hrs, NaHCO3(s) was added and the solvent was removed. The 
residue was diluted with EtOAc and was washed with saturated NaHCO3(aq), water and 
brine, and then dried over Na2SO4. After the removal of the solvents and purification 
with column chromatography (eluted with hexane/EtOAc from 100/0 to 70/30), the 
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product was obtained as an oil (0.09 g, 0.18 mmol, 71%). 1H NMR (CDCl3, 400 MHz) 
δ 8.07 (dd, J = 8.0, 1.5 Hz, 2H), 7.61 (td, J = 7.2, 1.2 Hz, 1H), 7.48 (td, J = 7.7, 1.5 
Hz, 2H), 6.0 (m, 2H), 5.64 (s, 1H), 5.07 (td, J = 9.6, 3.1 Hz, 1H), 4.0 (m, 1H), 3.9 (m, 
1H), 3.5 – 3.7 (m, 7H), 2.39 (dt, J = 13.4, 4.5 Hz, 1H), 1.63 (dt, J = 12.6, 11.5 Hz, 
1H); 13C NMR (CDCl3, 100 MHz) δ 167.2, 134.1, 130.2 (2 carbons), 128.9, 128.8 (2 
carbons), 128.4, 128.2, 95.0, 80.5, 76.9, 75.9, 69.8, 59.4, 58.6, 54.8, 51.7, 32.7; 
ESI/APCI Calcd for C19H21N12O5+ ([M+H]+) m/e 497.1758 ; measured m/e 497.1575. 
5,6-Di-O-acetyl-1,3,4',6'-tetraazido-2',3',4'-trideoxy-2'-enoneamine (103). To 
a solution of compound 99 (0.02 g, 0.051 mmol), Et3N (0.06 mL, 0.41 mmol) and 
DMAP (catalytic amount) in anhydrous CH2Cl2 (10 mL) at 0°C, Ac2O (0.02 mL, 0.26 
mmol) was added. After being stirred for 2 h, the solvent was removed. After 
purification with column chromatography (eluted with hexane/EtOAc from 100/0 to 
50/50), the product was obtained as an oil (0.02 g, 0.042 mmol, 82%). 1H NMR 
(CDCl3, 400 MHz) δ 6.02 (d, J = 10.2 Hz, 1H), 5.72 (dt, J = 10.1, 2.1 Hz, 1H), 5.19 (s, 
1H), 5.05 (t, J = 9.8 Hz, 1H), 4.92 (t, J = 10.0 Hz, 1H), 3.9 (m, 2H), 3.72 (t, J = 9.7 
Hz, 1H), 3.4 – 3.6 (m, 4H), 2.35 (dt, J = 9.1, 4.6, 1H), 2.06 (s, 3H), 2.04 (s, 3H), 1.5 
(m, 1H); 13C NMR (CDCl3, 100 MHz) δ 170.0, 169.7, 129.2, 127.4, 94.9, 78.4, 74.3, 
74.0, 69.8, 59.5, 58.2, 54.5, 51.5, 32.4, 20.9, 20.8; ESI/APCI Calcd for 
C16H20N12O6Na+ ([M+Na]+) m/e 499.1521; measured m/e 499.1519. 
3',4'-Dideoxyneamine (104). 1H NMR (D2O, 400 MHz) δ 5.66 (t, J = 3.4 Hz, 
1H), 4.1 (m, 1H), 3.86 (t, J = 9.4 Hz, 1H), 3.56 (t, J = 9.2 Hz, 1H), 3.4 – 3.5 (m, 3H), 
3.26 (dd, J = 12.5, 4.3 Hz, 1H), 3.22 (dd, J = 10.3, 4.2 Hz, 1H), 3.14 (dd, J = 13.5, 3.4 
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Hz, 1H), 2.98 (dd, J = 13.5, 7.2 Hz, 1H), 2.41 (td, J = 8.2, 4.1 Hz, 1H), 1.8 – 1.9 (m, 
4H); 13C NMR (D2O, 75 MHz) δ 95.2, 77.2, 75.3, 72.6, 65.8, 49.8, 48.8, 48.7, 42.6, 
28.3, 25.6, 20.5; ESI/APCI Calcd for C12H27N4O4Na+ ([M+Na]+) m/e 313.1846; 
measure m/e 313.1853. 
4'-Amino-2',3',4'-trideoxyneamine (105). To a solution of compound 101 (0.21 
g, 0.54 mmol), NaHCO3(s) (catalytic amount), several drops of water in THF (15 mL) 
at 50ºC, PMe3 (2.0 mL, 1 M in THF) was added. After being stirred for 30 min, the 
solvent was removed. The residue was added with degassed water, Pd/C (catalytic 
amount) and NaHCO3(s) (catalytic amount), and then charged with atmospheric H2. 
After being stirred for two days, the reaction was quenched by filtering through Celite 
and the residue washed with H2O and the combined solutions were concentrated. The 
crude product was purified with Amberlite CG50 (NH4+) eluted with a gradient of 
NH4OH solution (0% – 20%). After collection of the desired fractions and removal of 
solvent, the product was re-dissolved in water and loaded to an ion-exchange column 
packed with Dowex 1X8-200 (Cl- form), and eluted with water. After removal of 
solvent, the product was obtained as white solid (0.08 g, 0.27 mmol, 51%). 1H NMR 
(D2O, 400 MHz) δ 5.4 (m, 1H), 4.2 (m, 1H), 3.81 (t, J = 9.1 Hz, 1H), 3.2 – 3.5 (m, 
7H), 2.38(td, J = 8.8, 4.5 Hz, 1H), 1.8 – 2.9 (m, 5H); 13C NMR (D2O, 100 MHz) δ 
96.4, 77.8, 74.9, 72.6, 69.6, 50.0, 48.9, 47.1, 39.4, 28.3, 26.1, 21.1; ESI/APCI Calcd 
for C12H27N4O4Na+ ([M+Na]+) m/e 313.1846; measured m/e 313.1853. 
6-O-(1,2,3,6-Tetra-O-benzyl-α-D-galactopyranosyl)-1,3,4',6'-tetraazido-2',3',
4'-trideoxy-2'-enoneamine (107). A solution of compound 101 (0.20 g, 0.57 mmol), 
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compound 106 (0.39 g, 0.61 mmol), (1.2 equivalents), and activated 4A° molecular 
sieve was stirred in anhydrous Et2O and CH2Cl2 (Et2O: 4.5 mL; CH2Cl2: 1.5 mL) at 
room temperature overnight. The reaction mixture was cooled to -70ºC and 
N-iodosuccinimide (0.14g, 0.61 mmol) was quickly added into the reaction mixture. 
After the temperature of the solution warmed up to -30ºC, trifluoromethanesulfonic 
acid (catalytic amount) was added. The solution was stirred at low temperature till the 
complete consumption of the glycosyl donor (ca. 4 hours, monitored by TLC). The 
reaction mixture was quenched by the addition of Et3N (3 mL). After being stirred for 
10 min, the reaction mixture was filtered through Celite and the residue was washed 
with EtOAc. The combined organic solution washed with 10% aqueous Na2S2O3, 
saturated NaHCO3(aq) and brine, and dried over anhydrous Na2SO4. After removal of 
the solvents and purification with column chromatography (eluted with 
hexane/EtOAc from 100/0 to 65/35), the product was obtained as an oil (0.34 g, 0.38 
mmol, 74%). The other product, epi-107 was obtained as a minor product (0.02 g, 
0.022 mmol, 4%). 1H NMR (CDCl3, 300 MHz) δ 7.3 (m, 20H), 5.90 (d, J = 10.0 Hz, 
1H), 5.70 (d, J = 12.4 Hz, 1H), 5.49 (s, 1H), 4.7 – 5.0 (m, 7H), 4.57 (d, J = 11.7 Hz, 
1H), 4.41 (t, J = 11.3 Hz, 2H), 3.8 – 4.1 (m, 6H), 3.2 – 3.6 (m, 9H), 2.3 (td, J = 8.6, 
3.8 Hz, 1H), 1.4 (m, 1H); 13C NMR (CDCl3, 75 MHz) δ 138.9, 138.5, 138.3, 137.7, 
128.8 (2 carbons), 128.7 (2 carbons), 128.6 (2 carbons), 128.5 (4 carbons), 128.4 (2 
carbons), 128.2 (2 carbons), 128.0 (2 carbons), 127.9, 127.8 (2 carbons), 127.7 (2 
carbons), 127.4, 99.4, 95.0, 87.2, 80.0, 78.4, 77.6, 76.7, 76.0, 75.3, 74.7, 73.7 (2 
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carbons), 71.3, 70.0, 69.5, 59.8, 59.5, 54.7, 51.6, 32.8; ESI/APCI Calcd for 
C46H50N12O9Na+ ([M+Na]+) m/e 937.3721; measured m/e 937.3702. 
6-O-(1,2,3,6-Tetra-O-benzyl- β-D-galactopyranosyl)-1,3,4',6'-tetraazido-2',3',
4'-trideoxy-2'-enoneamine (epi-107). 1H NMR (CDCl3, 300 MHz) δ 7.3 (m, 20H), 
5.90 (d, J = 10.0 Hz, 1H), 5.74 (dt, J = 12.4, 2.1 Hz, 1H), 5.52 (s, 1H), 5.05 (d, J = 3.5 
Hz, 1H), 4.94 (t, J = 11.7 Hz, 1H), 4.91 (d, J = 8.3 Hz, 1H), 4.7 – 4.8 (m, 3H), 4.58 (d, 
J = 11.3 Hz, 1H), 4.4 (m, 3H), 4.1 (m, 2H), 4.0 (m, 1H), 3.9 (m, 2H), 3.81 (d, J = 1.7 
Hz, 1H), 3.2 – 3.6 (m, 9H), 2.24 (td, J = 13.4, 4.5 Hz, 1H), 1.4 (m, 1H); 13C NMR 
(CDCl3, 100 MHz) δ 138.9, 138.5, 138.3, 137.7, 128.8 (2 carbons), 128.7, 128.6 (2 
carbons), 128.5 (4 carbons), 128.4 (2 carbons), 128.3 (2 carbons), 128.0 (2 carbons), 
127.9, 127.8 (2 carbons), 127.7 (2 carbons), 127.4 (2 carbons), 99.4, 95.0, 87.2, 80.1, 
78.3, 76.7, 76.0, 75.3, 74.7, 73.7 (2 carbons), 71.3, 70.0, 69.5, 59.8, 59.6, 54.7, 51.7, 
32.8, 14.3; ESI/APCI Calcd for C46H50N12O9Na+ ([M+Na]+) m/e 937.3721; measured 
m/e 937.3699. 
6-O-(1,2,3,6-Tetra-O-benzyl- α-D-galactopyranosyl)-1,3,4',6'-tetraazido-3',4'-
dideoxy-3'-enoneamine (108). This compound was prepared similarly to the 
synthesis of compound 13. 1H NMR (CDCl3, 300 MHz) δ 7.2 -7.4 (m, 20H), 5.9 (m, 
2H), 5.08 (d, J = 3.4 Hz, 1H), 4.94 (t, J = 11.7 Hz, 1H), 4.7 – 4.9 (m, 5H), 4.4 – 4.6 
(m, 4H), 4.1 (m, 1H), 4.10 (d, J = 3.8 Hz, 1H), 3.95 (dd, J = 8.3, 2.8 Hz, 1H), 3.8 (m, 
1H), 3.7 (m, 2H), 3.2 – 3.5 (m, 8H), 2.27 (td, J = 13.4, 4.5 Hz, 1H), 1.6 (s, 1H), 1.46 
(td, J = 12.9, 12.7 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 139.0, 138.7, 138.5, 137.9, 
129.5, 128.7 (2 carbons), 128.6 (2 carbons), 128.6 (4 carbons), 128.5 (2 carbons), 
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128.4 (2 carbons), 128.1 (2 carbons), 128.1, 128.0, 127.9, 127.8 (2 carbons), 
127.7 ,123.7, 99.6, 96.9, 87.2, 79.1, 78.5, 76.7, 76.4, 75.3, 74.8, 73.8 (2 carbons), 73.7, 
71.2, 69.4, 69.0, 59.9, 59.8, 54.9, 54.0, 32.9; ESI/APCI Calcd for C46H50N12O9+Na+ 
([M+Na]+) m/e 937.3721; measured m/e 937.3704. 
6-O-(3-Azido-2-O-benzyl-3,6-dideoxyl-α-D-glucopyranosyl)-1,3,4',6'- 
tetraazido-3',4'-dideoxy-3'-enoneamine (110). The first step for the preparation of 
this compound was similar to the synthesis of compound 107. The product from the 
first step was dissolved in methanol (5 mL), and NaOMe (0.5 M in MeOH, 1 mL) was 
added. The reaction mixture was stirred at room temperature till the completion of the 
reaction (ca. 2 h, monitored by TLC, eluted with hexane/EtOAc = 50/50). The 
reaction mixture was filtered through Celite and the residue was washed with MeOH. 
After the removal of the solvents and purification with column chromatography 
(eluted with hexane/EtOAc from 90/10 to 35/65), the product was obtained as a solid 
(0.26 g, 0.40 mmol, 78%). 1H NMR (CDCl3, 300 MHz) δ 7.4 (m, 5H), 6.0 (m, 2H), 
5.60 (s, 1H), 4.6 – 4.9 (m, 4H), 2.9 – 4.2 (m, 13H), 2.4 (m, 1H), 2.26 (td, J = 13.1, 4.5 
Hz, 1H), 1.4 (m, 1H), 1.27 (d, J = 3.8 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 137.4, 
128.8 (2 carbons), 128.7, 128.5, 128.4 (2 carbons), 128.0, 97.7, 95.0, 87.2, 79.8, 78.3, 
76.0, 74.0, 73.4, 69.7, 69.0, 64.9, 59.5, 59.4, 54.8, 51.8, 32.9, 17.9; ESI/APCI Calcd 
for C25H35N16O7+ ([M+NH4]+) m/e 671.2896; measured m/e 671.2852. 
6-O-(3-Azido-2-O-benzyl-3-deoxy-α-D-xylopyranosyl)-1,3,4',6'-tetraazido-3',
4'-dideoxy-3'-enoneamine (112). This compound was prepared similarly to the 
synthesis of compound 110. 1H NMR (CDCl3, 400 MHz) δ 7.4 – 7.5 (m, 5H), 5.95 (d, 
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J = 10.5 Hz, 1H), 5.890 (d, J = 10.8 Hz, 1H), 5.8 (d, 4.3 Hz, 1H), 4.9 (d, J = 3.0 Hz, 
1H), 4.6 – 4.7 (m, 2H),  4.23 (d, J = 3.0 Hz, 1H), 4.09 (m, 1H),  3.6 – 3.9 (m, 6H), 
3.2 - 3.5 (m, 8H), 2.32 (ddd, J = 13.2, 4.5, 4.5 Hz, 1H), 1.36 (ddd, J = 13.2, 12.5, 12.5 
Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 136.5, 128.6, 128.0, 127.7, 127.6, 122.7, 
122.4, 97.1, 96.3, 85.0, 81.3, 79.0, 75.1, 73.0, 68.3, 67.5, 63.8, 62.7, 58.8, 58.7, 54.4, 
53.3, 32.0, 29.1; MALDI Calcd for C24H29N15O7Na ([M+Na]+) m/e 662.2267; 
measured m/e 662.2232. 
5-O-(4-Azido-4-deoxy-β-D-glucopyranosyl)-1,3,4',6'-tetraazido-3',4'-dideoxy
-3'-enoneamine (114). A solution of compound 113 (0.83 g, 2.0 mmol), compound 
102 (0.83 g, 1.7 mmol), and activated powder 4A° molecular sieve was stirred in 
anhydrous CH2Cl2 (8 mL) at 65ºC for 1 h and then added with BF3-OEt2 (0.05 mL, 
0.42 mmol). After the reaction was warmed to room temperature, the reaction was 
quenched by adding few drops of water. After being stirred for 20 min, NaHCO3(s) 
was added, and then reaction mixture was filtered through a short column packed with 
layers of Celite and silica gel and it was washed with EtOAc. After removal of the 
solvent and purification with column chromatography (eluted with hexanes/EtOAc 
from 100/0 to 60/40) afforded the intermediate product. The intermediate product was 
dissolved in methanol (5 mL) and few drops of water, and NaOMe (catalytic amount) 
was added. The reaction mixture was stirred at room temperature till the completion 
of the reaction (ca. 1 hour, monitored by TLC, eluted with hexane/EtOAc = 50/50). 
The reaction mixture was filtered through Celite and the residue was washed with 
EtOAc. After removal of the solvents and purification with column chromatography 
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(eluted with hexane/EtOAc from 90/10 to 30/70), the product was obtained as a solid 
(0.52 g, 0.92 mmol, 56%). 1H NMR (CD3OD, 300 MHz) δ 6.10 (dt, J = 10.3, 2.4 Hz, 
1H), 5.99 (d, J = 10.0 Hz, 1H), 5.63 (s, 1H), 4.60 (d, J = 8.2 Hz, 1H), 4.01 (dt , J = 
10.0, 4.1 Hz, 1H), 3.87 (dd, J = 10.0, 1.7 Hz, 1H), 3.6 (m, 2H), 3.2 – 3.5 (m, 8H), 
2.99 (t, J = 9.6 Hz, 1H), 2.16 (td, J = 13.4, 4.5 Hz, 1H), 1.33 (d, J = 6.2 Hz, 3H), 1.2 
(m, 1H); 13C NMR (CD3OD, 100 MHz) δ 128.9, 127.2, 104.4, 94.3, 85.5, 78.1, 77.0, 
75.9, 75.0, 70.9, 69.9, 68.3, 60.0, 59.9, 55.1, 51.6, 32.2, 17.7; ESI/APCI Calcd for 
C18H26N15O7+ ([M+H]+) m/e 564.2134; measure m/e 564.2125. 
6-O-Hexylaminocarbonyl-3',4'-dideoxyneamine (RR101). This compound 
was prepared similarly to the synthesis of compound 105 except no NaHCO3(s) was 
used in the first step, but MeOH and couple drops of HOAc/H2O (1/4) was used as the 
solvent in the second step. 1H NMR (D2O, 300 MHz) δ 5.66 (d, J = 3.5 Hz, 1H), 2.9 - 
4.1 (m, 13H), 2.44 (td, J = 12.4, 8.6 Hz, 1H), 1.9 (m, 1H), 1.7 – 1.8 (m, 2H), 1.3 (m, 
2H), 1.2 (m, 6H), 0.73 (t, J = 6.5 Hz, 3H); 13C NMR (D2O, 100 MHz) δ 157.2, 95.2, 
76.5, 74.1, 73.4, 66.0, 48.9, 48.6, 48.3, 42.8, 41.0, 30.9, 28.8, 28.4, 25.8, 25.7, 22.1, 
20.5, 13.5; ESI/APCI Calcd for C19H42N5O6+ ([M+H2O]+) m/e 436.3130; measured 
m/e 436.2763. 
4'-Amino-6-O-hexylaminocarbonyl-1,3,4',6'-tetraamino-2',3',4'- 
trideoxyneamine (NRR101). This compound was prepared similarly to the synthesis 
of compound 105 but using MeOH and couple drops of HOAc/H2O (1/4) as the 
solvent. 1H NMR (D2O, 300 MHz) δ 5.66 (d, J = 3.5 Hz, 1H), 2.9 – 4.3 (m, 11H), 2.4 
(m, 1H), 1.5 – 1.9 (m, 5H), 1.4 (m, 2H), 1.2 (m, 6H), 0.73 (t, J = 6.2 Hz, 3H); 13C 
  
 
                                                                                  197
NMR (D2O, 100 MHz) δ 157.3, 95.2, 74.3, 73.8, 73.0, 66.0, 48.9, 48.6, 48.3, 42.8, 
41.0, 40.8, 30.9, 28.8, 28.3, 25.8, 22.1, 20.6, 13.5; ESI/APCI Calcd for C19H41N5O5+ 
([M+H]+) m/e 418.3024; measured m/e 418.3027. 
4'-Amino-5,6-di-O-hexylaminocarbonyl-1,3,4',6'-tetraamino-2',3',4'-trideoxy
neamine (NRR102). The compound was prepared similarly to synthesis of compound 
105 but using MeOH and couple drops of HOAc/H2O (1/4) as solvent in the second 
step. 1H NMR (D2O, 300 MHz) δ 5.24 (d, J = 3.1 Hz, 1H), 4.9 (m, 2H), 4.33 (t, J = 
10.0 Hz, 1H), 4.1 (m, 1H), 3.6 (m, 3H), 3.4 (m, 1H), 3.15 (d, J = 5.9 Hz, 2H), 2.9 – 
3.0 (m, 3H), 2.48 (td, J = 12.7, 4.1 Hz, 1H), 2.0 (m, 4H), 1.8 (m, 1H), 1.3 (m, 4H), 1.2 
(m, 12H), 0.75 (t, J = 4.5 Hz, 6H); 13C NMR (D2O, 100 MHz) δ 156.8, 156.5, 93.2, 
75.2, 73.8, 72.6, 67.9, 48.7, 48.4, 48.1, 41.9, 41.2 (2 carbons), 31.2 (2 carbons), 29.1, 
29.0, 28.0, 26.2 (2 carbons), 24.0, 22.3 (2 carbons), 20.7, 13.7 (2 carbons); ESI/APCI 
Calcd for C26H54N6O6+ ([M+H]+) m/e 545.4021; measured m/e 545.4021. 
6-O-(α-D-galactopyranosyl)-2',3',4'-trideoxy-4'-aminoneamine (NRT014). 
This compound was prepared similarly to the synthesis of compound 105 but using 
MeOH and couple drops of HOAc/H2O (1/4) as the solvent in the second step. 1H 
NMR (D2O, 300 MHz) δ 5.32 (t, J = 4.8 Hz, 1H), 4.97 (d, J = 3.4 Hz, 1H), 4.2 (m, 
1H), 4.01 (t, J = 5.9 Hz, 1H), 3.88 (d, J = 2.4 Hz, 1H), 3.2 – 3.8 (m, 11H), 2.7 (m, 1H), 
2.37 (td, J = 12.4, 4.1 Hz, 1H), 1.7 – 2.0 (m, 5H); 13C NMR (D2O, 100 MHz) δ 101.8, 
96.6, 83.6, 77.9, 73.9, 72.1, 69.5(2 carbons), 69.1, 68.9, 61.1, 50.0, 48.7, 47.1, 39.4, 
27.8, 26.2, 21.1; ESI/APCI Calcd for C18H37N4O9+ ([M+H]+) m/e 453.2555; measured 
m/e 453.2549. 
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6-O-(α-D-galactopyranosyl)-3',4'-dideoxyneamine (RT014). This compound 
was prepared similarly to the synthesis of compound 105 except no NaHCO3(s) was 
used in the first step. 1H NMR (D2O, 300 MHz) δ 5.65 (d, J = 3.3 Hz, 1H), 5.01 (d, J 
= 3.6 Hz, 1H), 4.06 (t, J = 6.3 Hz, 2H), 3.6 – 3.9 (m, 9H), 3.4 – 3.5 (m, 2H), 3.13 (dd, 
J = 13.4, 3.1, 1H), 2.98 (dd, J = 13.4, 7.2 Hz, 1H), 2.38 (dt, J = 12.7, 4.1 Hz, 1H), 1.7 
– 1.9 (m, 4H), 1.5 (m, 1H); 13C NMR (D2O, 100 MHz) δ 101.7, 95.7, 83.8, 77.4, 74.4, 
72.6, 69.4, 69.1, 68.7, 66.0, 61.3, 49.7, 48.9, 48.6, 42.7, 28.0, 25.6, 20.6; ESI/APCI 
Calcd for C18H37N4O9+ ([M+H]+) m/e 453.2555; measured m/e 453.2565. 
6-O-(3-amino-3,6-dideoxy- α-D-glucopyranosyl)-2',3',4'-trideoxy-4'-aminone
amine (NRT040). This compound was prepared similarly to the synthesis of 
compound 105 but using MeOH and couple drops of HOAc/H2O (1/4) as the solvent 
in the second step. 1H NMR (D2O, 400 MHz) δ 5.31 (s, 1H), 4.91 (s, 1H), 4.2 (m, 1H), 
3.2 – 3.8 (m, 11H), 3.1 (m, 1H), 2.4 (m, 1H), 1.8 – 2.0 (m, 5H), 1.14 (d, J = 5.6 Hz, 
3H); 13C NMR (D2O, 100 MHz) δ 100.9, 96.8, 83.5, 78.2, 73.6, 71.0, 70.0, 68.9, 68.6, 
55.0, 50.3, 48.8, 47.0, 39.3, 27.8, 25.8, 21.0, 16.5; ESI/APCI Calcd for C18H38N5O7+ 
([M+H]+) m/e 436.2766; measured m/e 436.2771. 
6-O-(3-amino-3-deoxy-α-D-xylopyranosyl)-3',4'-dideoxyneamine (RT040). 
This compound was prepared similarly to the synthesis of compound 105 except no 
NaHCO3(s) was used in the first step. 1H NMR (D2O, 400 MHz) δ 5.79 (d, J = 3.5 Hz, 
1H), 5.04 (d, J = 3.6 Hz, 1H), 4.3 (m, 1H), 3.5 – 4.0 (m, 9H), 3.0 – 3.5 (m, 8H), 2.54 
(ddd, J = 13.2, 4.5, 4.5 Hz, 1H), 1.70 (ddd, J = 13.2, 12.5, 12.5 Hz, 1H,); 13C NMR 
(D2O, 100 MHz) δ 100.8, 95.2, 84.0, 77.1, 74.5, 68.3, 66.2, 65.6, 57.1, 55.3, 49.9, 
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48.9, 48.7, 42.8, 27.1, 25.6, 20.7; HRFAB Calcd for C17H36N5O7+ ([M+H]+) m/e 
422.2615; measured m/e 422.2603. 
6-O-(4-amino-4,6-dideoxy- β-D-glucopyranosyl)-2',3',4'-trideoxy-4'-aminone
amine (NRR501). This compound was prepared similarly to the synthesis of 
compound 105 but using MeOH and couple drops of HOAc/H2O (1/4) as the solvent 
in the second step. 1H NMR (D2O, 300 MHz) δ 5.83 (t, J = 3.4 Hz, 1H), 4.6 (m, 1H), 
3.89 (td, J = 8.6, 3.5 Hz, 1H), 2.8 – 3.6 (m, 11H), 2.61 (t, J = 10.0 Hz, 1H), 2.11 (td, J 
= 12.4, 3.8 Hz, 1H), 1.4 – 1.9 (m, 5H), 1.19 (d, J = 6.2 Hz, 3H); 13C NMR (D2O, 75 
MHz) δ 102.5, 96.8, 81.8, 78.3, 74.3, 73.8, 73.4, 70.4, 69.5, 57.4, 50.3, 49.0, 47.7, 
40.4, 31.2, 27.0, 23.2, 17.2; ESI/APCI Calcd for C18H38N5O7+ ([M+H]+) m/e 
436.2766; measured m/e 436.2762. 
3',4'-Di-O-benzyl-6-O-hexylaminocarbonyl-1,3,4',6'-tetraazidoneamine (116). 
1H NMR (CDCl3, 300 MHz) δ 7.2 – 7.4 (m, 10H), 5.33 (d, J = 3.8 Hz, 1H), 4.8 – 4.9 
(m, 5H), 4.62 (d, J = 11.0 Hz, 1H), 4.1 – 4.2 (m, 2H), 3.98 (t, J = 9.6 Hz, 1H), 3.2 – 
3.6 (m, 10H), 2.3 (m, 1H), 1.4 -1.5 (m, 3H), 1.3 (m, 6H), 0.88 (t, J = 6.2 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 156.1, 137.8, 137.7, 128.79 (2 carbons), 128.75 (2 
carbons), 128.3 (2 carbons), 128.0 (2 carbons), 99.3, 83.2, 80.8, 78.8, 76.4, 75.8, 75.7, 
75.5, 71.4, 64.2, 59.2, 58.5, 51.2, 41.7, 32.2, 31.8, 29.9, 29.8, 26.8, 26.6, 22.8, 14.2; 
ESI/APCI Calcd for C33H43N13O7+ ([M+H]+) m/e 734.3481; measure m/e 734.3485. 
3',4'-Di-O-benzyl-5,6-Di-O-hexylaminocarbonyl-1,3,4',6'-tetraazidoneamine 
(117). 1H NMR (CDCl3, 300 MHz) δ 7.2 – 7.4 (m, 10H), 5.33 (d, J = 3.4 Hz, 1H), 
4.89 (d, J = 12.7 Hz, 1H), 4.86 (d, J = 1.7 Hz, 2H), 4.60 (d, J = 11.0 Hz, 1H), 4.09 (t, 
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J = 9.6 Hz, 1H), 3.8 – 4.0 (m, 8H), 3.2 – 3.7 (m, 8H), 2.49 (td, J = 8.9, 5.2 Hz, 1H), 
1.5 -1.6 (m, 5H), 1.3 (m, 12H), 0.88 (t, J = 4.5 Hz, 6H); 13C NMR (CDCl3, 100 MHz) 
δ 156.6, 152.7, 137.69, 137.66, 128.8 (3 carbons), 128.3 (3 carbons), 128.2 (2 
carbons), 128.1 (2 carbons), 96.5, 81.0 (2 carbons), 79.9, 78.5, 75.8, 75.4, 75.2, 71.9, 
63.1, 60.2, 56.3, 51.1, 43.5, 40.9, 33.9, 31.7, 29.8, 29.0, 26.9 (2 carbons), 26.8 , 22.8 
(2 carbons), 14.2 (2 carbons); ESI/APCI Calcd for C40H56N14O8Na+ ([M+Na]+) m/e 
883.4289; measured m/e 883.4288. 
6-O-hexylaminocarbonylneamine (RR103). 1H NMR (D2O, 300 MHz) δ 5.77 
(d, J = 3.8 Hz, 1H), 3.7 – 3.9 (m, 4H), 2.9 -3.5 (m, 9H), 2.40 (td, J = 8.6, 4.1 Hz, 1H), 
1.84 (td, J = 12.5, 3.4 Hz, 1H), 1.35 (q, J = 6.5 Hz, 2H), 1.14 (m, 6H), 0.71 (t, J = 6.5 
Hz, 3H); 13C NMR (D2O, 100 MHz) δ 157.3, 96.0, 77.7, 74.4, 73.7, 70.9, 69.3, 68.4, 
53.7, 48.4, 48.3, 40.9, 40.3, 30.8, 28.9, 28.8, 25.8, 22.1, 13.5; ESI/APCI Calcd for 
C19H40N5O7+ ([M+H]+) m/e 450.2922; measured m/e 450.2928. 
5,6-Di-O-hexylaminocarbonylneamine (RR104).  This compound was 
prepared similarly to the synthesis of compound 105. 1H NMR (D2O, 300 MHz) δ 
5.20 (d, J = 3.8 Hz, 1H), 4.85 (t, J = 9.3 Hz, 1H), 4.74 (t, J = 10.0 Hz, 1H), 3.6 – 3.9 
(m, 3H), 2.8 – 3.4 (m, 10H), 2.15 (td, J = 8.9, 4.1 Hz, 1H), 1.55 (td, J = 12.6, 12.5 Hz, 
1H), 1.3 (m, 4H), 1.1 (m, 12H), 0.70 (t, J = 6.9 Hz, 6H); 13C NMR (D2O, 100 MHz) δ 
160.0, 156.7, 94.1, 75.6, 75.2, 73.3, 70.7, 69.3, 68.5, 53.5, 48.6, 48.3, 41.2, 41.1, 40.2, 
30.9 (2 carbons), 29.8, 28.8 (2 carbons), 25.9, 25.8, 22.1 (2 carbons), 13.5 (2 carbons); 
ESI/APCI Calcd for C26H53N6O8+ ([M+H]+) m/e 577.3919; measured m/e 577.3929. 
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